



UNIVERSITY OF
CALGARY

Department of **Oncology**



Annual Report July 1, 2013—June 30, 2014

TABLE OF CONTENTS

MEMBERSHIP	1
REPORTS	
Dr Peter Craighead, Head	9
Division of Fundamental Research	11
Division of Gynecologic Oncology	12
Division of Hematologic Malignancies & BMT (AHS Proposed)	15
Division of Medical Oncology	19
Division of Medical Physics	33
Division of Palliative Medicine	38
Division of Pediatric Oncology	43
Division of Preventive Oncology	46
Division of Psychosocial Oncology	55
Division of Radiation Oncology	66
Division of Surgical Oncology	75
Division of Translational Research & Laboratories	81
EDUCATION PROGRAMS	88
GRANTS	101
PUBLICATIONS	124
ONCOLOGY GRAND ROUNDS	161
APPENDIX	
2015 Directory	169

MEMBERSHIP

HEAD	CRAIGHEAD, P. S.			Professor	Oncology
Department Administrator	REHALUK, B.				
	CHAMBERS, C.	Adjunct	Assistant	Professor	Oncology
	VALLANCE, J.	Adjunct	Assistant	Professor	Oncology
<u>DIVISION</u>			<u>RANK</u>		<u>PRIMARY DEPT.</u>
Fundamental Research	ROBBINS, S. M. Division Head		Associate	Professor	Oncology
	BEATTIE, T.		Associate	Professor	Biochemistry & Molecular Biology
	BROWDER, L. W.			Professor	Biochemistry & Molecular Biology
	COBB, J. A.		Assistant	Professor	Biochemistry & Molecular Biology
	EDWARDS, D. R. W.	Adjunct	Associate	Professor	Biochemistry & Molecular Biology
	GOODARZI, A.		Assistant	Professor	Biochemistry & Molecular Biology
	GREWAL, S.		Assistant	Professor	Biochemistry & Molecular Biology
	JOHNSTON, R.			Professor	Biochemistry & Molecular Biology
	LEES-MILLER, S.			Professor	Biochemistry & Molecular Biology
	LOHKA, M.	Adjunct	Associate	Professor	Oncology
	RANCOURT, D.			Professor	Oncology
	RATTNER, J.			Professor	Cell Biology & Anatomy
	RIABOWOL, K. T.			Professor	Biochemistry & Molecular Biology
	SCHRIEMER, D.		Associate	Professor	Biochemistry & Molecular Biology
	SENGER, D. L.	Research	Assistant	Professor	Oncology
	SYME, R.	Adjunct	Assistant	Professor	Oncology
	TAMAOKI, T.		Emeritus	Professor	Biochemistry & Molecular Biology
	Van der HOORN, F.			Professor	Biochemistry & Molecular Biology
	YONG, V. W.			Professor	Biochemistry & Molecular Biology
	YOUNG, D. B.			Professor	Biochemistry & Molecular Biology
Gynecologic Oncology	NATION, J. G. Division Head			Professor	Obstetrics/Gynecology
	CHU, P.		Assistant	Professor	Obstetrics/Gynecology
	GHATAGE, P.		Associate	Professor	Obstetrics/Gynecology
	GLAZE, S.		Assistant	Professor	Obstetrics/Gynecology
	NELSON, G.		Assistant	Professor	Obstetrics/Gynecology
	STUART, G. C. E.	Adjunct		Professor	Oncology

MEMBERSHIP

DIVISION			RANK		PRIMARY DEPT.
Hematologic Malignancies & BMT	STEWART, D. Division Head			Professor	Oncology
	BAHLIS, N.		Associate	Professor	Medicine
	BLAHEY, W.	Clinical	Associate	Professor	Medicine
	BROWN, C.			Professor	Medicine
	CHAUDHRY, A.		Lecturer		Oncology
	DALY, A.	Clinical	Associate	Professor	Medicine
	DUGGAN, P.	Clinical	Associate	Professor	Medicine
	GEDDES, M.	Clinical	Assistant	Professor	Medicine
	GOODYEAR, D.	Clinical	Assistant	Professor	Medicine
	GROSSMAN, J.	Clinical	Assistant	Professor	Medicine
	JENKINS, D.	Clinical	Associate	Professor	Medicine
	JIMINEZ-ZEPEDA, V.	Clinical	Assistant	Professor	Medicine
	LATEGAN, J.	Clinical	Assistant	Professor	Medicine
	LEE, A.	Clinical	Assistant	Professor	Medicine
	MODI, M.	Clinical	Assistant	Professor	Medicine
	NERI, E. P.	Clinical	Assistant	Professor	Oncology
	OWEN, C.		Assistant	Professor	Medicine
	POON, M. C.			Professor	Medicine
	RYDZ, N.	Clinical	Assistant	Professor	Medicine
	SAVOIE, L.			Professor	Oncology
	SHAFEY, M.	Clinical	Assistant	Professor	Medicine
	SLABY, J.	Clinical	Assistant	Professor	Medicine
	STOREK, J.			Professor	Medicine
	STREET, L.	Clinical	Assistant	Professor	Medicine
	THAELL, J. F. (TED)	Clinical	Assistant	Professor	Medicine
	VALENTINE, K.	Clinical	Associate	Professor	Medicine
	WONG, M.	Clinical	Assistant	Professor	Medicine
	YAU, J.	Clinical	Assistant	Professor	Medicine
Medical Oncology	MORRIS, D. Division Head		Associate	Professor	Oncology
	ALIMOHAMED, N.	Clinical	Assistant	Professor	Oncology
	BEBB, G.		Associate	Professor	Oncology
	BRIGDEN, M.	Clinical	Associate	Professor	Oncology

MEMBERSHIP

DIVISION	RANK			PRIMARY DEPT.
BROWMAN, G.	Adjunct		Professor	Oncology
CAIRNCROSS, J. G.			Professor	Clinical Neurosciences
CARD, C.	Clinical	Assistant	Professor	Oncology
CHENG, T.		Associate	Professor	Oncology
DOWDEN, S.	Clinical	Assistant	Professor	Oncology
EASAW, J.	Clinical	Associate	Professor	Oncology
EL-GEHANI, F.	Clinical	Assistant	Professor	Oncology
FORESTELL, C. F.	Clinical	Assistant	Professor	Medicine
FORSYTH, P.	Adjunct		Professor	Oncology
GLÜCK, S.	Adjunct		Professor	Oncology
HANLEY, D.			Professor	Medicine
HAO, D.		Assistant	Professor	Oncology
HENG, D.	Clinical	Assistant	Professor	Oncology
HENNING, J. W.	Clinical	Assistant	Professor	Oncology
HOLLAND, D. R.	Clinical	Assistant	Professor	Medicine
JERRY, L. M.	Honorary	Clinical	Professor	Oncology
KHARFAN-DABAJA, M.		Assistant	Professor	Oncology, BMT
KRAUSE, V. S.	Clinical	Assistant	Professor	Oncology
KURWA, H.	Clinical	Associate	Professor	Medicine
KUMAR, A.	Clinical	Assistant	Professor	Oncology
LUPICHUK, S.	Clinical	Assistant	Professor	Oncology
MICHAUD, G.	Clinical	Assistant	Professor	Medicine
MONZON, J.	Clinical	Assistant	Professor	Oncology
PATERSON, A. G. H.	Clinical		Professor	Oncology
PICKERING, T. L.	Clinical	Assistant	Professor	Oncology
ROLDAN-URGOLITI, G.	Research	Assistant	Professor	Oncology
RUETHER, J. D.		Assistant	Professor	Oncology
RUSSELL, J. A.	Clinical		Professor	Medicine
SAYANI, F.	Clinical	Assistant	Professor	Medicine
STATHER, D.	Clinical	Assistant	Professor	Medicine
STEWART, D.			Professor	Oncology
TAENZER, P. A.	Adjunct	Assistant	Professor	Medicine
TAM, V. C.	Clinical	Assistant	Professor	Oncology
TANG, P.	Clinical	Assistant	Professor	Oncology

MEMBERSHIP

DIVISION			RANK		PRIMARY DEPT.
	TREMBLAY, A.	Clinical	Associate	Professor	Medicine
	TRUDEAU, M.	Clinical	Associate	Professor	Oncology
	TSANG, R. Y.	Clinical	Assistant	Professor	Oncology
	VICKERS, M.	Clinical	Assistant	Professor	Oncology
	WALLEY, B.		Assistant	Professor	Oncology
	WEBSTER, M.	Clinical	Assistant	Professor	Oncology
	WONG, A. O.	Clinical	Assistant	Professor	Medicine
	YAU, A.	Clinical	Assistant	Professor	Oncology
Medical Physics	DUNSCOMBE, P. B. Division Head			Professor	Oncology
	BREITMAN, K.	Adjunct	Associate	Professor	Radiology
	BROWN, D.	Adjunct	Assistant	Professor	Oncology
	KHAN, R.		Assistant	Professor	Oncology
	MEYER, T.	Adjunct	Assistant	Professor	Oncology
	NEWCOMB, C. H.	Adjunct	Associate	Professor	Oncology
	SMITH, W.		Assistant	Professor	Oncology
	SPENCER, D.	Adjunct	Assistant	Professor	Oncology
	TAMBASCO, M.		Assistant	Professor	Oncology
	VASSILIEV, O. N.	Adjunct	Assistant	Professor	Oncology
	VILLARREAL-BARAJAS, E.		Assistant	Professor	Oncology
Palliative Medicine	HAGEN, N. Division Head			Professor	Oncology
	BOYER, A.	Clinical	Lecturer		Oncology
	BRAUN, T.	Clinical	Associate	Professor	Family Medicine
	CHARY, S.	Clinical	Lecturer		Oncology
	ESMAIL, R.	Adjunct	Lecturer		Oncology
	FALK, D.	Clinical	Lecturer		Family Medicine
	GALLOWAY, L.	Clinical	Lecturer		Family Medicine
	HERX, L. M.	Clinical	Assistant	Professor	Pediatrics
	HUNTER, B.	Clinical	Lecturer		Oncology
	LABRIE, M.	Clinical	Assistant	Professor	Family Medicine
	LEMIEUX, L.	Clinical	Lecturer		Oncology

MEMBERSHIP

DIVISION			RANK		PRIMARY DEPT.
	MARR, H.	Clinical	Assistant	Professor	Oncology
	MURPHY, L.	Clinical	Lecturer		Oncology
	MURRAY, A.	Clinical	Assistant	Professor	Family Medicine
	PAWLIK, S.	Clinical	Lecturer		Family Medicine
	PEREIRA, J.	Adjunct	Associate	Professor	Oncology
	PERRI, G.	Clinical	Lecturer		Oncology
	SIMON, J. E.	Clinical	Assistant	Professor	Oncology
	SINCLAIR, S.	Adjunct		Professor	Oncology
	SINNARAJAH, A.	Clinical	Lecturer		Oncology
	SYME, R. M.	Adjunct	Assistant	Professor	Oncology
	WASYLENKO, E.	Clinical	Lecturer		Oncology
Pathology & Laboratory Medicine	MORRIS, D. Division Head		Associate	Professor	Oncology
	BEBB, G.		Associate	Professor	Oncology
	BISMAR, T.		Associate	Professor	Pathology
	CHAN, J.		Assistant	Professor	Pathology
	DEMETRICK, D.			Professor	Pathology
	DiFRANCESCO, L.		Assistant	Professor	Pathology
	MAGLIOCCO, A. M.	Adjunct		Professor	Oncology
	THIRUKKUMARAN, C.	Adjunct	Assistant	Professor	Oncology
	TROTTER, M.			Professor	Pathology
Pediatric Oncology	STROTHER, D. Division Head		Associate	Professor	Oncology
	ANDERSON, R.		Associate	Professor	Oncology
	BRIÈRE, M. È.	Adjunct	Associate	Professor	Oncology
	GUILCHER, G.		Assistant	Professor	Oncology
	LAFAY-COUSIN, L.		Assistant	Professor	Oncology
	LE, D. T.		Assistant	Professor	Pediatrics
	LEWIS, V.		Assistant	Professor	Oncology
	NARENDRAN, A.		Assistant	Professor	Oncology
	SCHULTE, F. S. M.	Research	Assistant	Professor	Pediatrics
	STEELE, J. M.	Clinical	Assistant	Professor	Pediatrics
	TRUONG, T. H.		Assistant	Professor	Oncology
WRIGHT, N. A. M.	Clinical	Assistant	Professor	Pediatrics	

MEMBERSHIP

DIVISION		RANK			PRIMARY DEPT.
Preventive Oncology	FRIEDENREICH, C. Division Head	Adjunct		Professor	Oncology
	ASHBURY, F.	Adjunct	Associate	Professor	Oncology
	BROCKTON, N.	Adjunct	Assistant	Professor	Oncology
	BRYANT, H. E.	Clinical		Professor	Community Health Sciences
	CSIZMADI, I.	Adjunct	Assistant	Professor	Oncology
	KOPCIUK, K.	Adjunct	Associate	Professor	Oncology
	McGREGOR, L.	Adjunct	Associate	Professor	Oncology
	SHACK, L.	Adjunct	Assistant	Professor	Oncology
	VALLANCE, J.	Adjunct	Assistant	Professor	Oncology
Psychosocial Oncology	BULTZ, B. Division Head	Adjunct		Professor	Oncology
	BRIÈRE, M. È.	Adjunct	Assistant	Professor	Oncology
	CAMPBELL, T.	Adjunct	Assistant	Professor	Oncology
	CARLSON, L. E.			Professor	Oncology
	CULOS-REED, N.	Adjunct	Assistant	Professor	Oncology
	de GROOT, J.		Assistant	Professor	Psychiatry
	GIESE-DAVIS, J.		Associate	Professor	Oncology
	HUSSAIN, S.	Clinical	Assistant	Professor	Psychiatry
	MACRAE, J. H.	Adjunct	Assistant	Professor	Oncology
	PELLETIER, G.	Adjunct	Assistant	Professor	Oncology
	ROBINSON, J. W.	Adjunct	Associate	Professor	Oncology
	SIMPSON, S.		Associate	Professor	Psychiatry
	SPECA, M.	Adjunct	Associate	Professor	Oncology
THOMAS, B.	Adjunct	Associate	Professor	Oncology	
Radiation Oncology	OLIVOTTO, O. Division Head	Clinical		Professor	Oncology
	ANGYALFI, S. J.	Clinical	Associate	Professor	Oncology
	BALOGH, A. G.	Clinical	Associate	Professor	Oncology
	BANERJEE, R.	Clinical	Assistant	Professor	Oncology
	CRAIGHEAD, P. S.			Professor	Oncology
	DOLL, C.	Clinical	Associate	Professor	Oncology
	GHOSE, A.	Clinical	Assistant	Professor	Oncology
	HUSAIN, S.	Clinical	Assistant	Professor	Oncology

MEMBERSHIP

DIVISION			RANK		PRIMARY DEPT.
	KERBA, M.	Clinical	Assistant	Professor	Oncology
	KURIEN, E.	Clinical	Associate	Professor	Oncology
	LAU, H.	Clinical	Associate	Professor	Oncology
	LIM, G.	Clinical	Assistant	Professor	Oncology
	LIU, H.	Clinical	Assistant	Professor	Oncology
	MACKINNON, J. A.	Clinical	Associate	Professor	Oncology
	NORDAL, R.	Clinical	Associate	Professor	Oncology
	PHAN, T.	Clinical	Assistant	Professor	Oncology
	SIA, M.	Clinical	Assistant	Professor	Oncology
	SINHA, R.	Clinical	Assistant	Professor	Oncology
	SKARSGARD, D. P.	Clinical	Associate	Professor	Oncology
	TROTTER, T.	Clinical	Associate	Professor	Oncology
	VORONEY, J. P.	Clinical	Assistant	Professor	Oncology
	WILSON, J.	Clinical	Assistant	Professor	Oncology
	WU, J.	Clinical	Associate	Professor	Oncology
Surgical Oncology	McKINNON, J. G. Division Head			Professor	Surgery
	ARLETTE, J. P.	Clinical		Professor	Oncology
	BALL, C.	Clinical	Assistant	Professor	Surgery
	BATHE, O.			Professor	Surgery
	BUIE, W. D.			Professor	Surgery
	CHANDARANA, S.	Clinical	Assistant	Professor	Surgery
	de HAAS, W. G.	Clinical	Assistant	Professor	Surgery
	DIXON, E.		Associate	Professor	Surgery
	DONNELLY, B.	Clinical	Assistant	Professor	Surgery
	DORT, J.			Professor	Surgery
	ELLIOTT, F. G.	Clinical	Assistant	Professor	Surgery
	GELFAND, G. A. J.	Clinical	Assistant	Professor	Surgery
	GRAHAM, A. J.	Clinical	Associate	Professor	Surgery
	HARDY, M.	Clinical	Assistant	Professor	Surgery
	HARVEY, A.	Clinical	Assistant	Professor	Surgery
	LAFRENIERE, R.			Professor	Surgery
	LINDSAY, R. L.	Clinical	Associate	Professor	Surgery

MEMBERSHIP

DIVISION		RANK		PRIMARY DEPT.
MACK, L.		Associate	Professor	Oncology
MAGI, E.	Clinical	Associate	Professor	Surgery
MATTHEWS, W.		Associate	Professor	Surgery
MCFADDEN, S.	Clinical	Assistant	Professor	Surgery
MCKINNON, J. G.			Professor	Surgery
MCWHAE, J. A.	Clinical	Associate	Professor	Surgery
MEW, D.	Clinical	Assistant	Professor	Surgery
PASIEKA, J.	Clinical		Professor	Surgery
PULOSKI, S.	Clinical	Assistant	Professor	Surgery
QUAN, M. L.		Associate	Professor	Surgery
SUTHERLAND, F.			Professor	Surgery
TEMPLE, W. J.			Professor	Oncology
TEMPLE-OBERLE, C. F.		Assistant	Professor	Oncology

What to say, what to do...

In this my final message as Department Head to the Department of Oncology, I want to encourage all of us to boldly support the importance of having an integrated academic unit, that takes aim at confronting the problem of cancer. Our department has a 20 year history of working together to confront this disease, and in the past five years we have also corralled the activities of those fighting to prevent cancer. I would like to acknowledge the work of our ten division heads, Doug Stewart (Deputy Head), Theresa Trotter (Associate Director of Education), and our administrative staff. All of us have worked tirelessly to ensure recruitments are done expeditiously, promotions are seen to happen, merit is assessed, and that the general activities are functional. At this the dawning of the Cumming School of Medicine (CSM) it is important to acknowledge how important a time we are living in, and seize any opportunities that arise.

Under my watch over the past eight years there has been steady growth in research productivity (both manuscripts and grants), the education programs have fostered well (all positions taken, and growth in fellowships), and we have enhanced our capacity to lead oncology by teaching leadership skills to emerging leaders. Our senior leadership structure is solid, with division heads in all domains. We are also striving to grow into several niche areas academically – Hematological Oncology wishes to become an academic body, and we are considering what a formal entity in Health Services Research looks like. Additionally, we are one of a few departments who systematically collect information on all our members electronically, and who use this to drive our promotions processes.

With that as a backdrop, may I leave a few suggestions that will help you as you move into the future with a new leader:

1. Stay true to your calling to be an integrated department. The research institutes within the CSM will, and should always be, places where we can put our research interests. They support us and collaborate with us, but they remain as a virtual entity. Their interests at the moment are focused on discovery and translational research; whereas our focus has to be the encouragement of research across all pillars, with strength in all of them. But more importantly, we need to take our responsibility to provide excellent care seriously, and our mandate to teach the best students is paramount to our success.
2. Strive to be better. Calgary started as an academic unit with one quarter the people we now have. The past eight years has seen significant focus in activity in a few areas. Over time we have reached a level of respectability, but it is only when our leaders are committed to doing better research and teaching, that we will reach the ultimate goal of being regarded as one of the best. Alberta is provided with some of the most paramount funding opportunities for academic cancer medicine. Calgary has been knocking on the door of being a top five cancer centre for some time. Your calling to be better is clear. How will you respond?

3. Be proud of what you have achieved. Develop a culture of success. Such a culture has as its main ingredients a sense of belonging and meaning, with members of the department committed to achieving results. However, this culture also focuses on where it came from, and celebrates the successes it has achieved. To not do this makes many people frustrated. Look back and see what many accomplishments have been achieved. This will ensure that the frustrations of what has happened in the past are balanced by the good things that have been done.

4. Make a difference. All of us usually move from achieving career success to being able to drive greater significance with our work. In this process it is important that we allow ourselves the breathing time to ascertain what it is we need to do to make a real difference. For many of you this will look like teaching or becoming a leader; others will choose clinical care as their focus. For some this may involve being available for volunteer work outside your career. Whatever this looks like, I challenge you to ensure that the activity you choose is relevant and will allow you to make the difference you desire.

In closing may I leave you all with the Irish blessing:

May the road rise up to meet you.
May the wind always be at your back.
May the sun shine warm upon your face,
and rains fall soft upon your fields.
And until we meet again,
May God hold you in the palm of His hand.

The privilege of leading a group as dedicated as you cannot be overestimated. You have added much to me personally. Your loyalty has carried me through many dark days; and your commitment to making this a place where others would want to work inspires me. Over the next six months I intend to take my time to find a role where I too can drive significance with my work. As always, I continue to be your servant...

Peter S Craighead MBChB FFRadT FRCPC
Professor & Head, Department of Oncology, University of Calgary
Calgary Zone Clinical Department Head, Alberta Health Services
Medical Director, Tom Baker Cancer Centre

DIVISION HEAD

Stephen Robbins, PhD

NO REPORT WAS SUBMITTED FOR THE 2013-2014 ACADEMIC YEAR.

DIVISION HEAD

Jill Nation, MD, FRCSC

DIVISION HIGHLIGHTS

Dr. Sarah Glaze joined the division as an Assistant Professor in July, 2013 and was on maternity leave from September, 2013 until February 18, 2014.

Dr. Pamela Chu became the Assistant Dean of PGME at the University of Calgary.

CURRENT ISSUES

Workforce planning continues due to increasing numbers of patients and lack of available space for expansion at TBCC on FMC site.

Wait lists for oncology surgery are continuing to increase and will be accentuated by planned summer closures at FMC operating rooms.

Functional planning for the new cancer centre was a major focus.

Relocation of our pre-invasive colposcopy program as a result of flooding of the Holy Cross site in June, 2013 presented significant challenges for our division over this reporting year.

STRATEGIC PLANNING

Funding for third year of Gynecologic Oncology Fellowship Training Program to enhance research opportunities and academic development for our fellows and make them competitive for recruitment after completion of fellowship.

Recruitment of a Research Assistant for the gynecological oncology group is underway.

RESEARCH HIGHLIGHTS

Our division is involved in gynecologic oncology clinical trials at a national level. Dr. Ghatage was local principal investigator for 16 funded clinical trials in this reporting period while the other four gynecologic oncologists participate in all trials as local sub-investigators. Dr. Gregg Nelson is the principal investigator of an in-house randomized clinical trial with analysis of results of the pilot study underway and is the Co PI for an AIHS-PRIHS operating grant.

Gynecologic oncologists published eight papers in 2013-2014, four posters and were involved in research projects with fellows in our training program resulting in presentations at the Department of Obstetrics and Gynecology Research Day.

PROGRAM

Multidisciplinary pre-invasive and invasive cancer care spanning initial diagnosis, cancer surgery, chemotherapy, collaborations with radiation oncology and palliative care. Gynecologic cancer consultation for Southern Alberta, South Eastern British Columbia and South Western Saskatchewan.

Leadership in colposcopy: Dr. Nation is the Director of Colposcopy at both the Tom Baker Cancer Centre and Women's Health Services Clinics and serves as the Provincial Chair of the Alberta Cervical Cancer Screening Program Advisory Committee.

Leadership in educational programs: Dr. Ghatage is the Program Director for the Royal College accredited University of Calgary residency program in gynecologic oncology. Dr. Chu serves as an oral examiner for the Royal College exams in obstetrics and gynecology and Dr. Ghatage is Chair of the MCQ Examination Committee for RCPSC fellowship examination in obstetrics and gynecology.

UNIVERSITY OF CALGARY PROFESSORSHIP/ENDOWED CHAIRS

AWARDS

- Glaze, S. Department of Obstetrics and Gynecology Faculty Award for the best gynecology research paper for her work with colleagues titled "Dose dense paclitaxel with carboplatin for advanced ovarian cancer: A feasible treatment alternative", 2013.
- Nation, J. Department of Obstetrics and Gynecology, Subspecialty Award, 2014.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Bernadini, M., Gien, L., Nelson, G., Lau S., Ferguson, S., Samouelian, V., Altman, A., Ho, T., & McAlpine, J. (2014, March). *Variations in practice for the management of high risk histologic subtypes in endometrial cancer: A CHREC (consortium of high risk endometrial cancer) Canadian project*. Presented at the 45th Annual Meeting on Women's Cancer-Society of Gynecologic Oncology, Tampa, FL, USA.
2. Chu, P. A. (2014, May). *Competency based medical education*. Presented at the Department of Obstetrics and Gynecology Rounds, Calgary, Alberta.
3. Doll, C., Klimowicz, A., Craighead, P., Ghatage, P., Bebb, G., Lees-Miller, S., Dean, M., & Ho, C. (2013, November). *Tumour ataxia telangiectasia-mutated (ATM) status and outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy* [Abstract]. Presented at the CARO-COMP 2013 Joint Scientific Meeting (Innovations in Imaging), Montreal, Quebec.
4. Ghatage, P. (2014, February). *Living with ovarian cancer symposium*. Presented at half day symposium for patients and healthcare workers, Calgary, Alberta.
5. Glaze, S. J. (2014, March). *Update on ovarian cancer landscape and fertility*. Presented at Western SOGC, Lake Louise, Alberta.

6. Glaze, S. J. (2014, May). *Dose dense paclitaxel with carboplatin for advanced cancer: A feasible treatment alternative*. Presented at the Department of Obstetrics & Gynecology, Annual Clara Christie Research Day, Calgary, Alberta. [Winner of best Faculty paper of 2013].
7. Lee, S. L., Sabourin, J., Gage, J., Nation, J. G., & Duggan, M. A. (2014, March). *P16 and Ki67 expression in squamous intraepithelial lesions of the uterine cervix which cannot be qualified: SILQ*. Poster presented at USCAP Annual Meeting, San Diego, USA.
8. Lee, S. L., Sabourin, J., Gage, J., Nation, J. G., & Duggan, M. A. (2014, March). *Squamous intraepithelial lesions of the uterine cervix which cannot be qualified: SILQ*. Poster presented at USCAP Annual Meeting, San Diego, USA.
9. Nation, J. G. (2014, June). *Quality performance indicators in colposcopy*. Presented at the Department of Obstetrics and Gynecology, Grand Rounds, Calgary, Alberta.
10. Nation, J. G. (2014, March). *Colposcopy management algorithms*. Presented at the Annual Provincial Colposcopy Update Meeting, Lake Louise, Alberta.
11. Nelson, G. S. (2014, May). *Enhancing patient's recovery after surgery (ERAS), strategy to transform care and maximize value*. Presented at the Surgery Strategic Clinical Network Meeting, Calgary Airport Delta Hotel, Calgary, Alberta.
12. Sabourin, J., Lee, S. L., Gage, J., Nation, J. G., & Duggan, M. A. (2014, May). *Risk factors associated with HSIL, AIS or carcinoma after an initial diagnosis of ungraded SIL and colposcopic follow up*. Poster presented at the Department of Obstetrics and Gynecology, Annual Clara Christie Research Day, Calgary, Alberta.

DIVISION HEAD

Peter R. Duggan MD, FRCPC

DIVISION HIGHLIGHTS

In the past year we added four new members to the division. Dr. Victor Jiminez-Zepeda has a strong clinical and research interest in plasma cell neoplasms, especially multiple myeloma and amyloidosis. Dr. Jiri Slaby joined the PLC group in November having completed bone marrow transplant training at the TBCC. Dr. Jennifer Grossman joined the division in May 2014 having trained in immune deficiencies at the NIH in Bethesda, Maryland. And Dr. Adrienne Lee will join the hematology group at the FMC, specializing in hemostasis.

There were three staff maternity leaves (C. Owen, L. Street, & D. Goodyear), and two trainee maternity leaves (O. Propachuk-Gauk, & S. Cerquozzi) during the year. Congratulations!

Dr. Andrew Daly continues to serve on the executive committee of the Canadian Blood and Marrow Transplant Group, while Dr. Lynn Savoie is the Vice-President of the Canadian Hematology Society.

CURRENT ISSUES

Clinic space is an ongoing and growing problem. The growing population of Southern Alberta, and the introduction of novel, effective therapies for hematologic cancers mean that more people are being treated for these disease, and for longer, than in past years. Yet available resources have not kept pace with this demand. This growth is also reflected in an increase in the number of stem cell transplants performed, as well as in the number of patients admitted to inpatient hematology services. The division continues to operate two high acuity inpatient services at two sites, one of which (PLC) is not affiliated with or linked to the cancer center, as is not able to provide access to inpatient or outpatient hematology research protocols.

Recruitment of new hematologists has been limited by a lack of available funded positions, clinic space, and other resources. Calgary currently does not have a clinical thrombosis program within the hematology division.

STRATEGIC PLANNING

Planning for a new cancer center is ongoing, with the promise of adequate inpatient and outpatient resources upon completion in 2020. In the meantime, the division continues to plan for the eventual consolidation of inpatient services at one site. A proposal to combine TBCC malignant hematology and BMT outpatient services into a single functional unit will hopefully improve access to outpatient clinic space and support, allowing the creation of new clinic resources starting in early 2015. This will help relieve our currently overbooked clinics and allow for recruitment to the cancer program.

A hematologist specializing in thrombosis is to be recruited in mid-2015, with plans to recruit one to two more. These thrombosis specialists will work with other groups (internal medicine, surgery, pulmonary medicine) to develop a formal thrombosis program.

RESEARCH HIGHLIGHTS

Congratulations to Dr. Carolyn Owen, Dr. Douglas Stewart, and Dr. Leslie Skieth (hematology trainee) for New England Journal of Medicine articles, and Dr. Nizar Bahlis for having a manuscript accepted by the NEJM. In all, members of the Hematology Tumour Group published 21 peer reviewed manuscripts and presented 19 abstracts at major meetings.

The Hematology Tumor Group led all TBCC tumor groups in clinical trial accrual for 2013, recruiting over 100 patients to interventional studies. Clinical trial activity care ongoing in multiple myeloma (N. Bahlis, P. Duggan, & V. Zepeda), lymphoma (D. Stewart, & C. Owen) leukemia/MDS (L. Savoie, & M. Geddes).

A number of investigator initiated transplant studies have started or are planned, including a study of a novel conditioning regimen for autologous stem cell transplant conditioning (Dr. Mona Shafey), and a study of pre-emptive therapy with ATG for patients at risk of graft-versus-host disease following allogeneic stem cell transplant.

PROGRAM

Bone Marrow Transplant Program (Director: A. Daly) TBCC, ACH and CCI

Hematology Tumor Group (Leader: C. Owen) TBCC

The division continues to provide inpatient hematology services at the Peter Lougheed Hospital and Foothills Medical Centre, an inpatient bone marrow transplant service at FMC, 24 hour consult service to all Calgary hospitals, outpatient malignant hematology services at PLC and FMC, and general hematology clinics at FMC, PLC, and South Health Campus. In addition, Calgary hematologists continue to attend outreach hematology clinics in Medicine Hat every three weeks, and BMT clinics in Edmonton every two weeks.

AWARDS

Duggan, P. Bronze Award for Undergraduate Teaching Contribution, University of Calgary School of Medicine.

Associate Dean's Letter of Excellence, University of Calgary School of Medicine.

Geddes, M. Bronze Award for Undergraduate Teaching Contribution, University of Calgary School of medicine.

Associate Dean's Letter of Excellence, University of Calgary School of Medicine.

-
- Goodyear, D. Bronze Award for Undergraduate Teaching Contribution, University of Calgary School of Medicine.
Associate Dean's Letter of Excellence, University of Calgary School of Medicine.
- Jenkins, D. Associate Dean's Letter of Excellence, The University of Calgary University of Calgary School of Medicine.
Gold Start Teaching Award, University of Calgary School of Medicine.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Brown, C. (2013, December). *Documentary Director/Producer, Ahdjaan (Teacher): A working adventure in Laos*. Presented at the Dean's Leadership Group, Calgary, Alberta.
2. Faridi, R. M., Kemp, T. J., Lewis, V., Berka, N., Storek, J., & Khan, F. M. (2013, December). *Donor-recipient matching for KIR genotypes confers protection against GVHD without affecting disease relapse after allogeneic HCT* [Abstract]. Presented at the American Society of Hematology Annual Meeting, New Orleans, LA.
3. Faridi, R. M., Kemp, T. J., Liacini, A., Dharmani-Khan, P., Lewis, V., Storek, J., Berka, N., & Khan, F. M. (2013, November). *KIRs and unique target-induced immune responses of NK cell subsets* [Abstract]. Oral presentation at the American Society for Histocompatibility and Immunogenetics (ASHI) Annual Meeting, Chicago, IL.
4. Faridi, R. M., Kemp, T. J., Liacini, A., Tripathi, G., Dharmani-Khan, P., Lewis, V., Berka, N., Storek, J., & Khan, F. M. (2013, November). *Development of PTLD after allogeneic HCT is influenced by the donor KIR centromeric B/x linkage group* [Abstract]. Presented at the American Society for Histocompatibility and Immunogenetics (ASHI) Annual Meeting, Chicago, IL.
5. Jenkins, D. (2013, September). *Innovations in Residency Education*. Invited speaker. Presented at the University of Calgary, Royal College of Physicians and Surgeons: International Conference on Residency Education (ICRE), Calgary, Alberta
6. Owen, C. J. (2013, October). *Approach to familial hematological malignancies*. Invited speaker. Presented at Cancer Care Manitoba, Winnipeg, Prince Edward Island, Canada.
7. Owen, C. J. (2013, October). *CLL*. Invited speaker. Presented at the Leukemia & Lymphoma Society of Canada, Calgary, Alberta.
8. Owen, C. J. (2013, October). *Blood Doping at the Calgary Laboratory Services*. Invited speaker. Presented at the Annual Continuing Education Event, Calgary Laboratory Services, Calgary, Alberta.
9. Owen, C. J. (2013, October). *CLL clinical trials in Canada*. Session Moderator. Canadian Conference on CLL, Winnipeg, Manitoba.
10. Owen, C. J. (2013, October). *Results of the CLL11 clinical trial*. Invited speaker. Presented at the Canadian Conference on CLL, Winnipeg, Manitoba.
11. Shafey, M. (2013, November). *Understanding leukemia better*. Invited speaker. Presented at the Leukemia and Lymphoma Society of Canada, Calgary, Alberta.
12. Shafey, M. (2013, November). *Blood and marrow transplants, the process and the experience*. Invited speaker. Presented at the Leukemia and Lymphoma Society of Canada, Calgary, Alberta.

13. Shafey, M. (2013, November). *CML - treatments and new developments*. Invited speaker. Presented at the Leukemia and Lymphoma Society of Canada, Calgary, Alberta.
14. Storek, J. (2014, March). *ATG prevents GVHD probably without increasing relapse*. Invited Speaker. Presented at EBMT, Sanofi, Milan, Italy.
15. Storek, J. (2014, April). *Immune reconstitution after HCT*. Invited Speaker. Presented at CBMTG, Winnipeg, Manitoba.
16. Tripathi, G., Lewis, V., Storek, J., Berka, N., & Khan, F. M. (2013, November). *IL-10 low producing genotype confers strong risk of GVHD* [Abstract]. Presented at the American Society for Histocompatibility and Immunogenetics (ASHI) Annual Meeting, Chicago, IL.

DIVISION HEAD

Don Morris, MD, PhD, FRCPC

DIVISION HIGHLIGHTS

TBCC Gastrointestinal Tumour Group Report – Dr. Patricia Tang

The GI Tumour Group and newly appointed leader, Dr. Patricia Tang, would like to thank Dr. Scot Dowden for his years of dedication to leading the group before stepping down in June of this year. Dr. Dowden was the local principal investigator of the pivotal phase III trial that established the role of nab-paclitaxel in pancreatic cancer, and culminated in a publication in the New England Journal of Medicine, “Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.” This trial was one of many that were conducted at the Tom Baker Cancer Centre with the support of the Clinical Research Unit and local investigators. Cooperative group trials continue to be a focus with local members playing prominent roles in IND.210 (national co-chair Dr. Tang), and CO.23 (Dr. Vickers, steering committee).

The commitment to patient care is evident within this group of oncology specialists (medical, radiation and surgeons) with four members, Dr. Monzon, Dr. Kerba, Dr. Sinha and Dr. Buie who were awarded grants to support the following studies which together add up to over 1.2 million dollars: Phase II trial of RosuvaSTatin combined with standard chemoradiation therapy in the treatment of high-risk locally advanced rectal cancer (The STARC Trial); A phase II study of palliative chemo-radiotherapy with carbo-taxol in non-curative cancer of the esophagus; stereotactic ablative body radiotherapy (SABR) for oligo-metastatic colorectal cancer with bio-marker evaluation for early progression; and Alberta rectal cancer clinical pathway initiative.

It is our pleasure to welcome Dr. Craighead who has joined the GI Tumour Group, seeing rectal cancer patients.

With respect to education, Dr. Soundouss Raissouni is continuing her GI medical oncology fellowship, Dr. Bill Hunter is starting a stereotactic ablative body radiotherapy fellowship and we have been able to enhance our presence at the Cummings School of Medicine.

Southern Alberta/TBCC Breast Tumor Group – Dr. Sasha Lupichuk

The Alberta Provincial Breast Cancer Program Retreat took place in Kananaskis March 7-9, 2014. Dr. Sasha Lupichuk and Dr. Karen King presented the Medical Oncology Update, Dr. Marc Webster presented The Year in Review, and Dr. Sandy Paterson presented data from the adjuvant bisphosphonate meta-analysis. Existing clinical practice guidelines were updated. Funding was obtained to launch OncotypeDX testing in Alberta and hence, the adjuvant systemic therapy guideline was updated to reflect use of this new technology. Pathology North and South are tracking requests and ordering medical oncologists are being asked to complete a short survey regarding perceived recurrence risk category and chemotherapy recommendation on the requisition.

Preliminary data from the internal audit retrospective study of adjuvant TAC versus FEC-D for node positive breast cancer was presented. There was further discussion of new guidelines such as neoadjuvant and metastatic. Newly funded therapies (everolimus, pertuzumab, trastuzumab emtansine) for metastatic breast cancer were reviewed with a focus on indication, benefit and important toxicities.

Theo Johnston, Triage RN, has been involved in the launch of E-Referral. Dr. Sasha Lupichuk and Theo Johnston will participate in updating and evaluating E-Referral. Cindy Railton, NP and Dr. Sasha Lupichuk have proposed an adjuvant systemic therapy clinic. Dr. Sasha Lupichuk, Dr. Jan-Willem Henning, and Dr. Douglas Stewart continue to participate in the Cardio Oncology Group within the Calgary Zone. Members have had the privilege of collaborating on research proposals with the cardiologists and are gaining experience with referring patients on to the Cardio-Oncology Clinic based at South Health Campus.

TBCC Genitourinary Tumor Group Report – Dr. Daniel Heng

This year, Dr. Dean Ruether completed his term as GU Tumor Group Leader and has been replaced by Dr. Daniel Heng in October 2013. We sincerely thank Dr. Ruether for all his years of leadership as he assumes larger roles at the Tom Baker Cancer Center. Other GU Tumor Group executives nominated this year include Dr. David Skarsgard (Radiation Oncology) and Dr. Geoffrey Gotto (Urology). We have also successfully recruited Dr. Nimira Alimohamed who completed a fellowship at Princess Margaret Hospital in Toronto in urologic oncology.

An annual retreat was organized by Dr. Ruether in October 2013 for which important clinical issues were discussed and practice guidelines updated. Quality initiatives including those in bladder cancer and prostate cancer were initiated and spearheaded by the GURU group. Joint GU Oncology CME events have been organized by Drs. Martin Duffy (Urology) and Daniel Heng so that there is constant collaboration and communication with the members of the Southern Alberta Institute for Urology.

Research is an important focus for the GU group. We are an active RTOG site and accrue well to GU clinical trials. The GU group has over 30 trials ongoing in prostate, kidney, and bladder cancers. We have a great team of clinical research nurses and coordinators and have met or exceeded all target accrual goals. We are pleased to be able to offer patients trials in rarer disease sites such as papillary renal cell carcinoma, bladder cancers that express certain proteins, and phase I trials investigating the cutting edge for cancer drugs and immunotherapy. We also maintain patient registries and databases in prostate, kidney and testicular cancers which have led to many publications this year.

Teaching and mentorship are also priorities and have been reflected by first-author publications by our Oncology Fellows including Drs. Jenny Ko, Richard Lee-Ying and Rene Lester, and preceptorships of our medical students and residents that have rotated through our clinics.

Our group remains quite busy clinically and we project that new patient consultations will increase as new therapies and clinical trials have emerged to significantly prolong overall survival for our patients.

Southern Alberta/TBCC Endocrine/NET Tumor Group Report- Dr. Dean Ruether

The TBCC Endocrine & Neuroendocrine Tumor group continued to grow and mature as a tumor team throughout the last year.

Neuroendocrine Tumor group rounds occur every two weeks and now have dedicated support from colleagues in nuclear medicine as well as interventional radiology while still enjoying excellent support from the involved medical and surgical specialties as well as pathology. Our colleagues in Saskatchewan continue to join us regularly for discussion of their cases. This has continued to improve patient care and flow for patients referred for radio isotope (PRRT) treatment and assisted us with accrual to clinical trials.

Thyroid cancer rounds occur monthly and are also now truly multidisciplinary with the involvement of endocrine and head and neck surgeons, endocrinologists, medical and radiation oncologists, radiologists, and pathologists as well as our trainees in endocrinology, medical oncology and surgical specialties.

The Endocrine/ NET Tumor group held its fourth provincial tumor group meeting in November of 2013 and expanded this to include representation from the four western provinces. Our plans continue for a second annual Western Canadian Endocrine Cancer Care Conference in November of this year in Edmonton, and we hope to have additional representation from across Canada this year.

The provincial team continues to work with GURU to develop guidelines pertaining to the treatment and follow up of patients with NET. A guideline for the use of PRRT in NET's is being developed with representation from Alberta, Saskatchewan and Manitoba.

The provincial NET team with participation from members of the team at TBCC, held its second annual patient education day in October of 2013 and was rewarded with attendance by patients from across Canada, and a site in the USA. More than 400 patients joined us for this educational event.

The clinical trial opportunities for patients at the TBCC include industry sponsored, and cooperative group trials for patients with NET's, pheochromocytomas and paragangliomas, and thyroid cancer. This is a significant achievement given the rarity of these tumors and the challenges with patient accrual for rare diseases.

The profile of the Endocrine/ NET Tumor program at TBCC is increasing across Canada. Members of the team are involved in local, regional and national efforts to raise awareness, improve access to care, develop guidelines and data bases and create access to clinical trials for this population of patients.

Provincial Hematology Tumor Team, Southern Alberta/TBCC Hematology Tumor Group and BMT Program – Dr. Doug Stewart

During this reporting year two new hematologists joined the Provincial Hematology Tumor Team; Dr. Victor Zepeda (multiple myeloma) and Dr. Jiri Slaby (general hematology).

Both individuals bring with them specialized training in blood and marrow transplantation. Dr. Zepeda has clinics at UCMC and TBCC and is now located at the FMC. Dr. Slaby has clinics at PLC and SHC and is located at the PLC.

Treatment guidelines for leukemia/MDS, myeloma/amyloidosis and lymphoma and CLL were discussed at the Annual Provincial Hematology Tumor Team Meeting held on May 16, 2014, in Edmonton. Also discussed were the topics of clinical data integration and the results of retrospective research projects. This meeting was well attended and provided a venue for ongoing discussion of hematology issues across the province.

In 2013-2014 we trained two fellows in Lymphoma (Dr. Joanna Graczyk & Dr. Danielle Oh). In terms of productivity, members of the TBCC Hematology Tumor Group published 26 peer reviewed manuscripts and presented 21 abstracts at national and international meetings. Over 100 patients were accrued to clinical trials at the TBCC, leading all tumor groups. In terms of research, approximately \$850,000.00 was brought in for research projects for which TBCC hematologists were PI's on. Funding agencies include: CIHR, ACF (donor designated funds), CHT, CLS, MMRF, DoM, NIH, Celgene and Novartis.

RESEARCH HIGHLIGHTS

Steady Course Through Stormy Waters- Clinical Trials Unit Report, Dr. Gwyn Bebb.

The last 12 months will go down as a period of significant growth for the TBCC clinical trials unit (CTU). After carefully setting out a vision, this was the time for making clear progress in the direction we wish to move. I am very happy to say that the TBCC CTU achieved several goals in terms of increasing capacity, improving accrual metrics, focusing on quality, and easing the process of enrolling patients on trials. Remarkably, all of this was achieved while adjusting to the aftermath of the flood of 2013. How did this happen?

Undoubtedly, housing CTU personnel displaced by the flood damage to the Holy Cross site was a major challenge. A temporary yet attractive space was made available to us at the Richmond Road facility, which allowed us to operate without major interruption to clinical trial activity. I want to thank all those CTU staff whose work life was interrupted by this experience for their commitment to high quality during this time. In addition, we owe a debt of gratitude to Paul Grundy and Kathryn Tod in making this space available in the first place. As we look back, we can say that trial activity was only minimally affected by this episode. Meanwhile as we anticipate moving back to the Holy Cross, we are keen to ensure that the renovations there will allow us to continue to grow as patient numbers increase.

Anticipating this growth is key to our success. One of our most notable achievements was the increased capacity created by completion of the renovation and expansion of the CTU space in the basement. The new ambience and increased brightness is very welcome to all whose workstations are located there. Furthermore, increased space for monitoring has improved the experience of the monitors when they visit: given 100 + monitor visits per month this is not a trivial challenge. Importantly, this new space has also allowed us to accommodate the new CTCs and CTNs that our growing trial activity has demanded.

It is fantastic to see the fruits of almost two years' worth of tireless planning, lobbying and preparation come to reality. If the CTU continues to grow as we anticipate, this space will be fully utilized just as we move to the new Calgary Cancer Centre.

Accrual metrics are always an important, if somewhat incomplete, measure of clinical trial activity. Given their significance, we made a point of opening a full and frank discussion with our major stakeholders and our partners at the Cross Cancer Institute on what constitutes an accrual to a clinical trial. A more precise definition was agreed on and adopted by ACCT earlier this year. So how did we do?

Our accrual numbers paint an optimistic picture of our activity. An impressive total of 486 patients were accrued to clinical trials in this 12 month period, 202 of them in the Bone Marrow Transplant program. Significantly, we are beginning to receive notable accolades as we set new accrual standards. Between January-June 2014, we became the leading site in Canada for NRG trial participation, recruiting 24 patients (vs nine patients at the Princess Margaret Hospital). We became the first site in North America to recruit a patient and to reach our accrual target for the GO28667 trial and the first site in Canada to screen and accrue a patient to MMY3003. We are the top accruing site in Canada and one of three Canadian sites in the top ten globally for EF-14, a trial of the NovoCure device in neuro-oncology.

These are noteworthy achievements. I specifically want to highlight the role of the trial launch team, specifically Kim Gerat and Klara Lavoie, in this success. Since its creation in April 2013, the Trial Launch Team has worked on a total of 54 trial protocols. Of those, four were not launched, 31 have been launched and 19 are currently still in the launch process. Of those that were launched, 75% met the trial launch turn-around target of 20 weeks. Importantly, this includes the 30% launched in under 12 weeks - the target industry requires for phase I trials. This is a very important measurement of the launch team's function ... but, it's not the only one!

The trial launch team and the rapid review process also form the cornerstone of our quality assurance. They highlight potential pitfalls in trial protocols that will compromise the delivery of the high quality we seek to deliver right at the outset of the trial launch process. Identifying such pitfalls early has led to a change in a trial protocol, a waiver on certain requirements or a decision to not proceed with the trial at all.

Our focus on quality, indeed our #1 priority, continues under the leadership of Marilyn David. We recently launched a more formal process of gathering data on protocol deviations and violations. When fully operational, this will provide us with the precise data we need to implement process improvements to minimize such events in future. We have dedicated two 0.5 FTE to assist with this initiative. We plan to provide all tumor groups with a score card for their FY14 trial activities that includes deviations, violations and accruals in Q4 2014. We have also partnered with AIW (AHS Improvement Way) to review processes related to scheduling and developed "Best Practice" recommendations for all related tasks.

This focus on quality has reaped significant rewards. We survived an NCIC audit and achieved a CPI index for 2013 of GOOD. We also endured a Health Canada inspection with a compliant rating. We are developing an enviable reputation among trial sponsors, a reputation that will lead to new phase I trials coming out way.

Clearly such success occurs only through the devotion and hard work of members of the CTU staff. I want to acknowledge every member of the CTU for their continued devotion to their duties and determination to help us achieve success despite the many unforeseen challenges that come our way. At our retreat last year, several individuals were acknowledged for their valuable contributions.

2012 Top Accruing Oncologist:

Dr. Nizar Bahlis (accrued 34 patients to Hematology trials -12% of all accruals)

2012 Outstanding Contribution to the CRU:

Dr. Jan-Willem Henning (created and led the 2012 Ride to Conquer Cancer Team, raised \$100,000 for CRU)

2012 Top Accruing Clinical Research Nurse and Outstanding Performer:

Jaclyn Anderson and Dianna Killick (helped enroll and supported 120 new hematology patients on trial in 2012, - 43% of all accruals)

2012 Top Accruing Clinical Research Coordinator and Outstanding Performer:

Kelly Mclachlan (handled 42 new patients on trial in 2012, 15% of all accruals)

2012 CRU Leadership Award:

Marilyn David (outstanding leadership in maintaining cohesion as acting manager in 2012)

2012 CRU Citizenship Award:

Amy Ng (outstanding attitude and work ethics, shows great initiative - GI clinical trials newsletter – great asset to the unit)

There are several other people to thank. I want to, once again, acknowledge Dr. Jan-Willem Henning and Michael Civitella for their unwavering commitment to raise additional funds for the CTU through leading the TBCC Cancer Conquerors in the Ride to Conquer Cancer this year and last year. The money raised this summer promises to exceed that raised in previous years, an extraordinary achievement. We owe a great deal to the Alberta Cancer Foundation for their continued support for clinical trials and the CTU. We owe a major thank you to Margaret Mac Isaac our SFA who has transformed our understanding of our fiscal situation since joining us. Finally, I want to thank Sabine Moritz for her dedication and commitment in leading the CTU in its pursuit of higher standards.

Meanwhile, what of next year? While we have not experienced another flood, there is currently great political uncertainty in our province: it is impossible to predict what winds or currents will disrupt our journey. We can however be certain of the following. We will remain mindful of the hope of better outcomes that we represent to our patients.

We will continue to grow in terms of number of new trials opened, number of patients accrued to trial, new members of staff and increased phase I activity. We will continue to hone the key processes that enable us to deliver rapid turn-around time, generate high quality data and accrue well in a fiscally responsible way. We will work hard to attract the phase I business that will help us become a true Clinical Research Unit.

As we become more successful, the challenges we face are likely to change. However, the vision and commitment to quality will not waver. Within such a framework, I am confident that the TBCC CTU will continue to see the growth and development that we all expect from a centre such as ours.

PROGRAM

Systemic Treatment and Clinics (Dorothy MacKay, RN, Manager)

During 2013-2014 the focus was to increase operational stability and address identified patient and staff quality of life issues in the DayCare Unit. Work focused on implementation of recommendations from a 2011 patient flow and chemotherapy unit and pharmacy operations report. Recommendations implemented included the split of “DayCare” into two separate units (achieved March 10, 2014): Chemotherapy Administration Unit and Oncology Clinics. Additional changes to the Chemotherapy Administration Unit included: introduction of a different chemotherapy appointment booking process; reduction of appointment booking “exceptions” in order to increase availability of chemotherapy treatment time; controlled “loading” of patients into the unit; introduction of a 1:3 nurse/patient care ratio; division of the Chemotherapy unit into “pods” with structured care accountability; introduction of “flex” beds to control patient flow; an extended (9.75 hour) work day; reduced hours of operation with no reduction in appointment availability; a new nurse rotation with 4.82 additional RN positions; and implementation of the role of Nurse Clinician. Expected positive results included marked reduction (i.e. 0-15 minutes) in patient wait time for a chemotherapy appointment, clarity with respect to nurse accountability, “fair” nurse rotation/assignments and marked reduction of registered nurse overtime. An unexpected positive impact was that patients reported the unit is now “quieter” and seems more controlled.

Provincial Systemic Council received support for both the TBCC and Cross Cancer Institute to propose plans to address lost treatment days due to closure on statutory holidays. Proposal is under development that will include three different operational scenarios for TBCC.

Assessment of capacity and operations/flow of oncology clinics is ongoing. The AHS Process Improvement team worked with staff in the neurologic, hematologic and gynecologic oncology clinics to assess patient and clinic flow. This assessment data will be compiled with other clinic assessment information to create “business rules” with associated accountabilities for TBCC oncology clinics.

Work has begun with Human Resources Advisor and the Manager of BMT to create a Hematology/BMT tumor group. It is expected this work will take approximately two years to complete. In addition, discussion continues with respect to re-structuring oncology clinics into a “tumor group” model of practice.

UNIVERSITY of CALGARY PROFESSORSHIP/ENDOWED CHAIRS

AWARDS

- Hao, D. Bronze Award Distinguished Service Award for Undergraduate Medical Teaching, 2013.
- Hao, D. Associate Dean’s Letter of Excellence for teaching in Communication Skills, 2013.
- Stewart, D. Appreciation Award for Leadership of the Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, 2013.
- Tam, V. Medical Oncology Fellows Teaching Award, Clinical Preceptor, Tom Baker Cancer Centre, University of Calgary, 2013.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Akhter, A., Farooq, F., Mahe, E., Shabani-Rad, M. T., Street, L., Morris, D., Stewart, D., & Mansoor, D. (2014). *Mantle cell lymphoma: Toll-like receptors (TLRs) and B-cell receptor (BCR) gene expression analysis identify a distinct BCR activated subset, with germinal center signature and indolent biology* [Abstract]. Presented at the American Society Of Clinical Oncology, Annual Meeting.
2. Akhter, A., Masir, N., Mahe, E., Elyamany, G., Shabani-Rad, M. T., Stewart, D., Morris, D., & Mansoor, D. (2014). *Gene expression analysis of B-cell receptors (BCR) pathway identify PDE4B gene as potential therapeutic target to overcome glucocorticoid resistance in primary CNS lymphoma* [Abstract]. Presented at the American Society Of Clinical Oncology, Annual Meeting.
3. Albiges, L., Xie, W., Lee, J. L., Rini, B. I., Srinivas, S., Heng, D. Y., ... Choueiri, T. K. (2014). *The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting.
4. Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., Heng, D. Y., ... Hammers, H. J. (2014). *Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting.
5. Amin, A., Ernstoff, M., Infante, J. R., Heng, D. Y., Rini, B. I., Plimack, E. R., ... Hammers, H. J. (2014). *A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting.

6. Azad, A., Lester, R., Leibowitz-Amit, R., Joshua, A. M., Heng, D. Y., Eigl, B. J., & Chi Kim, N. (2014). *Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting.
7. Bebb, G. (2014, June). *From genomics to medicine: New approaches to drug discovery & development*. Invited Speaker. University of Calgary, Calgary, AB, Canada.
8. Bebb, G. (2014, January). *Building a clinical research bridge at the new Calgary Cancer Centre*. Invited Speaker. New Calgary Cancer Centre Team, Calgary, AB, Canada.
9. Bebb, G. (2013, October). *The animal within: Cancer, metastasis and the ultimate metastatic phenotype*. Invited Speaker. Canadian Oncology Society, Webinar, Calgary, AB, Canada.
10. Bebb, G. (2013, October). *Lung cancer: Improving outcomes through early detection and research*. Invited Speaker. Alberta Cancer Foundation Conference, Lung Session, Banff, AB, Canada.
11. Bebb, G. (2013, September). *Clinical cancer research – Qu’ est-ce que c’est?* Invited Speaker. Network Fest, Edmonton, AB, Canada B.
12. Bebb, G. (2013, September). *Ataxia telangiectasia mutated (ATM): An emerging role in cancer*. Invited Speaker. Genomic Instability and Ageing Conference, Calgary, AB.
13. Cheng, T. (2014, February). *Ipilimumab side effect management*. Invited Speaker. VCCA, Kelowna, BC, Canada.
14. Cheng, T. (2014, February). *Cutaneous database: Data collection at care point*. Presented for Cutaneous Tumour Group Provincial Meeting, Banff, AB, Canada.
15. Dang, N., Ogura, M., Castaigne, S., Fayad, L., Jerkeman, M., Stewart, D., ... Ando, K. (2014). *Randomized phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting.
16. Diefenbach, C. S., Hailun, L., Hong, F., Gordon, L., Fisher, R., Stewart, D., ... Advani, R. (2013). *Evaluation of a novel 3 factor prognostic score (PS-3) for patients with advanced Hodgkin’s lymphoma (HL) treated on US Intergroup E2496* [Abstract]. Presented at the American Society of Hematology, Annual Meeting.
17. Dowden, S. (2014, June). *Early rectal cancer: What is the most appropriate approach?* Invited Speaker. Atlantic Canada Oncology Group (ACOG) in conjunction with CAMO, Halifax, NS, Canada.
18. Dowden, S. (2014, June). *Update on the new advances in the management of metastatic colorectal cancer*. Invited Speaker. Alberta Digestive Diseases Summit, Lake Louise, AB, Canada.
19. Dowden, S. (2013, December). *Expanding new options with the treatment of second line metastatic colorectal cancer*. Invited Speaker. McGill University, GI Workshop, Montreal, QC, Canada.
20. Feng, X., Freiheit, E., Morisky, D., Mulder, K., Chu, Q., Bramwell, V., & Morris, D. (2013). *A Prospective observational cohort study of adherence to oral tyrosine kinase inhibitors (TKIs) in gastrointestinal stromal tumor (GIST)* [Abstract]. Presented for SACRI/ Dept of Oncology Research Day.
21. Feng, X., Smylie, M., Cheng, T., Monzon, J., & Lee-Ying, R. (2014). *The Impact of Clinical Response to Induction Anti-CTLA4 Treatment on Overall Survival (OS) in Metastatic Melanoma (MM)* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Conference.

22. Hao, D. (2014, April). *When tissue is the issue: Molecular testing for lung cancer – What all respirologists should know*. Invited Speaker. Canadian Respiratory Conference, Calgary, AB, Canada.
23. Hao, D. (2014, February). *Optimizing use of targeted therapies in NSCLC: Tissue is the issue*. Presented for Tom Baker Cancer Centre Grand Rounds, Calgary, AB, Canada.
24. Hay, A. E., Monzon, J. G., McDonald, G., Pater, J. L., Meyer, R. M., Chen, E., Chen, B. E., & Dancey, J. (2014). *Correlation between phase 2 clinical trial design and subsequent phase 3 outcome* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Conference.
25. Heng, D. (2014, May). *Contemporary landscape and evolution of front-line targeted therapy for patients with mRCC*. Invited Speaker. Patient registries in mRCC, Asia Pacific Oncology Summit, Seoul, Korea, Democratic People's Republic of Korea.
26. Heng, D. (2013, July). *Predictive and prognostic factors in mRCC*. Invited Speaker. 44th Congress of Japanese Society of Renal Cancer Program, Tokyo, Japan.
27. Henning, J. W. (2014, April). *Clinical trials and overall survival: Make or break*. Presented for Medical Oncology Journal Club, Calgary, AB, Canada.
28. Henning, J. W. (2014, April). *Adjuvant therapy for GIST*. Presented for Provincial Sarcoma Meeting, Edmonton, AB, Canada.
29. Henning, J. W. (2014, February). *Febrile neutropenia*. Presented for Medicine Hat Cancer Centre Update, Calgary, AB, Canada.
30. Henning, J. W. (2014, January). *Side effects of chemotherapies: What the family doctor should know*. Presented for the CME Program at the University of Calgary, Calgary, AB, Canada.
31. Henning, J. W. (2013, October). *HER 2+ disease and new therapies*. Presented for Breast Treatment Update, Red Deer, AB.
32. Ko, J., Liu, M., Otsuka, S., Boland, W., Skolnik, K., Macklow, J., Morris, D., & Bebb, G. (2014). *Referral to a cancer centre, medical oncologist and use of systemic treatment in stage IV non-small cell lung cancer patients – comparison of years 2003 – 2006 and 2010 cohorts in a Canadian Institution* [Abstract]. Presented at the American Association of Cancer Research, Annual Meeting.
33. Kouroukis, C. T., Crump, M., MacDonald, D., Larouche, J. F., Stewart, D., Johnston, J. B., Sauvageau, S., Dubois, S., & Sehn, L. (2014). *Safety and use of bendamustine from the bendamustine expanded access trial in Canada (Bend-ACT)* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting.
34. Lee, L., & Bebb, G. (2013). *Digital differentiation of squamous cell carcinoma and adenocarcinoma of the lung by the geometry of their epithelial architecture* [Abstract]. Submitted to U of C PGME, winner of the Canadian Society for Clinical Investigation Award for excellence in resident research.
35. Lee-Ying, R., Feng, X., Smylie, M., Monzon, J., & Cheng, T. (2014). *Efficacy of two ipilimumab (IPI) doses (10 vs. 3 mg/kg) in Alberta, Canada, Tertiary Cancer Centers* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Conference, Chicago, Illinois.
36. Heng, D. (2014, April). *Prognostic scoring systems for RCC 2014: What relevance for the clinic?* Invited Speaker. Ninth European International Kidney Cancer Symposium, Dublin, Ireland.

-
37. Heng, D. (2014, April). *Kidney cancer trends around the world, clinical trials and future directions*. Invited Speaker. International Kidney Cancer Coalition, 4th International Conference for Organizations Representing Patients with Kidney Cancer, Amsterdam, Netherlands.
 38. Heng, D. (2014, January). *Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Consortium*. Invited Speaker. Genitourinary American Society of Clinical Oncology, San Francisco, California, USA.
 39. Heng, D. (2013, November). *Treating patients inside and outside clinical trials*. Invited Speaker. 2nd World Top Communications of the Year in Genitourinary Oncology, Arezzo, Italy.
 40. Heng, D. (2013, September). *Towards personalizing the management of RCC*. Invited Speaker. Africa – Middle East (AFME) Oncology Forum, Abu Dhabi, United Arab Emirates.
 43. Morris, D. (2014, February). *Update on the use of reovirus as at for breast cancer*. Invited Speaker. Canadian Breast Cancer Foundation Night of Honor, Calgary, AB, Canada.
 44. Morris, D. (2014, February). *Research as part of the oncologist's career*. Presented for TBCC Medical Oncology Resident Research Luncheon, Calgary, AB, Canada.
 45. Morris, D. (2014, February). *Chair at the Canadian Lung Cancer Conference: Should pharmaceutical companies pay for the biomarker companion test for their drugs?* Presented for Canadian Lung Cancer Conference. Debate, Vancouver, BC, Canada.
 46. Morris, D. (2013, November). *Highlights on lung cancer from ESMO and World Lung Congresses*. Presented for ESMO and WLC Lung Update Calgary, AB, Canada.
 47. Morris, D. (2013, September). *Research: Should it be woven into the fabric of patient care*. Presented for Special Oncology Grand Rounds, Tom Baker Cancer Centre, Calgary, AB, Canada.
 48. Neri, E. P., Duggan, P., Gratton, K., Ren, L., Stewart, D., Keats, J., & Bahlis, N. (2013). *Outcomes and correlative studies of phase I trial with the oral PARP1-2 inhibitor veliparib in combination with boretzomib in patients with relapsed or refractory multiple myeloma* [Abstract]. American Society of Hematology, Annual Meeting.
 49. Nguyen, T. P., Tam, V. C., Lester, R. E., Ruiz, J. C., Bouchard-Fortier, A., Card, C., Krzyzanowska, M. K., Chan, K. K., Wallace, J. E., & Tang, P. A. (2014). *Burnout among Canadian oncologists and oncology residents* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting, Chicago, Illinois, USA.
 50. Ruether, D. (2014, March). *Update on the Western Canadian Endocrine Cancer Care Program*. Invited Speaker. ENETS Conference, Barcelona, Spain.
 51. Ruether, D. (2013, November). *Targeted therapy in pancreatic neuroendocrine tumors, Where are we now?* Presented for Provincial Endocrine Tumor Meeting, Kananaskis Village, AB, Canada.
 52. Ruether, D. (2013, November). *Systemic therapy in advanced thyroid cancer*. Presented for the Provincial Endocrine Tumor Meeting, Kananaskis Village, AB, Canada.
 53. Leibowitz-Amit, R., Joshua, A. M., Ezzat, S., Bourdeau, I., Onley, H., Oosting, S., Ruether, J. D., Chin, S., Palmieri, C., Seah, J. A., Assa, S., & Kryzanowska, M. (2014). *A single arm, phase II, multicentre trial of sunitinib maleate (SU) in locally-advanced or metastatic pheochromocytoma/paraganglioma 9PC/PG: Interim results* [Abstract]. Genitourinary Cancers Symposium.
-

-
54. Lupichuk, S., Railton, C., Ko, J., McCormick, J., Joy, A., Walley, B., & Giese-Davis, J. (2013). *Assessing the need for a nurse-led breast cancer telephone follow-up clinic in Alberta, Canada*. Poster presentation at ASCO Breast Cancer Symposium, San Francisco, CA.
55. Morris, D (2014, June). *Immunological aspects of oncolytic viral treatments*. Invited Speaker. Terry Fox Canada-Wide Immunotherapy Program Workshop, Toronto, ON, Canada.
56. Morris, D (2014, May). *Reovirus from bench to bedside and back again: A promising oncolytic viral strategy for the treatment of cancer*. Invited Speaker. Hematology/Oncology Grand Rounds, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
57. Morris, D. (2014, May). *Next generation sequencing multiplex testing for lung cancer*. Presented for the Provincial Lung Tumor Team Meeting, Edmonton, AB, Canada.
60. Stewart, D. (2014, June). *Clinical data and integration*. Invited Speaker. CCI Special Rounds, Edmonton, AB, Canada.
61. Stewart, D. (2014, April). *A post-ASH update on lymphoma*. Presented for Hematology Update, Calgary, AB, Canada.
62. Stewart, D. (2014, March). *Doctor's data download dream do-able!* Presented for Department of Oncology Quarterly Meeting, Tom Baker Cancer Centre, Calgary, Alberta.
63. Stewart, D. (2014, March). *The Calgary experience using high dose chemotherapy and stem cell transplantation to treat primary and relapsed CNS lymphomas*. Invited Speaker. University of British Columbia Hematology Lecture Series, Vancouver, British Columbia, Canada.
64. Stewart, D. (2014, March). *Moderator, lymphoma session*. Canadian Conference on Lymphoproliferative Disorders. Invited Speaker. Whistler, British Columbia, Canada.
65. Stewart, D. (2013, November). *The role of high dose therapy for lymphoma in the rituximab era*. Invited Speaker. University of British Columbia Hematology Lecture Series, Vancouver, British Columbia, Canada.
66. Stewart, D. (2013, November). *Modifying our treatment approach to secondary CNS lymphoma*. Presented for Hematology Update, Calgary, Alberta, Canada.
67. Stewart, D. (2013, September). *The Calgary experience: Management of indolent lymphoma*. Invited Speaker. University of Ottawa Hematology Group, Ottawa, Ontario, Canada.
68. Tam, V. (2013, October). *NCIC NEC.1 clinical trial*. Invited Speaker. Provincial Gastrointestinal Tumor Group Meeting, Edmonton, Alberta, Canada.
69. Tam, V. (2013, October). *Undergraduate oncology education in Canada and the Canadian oncology education working group*. Presented for Medical Oncology Fall Retreat, Calgary, Alberta, Canada.
70. Tang, P. A., Hay, A. E., O'Callaghan, C. J., Mittmann, N., Chambers, C., Pater, J. L., & Leighl, N. B. (2014). Estimation of drug cost avoidance (DCA) and the pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase 3 clinical trials in Canada [Abstract]. Plenary session: National Cancer Institute of Canada Annual Meeting. Poster accepted at the American Society of Clinical Oncology Meeting.
71. Ruether, D. (2013, October). *Bladder sparing (multimodality) treatment for bladder cancer. Making the case for a multidisciplinary clinic*. Presented for Provincial GU Tumor Group Meeting, Kananaskis Village, AB, Canada.

-
72. Ruether, D. (2013, October). *Hematopoietic growth factor. Who, when, why?* Invited Speaker. Community Cancer Update, Edmonton, AB, Canada.
73. Ruether, D. (2013, October). *Update on the management of kidney cancer. Optimizing treatment and improving outcomes.* Invited Speaker. Community Cancer Update. Edmonton, AB, Canada.
74. Ruether, D. (2013, October). *Hypersensitivity reactions. What do I do now?* Invited Speaker. Community Cancer Update, Edmonton, AB, Canada.
75. Ruether, D. (2013, September). *Systemic therapy in neuroendocrine tumors.* Presented for the Saskatchewan Endocrine Tumor Program, Saskatoon Cancer Centre, Saskatoon, Saskatchewan.
76. Schorr, M., Carlson, L., Lau, H. Y., Zhong, L., Bultz, B., Waller, A., Groff, S. L., & Hao, D. (2013) *Examining distress levels in patients with oropharyngeal versus non-oropharyngeal squamous cell carcinomas of the head and neck* [Abstract]. Presented at the Eurogin Congress, Florence, Italy.
73. Tang, P. (2014, May). *Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC CTG phase 3 clinical trials in Canada.* Invited Speaker. NCIC CTG Annual Meeting, Toronto, Ontario, Canada.
74. Toumishay, E., Prasad, A., Dueck, G., Chua, N., Finch, D., Stewart, D., White, D., van der Jagt, R., Johnston, J., Belch, A., & Reiman, T. (2013). Final report of a phase II clinical trial of lenalidomide monotherapy for T-Cell lymphoma [Abstract]. Presented at the American Society of Hematology, Annual Meeting.
75. Vickers, M. (2014, May). *Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.* Presented for CAMO, Toronto, Ontario, Canada.
76. Vickers, M. (2014, January). *Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.* Presented for ASCO GI, San Francisco, California, United States.
77. Vickers, M. M., Mercer, J., Kumar, A., Gresham, G., Goodwin, R. A., Jiang, M., Tang, P. A., Raissouni, S., Powell, E. D., Price-Hiller, J. A., Monzon, J. G., Cheung, W. Y., & Heng, D. Y. (2014). *Association of adjuvant chemotherapy with clinical outcomes in patients treated with neoadjuvant chemoradiation for locally advanced rectal cancer* [Abstract]. Presented at the American Society of Clinical Oncology, Annual Meeting.
78. Villa, D., Crump, M., Panzarella, T., Savage, K., Toze, C., Stewart, D., MacDonald, D., Buckstein, R., Lee, C., Alzahrani, M., Rubinger, M., Foley, R., Xenocotas, A., Sabloff, M., Nuccilli, A., Chua, N., Couture, F., Larouche, J. F., Cohen, S., Connors, J., Amber, K., Abdulwahab, A. T., Ramaden, K., & Kuruvilla, J. (2013). *Autologous and allogeneic stem-cell transplantation for transformed non-follicular indolent lymphoma: A report of the Canadian Blood and Marrow Transplant Group* [Abstract]. Presented at the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland.
79. Webster, M. (2014, April). *Evolving trends in the management of breast cancer.* Presented for CANM Conference, Calgary, Alberta, Canada.
80. Webster, M. (2014, March). *Year in review and SABC update.* Presented for Provincial Breast Cancer Tumor Group meeting, Kananaskis, Alberta, Canada.
81. Webster, M. (2014, March). *Overview of the current systemic therapy for the management of breast cancer.* Presented for Research Rounds, Calgary, Alberta, Canada.

82. Webster, M. (2013, September). *Overview of endocrine therapy in the management of the metastatic breast cancer patient*. Presented for Clinical Associates dinner, Calgary, Alberta, Canada.
83. Webster, M. (2013, September). *Duration of endocrine therapy – how much is enough?* Presented for Breast Journal Club, Calgary, Alberta, Canada.

DIVISION HEAD

Peter Dunscombe, PhD, FCCPM, FAAPM, FCOMP

DIVISION HIGHLIGHTS

After 12 years in his role, Dr. Peter Dunscombe retired as Clinical Head of the Department of Medical Physics and Head of the Division of Medical Physics in the University Department of Oncology. He is continuing his work with quality and safety in medical physics as he eases into retirement. Dr. Wendy Smith took on the clinical and division head roles as of July 1st, 2014.

Dr. Greg Pierce joined the division as an Adjunct Assistant Professor and was successful at gaining membership in the Canadian College of Physicists in Medicine. Dr. Pierce earned his PhD in medical biophysics at Western University, and completed his medical physics residency at the London Regional Cancer Program in Ontario. His research interests focus motion management and education. This year, both Dr. Wendy Smith and Dr. Rao Khan were promoted to Associate Professor in the Department of Oncology.

The division hosted the 60th Annual Scientific Meeting of the Canadian Organization of Medical Physicists in Banff in July, 2014. Dr. Brown was the scientific chair, and Dr. Smith was the local arrangements chair. The conference was a great success with glowing reviews from attendees. Three members of the division, Alana Hudson, Dr. Tyler Meyer and Dr. Nicolas Ploquin were among the invited speakers at this conference.

CURRENT ISSUES

With the retirement of Dr. Dunscombe and the imminent departure of Dr. Brown for the University of California, San Diego, recruitment will be an important activity in the next months. With the introduction of new resource intensive clinical techniques, described below, meeting academic expectations while maintaining a high level physics program will continue to be a challenge.

STRATEGIC PLANNING

In the short term the division is gearing up for the installation of a replacement linear accelerator in Vault six. The timeline from turning off the old machine to turning on the new one is about a year, with intermittent spurts of intense activities. The new unit is expected to be treating patients in November 2014. For the longer term, many members of the division have been participating in the planning of the new Calgary Cancer Centre. We plan to expand our graduate level course offerings by one course in imaging for radiotherapy in Fall 2014.

In the past two years, we have had three new hires. With two more expected this year, nearly half of the 10.5 staff will have turned over in a very short period of time. The division is entering a phase of new growth, where new foci of research and clinical expertise can be developed. This holds obvious short-term challenges, but great opportunities for the future.

RESEARCH HIGHLIGHTS

The Monte Carlo modeling cluster is approaching critical mass. Dr. Ploquin, along with MSc student Jared Wiebe, and summer student Ben Roth, have successfully modeled the Novalis and TrueBeam treatment delivery systems using the GATE simulation platform. These models will be used for research on the stereotactic radiosurgery and lung radiotherapy programs. Dr. Spencer and Dr. Dunscombe, with graduate student Julia Stanley, are continuing their investigation into the sources and impact of errors in stereotactic radiosurgery.

The motion management group had a productive year. Dr. Sarah Quirk defended her PhD in August, under the supervision of Dr. Smith, with four papers published or accepted this year. She measured and modeled external respiratory motion. Her work then examined the impact of this motion on target coverage and plan quality for partial breast radiotherapy. PhD student Leigh Conroy and her supervisor Dr. Smith used an empirical modeling approach to determine dosimetric margins, which confirmed the assumptions proposed by previous work with much more simplistic calculation techniques. Dr. Pierce supervised fourth year student, Andrew Prescott, whose project investigated the interplay effect of IMRT sliding window delivery for liver SBRT.

Dr. Khan is working with his PhD student Philip McGeachy on advancing the intensity modulated radiation therapy into the fifth dimension of energy. One of his summer students, Joseph Madamesila is working on experimental validation of the transport based patient dose calculation algorithm for low density in-homogeneities. This involved designing and 3D printing of phantoms at our TBCC machine shop. Dr. Khan also collaborated with Dr. Villarreal (currently on sabbatical) on using radiochromic films for patient dose measurement in orthovoltage dosimetry. Dr. Ploquin also worked with resident James Grafe to supervise summer student Yann Sayous characterizing and implementing radiochromic film analyses.

Dr. Kirkby, Dr. Ghasroddashti and PhD student, Michael Balderson, are investigating bystander effects in a treatment planning context. They are developing a fruitful collaboration with Olga Kovalchuk of the University of Lethbridge. They recently published a paper that quantified the scatter doses in rat models used for investigating radiation induced bystander effects. This was important because previously scatter doses were ignored in these models. There has been a lot of positive feedback from the article, and out figures were featured on the cover of the International Journal of Radiation Biology. Dr. Kirkby, Dr. Ghasroddashti and graduated PhD student Dr. Yannick Poirier also collaborated with Rob Stewart at Washington State University to develop a method to couple a radiation transport code with an empirical simulation of DNA damage and used that to solve an interesting problem – that of summing imaging and therapeutic doses.

Dr. Brown and Alana Hudson continue with their work physics education. They are particularly interested in developing sustainable radiation oncology programs in the developing world and the on-going educational support required for these programs to succeed. They have three papers accepted for publication on these issues, including a framework for implementing new technologies and treatment techniques in low-income countries.

Clinical issues often drive the research in this division. With the new breast brachytherapy program, new opportunities for clinical research are emerging. Dr. Meyer and his graduate student, Elizabeth Watt, are investigating treatment uncertainties for this relatively new technique. Dr. Brown, and his PhD student, Stefano Peca, are developing a practical method of monitoring dose delivery in real time using existing technology. Other notable project by the group based on clinical issues included papers published on the difference between Acuros and AAA treatment calculation algorithms (Khan, Dunscombe), binning techniques for motion measurements (Smith, Becker), bolus air gaps (Villarreal), and gating system commissioning (Smith).

Finally, Dr. Yannick Poirier defended his PhD on modeling kilovoltage x-ray sources in December, with co-supervisors Dr. Mauro Tambasco (who is now at San Diego) and Dr. Wendy Smith. His thesis work was part of collaboration with examining kV dose deposition from a variety of sources, from orthovoltage treatment machines to CT and CBCT imaging equipment.

PROGRAM (CLINICAL/SERVICE)

The division of medical physics has led several important clinical programs with colleagues in radiation oncology and radiation therapy over the past year. Physics managed a major upgrade to the treatment planning and delivery control system in November 2013. This has expanded our capabilities in terms of treatment planning and delivery. As a result, we were able to commission a number of new treatment techniques, such as flattening filter free treatments, which deliver radiotherapy treatments at a much faster dose rate, and RapidArc treatments, where an intensity modulated treatment beam rotates around the patient while delivering dose. Both of the treatments are state of the art, and greatly increase the speed of radiotherapy delivery, which increase patient comfort and throughput, while decreasing the probability of patient movement during treatment. Recent upgrades to three linear accelerators have increased the number of RapidArc capable machines to four. The new unit being installed will double our flattening filter free capacity and add another RapidArc capable machine as well. The Aria 11 upgrade also implemented automatic feedback and process control for radiotherapy delivery, ensuring the workflow management was robust to deviations in process. This project has greatly improved the workflow efficiency and communication capabilities for the entire radiotherapy department.

Among these are the design, commissioning and implementation of a breast brachytherapy program. The TBCC is only the third centre in Canada to offer permanent seed breast brachytherapy treatments. Breast brachytherapy greatly increases patient convenience and comfort, allowing patients to be treated with only two visits to the cancer centre, rather than a standard course of external beam therapy, which can take between three and six weeks. Our group has led significant research and development on this project. We have collaborated with a large group, including physicians, nursing, machinists and dosimetrists. One of the innovations developed was a guide for directing the insertion of the implant needles. This has greatly increased the safety, precision and accuracy of breast brachytherapy delivery.

In addition, medical physics is providing on-going leadership and support for treatment programs under development such as Arc total body irradiation, deep inspiration breath hold for left sided breast radiotherapy and the provincial stereotactic body radiotherapy program. Many members of the division have also been participating in the planning of the new Calgary Cancer Centre.

AWARDS

Brown, D.	AAPM award for innovation in medical physics education, 2014.
Dunscombe, P.	AAPM award for innovation in medical physics education, 2014.
Mutic, S.	AAPM award for innovation in medical physics education, 2014.
Pawlicki, T.	AAPM award for innovation in medical physics education, 2014.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Brown, D. (2014, January). *A framework for implementing new technologies*. Presented to COMP Winter School, Quebec City, Quebec, CA.
2. Brown, D. (2013, August). *Practical quality improvement*. AAPM Annual Meeting, Indianapolis, IN.
3. Brown, D. (2014, January). *Process mapping*. Presented to COMP Winter School, Quebec City, Quebec, CA.
4. Brown, D. (2013, October). *Process maps and FMEA*. Presented to Sun Nuclear Corporation, Melbourne, FL.
5. Dunscombe, P. (2014, April). *Guidelines for radiotherapy resources in Europe: A HERO project*. Poster presented at European Society for Radiotherapy and Oncology, Vienna, AU.
6. Dunscombe, P. (2014, April). *Health economics in radiation oncology*. Invited Speaker. European Society for Radiotherapy and Oncology, Vienna, AU.
7. Dunscombe, P. (2014, February). *Making radiotherapy safer: What the experts tell us*. Invited Speaker. SUN Nuclear QA and Dosimetry Symposium, Orlando, FL.
8. Dunscombe, P. (2013, September). *Quality in radiation oncology: The contribution of IAEA/WHO dosimetry audit service*. Invited Speaker. IAEA 57th General Conference: Side Event, ReNuAL, Vienna, AU.
9. Dunscombe, P. (2014, April). *Radiotherapy departments and equipment in the European countries: Final results from the ESTRO-HERO survey*. European Society for Radiotherapy and Oncology, Vienna, AU.
10. Dunscombe, P. (2014, April). *Radiotherapy staffing in the European countries: Final results from the ESTRO-HERO survey*. European Society for Radiotherapy and Oncology, Vienna, AU.
11. Dunscombe, P. (2013, December). *Regional training course on accidents and errors in radiotherapy*. Invited Speaker. Argonne National Laboratory, IAEA, Chicago, IL.
12. Dunscombe, P. (2014, April). *Ten year experience of an intra-operative computer guided prostate brachytherapy procedure - What have we learned?* Poster presented at European Society for Radiotherapy and Oncology, Vienna, AU.

13. Dunscombe, P., Brown, D., Ford, E., Woodward, M., Sutlief, S., Greener, A., Yorke, M., & O'Neill, J. (2013, August). *A new tool for improving safety in radiation therapy*. AAPM Annual Meeting, Indianapolis.
14. Ghasroddashti, E. (2013, November). *Radiation therapy at the Jack Ady Cancer Centre*. Invited addressee. Café Scientifique, Galt Museum and Archives, Lethbridge, AB.
15. Jacso, F., Poirier, Y., Gräfe, J., Nygren, I., Khan, R., & Villarreal-Barajas., E. (2013, September). *Orthovoltage dosimetry using ion chambers, GAFchromic EBT3 film and kV dose computations*. Presented at COMP Annual Meeting, Montreal, QC.
16. Koger, B., & Kirkby, C. (2013, October). *Effects of varying beam energy in gold nanoparticle enhanced arc radiotherapy*. Poster session presented at Alberta Cancer Foundation Cancer Research Conference, Banff, AB.
17. Koulis, T., Brown, D., Bhayana, D., Traptow, L., Long, K., Patrick, M., Nelson, G., Craighead, P., Doll, C., & Phan, T. (2013, December). *Stepwise implementation of imaging changes for cervical cancer brachytherapy planning using existing infrastructure: A multidisciplinary approach to advancing patient care*. Presented at RSNA, Chicago, IL.
18. Koulis, T., Brown, D., Bhayana, D., Traptow, L., Long, K., Patrick, M., Nelson, G., Craighead, P., Doll, C., & Phan, T. (2013, September). *Stepwise implementation of imaging changes for cervical cancer brachytherapy planning using existing infrastructure: A multidisciplinary approach to advancing patient care*. Presented at CARO-COMP Annual Meeting, Montreal, QC.
19. McGeachy, P., Zinchenko, Y., Villarreal-Barajas, J. E., & Khan, R. (2014, May). *A linear programming approach for incorporating photon beam-energy modulation into intensity modulated radiotherapy (IMRT) optimization*. Workshop in high-performance numerical methods supporting radiation therapy treatment planning II, Bethlehem, PA.
20. Peca, S., Quirk, S., Granville, D., & Brown, D. (2013, September). *A simple 2D in-vivo dosimetry using the EPID during treatment*. Presented at COMP Annual Scientific Meeting, Montreal, QC.
21. Pierce, G. (2013, October). *Form and function: Imaging in radiation oncology*. Invited Speaker. Alberta Cancer Foundation Cancer Research Conference, Banff, AB.
22. Smith, W. (2014, March). *Waiting to exhale: Respiratory motion in radiotherapy*. Invited Speaker. Department of Oncology Visiting Speaker Series Announcement, Calgary, AB.
23. Villarreal-Barajas, J. E. (2014, May). *MV x ray dosimetry using the photoluminescence of LiF crystals: The clinical dosimetry challenge*. Presented at AAMP, Budapest, Hungary.
24. Villarreal-Barajas, J. E. (2013, September). *Orthovoltage dosimetry using ion chambers, GafChromic EBT3 film and kV dose computations*. Presented at CARO-COMP annual meeting, Montreal QC.
25. Wiebe, J., & Ploquin, N. (2013, November). *Modeling the novalis classic varian 6MV using geant4 Monte Carlo code and the GATE simulation platform*. Presented at ACF Annual Meeting, Banff, AB.

DIVISION HEAD

Jessica Simon, MB ChB, MRCP(UK), FRCPC

DIVISION HIGHLIGHTS

In October 2013 the Royal College of Physicians and Surgeons of Canada (RCPSC) recognized palliative medicine as a sub-specialty. This was the culmination of years of advocacy by many leaders, academic divisions across Canada and the Canadian Society of Palliative Physicians. It also marks the beginning of changes for palliative medicine, not least of which is preparing for the new residency education program, likely to start in 2016.

The division was extremely fortunate to be awarded hosting Dr. David Currow, the 2013 RCPSC Balfour Mount visiting professor in palliative medicine. Drs Herx, Pawlik, Hagen and Simon coordinated his two day visit in October 2013 and we benefited from the extensive experience of this international expert researcher and clinician in palliative medicine from Australia. He presented two grand rounds, conducted several workshops, advised on key service delivery and research issues, and gave input into the new Cancer Care Centre development.

Dr. Jessica Simon transitioned from interim to Division Head towards the end of the year and many members of the division continued or took on new leadership roles in Alberta and Nationally, the hi-lights of which are summarized here.

- Dr. Herx was appointed to the Working Group in palliative medicine for the RCPSC - charged with developing the newly recognized subspecialty in palliative medicine. Dr. Herx was also an invited member of the Programme Committee, 20th International Congress on Palliative Care (September 9-12, 2014, Palais des Congrès, Montréal, Canada), the 10th Annual Advanced Palliative Medicine Update “Stepping Stones & Milestones” May 29-31, 2014, Toronto and is now chairing the program committee for the next Annual Advanced Palliative Medicine Update to be hosted in Calgary in May 2015. Both Dr. Simon and Dr. Herx continued as board members of the CSPCP.
- Dr. Chary is Co-Chair, Caregiver Committee of Quality-end-of-Life Care Coalition of Canada (QELCCC); Co-Chair, Undergraduate Education Committee of Canadian Society of Palliative Care Physicians (CSPCP); Chairman of the Board, the Pallium Foundation of Canada and Director, Alberta Pain Society.
- Dr. Braun is Acting Associate Zone Medical Director and is Medical Leader, Primary Care, Chronic Disease Management, Public Health and Allied Health, Calgary Zone, AHS.
- Dr. Murphy continued as medical lead for Palliative and End of Life Care Service, Calgary Zone, AHS and as a member, of the Provincial Advisory Committee for Palliative/EOL Care which completed the framework document to guide provincial palliative service development. Dr. Marr and Dr. Murphy sit as members of the Care After Death Steering Committee.
- Dr. Dharmawardene took on the role as FMC site lead for palliative care.
- Dr. Sinnarajah continued as clinical informatics consultant, AHS Calgary zone; member, Millennium System Clinical & Operational Advisory Committee; Co-Chair, EHR Diagnostic Imaging and Laboratory Advisory Committee; member, Core Clinical

- Design Team, Patient Care Information System; member, Sunrise Clinical Manager/Millennium Transfusion Medicine Project and member, Alberta Scientific Assembly Planning Committee.
- Dr. Spice continued to champion rural palliative care and family medicine education as: member, Rural Palliative Care Resource Team; Chair, Rural Consultation Team Committee; Chair, Rural Alberta South (Residency) Leadership Committee; member, Family Medicine Residency Training Committee; member, Family Medicine Clerkship Committee; member, Education Leaders Committee; member, Residency Program Directors Committee and member, Rural Initiatives Committee.
- Dr. Wasylenko serves in numerous positions as medical advisor and ethicist, for example: Chair, Public Health Ethics Consultative Group, Public Health Agency of Canada; Ethics and End of Life Care Consultant, Health Quality Council of Alberta; Medical Advisor, Provincial Advance Care Planning/Goals of Care Designation Initiative, Alberta Health Services; member, Alberta Advisory Committee on Immunizations, Alberta Health; member, Emergency/Disaster Management Steering Committee; member, Steering Committee for Palliative and End of Life Care Strategy.

CURRENT ISSUES

The main challenge, which is shared by many divisions, is in managing the need and desire of our talented local faculty to expand patient-family focused academic activity, while also meeting the demands of increasing volumes of clinical service, on-going attention to quality improvement and assisting in AHS administrative activity focused on improving access to and delivery of provincial palliative care. We remain constrained by a clinical only ARP funding model.

STRATEGIC PLANNING

The Division of Palliative Medicine retreat on September 18, 2013 provided a forum to reflect on and plan to achieve our optimum academic potential. Participants provided unanimous support for the strategic intention to move forward with an increased emphasis on an academic activity in both education and research.

We identified the obstacles and strategies to enhance our academic agenda, the initial action plan was created and nine out of ten objectives were met in the subsequent 6 months. This included a successful application to Alberta Cancer Foundation for limited research assistant funding to help create grant proposals in key areas of palliative care research and increase our capacity to conduct research.

RESEARCH HIGHLIGHTS

This year saw the initiation of an innovative partnership between TBCC and the Calgary Zone Palliative and End of Life care programs, the ‘TBCC and Palliative Care Collaboration’; a two year project funded through the Alberta Cancer Foundation enhanced care grants. The project is working to enhance the quality of care for patients who are living with advanced cancer and of their caregivers, through the following actions:

- Assess current services-identify gaps and strengths.

- Develop and prioritize quality improvement activities.
- Establish a care pathway which models ‘best practice’ within TBCC services.
- Identify resources required to sustain an ongoing quality palliative and end of life approach and services within oncology.

Intensive Palliative Care Unit (IPCU) is an ongoing site for research activity related to acute medicine and end-of-life care in particular. Recently, our IPCU site and division members have been involved in academic work including:

- The CANHELP (Canadian Health Care Evaluation Project, Dr. D. Heyland) tool regarding patients’ and family’s experiences of end-of-life care,
- “Compassion at the End of Life,” Dr. Shane Sinclair.
- Management of Brain Metastases (through the interdisciplinary brain metastases clinic at the Tom Baker Cancer Centre).

The Alberta Innovates Health Solutions Collaborative Research and Innovation Opportunities, funded research program “Advance Care Planning and Goals of Care Alberta: A population based knowledge translation intervention study” also called “ACP CRIO” involves several faculty, residents and post-graduates in our division and across a number of departments and institutions. ACP CRIO asks how to optimally implement widespread uptake of a formalized ACP framework, across a large population and throughout a complex, multi-sector healthcare system. Partnering with Alberta Health Services and Covenant Health, this \$2.5 million, five year KT program employs a knowledge-to-action cycle in order to support a transformational change in practice and healthcare culture. We will identify the most effective methods to catalyse use of ACP, and will study its impact on health resource utilization and clinical outcomes.

PROGRAM

In November 2013, the clinical Palliative Care ARP received approval for an expansion. The application process was lengthy, but the end result was an increase in FTE up to 20.7. This FTE expansion occurred in the context of a continued year-on-year increase in the number of unique patients served by the palliative consult teams (e.g. from 1,563 in 2002 to 3,814 in 2012-2013) and the Intensive Palliative Care Unit (IPCU) expansion from 16 to 29 beds about two years ago. In 2013 there were 1,203 hospice admissions with average stay on the waitlist for hospice of 2.4 days, 639 IPCU admissions, 4,283 palliative consult initial service events and 1,093 palliative home care admissions. The primary diagnoses of patients seen by the palliative consult teams was cancer in 57% and non-cancer in 43%.

With these approved increases in physician resources we have been able to recruit three new physicians and into additional positions to support South Health Campus and the additional IPCU beds. Retirement and the move of one physician to Lethbridge however, mean that we are still stretched to provide clinical service in all the areas that could benefit, including more integrated support within TBCC, developing an interventional cancer pain service and in non-cancer areas of need.

AWARDS

- Labrie, M. University of Calgary Faculty of Medicine Class of 2015 Honour Roll Award.
- Undergraduate Medical Education Program 2013-2014 - Distinguished Service Award (Silver) for teaching commitment to the Population Health Course.
- Calgary and Area medical Staff Society: Advocacy Award, 2013.
- AIDS Calgary (now “HIV Community Link”) Leadership for Life Award, 2013.
- Sinclair, S. Avenue Magazine Calgary’s Top 40 under 40, 2013.
- New PI Best Poster Award, Canadian Cancer Research Conference, 2013.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Herx, L., & Siden, H. (2013, June). *Advanced pediatric stream: Challenging cases across the spectrum of pediatric palliative medicine*. Presented at 9th Annual Advanced Learning in Palliative Medicine Workshop, Vancouver, British Columbia.
2. Herx, L., & Liben, S. (2013, June). *Advanced pediatric stream: Pediatric palliative medicine training in Canada*. Presented at 9th Annual Advanced Learning in Palliative Medicine Workshop, Vancouver, BC.
3. Murray, A. (2014, May). *Managing end of life symptom crises in the home: An innovative partnership between palliative home care and emergency medical services in the Calgary Zone of the Alberta Health Services*. Invited Speaker. 10th Annual Advanced Palliative Medicine Update, Toronto, ON.
4. Murphy, L. (2014, February). *Managing end of life symptom crises in the home: An innovative partnership between palliative home care and emergency medical services in the Calgary Zone of the Alberta Health Services*. Invited Speaker. 59th Annual Scientific Assembly, Alberta College of Family Physicians, Banff, AB.
5. Simon, J. (2014, June). *Advance care planning in Canada – You can do it!* Invited Speaker. CHPCA Learning Institute, Banff, AB.
6. Simon, J. (2013, November). *Advance care planning and goals of care*. Geriatrics Update Workshop, Lethbridge, Alberta.
7. Simon, J. (2013, October). *Sign-posting end of life – what’s in a prognosis?* Invited Speaker. Geriatric service grand rounds, Lethbridge, AB.
8. Simon, J., Ghosh, S., Heyland, D., Cooke, T., Davison, S., Holroyd-Leduc, J., Wasylenko, E., Howlett, J., & Fassbender, K. (2014). *Evidence of increasing public engagement of advance care planning in Alberta* [Abstract]. Presented at the Advanced Learning Conference, Canadian Society of Palliative Care Physicians, Toronto, ON.
9. Sinnarajah, A. (2014, April). *Managing end of life symptom crises in the home: An innovative partnership between palliative home care and emergency medical services in the Calgary Zone of the Alberta Health Services*. Presented at the Hospice Palliative Care Ontario Annual Conference, Richmond Hill, ON.

10. Sinnarajah, A. (2013, December). *How to deal with life when you have lung cancer*. Invited Speaker. Breathing Life into Lung Cancer: Information and Support, Calgary, AB.
11. Sinnarajah, A. (2013, November). *Medical management of palliative patients*. Invited Speaker. Integrating Palliative Care in Intensive Care, Calgary, AB.
12. Sinnarajah, A. (2013, September). *Palliative Care Update*. Invited Speaker. Southern Alberta Cancer Update, Lethbridge, AB.
13. Wasylenko, E. (2013, August). *The interface between end of life care and primary care*. Invited Speaker. Canadian Medical Association Annual Meeting, Calgary, AB.
14. Wasylenko, E. (2013, September). *Goals of care designations/advance care planning: Improving joint decision-making*. Invited Speaker. Provincial Health Advisory Councils Conference, Edmonton, AB.
15. Wasylenko, E. (2013, September). *End of life decision: Ethics considerations*. Invited Speaker. Office of the Public Guardian Conference, Calgary, AB.
16. Wasylenko, E. (2014, January). *Physician workforce planning*. Invited Speaker. University of Alberta Medical Students Lecture Series, Edmonton, AB.
17. Wasylenko, E. (2014, March). *Vaccine hesitancy and ethics*. Invited Speaker. Western Canada Immunization Forum, Calgary, AB.
18. Wasylenko, E. (2014, April). *Advance care planning and goals of care designations*. Invited Speaker. Conference Board of Canada Healthy Aging Network Conference, Toronto, ON.
19. Wasylenko, E. (2014, April). *Conflicted commitments: Patient and their non-patient identities*. Invited Speaker. Royal Alexandra Hospitals Lunchtime Ethics Series, Edmonton, AB.
20. Wasylenko, E. (2014, May). *Ethics and good dying: Exploring the cliff edge*. Invited Speaker. Mary O'Connor Palliative Care Conference, Calgary, AB.
21. Wasylenko, E. (2013, July & November). *Palliative Sedation and Euthanasia*. Invited Speaker. University of Calgary Faculty of Nursing 517, Calgary, AB.
22. Wasylenko, E. (2014, May). *Ethics considerations: Pain management for incarcerated individuals*. Invited Speaker. Canadian Pain Society Annual Conference, Quebec City, QC.
23. Wasylenko, E. (2014, May). *Health ethics behind prison bars*. Invited Speaker. Canadian Bioethics Society Annual Conference, Vancouver, BC.

DIVISION HEAD

Douglas Strother, MD

DIVISION HIGHLIGHTS

The division provides comprehensive care to general- and neuro-oncology patients, to children undergoing hematopoietic stem cell transplant (SCT), and to long-term survivors of childhood cancer and SCT therapy. In the academic year 2013-2014 we continued to advance our clinical, education and research programs. All of our work is in partnership with the multidisciplinary, multiprofessional Hematology, Oncology and Blood and Marrow Transplant Program (HOT Program) of Alberta Children's Hospital. We are generously supported by the Alberta Children's Hospital Foundation, the Childhood Cancer Collaborative and Kids Cancer Care.

Members of the division hold several leadership roles: Drs. Lafay-Cousin, Guilcher, Strother and Lewis in the Children's Oncology Group (COG); Drs. Strother and Lewis in C17; Dr. Narendran in POETIC; Dr. Anderson in the Department of Pediatrics.

CURRENT ISSUES

The division is an integral partner to the Childhood Cancer Collaborative (CCC), which is, itself, in transition as an initiative fully funded through Alberta Children's Hospital Foundation (ACHF) to one funded jointly by ACHF, AHS and the University of Calgary.

The transition involves a critical review of all investments of the CCC, including their impact on the patients and families that we serve, as well as the clinical and research members of the HOT Program and research institutes.

Current challenges include the shortage of space for the HOT Program, in which the division is a large part, for all of our clinics, the increasing demands placed on clinical investigators to meet requirements of good clinical practices (GCP), and the ever present limitation of time to meet the demands of academia and the provision of timely and comprehensive clinical care.

STRATEGIC PLANNING

Drs. Strother and Lewis participate in management of the transition of CCC. Drs. Guilcher and Kathy Reynolds actively participate in planning of the new cancer hospital in which a clinic will be devoted to adolescents and young adults, and to adult survivors of pediatric cancer. Dr. Strother, as COG and C17 Principal Investigator, Dr. Patricia Hull (Quality Assurance and Research Support Lead), and Jennifer Crysedale, RN, Patient Care Manager lead the development of policies and practices to help us achieve GCP standards for all of our clinical research trials. In the domains of patient care and clinical research, we began to actively build our program of hematopoietic stem cell transplant as a treatment of sickle cell disease under the leadership of Dr. Guilcher.

RESEARCH HIGHLIGHTS

It was a productive year in terms of publications by division members; these are listed in the report. The 4th annual pediatric oncology research day was held in November 2013 in the Hotel Alma. Dr. Lafay-Cousin's study opened for patient accrual in COG institutions.

PROGRAM

Members of the division provide care to patients in four broad areas: general oncology, neuro-oncology, blood and marrow transplant, and long-term survivorship. We are invested in clinical research through various consortia and offer participation in clinical trials whenever possible.

UNIVERSITY OF CALGARY PROFESSORSHIPS/ENDOWED CHAIRS

The ACHF/Kids Cancer Care Chair awarded research grants to three researchers: Dr. Deborah Kurrasch for “Novel Screening Platform to Uncover Atypical Teratoid/Rhabdoid (AT/RT) Tumor Therapeutics”, Dr. Fiona Schulte for “An Innovative Approach to the Implementation of Screening for Distress in a Pediatric Oncology Program”, and Dr. Catherine Laing for “Stories that Heal: Understanding the Effects of Creating and Viewing Digital Stories with Pediatric Oncology Patients, Families and Healthcare Team”.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Hagerty, M., Jayanthan, A., Ruan, Y., Trippett, T., & Narendran, A. (2013). *Effective targeting of PI3K/mTOR pathways with GDC-0980 in FLT3 mutant pediatric leukemia* [Abstract]. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA.
2. Lafay-Cousin, L. (2014, May). *Update on current management of infant medulloblastoma*. Invited talk. PASPO, 3eme Printaineres d'Oncologie International Meeting, Annaba, Algeria.
3. Lafay-Cousin, L. (2014, May). *ATRT in children*. Invited talk. PASPO, 3eme Printaineres d'Oncologie International Meeting, Annaba, Algeria.
4. Lafay-Cousin, L. (2013, December). *Neurocognitive evaluation of long term survivor's patients with ATRT*, Presented at Curie Institute, Paris, France.
5. Moorjani, R., Truong, T. H., Lewis, V., & Guilcher, G. M. T. (2014). *Busulfan, fludarabine, anti-thymocyte globulin and low dose total body irradiation treatment of juvenile myelomonocytic leukemia with myeloablative stem cell transplantation* [Abstract]. Presented at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy.
6. Ruan, Y., Jayanthan, A., Nagashima, Y., Anderson, R., & Narendran, A. (2013). *The IGF1-mTOR pathway is an effective therapeutic target in the treatment of neurocutaneous melanosis, the IGF1-mTOR pathway is an effective therapeutic target in the treatment of neurocutaneous melanosis* [Abstract]. Presented at the SACRI/Oncology Trainee Research Day, Calgary, AB.

7. Ruan, Y., Jayanthan, A., Truong, T., & Narendran, A. (2013). *Preclinical testing of the proteasome inhibitor carfilzomib in pediatric cancers* [Abstract]. Presented at the Alberta Children's Hospital Research Institute, Molecular and Genetic Basis of Child Health Theme Retreat, Banff, AB.
8. Ruan, Y., Liu, D., Jayanthan, A., Truong, T., Boklan, J., & Narendran, A. (2013). *Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib* [Abstract]. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA.
9. Schulte, F., Wurz, A., Fay-McClymont, T., Scott-Lane, L., Pelletier, W., Guilcher, G., Strother, D., Bultz, B., & Dewey, D. (2013). *Screening for distress in pediatric cancer patients and their families: An assessment of feasibility* [Abstract]. Presented at the CCRA - Canadian Cancer Research Conference, Toronto, ON.
10. Trippett, T., Smith, A., Neville, K., Chi, S., Narendran, A., Arceci, R., Drenzo, J., & Gore, L. (2013). *Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors* [Abstract]. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA.
11. Truong, T. H., Moorjani, R., Dewey, D., Guilcher, G. M. T., & Lewis, V. (2014). *Predictors of adverse reactions during stem cell infusion in children receiving autologous and allogeneic stem cell transplantation* [Abstract]. Presented at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy.
12. Truong, T. H., Moorjani, R., Dewey, D., Guilcher, G. M. T., Lewis, V., & Prokopishyn, N. L. (2014). *Predictors of adverse reactions during stem cell infusion in children receiving autologous and allogeneic stem cell transplantation* [Abstract]. Presented at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy.
13. Truong, T. H., Yunus, R., Weitzman, S., & Doria, A. (2013). *Correlation between aggressive radiological findings and clinical outcome in Langerhan cell histiocytosis with bone involvement* [Abstract]. Presented at the Annual Meeting of the Society of Pediatric Oncology, Hong Kong, China.
14. Wurz, A. J., Chamorro-Vina, C., Guilcher, G., Schulte, F., & Culos-Reed, S. N. (2013). *Yoga for pediatric cancer out-patients* [Abstract]. Presented at the SACRI - Southern Alberta Cancer Research Institute Research Training Day, Calgary, AB.
15. Yibing, R., Jayanthan, A., Truong, T. H., & Narendran, A. (2013). *Preclinical testing of the proteasome inhibitor carfilzomib in pediatric cancers* [Abstract]. Presented at the Alberta Children's Hospital Institute, Molecular and Genetic Basis of Child Health Theme Retreat, Banff, AB.
16. Yibing, R., Liu, D., Jayanthan, A., Truong, T. H., Boklan, J., & Narendran, A. (2013). *Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib* [Abstract]. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA.

DIVISION HEAD

Christine Friedenreich, PhD

DIVISION HIGHLIGHTS

Dr. Christine Friedenreich was awarded the O. Harold Warwick Prize from the Canadian Cancer Society for 2013. She shares this prize with Dr. Will Foulkes of McGill University. This prize is awarded annually to a scientist or two scientists who have made a major contribution to cancer control in Canada.

Dr. Christine Friedenreich was awarded the Research (Basic Science) Award for Clinical and Adjunct Faculty, Faculty of Medicine, University of Calgary in April, 2014.

Dr. Christine Friedenreich was awarded the Canadian Society for Epidemiology and Biostatistics Distinguished Service Award in June, 2013.

Dr. S. Elizabeth McGregor resigned her position as the Interim Division Head for Preventive Oncology as she retired as a Research Scientist in Population Health Research at the end of October, 2013. Dr. McGregor is now a part-time (0.5 FTE) scientist with the Alberta Cancer Prevention Legacy Fund and maintains her appointment in the Division of Preventive Oncology. Dr. Friedenreich was appointed the new Division Head, Preventive Oncology effective November 1, 2013.

Dr. Linda Kelemen resigned her position as a member of the Division of Preventive Oncology as well as her position as a Research Scientist in the Department of Population Health Research effective April 24, 2014.

Dr. Karen Kopciuk was promoted to Adjunct Associate Professor in August, 2013.

The Department of Population Health Research was renamed the Department of Cancer Epidemiology and Preventive Research effective May 15, 2014. Recruitment for two new Research Scientists is currently on-going.

CURRENT ISSUES

The Division of Preventive Oncology has experienced another successful year despite many challenges that occurred because of the floods in June, 2013 in Calgary. Members of the division undertake a range of cancer epidemiology and prevention research with a focus on understanding the role of modifiable risk factors in reducing cancer burden and improving survival. Their success is clearly evident in the number of grants held (38), publications (56), oral presentations (46), abstracts and poster presentations.

One of the strengths of the division is the capacity for statistical and epidemiologic research as well as the conduct of complex research studies requiring the collection and management of large samples of epidemiologic and biologic data. Our division scientists were successful this

year in obtaining a Foundation Infrastructure grant from the Alberta Cancer Foundation to support the expansion of their capacity in the assessment of lifestyle risk factors associated with cancer risk and survival as well as enhancing their ability to provide data management and support to a broader audience of cancer researchers within the Department of Oncology. Our department members continue to be centrally involved in the Alberta Cancer Research Biorepository and the Bioprocessing Facility and were instrumental in assisting the ACRB in renewing its funding from the Alberta Cancer Foundation this year.

A major issue for our division scientists this year was the displacement of the Department of PHR Scientists and staff from the Holy Cross Centre in Calgary on June 20, 2013 because of the flooding that occurred in that building. Our department was relocated to temporary touchdown space at Quarry Park in SE Calgary for eight months and then moved to newly renovated, temporary space at the Richmond Road Diagnostic Treatment Centre (RRDTC) on February 24, 2014. Many of the department's staff had to work in alternate work arrangements either at home or in temporary work spaces during these eight months. Our ability to work effectively as a group of scientists and staff was severely impacted during this time period. Uncertainty still exists for our group as it is unclear whether or not we will be assigned new space in the RRDTC site or if we will remain in the temporary administrative space that has been allocated to us. Now that we are at the RRDTC site, we have re-instigated our weekly seminars, journal clubs, research forum and departmental meetings; staff professional development opportunities are greatly enhanced.

We are continuing to try to overcome some of the challenges in conducting our research programs in the complex and constantly changing AHS and University of Calgary environments. We have made some progress in this past year and are hopeful that more of these issues can be resolved in the upcoming year.

We are now seeking to recruit two research scientists with an international search now ongoing. We have also been involved in the recruitment of a biostatistician for the Department of Oncology with two of our members (Drs Friedenreich and Kopciuk) serving on the Search and Selection Committee.

STRATEGIC PLANNING

Since assuming the leadership for the Department of Population Health Research in November 2013 and the Division Head for Preventive Oncology, Dr. Friedenreich has engaged the core scientific team of PHR as well as the Scientific Director for the Alberta Tomorrow Project®, Dr. Paula Robson and the Medical Director and Scientific Lead for the Alberta Cancer Prevention Legacy Fund, Dr. Laura McDougall, in strategic discussions for how the three departments could interact and work together more collaboratively and strategically. To this end, a renewed vision and mission for the department has been created and the name of the department has been changed to Cancer Epidemiology and Prevention Research (CEPR) to reflect the strategic directions and core scientific activities of the department more accurately. At this time, our current vision, mission and goals for our department are provided here as context for future directions that we wish to pursue.

Vision: To be the leading centre for cancer epidemiology and prevention research in Canada.

Mission: To generate knowledge in cancer epidemiology and prevention that will make a significant impact on reducing cancer burden.

Goal 1: To increase the depth of research capacity in targeted areas of current strength.

Objective 1: To expand the program of research in modifiable lifestyle risk factors and cancer by increasing the number of scientists, trainees and research projects in this field.

Objective 2: To expand our research infrastructure to enhance the capacity of other cancer researchers and programs affiliated with cancer epidemiology by leveraging and building on expertise of our core support units.

Goal 2: To increase the productivity, profile, relevance and impact of the research conducted by the Department.

Objective 1: To increase the research output in the form of scientific communications and publications of the CEPR Scientists.

Objective 2: To enhance national and international recognition of our CEPR Scientists and their research programs through presentations at national and international scientific meetings.

Objective 3: To increase the number of funded interdisciplinary studies in which a CEPR Scientist is the Principal Investigator.

Objective 4: To increase the involvement of CEPR Scientists in service activities at the provincial and national levels focused on cancer prevention.

Goal 3: To be actively engaged in establishing strategic directions and priorities for cancer prevention and control activities at multiple levels and to ensure an alignment of our research activities with these priorities.

Objective 1: To establish closer collaboration and integration of research activities and priorities between CEPR and other entities within AHS, in Alberta and across Canada focused on cancer epidemiology and prevention.

Objective 2: To increase knowledge translation and exchange activities of the CEPR Scientists at the provincial and national level in cancer epidemiology and prevention.

Objective 3: To implement an effective communication strategy to raise awareness of the outcomes of CEPR research activities.

To this end, we have begun discussions to have our activities in cancer epidemiology and prevention research recognized and included in a national Cancer Prevention Research Network that is being established by the Canadian Cancer Society Research Institute (CCSRI). We are actively involved at the national and provincial level in helping set strategic directions for cancer prevention research. For example, Dr. Friedenreich is a member of the End 1 Development Committee for the CCSRI whose mandate is to enhance capacity in as well as quantity and quality of cancer prevention research in Canada.

RESEARCH HIGHLIGHTS

The Division of Preventive Oncology has nine (currently seven because of two departures) members who are involved to varying degrees in research. The core members are those based in the Department of Cancer Epidemiology and Prevention Research including: Drs Nigel Brockton, Ilona Csizmadi, Christine Friedenreich and Karen Kopciuk. Other members include Dr. Fred Ashbury currently based in Toronto, Dr. Heather Bryant, currently Vice-President for the Canadian Partnership Against Cancer in Toronto, Dr. Lorraine Shack, Director of Cancer Surveillance of CancerControl Alberta, AHS and Dr. Jeff Vallance, Athabasca University based in Medicine Hat. Our department also had two postdoctoral fellows actively involved in research during this year who both trained with Dr. Friedenreich. Dr. Shannon Conroy is currently a senior scientist with the Sacramento Department of Public Health and Dr. Darren Brenner is an on-going PDF. One Master’s student in epidemiology, Mr. Ted Pfister, was supervised by Dr. Friedenreich and was awarded his degree in June, 2014. Dr. Csizmadi also supervised two undergraduate students this past year: Pham Tram and Joshua Nicholas, who were both completing their 4th year Honours Thesis in the Bachelors of Health Sciences (BHS) program at the University of Calgary. Dr. Kopciuk is a mentor and supervisor for the Emerging Leaders Program at the University of Calgary, and is also co-supervisor of Longlong Huang, a PhD candidate at the University of Calgary.

The division scientists have been successful in securing new funding during this past year from the Canadian Institutes for Health Research (two grants as PI for both Drs Friedenreich and Kopciuk) and the Canadian Cancer Society Research Institute (Dr. Friedenreich). In addition, the core scientists from CEPR secured a Foundation Infrastructure grant from the ACF. Drs Friedenreich, Brockton and Brenner were also co-investigators on a large scale project funded by the Canadian Breast Cancer Foundation and CIHR for a program of research in breast cancer in women under 40 years that is being led by Drs Steven Narod (Women’s College Hospital) and May Lynn Quan (AHS) (note: funding for this grant will begin in the third quarter of 2014 hence is not reported under current funding).

The division scientists’ research continues to be focused on a range of topics in cancer epidemiology and prevention with a major emphasis on lifestyle factors, molecular and genetic mechanisms of cancer etiology and survival.

The CEPR scientists have initiated collaborative research with the ACPLF and are currently undertaking a project to estimate the population attributable risks associated with exposure to modifiable lifestyle and environmental risk factors associated with cancer incidence. A similar large scale project is being submitted in July, 2014 for a Canada-wide project to the CCSRI.

UNIVERSITY OF CALGARY PROFESSORSHIPS/ENDOWED CHAIRS

- 2012-2017 Christine Friedenreich, PhD – ACF Weekend to End Women’s Cancers Breast Cancer Chair.
- 2011-2016 Hans Vogel, PhD – Lance Armstrong Chair in Molecular Cancer Epidemiology.

AWARDS

- Friedenreich, C. Alberta Cancer Foundation Weekend to End Women's Cancers Breast Cancer Chair, Faculty of Medicine, University of Calgary, 2012-2017.
Health Research Senior Scholar Award, Alberta Heritage Foundation for Medical Research, 2008-2015.
Research (Basic Science) Award for clinical, adjunct and research faculty, Faculty of Medicine, University of Calgary, 2014.
O. Harold Warwick Prize, Canadian Cancer Society, 2013.
Canadian Society for Epidemiology and Biostatistics Distinguished Service Award, 2013.
- Vallance, J. Tier II Canada Research Chair in Health Promotion and Chronic Disease Management, 2013-2018.
AIHS Population Health Investigator Award, 2009-2016.
CIHR New Investigator Award (terminated early due to CRC appointment), 2009-2014.

STUDENTS' AWARDS

- Brenner, D. Alberta Innovates-Health Solutions Postdoctoral Fellowship, 2014-2016.
- Conroy, S. Canadian Institutes for Health Research, Postdoctoral Fellowship, 2012-2014.
Alberta Innovates-Health Solutions, Postdoctoral Fellowship, 2012-2014.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Ashbury, F. D. (2013, October). *Supportive care for cancer patients: Key issues & lessons learned*. Invited Keynote Speaker. Annual Meeting of the Canadian Association of Nurses in Oncology, Vancouver, BC.
2. Ashbury, F. D. (2014, April). *Key issues and lessons learned in project management, social and behavioural sciences*. Workshop at Dalla Lana School of Public Health, University of Toronto, ON.
3. Ashbury, F. D. (2014, April). *Writing for peer-reviewed journals, social and behavioural sciences*. Workshop at Dalla Lana School of Public Health, University of Toronto, ON.
4. Ashbury, F. D. (2014, January). Medical Oncology Care Plan Summit. Invited. Karmanos Cancer Institute, Conference Chair, Detroit, MI.
5. Ashbury, F. D. (2014, June). *Global development of supportive cancer care: Experiences, issues & lessons learned*. Invited. Annual Meeting, Multinational Association of Supportive Care in Cancer, Miami, FL.

6. Ashbury, F. D. (2014, March). *Exercise as it relates to cancer and its toxicities*. Invited. Canadian Conference on Lymphoproliferative Disorders, Whistler, BC.
7. Boyle, T., Courneya, K. S., Lynch, B. M., & Vallance, J. (2014, April). *Agreement between accelerometer-assessed and self-reported physical activity and sedentary time in colon cancer survivors*. Poster presented at International Congress on Physical Activity and Public Health, Rio de Janeiro, Brazil.
8. Boyle, T., Lynch, B. M., & Vallance, J. (2014, June). *Associations between objectively-assessed sedentary time and moderate-vigorous intensity physical activity and sleep quality and duration among breast cancer survivors*. Poster presented at Society for Epidemiologic Research Annual Meeting, Seattle, WA, USA.
9. Boyle, T., Vallance, J., & Lynch, B. M. (2014, June). *Associations between objectively-assessed sedentary time and moderate-vigorous intensity physical activity and obesity among breast cancer survivors*. Poster presented at Society for Epidemiologic Research Annual Meeting, Seattle, WA, USA.
10. Courneya, K. S., Forbes, C. C., Trinh L, Sellar, C. M., Friedenreich, C. M., & Reiman T. (2013, February). *Patient satisfaction with participation in a randomized exercise trial: Effects of randomization and usual care crossover*. Oral presentation at the 2013 Pan Pacific Conference of Medicine and Science in Sport, Honolulu, Hawaii, United States.
11. Courneya, K. S., McKenzie, D. C., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Yasui, Y., . . . Segal, R. J. (2013, December). *Effects of exercise dose and type during breast cancer chemotherapy: Multicenter randomized trial*. Poster presented at San Antonio Breast Cancer Symposium, San Antonio, Texas.
12. Courneya, K. S., Segal, R. J., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Yasui, Y., Reid, R. D., Jespersen, D., Cook, D., Proulx, C., Trinh, L., Dolan, L. B., Wooding, E., Forbes, C. C., & McKenzie, D. C. (2014, February). *Effects of exercise dose and type on sleep quality in breast cancer patients receiving chemotherapy: A multicenter randomized trial*. Oral presentation at the American Psychosocial Oncology Society, Tampa, FL.
13. Courneya, K. S., Segal, R. J., McKenzie, D. C., Dong, H., Gelmon, K., Friedenreich, C. M., . . . Mackey, J. R. (2013, December). *Effects of exercise during adjuvant chemotherapy on clinical outcomes in early stage breast cancer*. Poster presented at San Antonio Breast Cancer Symposium, San Antonio, Texas.
14. Csizmadi, I., Asgari, S., Kopciuk, K., Khandwala, F., Friedenreich, C. M., Yasui, Y., . . . Robson, P. J. (2014, June). *Classification of energy intake reporting using the Goldberg method and the sedentary time activity reporting questionnaire (STAR-Q): Validation against doubly labeled water*. Poster presented at Society for Epidemiologic Research, Seattle, WA.
15. Friedenreich, C. M. (2013, December). *Recent advances in physical activity and cancer control*. Invited. Centre Leon Bérard, Lyon, France.
16. Friedenreich, C. M. (2014, January). *How physical activity reduces cancer risk: Review of evidence*. Invited. Canadian Cancer Society, Saskatchewan Division, webinar.
17. Friedenreich, C. M. (2014, June). *Physical activity in cancer control: From prevention to survival*. Invited. Universite de Rennes, France.

18. Friedenreich, C. M., Langley, A. R., Speidel, T. P., Courneya, K. S., Magliocco, A. M., & Cook, L. S. (2013, June). *Case-control study of lifetime alcohol consumption and endometrial cancer risk*. Poster presented at Canadian Society for Epidemiology and Biostatistics Conference, St. John's, Newfoundland.
19. Friedenreich, C. M. (2014, April). *Preventing cancer through lifestyle changes*. Bringing Prevention into Focus: Developing Cancer Solutions for Tomorrow. Alberta Cancer Prevention Legacy Fund Symposium, University of Calgary, Calgary, AB.
20. Gardiner, P., Rosenberg, D., Johnson, S. T., Lynch, B. M., & Vallance, J. K. (2014, April). *Systematic review of sedentary time and physical function*. Poster presented at International Congress on Physical Activity and Public Health, Rio de Janeiro, Brazil.
21. Huang, L., Kopciuk, K., & Lu, X. (2013, May). *Jackknife empirical likelihood based variable selection for accelerated failure time model*. Poster presented at Statistical Society of Canada (SSC) Annual Meeting, Edmonton, AB.
22. Karvinen, K. H., Balneaves, L., Perry, B., Courneya, K. S., Truant, T., & Vallance, J. K. (2014, April). *Bridging the gap from physical activity and cancer research to practice: A knowledge translation strategy for oncology nurses*. Poster presented at Society of Behavioral Medicine Annual Meeting, Philadelphia, United States.
23. Kelemen, L. E., Tyrer, J., Phelan, C. M., Ramus, S. J., Berchuck, A., Gayther, S. A., . . . on behalf of the Ovarian Cancer Association Consortium. (2014, April). *GWAS identifies risk variants for mucinous ovarian carcinoma*. Poster presented at The 105th Annual Meeting of the American Association of Cancer Research, San Diego, CA.
24. Kopciuk, K. A. (2013, November). *Why statistics is crucial in the fight against cancer*. Invited plenary speaker. International Year of Statistics Conference, Mount Royal University, Calgary, AB.
25. Kopciuk, K. A., Choi, Y. H., Swaminathan, B., & Briollais, L. (2014, May). *Could a major gene explain the aggregation of colorectal cancer in type x families?* Poster presented at Canadian Human and Statistical Genetics Conference, Victoria, BC.
26. Lacombe, J., Sabiston, C. M., Vallance, J., Brunet, J., & Trinh, L. (2014, April). *Does weight status affect changes in sedentary behaviour over time in a sample of breast cancer survivors?* Poster presented at Canadian Association of Psycho Oncology, Vancouver, BC.
27. Lu, D., de Leon, A., Bathe, O., Weljie, A., McConnell, Y., & Kopciuk, K. A. (2013, August). *Lassoing metabolites: Feature selection methods that find biological signals*. Oral presentation at the Southern Alberta Cancer Research Institute Summer Student Research Day, Calgary, AB.
28. Lynch, B. M., Boyle, T., Sethi, P., Courneya, K. S., & Vallance, J. (2014, April). *Correlates of objectively-assessed sedentary time and moderate-vigorous intensity physical activity amongst colon cancer survivors*. Poster presented at International Congress on Physical Activity and Public Health, Rio de Janeiro, Brazil.
29. Lynch, B. M., Friedenreich, C. M., & Csizmadi, I. (2013, October). *Convergent validity and test-retest reliability of the SIT-Q*. Poster presented at AEA Annual Scientific Meeting, Brisbane, Australia.

-
30. Nicholas, J., Lo Siou, G., Robson, P., Lynch, B. M., Friedenreich, C. M., & Csizmadi, I. (2013, October). *The association between occupational sedentary behavior and anthropometric measures and obesity-related disorders*. Poster presented at ACF Cancer Research Conference, Banff, AB.
 31. O'Reilly, R., Conroy, S., Woolcott, C. G., Courneya, K. S., Stanczyk, F. Z., Jones, C. A., & Friedenreich, C. M. (2013, October). *Endogenous estrogen levels and C - reactive protein in postmenopausal women: Results from the Alberta physical activity and breast cancer prevention trial*. Poster presented at Alberta Cancer Foundation Research Conference, Banff, AB.
 32. Palmnas, M. S. A., Shaykhutdinov, R. A., Robson, P. J., Vogel, H. J., & Csizmadi, I. (2013, October). *Energy expenditure, body composition and metabolic syndrome: The impact on serum metabolome in men and women*. Poster presented at Alberta Cancer Foundation Annual Research Conference, Banff, AB.
 33. Pfister, T., Wang, Q., Kopciuk, K. A., Doyle-Baker, P., McLaren, L., Matthews, C. E., . . . Friedenreich, C. M. (2013, June). *A comparison of two accelerometers for measuring physical activity and sedentary behaviour*. Poster presented at University of Massachusetts, 2013 International Conference on Ambulatory Monitoring of Physical Activity and Movement, Amherst, MA, USA.
 34. Pfister, T., Wang, Q., Kopciuk, K. A., Doyle-Baker, P., McLaren, L., Matthews, C. E., . . . Friedenreich, C. M. (2013, June). *A comparison of two accelerometers for measuring physical activity and sedentary behaviour*. Poster presented at the Canadian Society for Epidemiology and Biostatistics Student Conference, Memorial University, St. John's, NL.
 35. Pfister, T., Wang, Q., Kopciuk, K. A., Doyle-Baker, P., McLaren, L., Matthews, C. E., . . . Friedenreich, C. M. (2013, September). *A comparison of two accelerometers for measuring physical activity and sedentary behaviour*. Poster presented at Southern Alberta Cancer Research Institute Trainee Day.
 36. Taylor, L., Johnson, S., Eurich, D., Gardiner, P., & Vallance, J. (2014, May). *Comparing two screening tools used to identify adults at risk for diabetes: An example from the Alberta older adult health behavior (ALERT)*. Poster presented at the International Society for Behavioral Nutrition and Physical Activity, San Diego, United States.
 37. Taylor, L., Johnson, S., Eurich, D., Gardiner, P., Stevens, G., & Vallance, J. (2014, May). *Utility of telephone survey methods in population-based health studies of older adults: An example from the Alberta older adult health behavior (ALERT) study*. Poster presented at International Society for Behavioral Nutrition and Physical Activity, San Diego, United States.
 38. Vallance, J. K. (2013, October). *Exercise guidelines for those living with and beyond cancer*. Invited. Living Your Best Life with Cancer and Beyond, Cancer Bridges event, Medicine Hat, AB.
 39. Vallance, J. K. (2014, April). *Understanding sedentary behavior across the cancer context*. Invited. School of Nutrition and Health Promotion, Arizona State University, Phoenix, AZ.
 40. Vallance, J. K. (2014, January). *Understanding physical activity and sedentary behavior across the cancer context*. Invited. School of Kinesiology, University of British Columbia, Vancouver, BC.
-

41. Vallance, J. K., & Boyle, T. (n.d.). *Objectively-assessed physical activity and sedentary behaviour among breast cancer, colon cancer and non-Hodgkin lymphoma survivors*. Invited. Cancer Council Western Australia, Perth, Australia.
42. Vallance, J., Boyle, T., Courneya, K. S., & Lynch, B. M. (2014, April). *Associations of objectively-assessed physical activity and sedentary time with health-related quality of life among colon cancer survivors*. Poster presented at International Congress on Physical Activity and Public Health, Rio de Janeiro, Brazil.
43. Vallance, J., Buman, M. P., Stevinson, C., & Lynch, B. M. (2014, April). *Associations of objectively-assessed sedentary time and self-reported screen time with sleep: NHANES (2005-2006)*. Poster presented at International Congress on Physical Activity and Public Health, Rio de Janeiro, Brazil.

DIVISION HEAD

Barry D. Bultz, PhD

DIVISION HIGHLIGHTS

The Division of Psychosocial Oncology has had another very successful academic year with ongoing involvement in research activity to more than \$13.5 million dollars. This includes \$3.8 million in Primary Investigator (PI) grant funding with a further \$9.7 million in projects where members have a co-investigator role. All members of the department/division are involved in academic psychosocial oncology: research and publication, clinical program development and educational activities including teaching (MDSC 535/635) training and mentorship of students and interns.

Dr. Barry Bultz continues his term as President of the International Psycho-oncology Society (IPOS), and steers the global initiative to see screening endorsed and implemented in all cancer care internationally. Today, more than 75 international societies and cancer programs have endorsed Screening for Distress, as the 6th Vital Sign as a clinical standard of care for cancer patients. Dr. Bultz received the Queen Elizabeth II Diamond Jubilee Medal in 2013. Dr. Linda Carlson (Research Lead) continues to work on her new initiative under the Enbridge Research Chair in Psychosocial Oncology- investigating Complementary and Alternate Medicine (<http://tbccintegrative.com/>). Dr. Janine Giese-Davis continues to lead CancerBRIDGES survivorship research and program for Alberta and explore the importance of emotional expression in the cancer journey. The Alberta Cancer Foundation has committed to increasing its investment in survivorship in the Alberta. Ms. Lisa Lamont (Clinical Social Worker) has created a unique therapeutic group for caregivers of cancer patients. Ms. Celestina Martopullo (Clinical Social Worker) received a donor designated grant (\$42,000) to research and improve psychosocial care for GI patients. Dr. Guy Pelletier co-leads MDSC 535/635 (psychosocial oncology course) and has begun critical work in cognitive impairment post chemotherapy. Ms. Martina Quinn (Clinical Social Worker) is currently leading a new initiative that will see greater involvement between the Faculty of Social Work, University of Calgary and the Department in research, education and clinical work. Dr. John Robinson (Education Lead) along with Dr. Lauren Walker, the first PhD Fellow (2013-2015) in the Department of Oncology are pioneering the Oncology and Sexuality, Intimacy and Survivorship (OASIS) program in Alberta. Dr. Michael Specca (Clinical Lead), has co-authored on Mindfulness Based Cancer Recovery with Dr. Carlson, and continues to offer Mindfulness Based Stress Reduction (MBSR) courses for patients (drop-in, non-metastatic and metastatic breast groups. Dr. Bejoy Thomas (Administrative Coordinator) is planning a community based program focusing on increasing psychosocial and supportive care service uptake amongst South Asian and Ismaili breast cancer patients. Dr. Thomas was promoted to Adjunct Associate Professor this academic year. Dr. Lauren Walker is the first PhD Fellow in the Department of Oncology.

The BMT psychosocial group Ms. Holly Minor (Clinical Social Worker), Dr. Laura Labelle, and Dr. Chee-Ping Tsai, were successful in facilitating Dr. Sara Beattie's application to be the BMT Fellow for 2014. Drs. Steve Simpson and Norman Monkman (psychiatrists) continue provide an essential consultation psychiatry service for our cancer patients and their families now provide Telehealth consults to remote locations in Alberta.

Resource Social Workers, Ms. Bernie Dunlop and Joan Furtney, now function without casual employee support despite the high demand for resource needs. Mr. Navdeep Mahendru is a trained Pharmacy Technician who joined the department this year as the Drug Access Coordinator. His role (funded externally by the pharmaceutical industry) facilitates a liaison with Pharmaceutical companies on identifying drugs on compassionate grounds. This position facilitates seamless access to drugs on compassionate grounds thus freeing up clinical time (physicians, nurses, and resource counselors) spent on this activity. Navdeep has created an indelible presence in the clinical team structure. He receives over 60 new referrals per month for more than 20 different types of drugs and ensures minimal disruption to clinical care of the uninsured or underinsured clients.

CURRENT ISSUES

The main challenges for this academic year have included:

The Division of Psychosocial Oncology had been spread over several sites in three geographic locations – for efficiency and greater ease of support for patients and academic collaboration, there is a strong need to consolidate in one location. The fragmentation we already had was compounded by the June 2013 flood, when we had to vacate the Holy Cross Site. Many of the clinical staff of the division are situated at the Tom Baker Cancer Centre but on all three floors – again the need for consolidation. One positive note in this difficult time was that being located at the cancer center again has had an impact on becoming visible (accessible) to patients and the clinical staff. The BMT clinicians and the resource counselors have always remained onsite at the TBCC to maintain proximity with the BMT Program and with the high need inpatient units. The research staff is divided between the University of Calgary Heritage building (Dr. Giese's lab) and on the main floor of the Tom Baker Cancer Centre. We do not have sufficient offices/ infrastructure to accommodate all the staff in a fulltime capacity on site. Hence most staff attends scheduled meetings in the Center but work primarily from home.

The disruption caused by the flood has created a significant negative impact on the division's research output. There was a lot of apprehension on commitments made to Honors several students with all the logistical issues (change in clinics, approaching medical staff for access to patients in very limited spaces, etc.). We are happy to note that the commitments were successfully executed and all the students have completed their work with great grades. Given that the departmental infrastructure is still in flux, the impact on research grants, papers, and students will still be felt for some more time to come. We have had requests from international students, clinicians and researchers come to the department for further training, we have had to put these on hold. As a result, this academic year we will have to limit our research and training to fewer students because dislocation due to the flood and the subsequent relocation to multiple sites.

With the plans of relocating to the Holy Cross back on the drawing board, the interim plans for the research component to be accommodated in the Richmond Road Diagnostics and Treatment Center have also been put on hold. Until this a consolidated work environment is created, we will always have the risk of losing good staff who feels disconnected and possibly undervalued. The plans for the new Cancer Center will be critical in mitigating this concern bring the clinical team closer to the tumor clinics and having the evidence based research arm closer at hand – but this is at least seven years away if not more.

STRATEGIC PLANNING

The department mode of activity has always been to strategically plan and sustain at the highest level clinical care, research and education. With the creation of Alberta Health Services and the goal-at-large to see provincial programs, senior cancer care administration has expressed the need for a more provincial psychosocial oncology collaboration. This would require that the departments at the Tom Baker Cancer Centre and the Cross Cancer Institute begin to think together about service delivery to the whole of the Alberta cancer populations we serve. These discussions are beginning to happen and could be the next phase in the department's focus on clinical service, research, and education.

The Dr. Linda Carlson, as the holder of the Enbridge Endowed Research Chair in psychosocial oncology has been exploring the development of an Integrative Oncology (IO) program. This resource seeks to enhance the treating oncologists' access to the evidence and efficacy of complimentary therapies (CT). They continue to develop educational resources for patients and health care professionals. They are currently testing an educational program for Alberta health care providers on outcomes of CT knowledge and communication with patients. They continue to apply to various granting agencies and donors for funding to carry out the IO vision. The main barriers to implementation have been funding and space issues.

Going forward, a sexual health clinic has been discussed for 2014-2015. Dr. John Robinson and Dr. Lauren Walker (2013-2015 Clinical Fellow) are playing an active role in the fruition of such a clinical service. At the most broad level this initiative seeks to improve web-based patient resources, promoting patient education and improving access to resources. Through MyHealthAlberta we will offer an "Asked and Answered" patient question forum - where patients can post questions and get answers from experts. They will also offer links to reputable resources including videos of lectures on sexual health that were developed in-house, with suggestions for addressing common sexual difficulties.

The Alberta Cancer Foundation has supported the need to increase the focus on developing a provincial Survivorship program. Dr. Janine Giese-Davis and her team continue their work of spearheading survivorship initiative across the province. These efforts include the CancerBridges website, survivorship education sessions across the province, creating and enhancing the survivor network, etc.

The focus on health outcomes amongst diverse populations continues to grow. Funding success has been in the area of Health Literacy amongst immigrant populations.

RESEARCH HIGHLIGHTS

Members of the division are involved in ongoing research. The main areas of focus are: mind-body interactions, survivorship, clinical care, screening for distress - the 6th vital sign, health service delivery, health literacy and program evaluations. Total external peer-reviewed competition grant funding (from local, provincial and national granting agencies) available to faculty and staff of the division is \$13,616,850.98. That is \$882,422 in new PI grants and \$2,408,318.66 in new co-investigator grants for 2013-2014. The department also published 57 peer-reviewed manuscripts, 33 published abstracts and seven published book chapters this academic year. This enables the division to continue to excel in clinically based research which aims to influence and enhance patient care.

PROGRAM

- MINDSET is a research embedded study that offers patients at the TBCC and the BC Cancer Agency in Vancouver three psychosocial therapies. Participants are randomly assigned to one of three treatment groups: Mindfulness-Based Stress Reduction, Supportive Expressive Group Therapy or Stress Management Seminar.
- The Best Group is an ongoing weekly group offered to patients with metastatic breast cancer.
- The Brief_Supportive Expressive Therapy (SET) is offered to women in the first year of their cancer experience with stage one-two non-metastatic breast cancer in a group format.
- Women with Ovarian Cancer.
- eCalm offers an online version of our Mindfulness-Based Stress Reduction program to cancer patients in Alberta who are unable to attend in-person groups (e.g. those with physical limitations, or live in rural areas or are too ill).
- The Metastatic group is a professionally led therapeutic monthly group for patients with advanced breast cancer.
- The GI Men's Support Group is for male patients within the Gastro-Intestinal tumor group and is therapist lead.
- The I Can Sleep program was expanded from a research program and offers Cognitive Behavioral Therapy for post-treatment cancer patients who are experiencing difficulty sleeping - fatigue and sleep problems are the most frequently reported concern of cancer patients.
- The Kids/Teens Can Cope group program is therapist lead and offered to address a host of issues the children would be facing with a sick parent. We are proposing to review the process of this program to improve its format and care delivery.
- The professionally led drop-in Lung Cancer Support Group is offered to reducing isolation, building hope, and living well with the disease.
- As part of a research initiative we also offer several Online Support Groups (OSG) for breast cancer patients (including a young breast cancer survivors group) whose access to support is limited due to their rural location, disability or other impediments.
- The Mindfulness Based Stress Reduction (MBSR) programs (group and drop-in format) are offered to cancer patients who wish to learn meditation for personal growth, coping strategies, relaxation and stress reduction.

- Screening for Distress, 6th Vital Sign continues to be offered as part of CancerCare standard of care which aims to screen and address all cancer patients for emotional, physical and practical distress.
- The monthly Prostate Cancer and Sexuality information session address how treatments for prostate cancer will influence sexuality addresses measures to help overcome these effects. The Prostate Cancer Information Session offers new prostate cancer patients information about a range of treatment options, as well as diagnostic services, counseling and therapeutic support.
- CancerBRIDGES addresses use of Survivorship Care Plans to assist in the transition from the care of the oncology centre to the family physician.

NON-CLINICAL EDUCATION/ACCESS PROGRAMS

The division's resource counselors offer the Resource Class to address financial burdens for cancer patients and their families. Some people may experience a change in their lifestyle because of a lower income. The Drug Access Coordinator (DAC) is a brand new program that assists in addressing drug coverage needs that patients may have (drugs not covered on the Cancer Care Drug Benefit List).

UNIVERSITY OF CALGARY PROFESSORSHIP/ENDOWED CHAIRS

Dr. Linda Carlson holds the Enbridge Research Chair in Psychosocial Oncology. The focus areas currently are 1) Integrative Oncology and 2) Survivorship. Significant strides have been made in each of these areas.

1) Integrative Oncology: UPDATE

Dr. Carlson and her team are working towards establishing a 4-pronged approach to integrative oncology education, research and program implementation, which involves:

- A. Patient and provider education programs: Designed to optimize knowledge and improve communication around evidence-based CT use modules will be available for both patients and providers.
- B. Patient consultation service: Personalized individual consultation, decision-support and recommendations for integrative oncology care from trained specialists.
- C. Complementary therapy provision: Provision and/or referral to of a full range of evidence-based CTs.
- D. CT clinical trials program: Development of an integrative oncology clinical trials program (within the existing clinical trials unit) for promising CTs.

They have developed educational resources from a review of over 900 studies, 72 different natural health products in cancer risk and treatment. They have also conducted a survey of CT use, knowledge and information needs in TBCC patients (n=500), and attitudes, beliefs, knowledge and information needs in health care providers (n=100). Dr. Carlson has used this data to develop monthly patient education seminars (facilitated since 2012). They have also conducted literature reviews on the use of antioxidants during cancer treatments, and a nationwide survey of over 75 cancer agencies on policies and guidelines for the use of antioxidants for cancer prevention, treatment and survivorship. They are currently testing the CAMEO

educational program for Alberta health care providers on outcomes of CT knowledge and communication with patients.

2) Survivorship: UPDATE

This past year, Dr. Giese-Davis laid the important groundwork for developing a Provincial Integrated Survivorship Program in Alberta along with community oncology, and an advisory board of professionals and patients and families. They also held a meeting hosted by the Cancer Society and Ovarian Cancer Canada with 18 other community-based agencies throughout Alberta to understand how better to collaborate with them to serve survivors. This effort has been rewarded with funding from the Alberta Cancer Foundation for a two-year Provincial Integrated Survivorship Program.

As the director of CancerBridges, Dr. Giese-Davis oversaw the ongoing development of a survivor website with more than 64,000 visits to date, accessed by survivors in 60 Alberta communities, with visitors throughout Canada and worldwide. They have signed up over 500 survivors to the survivor network, over 1700 have attended their survivor educational sessions, and have delivered six half-day survivor symposia in Calgary, Edmonton, Medicine Hat, Lethbridge, and Bonnyville. They continue to provide links to community-based agencies through the website and actively collaborate with a number of these agencies to post supportive and educational events on a province-wide live calendar so that survivors can quickly access information on daily events, and quickly see the times, locations, and maps to attend these. They continue to support the innovative translational video library called the Myths of Survivorship. They also send out a monthly email and print CancerBridges newsletter to the survivor network and interested professionals. Mike Lang has created and sustained this effort on behalf of CancerBridges for three years.

CancerBridges research team also facilitated application for an ASAP network grant through Prostate Cancer Canada to develop a number of survivorship programs nationwide and in Alberta with Alberta's lead, John Robinson. They have also facilitated an application to the Alberta Cancer Prevention Legacy Fund to study and design interventions for the transition to primary care for cancer survivors after treatment. This study is currently underway. Applications are under review (NIH and CIHR) for a nationwide kidney cancer survivor care plan randomized trial in collaboration with Princess Margaret and the Kidney Cancer Network. They are currently researching adherence to follow-up and quality of life for adult survivors of childhood cancer across the province, and the difficulties their primary care providers may report caring for them.

Future directions are to analyze and publish the survivorship data that they have collected, and on behalf of survivors to continue to use research to help move innovation forward in Alberta. They are also in the process of forming a Scientific Advisory Board to facilitate survivorship research in collaboration with the PISP in Alberta.

These programs are designed to reduce the suffering and the burden that cancer patients face throughout the disease trajectory, from the time of diagnosis through screening for distress and appropriate triage to support services, to the time of active treatment through participation in integrative oncology interventions, and through discharge and survivorship by creating seamless care plans and support programs.

AWARDS

- Bultz, B. The Queen Elizabeth II Diamond Jubilee Medal, 2013.
President, International Psycho-Oncology Society, 2012-2014.
- Calrson, L. Dr. Rogers Prize in Complimentary and Alternative Medicine Shortlist, 2013.
- Culos-Reed, N. Calgary Award of Excellence in Education, City of Calgary, 2014.
Roger Jackson Centre for Health and Wellness Research, Faculty Excellence award, 2013.
Nominated for the University of Calgary Graduate Supervision award, 2013.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Armstrong, M. J., Campbell, T. S., Lewin, A. M., Khandwala, F., Culos-Reed, S. N., & Sigal, R. J. (2013, December). *Motivational interviewing-based counseling promotes maintenance of exercise in people with type 2 diabetes* [Abstract]. Presented at the International Diabetes Federation World Congress, Melbourne, Australia.
2. Armstrong, M. J., Campbell, T. S., Lewin, A. M., Khandwala, F., Culos-Reed, S. N., & Sigal, R. J. (2013, October). *Motivational interviewing-based exercise counseling promotes maintenance of physical activity in people with type 2 diabetes* [Abstract]. Presented at the Canadian Diabetes Association Annual Meeting, Montreal, Canada.
3. Baron, D. M., Bultz, B. D., Groff, S., & Fassbender, K. (2013, October). *Economic evaluation of screening for distress, the 6th vital sign in cancer patients*. 24th Annual Palliative Care Conference: Education and Research Days. Edmonton, Alberta.
4. Boldt, K. R., & Culos-Reed, S. N. (2013, June). *Evaluation of exercise motivation and adherence in prodromal psychosis youth using self-determination theory*. The Biomedical Basis of Human Performance International Workshop. Presentation conducted from the Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
5. Bultz, B. D. (2014, May). *Opening address from the president of IPOS*. The first joint International Psycho-Oncology Academy of the International Psycho-Oncology Society (IPOS), World health Organization (WHO) and the 4th (POSON). Invited Address. National Conference Department of Radiotherapy, University College Hospital, Ibadan, Nigeria.
6. Bultz, B. D., & Grassi, L. (2013, November). *IPOS meeting of federated societies: Growing and developing a global network of psycho-oncology societies*. Presented at the IPOS World Congress, Rotterdam, Netherlands.
7. Bultz, B. D. (2014, May). *The state-of the psycho-oncology today: Screening for distress: Identifying and addressing patients supportive care needs via audio*. The first joint International Psycho-Oncology Academy of the International Psycho-Oncology Society (IPOS), World health Organization (WHO) and the 4th (POSON). Invited Guest speaker. National Conference Department of Radiotherapy, University College Hospital, Ibadan Nigeria.

8. Bultz, B. D. (2014, April). *Screening for distress: Identifying and addressing patients supportive care needs*. Invited Guest Speaker. City of Hope, Los Angeles, California.
9. Bultz, B. D. (2013, October). *Screening for distress: Identifying and addressing patients supportive care Needs*. Invited Guest Speaker. Mount Sinai Medical Centre, New York, New York.
10. Bultz, B. D., Grassi, L., Travado, L., Hoefsmit, N., Cummings, G., Ulrich, A., & Watson, M. (2013, November). *IPOS President's Symposium: Embracing the IPOS standards as a means of enhancing whole patient care*. IPOS World Congress, Rotterdam, Netherlands.
11. Bultz, B. D. (2013 November). *Opening Address*. International Psycho-Oncology Society, 2013 World Congress, Rotterdam, Netherlands.
12. Carlson, L. E. (2013, November). *Mind-body interventions in oncology*. Italian Psychosocial Oncology Society/Italian PNEI Society joint meeting. Invited Keynote speaker. Brescia, Italy.
13. Carlson, L. E., Beattie, T., Giese-Davis, J., Faris, P., Tamagawa, R., Fick, L., Stebner, E., & Specca, M. (2014, May). *Mindfulness-based cancer recovery (MBCR) and supportive expressive therapy (SET) maintain telomere length (TL) and cortisol slopes relative to control in distressed breast cancer survivors*. The International Research Congress on Integrative Medicine and Health (IRCIMH). Miami, Florida, United States.
14. Carlson, L. E. (2013, November). *Mindfulness-based stress reduction: Program history and research results*. Italian Psychosocial Oncology Society/Italian PNEI Society joint meeting. Invited Keynote speaker. Brescia, Italy.
15. Carlson, L. E. (2013, November). *Meditation for cancer patients*. Italian Psychosocial Oncology Society/Italian PNEI Society joint meeting. Invited workshop. Brescia, Italy.
16. Carlson, L. E. (2013, November). *Mindfulness-based cancer recovery: Program curriculum*. Italian Psychosocial Oncology Society/Italian PNEI Society joint meeting. Invited workshop. Brescia, Italy.
17. Carlson, L. E. (2013, October). *Mind-body interventions in cancer: From the immune system to the internet. Specific talk: Mindfulness-based cancer recovery vs. supportive expressive therapy in breast cancer survivors*. Society for Integrative Oncology 10th International Meeting. Invited plenary symposium chair, Vancouver, British Columbia.
18. Carlson, L. E. (2013, April). *Mindfulness-based cancer recovery*. Canadian Association of Psychosocial Oncology. Invited Keynote speaker (opening plenary). Ottawa, Ontario.
19. Chamorro-Vina C, Keats, M., & Culos-Reed, S. N. (2014). *POEM (pediatric oncology exercise manual): A tool to fight sedentary behavior* [Abstract]. Presented at the 2014 Global Summit on the Physical Activity of Children presented by Active Healthy Kids Canada, Toronto, Canada.
20. Chamorro-Vina, C., Keats, M., & Culos-Reed, S. N. (2014). *POEM (pediatric oncology exercise manual): A resource for clinicians, fitness professionals and educators* [Abstract]. Presented at the Canadian Association of Psychosocial Oncology Annual Meeting. Winnipeg, Manitoba.
21. Cummings, G., Bultz, B. D., Krol, A., & McLeod, D. (2013 Nov). *Integrating screening for distress, the 6th vital sign, into nursing practice*. International Psycho-Oncology Society, 2013 World Congress, Rotterdam, Netherlands.
22. Dirkse, D., Lamont, L., Li, Y., Simonič, A., Bebb, G., & Giese-Davis, J. (2014, April). *Shame, guilt, and communication in lung cancer patients and their partners*. Paper presented at the Canadian Association for Psychosocial Oncology, Winnipeg, Manitoba.

23. Dumanowski, B., Brandelli, Y., Yong, L., Golant, M., Spiegel, D., & Giese-Davis, J. (2014). *Therapeutic mechanisms of change in breast cancer support groups: Does what you talk about in sessions matter to improvement in trauma symptoms and emotional self-efficacy?* Paper presented at the 72nd Meeting of the American Psychosomatic Society. San Francisco, United States.
24. Garland, S., Carlson, L. E., & Campbell, T. (2014, May). *A comparison of mindfulness-based stress reduction and cognitive behavioral therapy for improving sleep and mood outcomes in cancer patients with insomnia.* Poster presented at The International Research Congress on Integrative Medicine and Health (IRCIMH), Miami, Florida, United States.
25. Giese-Davis, J. (2014, June). *Loss and meaning.* Young Adult Cancer Canada Annual Conference: “Ignite 2014”. Keynote Speaker. Toronto, Ontario.
26. Giese-Davis, J. (2014, April). *Support for living your best life: Survivorship research and new developments.* “Living Your Best Life With and Beyond Cancer” CancerBridges Survivorship Education Day. Keynote Speaker. Edmonton, Alberta.
27. Giese-Davis, J., & Watson, L. (2014, January). *Provincial integrated survivorship program.* Canadian Cancer Society-Alberta for Cancer Serving Community-Based Agencies. Keynote Speakers. Calgary, Alberta.
28. Giese-Davis, J., & Watson, L. (2014, January). *Provincial integrated survivorship progra.* Provincial Advisory Council on Cancer. Keynote Speakers. Calgary, Alberta.
29. Giese-Davis, J. (2013, October). *Support for living your best life: Survivorship research and new developments.* “Living Your Best Life With and Beyond Cancer” CancerBridges Survivorship Education Day. Keynote Speaker. Lethbridge, Alberta.
30. Giese-Davis, J. (2013, October). *Support for Living Your Best Life: Survivorship Research and New Developments.* “Living Your Best Life With and Beyond Cancer” CancerBridges Survivorship Education Day. Keynote Speaker. Medicine Hat, Alberta.
31. Giese-Davis, J. (2013, October). *Support for living your best life: Survivorship research and new developments.* “Living Your Best Life With and Beyond Cancer” CancerBridges Survivorship Education Day. Keynote Speaker. Bonnyville, Alberta.
32. Giese-Davis, J. (2013, October). *Support for living your best life: Survivorship research and new developments.* “Living Your Best Life With and Beyond Cancer” CancerBridges Survivorship Education Day. Keynote Speaker. Cross Cancer Institute. Edmonton, Alberta.
33. Giese-Davis, J. (2013, September). *Support for living your best life: Survivorship research and new developments.* “Living Your Best Life With and Beyond Cancer” CancerBridges Survivorship Education Day. Keynote Speaker: Tom Baker Cancer Centre, Calgary, Alberta.
34. Giese-Davis, J. (2013, September). *Support for living your best life: Survivorship research and new developments.* “Living Your Best Life With and Beyond Cancer.” Keynote Speaker. Myeloma Society Meeting, Calgary, Alberta.
35. Groff, S., Holroyd-Leduc, J., White, D., & Bultz, B. D. (2013 November). *Examining the sustainability of screening for distress, the 6th vital sign, in two outpatient oncology clinics.* Poster presented at the IPOS 15th World Congress of Psycho-Oncology, Rotterdam, Netherlands.
36. Horsley, K. J., Rouleau, C. R., & Campbell, T. S. (2014, March). *Difficulty falling asleep is associated with attenuated heart rate recovery among cardiac rehabilitation patients with insomnia* [Abstract]. Presented at American Psychosomatic Society 72nd Annual Scientific Meeting. San Francisco, California, United States.

-
37. Horsley, K. J., Rouleau, C. R., & Campbell, T. S. (2013, October). *Symptoms of depression but, not anxiety, are associated with attenuated heart rate recovery following exercise stress testing in cardiac rehabilitation patients* [Abstract]. Presented at the Canadian Association of Cardiac Rehabilitation. Montreal, Quebec.
 38. Johnson, J. A., Garland, S. N., Carlson, L. E., Simpson, J. S., Savard, J., Ancoll-Isreal, S., & Campbell, T. S. (2014, March). *A pilot trial of light therapy for post-treatment cancer-related fatigue* [Abstract]. Presented at American Psychosomatic Society 72nd Annual Scientific Meeting. San Francisco, California, United States.
 39. King, N., Balneaves, L., Card, C., Nation, J., Nguyen, T., & Carlson, L. E. (2014, May). *Surveys of cancer patients and cancer care providers regarding complementary therapy use, communication and informational needs*. Poster presented at The International Research Congress on Integrative Medicine and Health (IRCIMH), Miami, Florida, United States.
 40. Lang, M., & Giese-Davis, J. (2014, April). *The digital one-way mirror: Video as a tool to strengthen emotional intelligence and clinical interviewing skills in cancer care professionals*. Paper presented at the Canadian Association for Psychosocial Oncology, Winnipeg, Manitoba.
 41. Mackenzie, M. J., Carlson, L. E., Paskevich, D. M., Ekkekakis, P., Wurz, A. J., Wytsma, K., Krenz, K. A., & Culos-Reed, S. N. (2013, June). *Associations between affect, attention and heart rate variability in a single yoga session for cancer survivors: A neurophenomenological approach*. Presented at the Mind and Life Summer Research Institute. Garrison, New York.
 42. Manerikar, S., Brandelli, Y., & Giese-Davis, J. (2014, April). *An exploration of cancer patients' trust in health-care providers*. Paper presented at the Canadian Association for Psychosocial Oncology. Winnipeg, Manitoba.
 43. Martopullo, C. (2014, February). *Cognitive behavioural stress management and relaxation seminar*. Tom Baker Cancer Centre, Calgary, Alberta.
 44. Rash, J. A., Sajid, U., Campbell, T. S., Letourneau, N., & Giesbrecht, G. (2014, March). *Fetal programming of infant hypothalamic-pituitary-adrenal axis function* [Abstract]. Presented at American Psychosomatic Society 72nd Annual Scientific Meeting. San Francisco, California, United States.
 45. Rash, J. A., & Campbell, T. S. (2014, March). *Intranasal oxytocin administration lowers reports of acute pain relative to a placebo* [Abstract]. Presented at American Psychosomatic Society 72nd Annual Scientific Meeting, San Francisco, California, United States.
 46. Rouleau, C. R., Horsley, K. J., Morse, E., Hauer, T., Aggarwal, S., Arena, R., & Campbell, T. S. (2013, October). *Insomnia symptoms are not associated with adherence to a phase-II cardiac rehabilitation program* [Abstract]. Presented at the Canadian Association of Cardiac Rehabilitation, Montreal, Quebec.
 47. Schulte, F., Wurz, A. J., Fay-McClymont, T., Scott-Lane, L., Pelletier, W., Strother, D., Bultz, B. D., & Dewey, D. (2013, November). *Screening for distress in pediatric oncology patients and their families: An assessment of feasibility*. Canadian Cancer Research Conference. Toronto, Canada.
 48. Thomas, J. C., Rash, J. R., Sajid, U., Campbell, T., Letourneau, N., & Giesbrecht, G. F. (2014, March). *Maternal prenatal psychological distress and early infant respiratory sinus arrhythmia at rest and during stress* [Abstract]. Presented at American Psychosomatic Society 72nd Annual Scientific Meeting, San Francisco, California, United States.
-

-
49. Travado, L., Watson, M., Bultz, B. D., & Borrás, J. (2013, November). *Screening for distress as the 6th vital sign*. Poster presented at a European Standard for Quality Cancer Care, EPAAC Open Forum, Ljubljana, Slovenia.
 50. Travado, L., Watson, M., Bultz, B. D., & Borrás, J. (2013, November). *Screening for distress as the 6th vital sign: A European standard for quality cancer care* [Abstract]. Presented at EPAAC Open Forum, Ljubljana, Slovenia.
 51. Tsai, C. P. (2013, November). *Dealing with your thoughts and feelings: How to cope better with Leukemia*, Tom Baker Cancer Centre, Calgary, Alberta.
 52. Tsai, C. P. (2013, September). *Dealing with your emotions*. Presented at the You, Me, and Myeloma event, Tom Baker Cancer Centre, Calgary, Alberta.
 53. Walker, L. (2014, April). *The heart of the matter: Connecting knowledge, creativity & compassion*. Presented at the Canadian Association of Psychosocial Oncology 2014 Conference, Winnipeg, Manitoba.
 54. Walker, L., Campbell, L., & Kallos-Lilly, V. (2013, October 6-9). *Emotion focused therapy externship*. Presented at the International Centre for Excellence in Emotion Focused Therapy, Calgary, Alberta.
 55. Walker, L., & Craighead, P. (2013, September 25). *Department of oncology leadership workshop*. Calgary, Alberta.
 56. Wurz, A. J., Chamorro-Vina, C., Guilcher, G. M. T., Schulte, F., & Culos-Reed, S. N. (2013, September). *Yoga for pediatric cancer out-patients* [Abstract]. Presented at the Southern Alberta Cancer Research Institute Trainee Day, Calgary, Alberta.
 57. Zernicke, K. A., Campbell, T. S., Specá, M., McCabe-Ruff, K., Flowers, S., & Carlson, L. E. (2014, April 4). *The eCALM trial: eTherapy for cancer applying mindfulness – Online mindfulness-based cancer recovery program for underserved people living with cancer in Alberta: Feasibility and trial results*. Presented at the Investigating and Integrating Mindfulness in Medicine, Health Care, and Society 12th Annual International Scientific Conference for Clinicians, Researchers and Educators, Worcester, Massachusetts, United States.

DIVISION HEAD

Ivo Olivotto BSc, MD, FRCPC

DIVISION HIGHLIGHTS

The division saw a change in leadership, three new recruits, and the opening of the Central Alberta Cancer Centre in Red Deer. The division now includes 23 members (20.7 FTE) including Dr. Liu in Red Deer and Drs. Ghose and Wilson in Lethbridge.

Dr. Ivo Olivotto was recruited as the new Division Head in September 2013, a transition from Dr. Elizabeth Kurien, who was the acting-head for the prior year. Prior to relocating to the University of Calgary (UofC) and Tom Baker Cancer Centre (TBCC), Dr. Olivotto was the Professor and Head of the Division of Radiation Oncology and Developmental Radiotherapeutics at the University of British Columbia and the Vice-President of Radiation Therapy and Functional Imaging for the BC Cancer Agency.

Dr. Robyn Banerjee, a graduate of the UofC/TBCC Residency Training Program (2012) joined the faculty in September 2013 after a brachytherapy fellowship at UCLA. He is working to implement interstitial gynecologic brachytherapy as a provincial resource for women with cancer of the cervix in Alberta.

Dr. Hongwei Liu, joined the faculty with a clinical appointment at the newly opened (November 2013) Central Alberta Cancer Centre in Red Deer following an academically successful stereotactic radiation therapy fellowship in Calgary. He is already working closely with the Division of Medical Physics and radiation therapist colleagues on several technical innovation projects and will be working to implement stereotactic ablative radiation therapy in Red Deer over the next year.

CURRENT ISSUES

Divisional members are distributed across three cancer centers: The Jack Ady Cancer Centre (JACC) in Lethbridge (n=2); the Tom Baker Cancer Centre (TBCC) in Calgary (n=20; 17.5FTE); and the Central Alberta Cancer Centre (CACC) in Red Deer (n=1).

There is an increasing role for curative-intent, highly-conformal, image-guided radiation therapy techniques to achieve cancer control. As an example, for patients with stage I lung cancer whom are medically inoperable, stereotactic ablative body radiotherapy (SABR) can provide well-tolerated, non-invasive, curative-intent, treatment with high rates of long term local control as compared to a palliative approach or no treatment which was the standard previously. For patients to access SABR safely, one needs 'modern' linear accelerators capable of beam modulation and with built in KV-imaging. The JACC (opened 2010) and CACC (opened 2013) are well-equipped but, as of January 2014, 5 of 9 (55%) of TBCC linear accelerators were > 11 years old as compared to just 3% of 31 linear accelerators in BC and 0% of 103 linear accelerators in Ontario being that old.

There is also an expanding role for the use of SABR techniques for patients with primary and metastatic liver disease. Recognition of the benefits of liver SABR and the development of the technical capability to deliver highly conformal radiation therapy to a moving target, has substantially increased referrals for the Division of Radiation Oncology consultations. The division is working on personnel development and the distribution of workload to accommodate these innovations, and others, into practice. A significant capital investment is required to bring the TBCC into the ‘modern’ treatment era.

STRATEGIC PLANNING

A divisional retreat was held on January 24, 2014 to assess priorities, define group actions and assess readiness for change over the next two to three years. After collaborative discussion, it was agreed that five action priorities for division members, and the lead priority champion, will include:

- Improve prospective data collection and outcomes evaluation – D. Skarsgard
- Centre of Excellence in Brachytherapy – R. Banerjee
- Centre of Excellence in Stereotactic Ablative Radiation Therapy – G. Lim (CNS) and R. Sinha (Body)
- Improve quality and efficiency of care – T. Trotter
- Develop a position document on the role of proton therapy in Alberta – I. Olivotto

RESEARCH HIGHLIGHTS

- Drs. Doll and Lau shared the Department of Oncology, Excellence in Research Award at the annual recognition dinner in September 2013.
- Two residents won travel awards for their research: Dr. Rosanna Yeung to the American Society of Radiation Oncology (ASTRO) annual meeting in San Francisco in September 2013 and Dr. Theodora Koulis to the Radiological Society of North America (RSNA) conference in Chicago in December 2013.
- Six of the seven PGY3-5 residents presented research as posters or oral presentations at national or international radiation oncology meetings.
- Divisional members held over \$900,000/year in active research funding in 2013-2014 including a new AHS CRIO grant of \$750,000 over three years awarded to C. Doll and colleagues and an ACF-funded Investigator Initiated Trial Grant award to M. Kerba and colleagues.

Research productivity as lead or senior authors by faculty members was seen across the spectrum of cancer control research including basic science, clinical innovations, large-scale clinical trials, and the evaluation of health service and quality of life outcomes. Radiation therapy is used to cure or relieve suffering for patients with cancer. Divisional members and trainees believe that research is about improving care and have been active in evaluating the care we provide to improve care for future patients. Please see the publications lists.

PROGRAM (CLINICAL/SERVICE)

Radiation therapy (RT) may be used as 1) the primary curative cancer treatment (e.g. for patients with cervix or head and neck cancer); 2) organ conservation (e.g. lumpectomy plus radiation therapy instead of mastectomy or a single brachytherapy outpatient procedure instead of radical prostatectomy); or the palliation of symptoms from cancer spread (e.g. to relieve pain from bone metastases, or neurologic symptoms from brain metastases or spinal cord compression). Radiation therapy is also beneficial for some non-malignant conditions such as painful fibromatosis, heterotopic ossification following hip surgery, recurrent keloid and Graves' ophthalmopathy.

Division members provide oncologic consultations, and for those patients with indications for radiation therapy, the prescription and supervision of treatment through the three cancer centers providing care to patients across Southern Alberta. In addition, the TBCC is a provincial resource for patients requiring total body irradiation as a conditioning regimen prior to bone marrow transplant, RT services for about 25-30 pediatric patients with cancer per year and stereotactic radiosurgery through the Alberta Radiosurgery Centre serving patients with benign (AV malformations, some functional disorders, or benign tumors such as acoustic neuromas) or malignant CNS lesions. In 2013-2014 there were 480 courses of radiation therapy provided at the JACC and 3110 courses provided at the TBCC including 93 patients treated solely with brachytherapy. There were 46,671 individual radiation treatment sessions provided between the two cancer centers in Southern Alberta. The Central Alberta Cancer Centre has not had a full year of operation.

Appropriate patient selection, treatment planning and treatment delivery is highly dependent upon close communication and collaboration with colleagues in the Division of Medical Physics, the Department of Radiation Therapy, nursing and clerical staff.

Innovations and practice changes in the past year have included:

- The launch of a permanent breast seed implant program in which women with early-stage breast cancer treated with breast conserving surgery receive a single, outpatient procedure in which 80-100 rice-grain sized, radioactive pellets are inserted into the breast around the primary site rather than using four to six weeks of daily external beam treatments to the whole breast.
- An expansion of stereotactic ablative body radiation therapy for patients with oligometastatic disease to the liver.
- The use of a two-minute continuous arc of radiation therapy as curative treatment for prostate cancer rather than an 8-15 minute series of multiple fixed beams.
- Substantial expansion of real-time peer-reviewed audit of radiation therapy plans to improve the consistency and quality of RT delivered to patients.

AWARDS

Doll, C. Research Excellence Award, University of Calgary, Department of Oncology (co-recipient), 2013.

-
- Kurien, E. Quality of Life Award from University of Calgary Radiation Oncology Residents (for the faculty member most contributing to the Residents' overall experience in the training program), 2013.
Associate Dean's Letter of Excellence: Teaching Communication skills, University of Calgary, Faculty of Medicine (year two).
Bronze Award for Distinguished Service: Teaching of Year two communication skills, Faculty of Medicine, University of Calgary.
- Lau, H. Research Excellence Award, University of Calgary, Department of Oncology (co-recipient), 2013.
- Olivotto, I. A. 'Door Opener Award', Canadian Breast Cancer Foundation – BC/Yukon Chapter (Life-time achievement in breast cancer care and mentorship).
- Sinha, R. Preceptor of the Year Award - as voted by members of the University of Calgary Radiation Oncology Resident staff, 2013.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Angyalfi, S. (2014, February). *PSA – The double edged sword*. Presented to Family Practice Journal Club, Calgary, Alberta.
2. Balogh, A. (2013, January). *RT in HL and NHL*. Presented at Radiation Oncology Journal Club, Tom Baker Cancer Centre, Calgary, Alberta.
3. Balogh, A. (2013, February). *RT in extranodal non-Hodgkin's lymphoma*. Presented at Hematology Rounds, Foothills Medical Centre, Calgary, Alberta.
4. Balogh, A. (2013, September). *Adjuvant/salvage post radical prostatectomy RT*. Presented at the Genitourinary Journal Club, Tom Baker Cancer Centre, Calgary, Alberta.
5. Balogh, A. (2013, October). *Radium-223 in metastatic prostate cancer*. Presented at the Alberta Provincial Genitourinary Tumor Group Meeting, Kananaskis, Alberta.
6. Balogh, A. (2013, October). *Radiotherapy: Adjuvant vs. salvage following radical prostatectomy*. Presented at the Alberta Provincial Genitourinary Tumor Group Meeting, Kananaskis, Alberta.
7. Banerjee, R., Park, S-J., Kayode, O., Wang, J., Demanes, J., & Kamrava, M. (2013). *An assessment of organ at risk dose and inter-fraction variability using four different applicators for intracavitary gynecologic HDR brachytherapy* [Abstract]. Presented at ASTRO meeting, Atlanta, GA.
8. Banerjee, R. (2013, April). *Proffered paper session*. Moderator at the ABS Meeting, New Orleans, LA.
9. Clayton, R., Liu, H., Lau, H., Dunscombe, P., Nugent, Z., & Khan, R. (2013). *Clinical impact and utility of acuros XB dose calculation algorithm in lung stereotactic body radiation therapy* [Abstract]. Presented at ASTRO meeting, Atlanta, GA.
10. Doll, C. (2013, March). *Anal cancer: An overview*. Oral Presentation at the Department of Oncology Grand Rounds, Tom Baker Cancer Centre, Calgary, Alberta.

11. Doll, C. (2013, September). *Tumor ataxia telangiectasia-mutated (ATM) status and outcome in patients with cervical cancer treated with chemotherapy*. Oral Presentation at the Canadian Association for Radiation Oncology Meeting (CARO), Montreal, Quebec.
12. Doll, C. (2013, October). *PI3KCA mutational and associated pathway activation status and survival in patients with cervical cancer: Quantifying the risk and testing the solution*. Oral Presentation at the Alberta Cancer Foundation Research Conference, Banff, Alberta.
13. Doll, C. (2013, October). *DNA damage repair and genomic instability: Introduction and clinical perspective*. Oral Presentation at the Alberta Cancer Foundation Research Conference, Banff, Alberta.
14. Ho, C., Leugner, D., Easaw, J., & Lim, G. (2013). *Predication score of symptomatic venous thromboembolism in patients with glioblastoma multiforme* [Abstract]. Presented at CARO 2013, Montreal, QC.
15. Husain, S. (2013, August). *RT for prostate cancer*. Presented at the Prostate Centre Public Forum, Calgary, Alberta.
16. Husain, S. (2013, October). *Brachytherapy for prostate cancer*. Presented at the Prostate Centre Public Forum, Calgary, Alberta.
17. Husain, S. (2013, November). *Prostate cancer update*. AHS knowledge transfer workshop. Presented at the Tom Baker Cancer Centre, Calgary, Alberta.
18. Husain, S. (2013, June) *10 Years of intraoperative-planned prostate brachytherapy*. Presented at the Grand Therapy Rounds at the Institute Curie, Paris, France.
19. Kamrava, M., Mesko, S., Banerjee, R., Huang, J., Demanes, J., & Marks, L. (2013). *Inter-, intra-prostatic, and intra-lesional variation of Ki-67 in prostate cancer* [Abstract]. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Orlando, Florida.
20. Klimowicz, A. C., Jagdis, A., Phan, T., Laskin, J., Lau, H., Siever, J., Petrillo, S., Thomson, T., Rose, M. S., Magliocco, A. M., & Hao, D. (2013). *ATM, TS and RRM1 protein expression in nasopharyngeal carcinomas (NPC) treated with curative intent* [Abstract]. Presented at the American Association for Cancer Research 2013 Annual Meeting.
21. Klimowicz, A., Kornaga, E., Dean, K., Bebb, G., Craighead, P., Ghatage, P., Magliocco, A., Lees-Miller, S., & Doll, C. (2013). *Tumour ataxia telangiectasia-mutated (ATM) status and outcome in patients with cervical cancer treated with chemoradiotherapy* [Abstract]. Presented at CARO 2013, Montreal, QC.
22. Koulis, T., Brown, D., Bayana, D., Traptow, L., Patrick, M., Doll, C. M., & Phan, T. (2013). *Stepwise implementation of imaging changes for cervical cancer brachytherapy planning using existing infrastructure: A multidisciplinary approach to advancing patient care* [Abstract]. Presented at CARO 2013, Montreal, QC.
23. Koulis, T., Brown, D., Bayana, D., Traptow, L., Patrick, M., Doll, C. M., & Phan, T. (2013). *Stepwise implementation of imaging changes for cervical cancer brachytherapy planning using existing infrastructure: A multidisciplinary approach to advancing patient care* [Abstract]. Presented at the Radiological Society of North America (RSNA), Chicago, IL.
24. Kerba, M. (2013, October). *Patient preference for prostate cancer treatment options in Alberta*. Presented at the Provincial GU Tumor Group Retreat, Kananaskis, Alberta.
25. Kerba, M. (2013, November). *Health services research in the new Calgary cancer centre*. Presented at the AHS Knowledge Transfer Workshop in the Tom Baker Cancer Centre, Calgary, Alberta.

26. Kummer, N., Mesko, S., Kupelian, P., Raman, S., Margolis, D., Banerjee, R., & Kamrava, M. (2013). *Improving Prostate cancer risk stratification through multiparametric MRI prostate imaging* [Abstract]. Presented at the American Radium Society Meeting.
27. Kurien, E. (2013, April). *RT for desmoid tumors*. Presented at the Provincial Sarcoma Meeting, Edmonton, Alberta.
28. Kurien, E. (2013, September). *Going beyond the 'see one, do one': Teaching medical professionalism*. Presented in the Cross Cancer Institute Grand Rounds, Edmonton, Alberta.
29. Kurien, E., & Olivotto, I. (2013, December). *10 Year provincial radiation medicine capital equipment replacement plan*. Presented at the Radiation Medicine Council in the Tom Baker Cancer Centre, Calgary, Alberta.
30. Kurien, E., & Olivotto, I. (2014, January). *Sustaining access to radiation therapy for Albertans: A 10 year capital plan*. Presentation to Cancer Control Executive Leadership Committee (CCELC) video-linked from the Tom Baker Cancer Centre, Calgary, Alberta.
31. Kurien, E. (2014, February). *Advances in RT for lung cancer patients*. Presented at the Grand Rounds, Tom Baker Cancer Centre, Calgary, Alberta.
32. Kurien, E. (2014, June). *Lung cancer radiation research*. Presented at the Radiation Oncology Rounds, Tom Baker Cancer Centre, Calgary, Alberta.
33. Lau, H. (2013, February). *Stereotactic lung program at TBCC*. Presented at the Western Canadian Lung Conference, Vancouver, BC.
34. Lau, H. (2013, May). *Stereotactic lung radiotherapy for medically inoperable non-small cell lung cancer*. Presented at the Grand Rounds in the Lethbridge Cancer Centre, Lethbridge, Alberta.
35. Lau, H. (2013, September). *Harnessing the immune response to cancer with radiotherapy*. Presented at the Radiation Oncology Journal Club, Calgary, Alberta.
36. Lau, H. (2013, October). *Head and neck symposium: From bench to bedside*. Presented at Alberta Cancer Foundation Annual Research Meeting, Banff, Alberta.
37. Lim, G. (2013). *RT for adult glioblastoma*. Presented at the CNS Provincial Meeting, Calgary, Alberta.
38. Lim, G. (2014, February). *What's going on in the brain?* Presented at the Radiation Oncology Journal Club, Tom Baker Cancer Centre, Calgary, Alberta.
39. Liu, H., Gabos, Z., Ghosh, S., Lau, H., & Kerba, M. (2014). *SBRT in the treatment of stage I non-small cell lung cancer* [Abstract]. Presented at the European Society for Therapeutic Radiation and Oncology annual meeting, Vienna, Austria.
40. McIntyre, J., Jewett, G., Kornaga, E., Wang, X., Lees-Miller, S., Craighead, P., Ghatage, P., Robbins, S. M., Magliocco, A. M., & Doll, C. M. (2013). *Differential gene expression profiling and association with clinical outcome in cervical cancer histological subtypes* [Abstract]. Presented at the Canadian Cancer Research Conference, Toronto ON.
41. Nordal, R. (2013, December). *Chemotherapy alone for older patients with glioblastoma*. Presented at the Radiation Oncology Journal Club, Tom Baker Cancer Centre, Calgary, Alberta.
42. Olivotto, I. (2013, August). *Patient centered service design in radiation therapy*. Six sequential presentations at the BC Cancer Agency's centers in Prince George, Victoria, Vancouver, Surrey, Abbotsford and Kelowna, British Columbia.
43. Olivotto, I. (2013, October). *Interim cosmetic outcomes from RAPID: A cautionary tale from a randomized clinical trial*. Presentation at the Alberta Cancer Foundation Research Retreat, Banff, Alberta.

-
44. Olivotto, I. (2013, November). *Observation vs. RT after breast conserving surgery for favorable, luminal a breast cancer*. Presented at the 5th International Breast Cancer Conference, Jeddah, Saudi Arabia.
 45. Olivotto, I. (2013, November). *Interim cosmetic outcomes from RAPID: A cautionary tale from a randomized clinical trial*. Presented at the 5th International Breast Cancer Conference, Jeddah, Saudi Arabia.
 46. Olivotto, I. (2014, January). *Partial breast radiotherapy: Results from the randomized trials*. Presented at the Oncology Grand Rounds in the Cross Cancer Institute and the University of Alberta, Edmonton, Alberta.
 47. Olivotto, I. (2014, February). *Rationale for proton therapy in Alberta or western Canada*. Presentation to the Radiation Medicine Council. Provincial video-link from Foothills Medical Centre, Calgary, Alberta.
 48. Olivotto, I., Soo, J., French, J., Olson, R., Rowe, L., & Halperin, R. (2014). *How should RT services be scheduled to meet patient preferences for time of day, day of week, and travel duration to receive radiation therapy?* [Abstract]. Presented at the Applied Research in Cancer Control annual conference, Toronto, Ontario.
 49. Olivotto, I. (2014, February). *A cautionary tale from the conduct of randomized trials of partial breast RT*. Presented at the Nursing In-service Rounds, Tom Baker Cancer Centre, Calgary, Alberta.
 50. Olivotto, I. (2014, February). *20 Years of outcome evaluation: Lessons learned*. Presented at the Dalhousie University Department of Radiation Oncology, Halifax, Nova Scotia.
 51. Olivotto, I., Olson, R., Tiwana, M., Barnes, M., Miller, S., Hoegler, D., French, J., & Halperin, R. (2014). *Impact of a multi-pronged intervention to improve the use of single fraction radiotherapy for bone metastases across six centre's* [Abstract]. Presented at the Applied Research in Cancer Control annual conference, Toronto, Ontario.
 52. Olivotto, I. (2014, May). *Update on NCIC-CTG MA33: A randomized trial of boost RT and fractionation for DCIS of the breast*. Presented at the NCIC-CTG Annual Meeting, Toronto, Ontario.
 53. Olivotto, I. (2014, May). Closing Debate Co-Moderator. *How does proton therapy fit in Ontario/Canada?* Presented at the VIIIth Target Insights Conference: 4PRT: Photons, Protons, Particles and Progress in Radiation Therapy, Toronto, Ontario.
 54. Park, S-J., Demanes, J., Banerjee, R., & Kamrava, M. (2013). *Optimal design and development of a new vaginal multichannel cylinder applicator for gynecologic brachytherapy* [Abstract]. Presented at ASTRO 2013, Atlanta, GA.
 55. Park, S-J., Kamrava, M., Banerjee, R., & Demanes, J. (2013). *Dosimetric analysis of catheter displacement in high dose rate prostate brachytherapy* [Abstract]. American Association of Physicists in Medicine AAPM 2013.
 56. Phan, T. (2013, January). *3D Brachytherapy for cervix cancer*. Presented at the RO Journal Club in the Tom Baker Cancer Centre, Calgary, Alberta.
 57. Phan, T. (2014, January). *Complementary medicine*. Presented at the RO Journal Club in the Tom Baker Cancer Centre, Calgary, Alberta.
 58. Schorr, M., Carlson, L., Lau, H., Zhong, L., Bultz, B., Waller, A., Groff, S., & Hao, D. (2013). *Examining distress levels in patients with oropharyngeal versus non-oropharyngeal squamous cell carcinomas of the head and neck*. European Organisation on Genital Infections and Neoplasia [Abstract]. Presented at EUROGIN 2013, Florence Italy.
-

-
59. Sia, M. (2013, February). *Prostate cancer radiotherapy: What is it and who benefits?* Presented at the Prostate Cancer Public Forum, Calgary, Alberta.
 60. Sia, M. (2013, May). *Prostate cancer radiotherapy: What is it and who benefits?* Presented at the Prostate Cancer Public Forum, Calgary, Alberta.
 61. Sia, M. (2013, July). *Prostate cancer radiotherapy: What is it and who benefits?* Presented at the Prostate Cancer Public Forum, Calgary, Alberta.
 62. Sia, M. (2013, October). *Prostate cancer radiotherapy: What is it and who benefits?* Presented at the Prostate Cancer Public Forum, Calgary, Alberta.
 63. Sia, M. (2013, October). *Post-prostatectomy adjuvant and salvage radiotherapy.* Presented at the Alberta GU Tumor Group Meeting, Calgary, Alberta.
 64. Skarsgard, D. (2014, February). *Fast track lung cancer clinic: Who was seen? What was done? What happened next?* Presented at the Department of Oncology Grand Rounds, Tom Baker Cancer Centre, Calgary, Alberta.
 65. Skarsgard, D. (2014, April). *Prognostication in patients with metastatic cancer.* Presented at Radiation Oncology Journal Club, Tom Baker Cancer Centre, Calgary Alberta.
 66. Taggar, A., Lau, H., Lim, G., Nordal, R., Khan, R., Breitman, K., Hudson, A., Spencer, D., & Voroney, J-P. (2013). *Report on analysis of first 100 frameless stereotactic radiosurgery cases from the Tom Baker Cancer Centre* [Abstract]. Presented at the ACF Research Retreat, Banff, Alberta.
 67. Tiwana, W., Barnes, M., Miller, S., Hoegler, D., Olivotto, I., & Olson, R. (2014). *Palliative radiotherapy for bone metastases: Population-based utilization near the end of life in a Canadian province* [Abstract]. Presented at the American Society of Clinical Oncology, Chicago, IL.
 68. Trotter, T. (2014, May). *The status of radiation oncology as a specialty in Canada.* Presentation to the Committee on Specialties of the Royal College of Physicians and Surgeons of Canada, Ottawa, Ontario.
 69. Voroney, J-P. (2014, February). *Review of critical incidents in the Alberta radiosurgery centre.* Presented at the Alberta Radiosurgery Retreat at the University of Calgary, Calgary, Alberta.
 70. Voroney, J-P. (2014, January). *Melanoma radiation oncology research.* Presented at the Provincial Cutaneous Tumor Group Meetings, Kananaskis, Alberta.
 71. Voroney, J-P. (2014, June). *New agents and trials in the cutaneous clinic.* Presented at the Radiation Oncology Rounds, Tom Baker Cancer Centre. Calgary, Alberta.
 72. Wilson, J. (2013, September). *GU radiation oncology update.* Presented at the Southern Alberta Cancer Update, Lethbridge, Alberta.
 73. Wilson, J. (2013, October). *GU radiation oncology at the JACC-an update.* Presented at the Provincial GU Tumor Group Retreat, Edmonton, Alberta.
 74. Wilson, J. (2013, October). *Alberta radiation treatment corridor-the first 3 years.* Presented at Oncology Grand Rounds, Cross Cancer Centre, Edmonton, Alberta.
 75. Wu, J. (2013, September). *Research methods workshop (topic4): P-value fallacies and other common statistical errors.* Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Scientific Meeting, Montreal, Quebec.
 76. Wu, J. (2013, October). *Critical appraisal of adjuvant radiotherapy for prostate cancer after radical prostatectomy.* Presented at Provincial GU Tumor Group Retreat, Edmonton, Alberta.

77. Wu, J. (2013, October). *Intensity of end-of-life cancer care at TBCC, 2003-2010 review*. Presentation at the TBCC Visiting Speaker Series at the Oncology Grand Rounds, Calgary, Alberta.
78. Wu, J. (2013, October). *Integrating palliative care in outpatient oncology: Lessons from the TBCC multidisciplinary brain metastasis clinic*. Presentation at the TBCC Visiting Speaker Series at the Oncology Grand Rounds, Calgary, Alberta.
79. Yeung, R., McConnell, Y., Roxin, G., Banerjee, R., MacLean, A., Buie, W. D., Mulder, K., Vickers, M., Joseph, K., & Doll, C. M. (2013). *One versus 2 cycles of mitomycin-C in concurrent chemoradiation for treatment of anal canal carcinoma: An analysis of outcomes and toxicity* [Abstract]. Presented at the Alberta Cancer Foundation Research Conference, Banff, Alberta.

DIVISION HEAD

J. Gregory McKinnon MD FRCSC

DIVISION HIGHLIGHTS

Recruitment: The division is pleased to report the successful recruitment of a new general surgical oncologist to step into a role of leading breast and advanced gastrointestinal cancer. This was the culmination of a long search process with several international applicants. The new position will be appointed to the Department of Surgery with a cross-appointment to the Department of Oncology. Although this individual will be located in the Foothills Hospital we hope and expect to eventually attract full participation in the Cancer Centre. In addition, the Department of Surgery has recruited Dr. Michael Monument, a researcher and expert in soft tissue sarcoma, to begin working at the Tom Baker Cancer Centre (TBCC) in the fall of 2014. Dr. Monument is an outstanding individual who will eventually help fill the gap in sarcoma care left by the retirement of Dr. Norman Schachar.

Programs: The development of a world class program in breast cancer suffered a setback due to the cancellation of plans to develop a freestanding facility. However plans to develop a multidisciplinary unit in the new cancer center are proceeding and will hopefully lead to a national regional program in the next five to seven years.

Events: An International Symposium on Cancer Surgery Honoring Dr. Walley Temple was held in November 2013 in the TBCC. This attracted international attention with participants from many different countries. Dr. Temple-Oberle hosted Breast Reconstruction Awareness day (BRA day) which attracted hundreds of lay and media participants to the TBCC. This will become an annual event.

The division hosted the annual Department of Surgery Retreat. The subject was new strategies to deliver cancer care and included participation of representatives from CancerControl Alberta.

STRATEGIC PLANNING

The most important strategic initiative of the division is to attract surgical leaders in cancer care to participate in the Department of Oncology and the provincial cancer control program. Constrained resources and competing interests present a challenge to this aim. Strategic planning with new resources from the new Cancer Centre, along with new provincial resources, will hopefully promote this goal and ultimately bring a huge benefit to the welfare of Alberta cancer patients.

RESEARCH HIGHLIGHTS

Division members continue to be active in publishing and speaking on their various areas of clinical expertise. Dr. Temple holds several large grants to continue his work in Cancer Surgery Alberta and synoptic operative reports. An important new project in patient reported outcome was successfully completed. Dr. Quan was the recipient of a three million dollar grant to study

breast cancer in young women. Dr. Dort was awarded the prestigious Janes Visiting Professorship in Surgery by the Royal College of Physicians and Surgeons of Canada. He also, along with colleagues Drs. Karl Riabowol and Don Morris, was successful in the 2014 AIHS Cancer CRIO competition.

PROGRAM

Surgical oncology is providing leadership of the following clinical programs: breast, advanced gastrointestinal, soft tissue sarcoma, cutaneous and hepatobiliary.

The Peritoneal Surgery program remains a national leader in the provision of this treatment.

Cancer Surgery Alberta was created by Dr. Temple and the Division of Surgical Oncology and although it has expanded to a national program, its center will remain at the TBCC. There are now over 30,000 patients in the database.

Dr. Bathe is now the Provincial Tumor Group Leader for G.I. and Dr. Mack of the Provincial Sarcoma Tumor Group. Dr. Temple-Oberle assumed leadership of the cutaneous clinic.

U OF C PROFESSORSHIP/ENDOWED CHAIRS

The division is actively fundraising for a Chair in Surgical Oncology.

AWARDS

Quan, M. L. Award for Researcher of the Year in the Department of Oncology, 2013.

Mack, L. Award for Teacher of the Year in the Department of Surgery.

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Arlette, J. P. (2013, November). *Advances in our approach to skin cancer prevention and detection*. Keynote speaker. Presented at the Family Practice Review and Update Course, Calgary, AB.
2. Arlette, J. P. (2013, October). *Approaching the sun damaged patient*. Invited speaker. Rural Video Conference, Calgary, AB.
3. Arlette, J. P. (2013, October). *Simplifying the complexity of skin cancer management*. Invited speaker. Presented at the Department of Family Medicine, University of Calgary, Calgary, AB.
4. Arlette, J. P. (2013, October). *Skin cancer evaluation and investigation*. Invited speaker. Christie Theatre, University of Calgary, Calgary, AB.
5. Arlette, J. P. (2013, September). *Dermatology: Cancer to cosmetic, horror to beauty*. Invited speaker. Presented at the Update in Medicine for Psychiatrists Meeting, Banff, AB.
6. Arlette, J. P. (2013, September). *Diagnosis and management of skin cancer*. Invited speaker. Presented at University of Calgary Medical School, Calgary, AB.

7. Arlette, J. P. (2013, September). *Simplifying the complexity of skin cancer management*. Invited speaker. Presented at the Department of Family Medicine, University of Calgary, Calgary, AB.
8. Arlette, J. P. (2014, April). *Fillers*. Invited speaker. Breakfast Television, Calgary, AB.
9. Arlette, J. P. (2014, February). *Simplifying the complexity of skin cancer management*. Invited speaker. Presented at the Department of Family Medicine, University of Calgary, Calgary, AB.
10. Arlette, J. P. (2014, January). *Simplifying the complexity of skin cancer management*. Invited speaker. Presented at the Department of Family Medicine, University of Calgary, Calgary, AB.
11. Arlette, J. P. (2014, March). *Advances in management in skin cancer*. Invited speaker. Primary Care Network, Calgary, AB.
12. Butte, J. M., Grendar, J., Bathe, O., Sutherland, F., Ball, C. G., & Dixon, E. (2014, February). *What is the current role of perihepatic drain (PD) placement in surgery? A prospective analysis*. Invited speaker. Presented at the AHPBA Annual Meeting, Miami, FL.
13. Dixon, E. (2013, July). *Intraductal papillary mucinous neoplasm*. Invited speaker. Presented at the Mexican Hepato-Pancreatico-Biliary Association 1st International Hepato-Pancreatico-Biliary Congress, Cancun, Mexico.
14. Dixon, E. (2013, November). *Current management of bile duct injuries*. Invited speaker. Presented at The Uruguayan Hepato-Pancreatico-Biliary Association 1st International Hepato-Pancreatico-Biliary Congress, Montevideo, Uruguay.
15. Dixon, E. (2013, November). *Why become a member of the AHPBA?* Invited speaker. Presented at The Uruguayan Hepato-Pancreatico-Biliary Association 1st International Hepato-Pancreatico-Biliary Congress, Montevideo, Uruguay.
16. Dixon, E. (2013, November). *What is the future of minimally invasive HPB surgery?* Invited speaker. Presented at The Uruguayan Hepato-Pancreatico-Biliary Association 1st International Hepato-Pancreatico-Biliary Congress, Montevideo, Uruguay.
17. Dort, J. C. (2013, October). *Transforming head and neck cancer surgical care*. Invited speaker. Presented at the Alberta Cancer Foundation meeting, Calgary, AB.
18. Dort, J. C. (2014, April). *Care pathways as a tool to improve patient care*. Invited speaker. Presented at the Department of Surgery Retreat, Banff, AB.
19. Dort, J. C. (2014, May). *A provincial pathway for head and neck surgical care*. Invited speaker. Presented at the Surgery Strategic Clinical Network meeting, Calgary, AB.
20. Dort, J. C. (2014, May). *Care pathways as a tool to improve patient care in head and neck surgery*. Invited speaker. Presented at the Anesthesia Grand Rounds, Calgary, AB.
21. Dort, J. C. (2014, May). *Head & neck surgical care: A pathway to better outcomes*. Invited speaker. Presented at the Tom Baker Cancer Centre Grand Rounds, Calgary, AB.
22. Edwards, J., Bressan, A., Grondin, S., Datta, I., Dixon, E., & Ball, C. (2014, May). *Hepato-pancreatico-biliary surgery in Canada: Workforce and wait times*. Poster presented at the Pancreas Club Annual Meeting, Chicago, IL.
23. Edwards, J., Datta, I., Grondin, S., Bressan, A., Dixon, E., & Ball, C. (2014, May). *Hepato-pancreatico-biliary surgery in Canada: Workforce and wait times*. Poster presented at the Society for Surgery of the Alimentary Tract 54th Annual Meeting, Chicago, IL.

24. Edwards, J., Datta, I., Hunt, J. D., Stefan, K. J., Ball, C. G., Dixon, E., & Grondin, S. (2013, September). *A novel approach to the thoracic surgery workforce planning: Are we training too many or too few?* Invited speaker. Presented at the Canadian Association of Thoracic Surgeons Annual Meeting, Ottawa, ON.
25. Farshidfar, F., Weljie, A., Kopciuk, K. A., Vogel, H. J., Hilsden, R., McGregor, E., & Bathe, O. F. (2014, January). *Targeted analysis of progressive metabolic perturbations in colorectal cancer and colorectal adenoma: Potential for a serum metabolomics-based screening test.* Poster presented at the ASCO Gastrointestinal Symposium, San Francisco, CA.
26. Farshidfar, F., Weljie, A. M., Kopciuk, K., Vogel, H. J., Hilsden, R., & Bathe, O. F. (2013, November). *Successive metabolomics changes during progression of colorectal cancer: Identifying metabolites for targeted analysis for early detection of colorectal cancer.* Poster presented at the Canadian Cancer Research Conference, Toronto, ON.
27. Farshidfar, F., Weljie, A. M., Kopciuk, K., Vogel, H. J., Hilsden, R., Bathe, O. F. (2013, October). *Identification of metabolites for targeted analysis for early detection of colorectal cancer.* Invited speaker. Presented at the Alberta Cancer Foundation Cancer Research Conference, Banff, AB.
28. Grendar, J., Ouellet, J. F., Sutherland, F., Bathe, O., Ball, C. G., & Dixon, E. (2014, February). *In search of the best reconstructive technique in the Whipple operation: Pancreaticojejunostomy versus pancreaticogastrostomy: A randomized controlled trial.* Invited speaker. Presented at the AHPBA Annual Meeting, Miami, FL.
29. Laffin, M., Quan, M. L., Dixon, E., Ball, C., Maclean, A., & Shaheen, A. A. (2013, October). *Surgical Safety Checklist: Missing when we need it most?* Invited speaker. Presented at the American College of Surgeons 99th Clinical Congress, Washington, DC.
30. Lafrenière, R. (2013, November). *Horologists, pilots and surgeons.* Presidential address at the North Pacific Surgical Association Annual Meeting, Victoria, BC.
31. Mack, L. A. (2013, July). *Cytoreductive surgery with heated intraperitoneal chemotherapy – An emerging treatment option for advanced goblet cell tumours of the appendix.* Invited speaker. Presented at the Association of Coloproctology of GB & I Annual Meeting, Great Britain and Ireland.
32. Mack, L. A. (2013, November). *Evaluating population-based breast cancer surgical practice in real-time with a web-based synoptic operative reporting system (WebSMR).* Invited speaker. Presented at the North Pacific Surgical Association Annual Meeting, Victoria, BC.
33. Mack, L. A. (2013, November). *Learning curve analysis for cytoreductive surgery – A useful application of the cumulative sum (CUMSUM) method.* Invited speaker. Presented at the General Surgery Faculty Academic Half Day, Calgary, AB.
34. Mack, L. A. (2013, November). *Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis.* Invited speaker. Presented at the North Pacific Surgical Association Annual meeting, Victoria, BC.
35. Mack, L. A. (2013, November). *Treatment of superficial soft tissue sarcoma: Is surgery along enough?* Invited speaker. Presented at the International Symposium on Cancer Surgery honoring Dr. Walley J. Temple, Calgary, AB.
36. Mack, L. A. (2013, September). *Improving residency training in end-of-life care – A survey of Canadian general surgical faculty and trainees.* Invited speaker. Presented at the Canadian Surgical Forum, Ottawa, ON.

-
37. Mack, L. A. (2014, April). *Surgical approach to desmoid tumours*. Invited speaker. Presented at the Alberta Provincial Sarcoma Meeting, Edmonton, AB.
 38. Mack, L. A. (2014, May). *Quality of life and functional outcomes in patients with soft tissue sarcomas treated with preoperative chemoradiation: A prospective study*. Invited speaker. Presented at the Canadian Society of Surgical Oncology Annual Meeting, Toronto, ON.
 39. Rivard, J., Kostaras, X., Shea-Budgell, M., Chin-Lenn, L., Quan, M. L., & McKinnon, J. G. (2014, March). *A population-based assessment of melanoma: Does treatment in a regional cancer centre make a difference?* Poster presented at the Society of Surgical Oncology (SSO) Annual Meeting, Phoenix, AZ.
 40. Sabogal, J. C., Ball, C. G., Bathe, O., Sutherland, F., & Dixon, E. (2013, August). *ALPPS: Liver resection in two stages: Experience at Foothills Medical Centre in Calgary*. Invited speaker. Presented at the XXXIX Congreso Nacional Avances en Cirugia, Bogota, Colombia.
 41. Sabogal, J. C., Ball, C. G., Sutherland, F. R., & Dixon, E. (2013, August). *Pancreatoduodenectomies in Colombia: A qualitative study of pancreatic surgery from the surgeon's perspective*. Invited speaker. Presented at the XXXIX Congreso Nacional Avances en Cirugia, Bogota, Colombia.
 42. Sutherland, F. R. (2014, January). *Bile duct injuries and the surgical mind: What were you thinking?* Invited speaker. Presented at the Alberta Association of General Surgeons (AAGS) Review in the Rockies, Banff, AB.
 43. Sutherland, F. R. (2014, March). *Bile duct injuries: New cognitive therapy*. Invited speaker. Presented at the Division of General Surgery City-Wide Rounds, Calgary, AB.
 44. Temple, W. J. (2013, November). *Science is our inspiration – Caring is our instrument*. Keynote speaker. Presented at the International Symposium on Cancer Surgery honoring Dr. Walley J. Temple, Calgary, AB.
 45. Temple, W. J. (2014, May). *Synoptic reporting*. Invited speaker. Presented at the Saskatoon Health Quality Summit, Saskatoon, SK.
 46. Temple-Oberle, C. F. (2013, November). *An approach to immediate breast reconstruction*. Invited speaker. Presented at the International Symposium on Cancer Surgery honoring Dr. Walley J. Temple, Calgary, AB.
 47. Temple-Oberle, C. F. (2013, October). *Breast reconstruction awareness*. Invited speaker. Presented to the Trophy Club at the Calgary Petroleum Club, Calgary, AB.
 48. Temple-Oberle, C. F. (2013, October). *Immediate breast reconstruction*. Invited speaker. Presented at the Atlantic Society of Plastic Surgeons Meeting, Halifax, NS.
 49. Temple-Oberle, C. F. (2013, October). *Management of in-transit melanoma*. Invited speaker. Presented at the Atlantic Society of Plastic Surgeons Meeting, Fox Harbour, NS.
 50. Temple-Oberle, C. F. (2013, September). *Alberta clinical practice guidelines – Breast reconstruction*. Invited speaker. Presented at the Alberta Society of Plastic Surgeons Annual Meeting, Banff, AB.
 51. Temple-Oberle, C. F. (2014, April). *Pathway development in cancer care: Oncologic reconstruction*. Invited speaker. Presented at the Department of Surgery Retreat, Banff, AB.
 52. Temple-Oberle, C. F. (2014, April). *Role in limb salvage surgery*. Invited speaker. Presented at the 2014 Annual Sarcoma Tumour Team Meeting, Edmonton, AB.
 53. Temple-Oberle, C. F. (2014, April). *Validity of the DASH for functional outcome evaluation in upper extremity sarcoma limb salvage therapy*. Invited speaker. Presented at the 2014 Annual Sarcoma Tumour Team Meeting, Edmonton, AB.
-

54. Temple-Oberle, C. F. (2014, February). *Breast reconstruction options and timing*. Keynote Invited speaker. Presented for the Breast Cancer Supportive Care Foundation, Calgary, AB.
55. Temple-Oberle, C. F. (2014, January). *Enhanced recovery*. Invited speaker. Presented at the Plastics/Anesthesia Joint Rounds, Foothills Medical Centre, Calgary, AB.
56. Temple-Oberle, C. F. (2014, March). *An update on breast reconstruction in Alberta*. Invited speaker. Presented at the Annual Provincial Breast Tumour Team Meeting, Kananaskis, AB.
57. Temple-Oberle, C. F. (2014, March). *ILI and IL-2 for in transit melanoma*. Invited speaker. Presented at the Victoria BC Melanoma Group meeting, Victoria, BC.

DIVISION HEAD

Don Morris, MD, PhD, FRCPSC

DIVISION HIGHLIGHTS

The Translational Laboratory (TransLab) is located at the Tom Baker Cancer Centre (TBCC) in Calgary, Alberta. The facility's main objective is to translate research discoveries into clinically useful laboratory assays that benefit patients. The TransLab provides high quality Molecular Analysis, Tissue Imaging, Pharmacokinetic, and Circulating Tumor Cell services for clients that support Clinical Diagnostics and Translational Research within the scope of Cancer Care in Alberta. Since inception in 1999, the lab has become a well-known and accessible hub for comprehensive studies *Translating* Genomic Signatures & Biomarker Discovery to Patient Care. The facility is recognized by Cancer Care professionals as one of the leading cancer biomarker development and core service centers in the country for innovation, efficiency and quality.

TransLabs will continue to explore applications to move gene mutation analysis protocols to clinical applications. An example of this is an EGFR (Epidermal Growth Factor Receptor) gene mutation analysis protocol has become a standardized clinical test. The assay aids clinicians in identifying lung cancer patients who may benefit from EGFR tyrosin kinase inhibitor therapies such as *Iressa* and *Tarceva*. This technology was successfully transferred to clinical sites in Alberta that currently serve as the testing hubs for multiple regions (Alberta, Saskatchewan, Manitoba, and Northwest Territories). The TransLab advanced the study from bench biomarker discovery to an implemented clinical assay in an unprecedented two-year period. This was a trans-Canadian study involving five Canadian centers of excellence.

There are currently more than 60 on-going and prospective projects/collaborations of various scales involving the TransLab. The units support a growing clientele that includes 40 local Principal Investigators and 21 External and Industry clients. Examples of internal clients include members of UofC, SACRI, ACRB, AHS oncology, and CLS pathology. Examples of external clients include the University of Alberta, Stanford University, Moffitt Center, Biotech and Pharmaceutical companies, and Cooperative clinical trial groups such as RTOG and NCIC-CTG.

The Translational Labs welcomed the new Functional Tissue Imaging Unit Leader, Emeka Enwere in June, 2014.

The Gwyn Bebb Research Lab welcomed Adrijana D'Silva as the new Lung Project Coordinator in 2014.

CURRENT ISUSES

Wet and dry lab work space continues to be an issue to support the students, post docs and pathology fellows. Funds for renovations to address the safety issues are required in order to get projects in the AHS renovation and construction queue. This includes things such as a door

between clean and dirty lab space and eyewash stations. It is not possible to fund these initiatives through research grants.

There is a lack of appropriate storage space creating clutter and taking up premium wet lab space.

STRATEGIC PLANNING

The Translational Labs is in the process of defining its Fee-for-Service Business Model in conjunction with seeking core infrastructure support in order to achieve a balanced, sustainable and predictable outlook for the future.

In regards to research, there is an increasing demand from funding agencies to support cooperative efforts that utilize resources across multiple labs and Principle Investigators. With specialized services that are applicable across a broad spectrum of cancer research focuses and access to both researchers and clinicians, the Translational Labs is ideally positioned for this movement. The Lab is strategically positioned to promote interaction between stakeholders, including the Southern Alberta Cancer Research Institute (SACRI) and University of Calgary (UofC) Researchers, Alberta Health Services (AHS), Calgary Laboratory Services (CLS) and the Alberta Cancer Research Biorepository (ACRB). This relationship is the platform for investigators/health professionals to rapidly translate translational research into practice.

FUNCTIONAL TISSUE IMAGING UNIT

The Functional Tissue Imaging Unit (FTIU) focuses on the identification and characterization of biomarkers, which are proteins whose detection is vital to the management and treatment of cancer. Our work with clinical and basic research scientists contributes to discovery of biomarkers that are predictive (of tumour responsiveness to a particular treatment), or prognostic (of the severity or course of disease). Existing diagnostic techniques employed to identify such biomarkers are very similar to the techniques employed by the FTIU, and thus our research findings can translate readily into the workflow of a diagnostic lab. These techniques involve immunohistochemistry, which is a method to identify and measure biomarkers within the tissue under analysis. The most essential component of immunohistochemistry is the primary antibody, which is a protein that binds to a specific target, and is then used to measure the presence of that target within the tissue. While immunohistochemistry is used extensively in a clinical environment, it is very difficult to confirm that antibodies bind to their desired targets, and only to their desired targets. Non-specific binding of an antibody to a different target leads to false positive diagnoses and consequent errors in treatment management. We propose to address this problem using a technology known as RNA interference (RNAi). In cells, grown in tissue culture, RNAi can specifically and effectively eliminate only a particular biomarker of interest. These cells can then be subjected to the same preparative and analytical procedures as clinical or research samples. Antibodies that are highly specific to a biomarker can be expected to detect no signal in cells that are RNAi-treated to remove that biomarker, whereas antibodies binding non-specifically to different targets will continue to detect a signal and can thus be eliminated from use. We propose to dedicate these funds towards the recruitment of a technician who can develop RNAi-based controls in the FTIU.

This would greatly facilitate biomarker research in our environment, and ultimately enhance the precision of clinical diagnostic approaches to cancer and other diseases.

Development of a Pharmacokinetic Method Library, Proposed by Tom Baker Cancer Centre, Translational Labs, Pharmacokinetics Division

Phase I trials are the first stage of testing in human subjects and often involve dose escalation studies in combination with pharmacokinetic sampling so that the appropriate dose for therapeutic use of the drug can be determined.

Often by the time a novel agent is being tested in a phase I trial at the Tom Baker Cancer Centre, it will be in combination with existing standard chemotherapy or targeted agents. Therefore, pharmacokinetically, it is not only important to determine the kinetics of the novel agents but also that of the existing chemotherapy / target agent given in combination, in order to elucidate any synergistic, additive or antagonistic effects or any changes to the overall kinetics.

Pharmacokinetic analysis requires time and concentration variables. Time is obtained from the actual sampling time and the drug concentration at that particular sampling time is determined by means of a quantitative assay. Often times for small molecules < 2000 Daltons the quantitative method of choice is tandem mass spectrometry coupled to liquid chromatography. The mass spectrometry assay is often a technically challenging and time consuming procedure which involves method development for extraction of the compound of interest from the biological matrix, analytical chromatography and development of the quantitative assay on the mass spectrometer instrument, which overall can take up to six months per compound.

In this initiative we are proposing to develop a library of quantitative methods for key classes of compounds that are currently in use in our clinics. This work will be completed over the next two years. We have consulted with our in centre oncologists and have already put together a list of key compounds that would most likely be considered standard treatment which would be given with any up and coming novel agent being considered for a phase I trial.

Having such a method library on hand will give the Tom Baker Cancer Centre's phase I clinical trials division a distinctive advantage for attracting new phase I trials. The selling point will be that we can conduct the pharmacokinetic component of the combination standard treatment in-house, and this will save time and money and would allow us to design this component of the PK trial giving us control over the study design in relation to the clinical questions and ultimately keeping the data within the centre.

In addition, expansion of chemotherapy quantitative method library will benefit basic research and preclinical models where the desire is to measure the concentration of a particular chemo agent in cells, animal models etc. Having the quantitative method on hand will save the SACRI researcher the upfront cost of method development (which is the bulk of the expense), and speed-up project time lines, hence a win-win situation.

RESEARCH HIGHLIGHTS

A current study extensively involving the TransLab is the AIHS-Collaborative Research and Innovation Opportunities funded project: *PIK3CA Mutation and Associated Pathway Activation Status and Survival in Patients with Cervical Cancer: Quantifying the Risk and Testing the Solution*.

The objective of this study is to characterize PIK3CA mutation frequency and evaluate associated pathway alterations in cervical cancers, their association with pathologic and outcome factors, and acquire pre-clinical data necessary to initiate biomarker-driven clinical trials of PI3K inhibitors. This is an on-going three year study that is utilizing TransLab Tissue Imaging and Molecular Analysis expertise.

(Lung Project Updates): The retrospective data collection conducted in the last year has contributed to a complete comprehensive chart review for 5,500 patients diagnosed with NSCLC between 1999 and 2010. During this past year, full chart reviews were completed for all 2009-2010 patients.

Recently, we received the 2011 and 2012 cohort from the Alberta Cancer Registry and reviewing these charts that will be our focus to the following year. We are hoping to receive the 2013 cohort early next year.

The success of this project is reflected in the data it has already generated. By incorporating the capability of the Translational Research Laboratory in the Tom Baker Cancer Centre, it has been possible to utilize this information for Oncologists in Calgary to determine the following:

- Survival of non small cell lung cancer in Calgary matches seen in published historical data from across the world.
- Median overall survival of stage IV non small cell lung cancer patients who received systemic treatment between 2003 and 2006 is over 11 months, comparing very favorably with the best data from published phase III clinical trials.
- Only 23% of stage IV NSCLC patients receive chemotherapy. Reasons for this are the focus of an ongoing project.
- Outcome for similarly staged NSCLC patients in 2010 is only marginally better than for those of 2000.

PROGRAM

Pharmacokinetic monitoring and dose adjustment of busulfan in BMT (Adults and Pediatrics) – On-going clinical testing by the Pharmacokinetic Unit

PRESENTATIONS / INVITED ADDRESSES / SYMPOSIUMS

1. Akhter, A., Farooq, F., Mahe, E., Shabani-Rad, M. T., Street, L., Morris, D., Stewart, D., & Mansoor, D. (2014). *Mantle cell lymphoma: Toll-like receptors (TLRs) and B-cell receptor (BCR) gene expression analysis identify a distinct BCR activated subset, with germinal center signature and indolent biology* [Abstract]. Presented at the American Society Of Clinical Oncology, Annual Meeting.

2. Akhter, A., Masir, N., Mahe, E., Elyamany, G., Shabani-Rad, M. T., Stewart, D., Morris, D., & Mansoor, D. (2014). *Gene expression analysis of B-cell receptors (BCR) pathway identify PDE4B gene as potential therapeutic target to overcome glucocorticoid resistance in primary CNS lymphoma* [Abstract]. Presented at the American Society Of Clinical Oncology, Annual Meeting.
3. Bebb, D. G. (2013). *ATM deficiency increases radiation sensitivity in NSCLC cell lines in vitro and confers a poor outcome in early resected NSCLC* [Abstract]. Poster presented at the IASLC 15th World Conference on Lung Cancer, Sydney, Australia.
4. Bebb, G. (2014, June). *From genomics to medicine: New approaches to drug discovery & development*. Invited Speaker. University of Calgary, Calgary, AB, Canada.
5. Bebb, G. (2014, January). *Building a clinical research bridge at the new Calgary Cancer Centre*. Invited Speaker. New Calgary Cancer Centre Team, Calgary, AB, Canada.
6. Bebb, G. (2013, October). *The animal within: Cancer, metastasis and the ultimate metastatic phenotype*. Invited Speaker. Canadian Oncology Society, Webinar, Calgary, AB, Canada.
7. Bebb, G. (2013, October). *Lung cancer: Improving outcomes through early detection and research*. Invited Speaker. Alberta Cancer Foundation Conference, Lung Session, Banff, AB, Canada.
8. Bebb, G. (2013, September). *Clinical cancer research – Qu' est-ce que c'est?* Invited Speaker. Network Fest, Edmonton, AB, Canada.
9. Bebb, G. (2013, September). *Ataxia telangiectasia mutated (ATM): An emerging role in cancer*. Invited Speaker. Genomic Instability and Ageing Conference, Calgary, AB, Canada.
10. Bebb, G. (2013, September). *ATM deficiency in non small cell lung cancer*. International Meeting on Genetic Instability and Ageing, Calgary, Alberta Canada.
11. Box, A., McIntyre, J. B., Perizzolo, M., Winkfein, B., & Demetrick, D. (2013, October). *Development of a rapid RT-PCR detection of EGFRvIII mutants in formalin-fixed paraffin embedded (FFPE) tissue*. Poster presented at the University of Calgary Department of Pathology Research Day, Calgary, Alberta [Awarded best overall poster presentation].
12. Elegbede, A. A., Petersen, L. F., Kubota, E., Lees-Miller, S. P., & Bebb, D. G. (2013, October). *Role of ATM in response to therapeutic agents in NSCLC cell lines*. Poster presented at the Alberta Cancer Foundation Cancer Research Conference, Banff, Alberta, Canada and IASLC 15th World Conference on Lung Cancer, Sydney, Australia.
13. Feng, X., Freiheit, E., Morisky, D., Mulder, K., Chu, Q., Bramwell, V., & Morris, D. (2013). *A prospective observational cohort study of adherence to oral tyrosine kinase inhibitors (TKIs) in gastrointestinal stromal tumor (GIST)* [Abstract]. Presented for SACRI/ Dept of Oncology Research Day.
14. Griffiths, C. D., Ng, E. S. M., Kangarloo, B., Williamson, T. S., Booker, R., Yue, P., Duggan, P., Savoie, M. L., Brown, C., Daly, A., Russell, J. A., Storek, J. (2013, November). *Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function*. *Blood*, 122(21). Poster presentation at the 55th Annual Meeting of the American Society of Hematology, DEC 07-10, 2013, New Orleans, LA.

15. Ko, J., Liu, M., Otsuka, S., Boland, W., Skolnik, K., Macklow, J., Morris, D., & Bebb, G. (2014). *Referral to a cancer centre, medical oncologist and use of systemic treatment in stage IV non-small cell lung cancer patients – comparison of years 2003 – 2006 and 2010 cohorts in a Canadian institution* [Abstract]. Presented at the American Association of Cancer Research, Annual Meeting.
16. Kornaga, E., Paterson, A. H. G., Morris, D., Magliocco, A., & Klimowicz, A. (2013). *A better clinical cutpoint for progesterone receptor expression in tamoxifen treated breast cancer*. Presented at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting, San Antonio, Texas, USA.
17. Kornaga, E., McIntyre, J. B., Klimowicz, A., Guggisberg, N., Morris, D., & Magliocco, A. (2014). *Evaluation of RT-qPCR and luminex-based methodologies in HER2 breast cancer testing*. Presented at the San Antonio Breast Cancer Symposium.
18. Lee, L., & Bebb, G. (2013). *Digital differentiation of squamous cell carcinoma and adenocarcinoma of the lung by the geometry of their epithelial architecture* [Abstract]. Submitted to U of C PGME, winner of the Canadian Society for Clinical Investigation Award for excellence in resident research.
19. McIntyre, J. B., Jewett, G., Kornaga, E., Wang, X., Lees-Miller, S., Craighead, P. S., Ghatage, P., Robbins, S. M., Magliocco, A. M., & Doll, C. M. (2013). *Differential gene expression profiling and association with clinical outcome in cervical cancer histological subtypes*. Poster Presented at the Alberta Cancer Foundation 2013 Cancer Research Conference, Banff, Alberta.
20. McIntyre, J. B., Jewett, G., Kornaga, E., Wang, X., Lees-Miller, S., Craighead, P. S., Ghatage, P., Robbins, S. M., Magliocco, A. M., & Doll, C. M. (2013). *Differential gene expression profiling and association with clinical outcome in cervical cancer histological subtypes*. Poster Presented at The Canadian Cancer Research Conference. Toronto, Ontario.
18. Morris, D (2014, June). *Immunological aspects of oncolytic viral treatments*. Invited Speaker. Terry Fox Canada-Wide Immunotherapy Program Workshop, Toronto, ON, Canada.
19. Morris, D (2014, May). *Reovirus from bench to bedside and back again: A promising oncolytic viral strategy for the treatment of cancer*. Invited Speaker. Haematology/Oncology Grand Rounds, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
20. Morris, D. (2014, May). *Next generation sequencing multiplex testing for lung cancer*. Presented for the Provincial Lung Tumor Team Meeting, Edmonton, AB, Canada.
21. Morris, D. (2014, February). *Update on the use of reovirus as at for breast cancer*. Invited Speaker. Canadian Breast Cancer Foundation Night of Honor, Calgary, AB, Canada.
22. Morris, D. (2014, February). *Research as part of the oncologist's career*. Presented for TBCC Medical Oncology Resident Research Luncheon, Calgary, AB, Canada.
23. Morris, D. (2014, February). *Chair at the Canadian Lung Cancer Conference: Should pharmaceutical companies pay for the biomarker companion test for their drugs?* Presented for Canadian Lung Cancer Conference. Debate, Vancouver, BC, Canada.
24. Morris, D. (2013, November). *Highlights on lung cancer from ESMO and World Lung Congresses*. Presented for ESMO and WLC Lung Update Calgary, AB, Canada.
25. Morris, D. (2013, September). *Research: Should it be woven into the fabric of patient care*. Presented for Special Oncology Grand Rounds, Tom Baker Cancer Centre, Calgary, AB, Canada.

26. Otsuka, S., Boland, W., Hao, D., Morris, D., & Bebb, D. G. (2013, October). *Metastatic NSCLC outcomes at a single Canadian institution over a decade*. Poster presented at the IASLC 15th World Conference on Lung Cancer, Sydney.
27. Petersen, L. F., McIntyre, J. B., Elegbede, A. A., Lees-Miller, S. P., & Bebb, D. G. (2013). *Deep sequencing mutational analysis of ATM in NSCLC cell lines*. Invited talk, Alberta Cancer Foundation Cancer Research Conference, Banff, Alberta, Canada.
28. Petersen, L. F., McIntyre, J. B., Elegbede, A. A., Lees-Miller, S. P., & Bebb, D. G. (2013, October). *Deep sequencing mutational analysis of ATM in NSCLC cell lines*. Poster presented at the IASLC 15th World Conference on Lung Cancer, Sydney, Australia.
29. Riess, J. W., West, R., Padda, S. K., Kong, C., Dean, M., Klimowicz, A. C., Huong, C., Neal, J. W., & Wakelee, H. A. (2013, September). *Gli1, notch1 and CTNNB1 expression by automated quantitative immunofluorescence (AQUA) in a thymic malignancy tissue microarray (TMA)* [Abstract]. Presented at the International Thymic Malignancy Interest Group (ITMIG), Annual Meeting, Bethesda, MD, USA.
30. Riess, J. W., West, R., Padda, S. K., Kong, C., Dean, M., Klimowicz, A. C., Huong, C., Neal, J. W., & Wakelee, H. A. (2013, October). *Gli1, notch1 and CTNNB1 expression by automated quantitative immunofluorescence (AQUA) in a thymic malignancy tissue microarray (TMA)* [Abstract]. Presented at the World Conference on Lung Cancer, Annual Meeting, Sydney, Australia.
31. Shahbal, B., Kangaroo, E., Ng, S. M., Bramwell, V. H. C., Pritchard, K. I., Shepherd, L., Tu, D., Magliocco, A. M., & Tang, P. A. (2014, May). *Pharmacokinetic analysis of tamoxifen and its metabolites in premenopausal women with early breast cancer treated with tamoxifen: A substudy of NCIC CTG MA.12 randomized clinical trial*. Poster presented at ASCO (American Society of Clinical Oncology).
32. Withecomb, S., Otsuka, S., Petersen, L. F., Klimowicz, A. C., Pohorelic, B., Kopciuk, K., Zhang, Y., Petrillo, S. K., Konno, M., Morris, D., & Bebb, G. (2013, October). *Role of CXCR4 and estrogen/progesterone receptor (ER/PR) pathway interaction in metastatic non-small cell lung cancer* [Abstract]. Poster presented at the Alberta Cancer Foundation Cancer Research Conference, Banff, Alberta, Canada, and IASLC 15th World Conference on Lung Cancer, Sydney, Australia.
33. Yee, R. A., Petersen, L. F., Elegbede, A. A., & Bebb, D. G. (2013, October). *Synergistic study of chemotherapeutic drugs according to ATM and p53 status in NSCLC cell lines* [Abstract]. Poster presented at the Alberta Cancer Foundation Cancer Research Conference, Banff, Alberta, Canada.
34. Yee, R. A., Petersen, L. F., Elegbede, A. A., & Bebb, D. G. (2013, October). *Synergistic study of chemotherapeutic drugs according to ATM and p53 status in NSCLC cell lines* [Abstract]. Poster presented at the IASLC 15th World Conference on Lung Cancer, Sydney, Australia.

FUNDAMENTAL RESEARCH

NO REPORT WAS SUBMITTED FOR THE 2013-2014 ACADEMIC YEAR.

GYNECOLOGIC ONCOLOGY

TRAINING PROGRAMS

UNDERGRADUATE

The gynecologic oncology service contributes to undergraduate lectures and small group sessions in the reproduction course as well as clinical sessions for the University of Calgary clinical clerks.

We provided electives for 24 undergraduate medical students from across the country for two to four electives on our clinical service.

GRADUATE

Fourth year residents from obstetrics and gynecology do three to four month blocks of clinical service on gynecologic oncology. Our service has consistently received excellent ratings from the residents. In addition, we provided gynecologic oncology electives for three visiting residents and one international medical graduate as well as provided oncology experiences at the PGY1 level for residents from radiology, pathology, radiation oncology and PGY 4/5 level for medical oncology. PGY2 residents in obstetrics and gynecology joined our service and each do a one month rotation as an introduction to gynecologic oncology and colposcopy.

POSTGRADUATE

Our fellowship program is accredited by the Royal College of Physicians and Surgeons of Canada. We had six fellows in 2013-2014.

CONTINUING PROFESSIONAL DEVELOPMENT

All five gynecologic oncologists participated in the Royal College Maintenance of Competence Program.

HEMATOLOGIC MALIGNANCIES & BMT (AHS PROPOSED)

TRAINING PROGRAMS

Hematology, program director: Dr. Michelle Geddes
Bone Marrow Transplantation, program director: Dr. Mona Shafey
Lymphoma, program director: Dr. Peter Duggan

UNDERGRADUATE

The “Blood” course, chaired by Dr. Lynn Savoie, continues to be one of the most highly rated undergraduate courses at the University of Calgary medical school.

POSTGRADUATE

Three new trainees started their hematology training July 1, 2014, for a total of eight fellows currently in the program. Dr. Joanna Graczyk began a 1-year lymphoma fellowship program in January 2014, while Dr. Danielle Oh is completing a lymphoma research fellowship.

CONTINUING PROFESSIONAL DEVELOPMENT

The Division of Hematology continues to host weekly educational rounds. This very successful and very well attended program is organized by the post-graduate education program within the division (Dr. Michelle Geddes). It covers a broad range of topics in both benign and malignant hematology.

Dr. Michelle Geddes is Chair, and Dr. Lynn Savoie is a member of the planning committee for the 2014 Canadian Conference on Myelodysplastic Syndromes being held this year in Banff, Alberta.

MEDICAL ONCOLOGY

TRAINING PROGRAMS

Medical Oncology Residency Training Program Report – Dr. Scot Dowden

The Medical Oncology Training program had another very successful year. We've blossomed into a huge program. We now have ten residents in the R4 and R5 years. We were the highest sought residency training program at the U of C in 2013. Clinical fellowships have been established in Lung, Breast, Sarcoma, and Gastrointestinal Cancers as well as a Research fellowship in Genitourinary tumors. In June of 2014 Dr. Fahad Ibnshamsha graduated and has subsequently returned to Saudi Arabia where he is a staff Oncologist with a major focus on cancers of the GI Tract in Dammam. Dr. Hani Al-Hashmi, who graduated our program in 2011 has now started a successful Medical Oncology Training Program in Dammam at the King Fahad Specialist Hospital. Dr. Scot Dowden also ran another successful Resident Retreat in Banff in March 2013. This hosted residents in Medical Oncology, Radiation Oncology, and Palliative Care from both Edmonton and Calgary. Issues of Interpersonal Skills, Quality of Resident Life and Financial Planning were discussed.

MEDICAL PHYSICS

TRAINING PROGRAMS

UNDERGRADUATE

The division of medical physics runs a full complement of educational programs. The undergraduate educational programs are organized by Dr. Ploquin. This summer, the group is hosting four undergraduate students, one on a four month visit from France, and three from Canadian universities. Last year, there were two undergraduate summer research students. We also had two students enrolled in undergraduate research projects through the PHYS 598/599 courses at the University of Calgary.

GRADUATE

The graduate program is the engine of much of the research productivity of the division. Currently there are ten students enrolled in this program. We teach five half-credit courses and one quarter credit course, as well as a variety of non-credit courses, such as journal club and ethics and errors. Two PhD students successfully defended their theses this year, Drs. Sarah Quirk and Yannick Poirier. Both have gone on to residencies in medical physics. The medical physics courses are also taken by the students in the certificate program. This year, one student completed the certificate program, Dr. Casey Bojecho, who has since begun a post-doctoral fellowship in medical physics.

POSTGRADUATE

The two-year residency program in medical physics has two residents currently enrolled. Ian Nygren completed his residency in August 2013, and is now a physicist with the Cancer Corridor. Dr. Quirk began her residency in September 2013. The department teaches six courses for this residency, which are a combination of didactic teaching, clinical rotations and project work.

In addition, the division provides support for the radiation oncology residency program, teaching both PGY-1 and PGY-4 courses.

CONTINUING PROFESSIONAL DEVELOPMENT

Members of the division attended and presented at a variety of conferences for the past year. Dr. Brown was an organizer for the Canadian Organization of Medical Physicists Winter School this year, as well as being an invited speaker there. Dr. Brown was the scientific chair, and Dr. Smith was the local arrangements chair, for the 60th Annual Scientific Meeting of the Canadian Organization of Medical Physicists in Banff in July 2014.

PALLIATIVE MEDICINE

TRAINING PROGRAMS

UNDERGRADUATE

Dr. Lyle Galloway and Dr. Alison Murray championed undergraduate education in 2012-2013. They encouraged further integration of a palliative care approach across the University of Calgary undergraduate curriculum and co-coordinated student placements. The members of the division of palliative care supervised a total of 11 University of Calgary undergraduate medical students during the 2013-2014 academic year. Students have ranged from second year students completing their pre-clerkship elective, to second year students completing their Med440 Evidence Based Medicine elective, to 3rd year students completing clerkship electives. Members of our division also continue to act as preceptors in course 5, small group teaching on the topics of pain and palliative care.

GRADUATE

The division educates a large number of residents from different disciplines, building community capacity for palliative care delivery in primary and specialist care. In 2013-2014, the division trained 113 residents, 72 of which hail from the Department of Family Medicine. Other trainees include residents in internal medicine, oncology, neurology, anaesthesia, physical medicine and rehabilitation. Residents are exposed to palliative care environments such as the Intensive Palliative Care Unit, inpatient hospital consult services, as well as home care and hospice. Residents also receive academic teaching through weekly seminars, journal club, and rounds presentations. Through these experiences, residents gain greater confidence and ability to provide competent and compassionate palliative care to patients and families in the community as well as in hospital.

POSTGRADUATE

Dr. Pawlik, Residency Program Director continued to direct the residency program to provide advanced training for physicians wishing to develop added competence in palliative medicine. During the 2013-2014 academic year, the program enrolled three trainees, from both the Department of Family Medicine and the Department of Anesthesia. Their academic output included presentations at Advanced Practice Rounds, journal club presentations and participation and presentation at Mortality and Morbidity (M & M) Rounds as well as Palliative Grand Rounds. Residents all completed a scholarly project, which led to submission of papers, presentations and/or development of local protocols and educational tools.

Dr. Herx transitioned to Past-Chair for the Postgraduate Education Committee, Canadian Society for Palliative Care Physicians. One of her responsibilities was to organize the National Academic Half Day shared by all the residency programs in Canada.

CONTINUING PROFESSIONAL DEVELOPMENT

Division members gave numerous presentations to support CME at the local, provincial and national level. We participate in multiple forms of teaching and maintain our own CME program approved by the College of Family Physicians as well as the Royal College for Mainpro-M1 points.

PEDIATRIC ONCOLOGY

TRAINING PROGRAMS

Drs. Anderson, Guilcher, Lafay-Cousin, Lewis, Strother and Truong all participate in pediatric resident and medical school clerk education. Dr. Narendran supervises students and trainees in his lab. All members contribute to Tumour Board, Neuro-Oncology Tumour Board, and Research and Protocol Rounds, that are held on a regular basis. In addition to these, members contributed to education in various forms.

EDUCATION PROGRAMS

UNDERGRADUATE

Dr. Greg Guilcher

2009 - Present MDCN 460, UME Lectures, "Could this child have cancer? An approach to common presentations of cancer". University of Calgary, Faculty of Medicine, Alberta Children's Hospital.

Dr. Lucie Lafay-Cousin

2008 - Present Mentoring, Eve Purdy, Undergraduate
2011 - Present Evaluator, Preceptor for Erin Nicholls, MD 440 Course, undergraduate
2013 - 2013 Primary supervisor, Janet Kim, Undergraduate
2013 - 2013 Primary supervisor, Mary Fossey, Undergraduate

Dr. Victor Lewis

2013 - Present Medical Clerk teaching on Oncology/Pediatric Rotations

Dr. Aru Narendran

2013 - 2014 Medical students
2013 - Present Mentoring, Justin Reimer, undergraduate
2013 - Present Mentoring, Janet Kim, undergraduate

GRADUATE

Dr. Greg Guilcher

2014/02 Tumor Board, 10 y.o. boy with angiomatoid fibrous histiocytoma, Alberta Children's Hospital, presentation at rounds.
2014 - Present Tumor Board, 15 y.o. girl with a history of metastatic OS, Alberta Children's Hospital, presentation at rounds.
2014 - Present Primary supervisor, Robyn Long, PhD
2013 - Present Supervisory committee member, Amanda Wurz, Graduate MSc
2013 - 2014 Co-supervisor, Carolina Chamorro, PhD

Dr. Victor Lewis

2013-Present Pediatric resident teaching for residents rotating on in-patient and outpatient settings.
2013-Present Teaching of pediatric residents rotating from outside the University of Calgary.

EDUCATION PROGRAMS

Dr. Aru Narendran

- 2014/02 Cancer Biology for nurses, educational seminar or talk.
- 2013/12 Research and Protocol Rounds, Genome-wide search for druggable targets in unique and refractory pediatric tumors: Studies in development in the POETIC - Narendran Laboratory, Alberta Children's Hospital, presentation at rounds.
- 2013/09 Research and Protocol Rounds, Molecularly targeted agents for future clinical trials in pediatric cancer, Alberta Children's Hospital, presentation at rounds.

POSTGRADUATE

Dr. Ronald Anderson

- 2014-04 "Ethics in Medical Education", Teaching (Lecture) at TBCC Ethics and Errors course to postgraduate trainees.

Dr. Greg Guilcher

- 2013/12 Pediatric Hematology/Oncology , educational seminar or talk, Pediatric Hematology/Oncology Subspecialty Resident Academic Half Day, University of Calgary, Faculty of Medicine, Alberta Children's Hospital.
- 2014 - Present Supervisory committee member, Robyn Long, Post graduate (PGME)

Dr. Lucie Lafay-Cousin

- 2014/06 Ped Hem/Onc DNGR, Current Management of ATRT, educational seminar or talk, Pediatric Hematology/Oncology DNGR/Developmental Neurosciences Grand Rounds, Alberta Children's Hospital.
- 2013/09 Ped Hem/Onc Core Curriculum, Implementation of a low risk febrile neutropenia management protocol objectives, educational seminar or talk, Session by Dr. Lucie Lafay-Cousin and Dr. Gurpreet Singh, University of Calgary, Department of Pediatric Oncology, Alberta Children's Hospital.

Dr. Victor Lewis

- 2013 - Present Core Curriculum development for Pediatric Heme/Onc/BMT residents, University of Calgary.
- 2013 - Present Teaching at Tumor Boards/Research and Protocol Rounds for Pediatric Heme/Onc/BMT residents. Alberta Children's Hospital.
- 2013 - Present Development of Core Curriculum for Pediatric BMT residency at Alberta Children's Hospital.

PREVENTIVE ONCOLOGY

TRAINING PROGRAMS

UNDERGRADUATE

Our faculty members are involved in teaching in the medical undergraduate program at the University of Calgary as well as cancer biology undergraduate courses in the Faculty of Science. Dr. Kopciuk is a lecturer in statistical genetics (CMMB 413 Statistical Genetics: How useful is CMMB without the Math?).

GRADUATE

Our faculty members participate in the teaching of the epidemiology courses in the Department of Community Health Sciences, Faculty of Medicine. Dr. Kopciuk is a co-instructor for a Longitudinal Data Analysis course in the Faculty of Math and Statistics. Dr. Vallance is a Course Instructor for the Master of Health Studies program at Athabasca University. Dr. Ashbury teaches a Qualitative Research Methods course at Henley Business School/Rotman School of Business.

PSYCHOSOCIAL ONCOLOGY

TRAINING PROGRAMS

UNDERGRADUATE

Eight Honors students, five summer students, and eight emotional Coding interns.

GRADUATE

One MSW intern, ten students in Masters or PhD programs, and one Psychology resident Postgraduate

POSTGRADUATE

Two Postdoctoral Fellows, and one Clinical Fellow.

CONTINUING PROFESSIONAL DEVELOPMENT

The Department of Psychosocial Resources has developed a comprehensive internal program of educational activity which includes Psychosocial Oncology Rounds - Clinical Case Presentations, Oncology Research Seminars and a Journal Club. The meetings, organized and led by Dr. Chee-Ping Tsai (and Dr. Laura Labelle – on maternity leave), are held on Monday afternoons and all members of the team are encouraged to attend and present. In addition, invited guest speakers external to our department, have presented on topics relevant to our work. Between July, 2013 and June 2014, we have hosted: Bev Foster, Executive Director, Room 217 Foundation; Linda Watson, RN, PhD(c), Leader Interdisciplinary Practice, Cancer Patients Navigation; Dr. Stewart Longman, Rehabilitation Psychologist; Dr. Zeev Rosberger, Director of Psychosocial Oncology, Segal Cancer Centre and McGill University, Montreal,

Quebec; Bert Enns, Project Lead TBCC & Palliative Care Collaboration, Spiritual Care Specialist, and Dr. Srinu Chary, Consulting Physician, Regional Palliative & Hospice Care and Chronic Pain Service, AHS, Palliative Medicine, Department of Oncology, U of C., Director & Chair of the Board, Pallium Foundation of Canada; Dr. Juliet Guichon, Assistant Professor, Faculty of Medicine, U. of Calgary; Dr. Ian Mitchell, Professor of Pediatrics, Bioethicist, Faculty of Medicine, U. of Calgary; Dr. Petra Grandarova, Radiation Oncologist Resident TBCC; Dr. Jessica Simon Physician Consultant, Advance Care Planning & Goals of Care, Calgary Zone, Interim Division Head and Clinical Assistant Professor, Division of Palliative Medicine, U. of Calgary; Kevin Crowe, Founder of “Give a mile”; Dr. Nancy Moules, Faculty of Nursing, University of Calgary; Dr. Terence Singh, PhD, R. Psych; Anne Walker, Community Services Coordinator, Support and Information, Canadian Cancer Society; Linda McCracken, Calgary Zone Domestic Violence Program Coordinator; Alex Cameron, Male Domestic Abuse Outreach Program Coordinator- Calgary Counsellor Centre.

In addition, department members of present their research at relevant events over the year. A summary of this educational activity is provided further below

RADIATION ONCOLOGY

TRAINING PROGRAMS

UNDERGRADUATE

Medical undergraduate students can elect two to four week rotations within the division. In 2013-2014, there were just six medical students from five Canadian universities who did an elective with the division, including one University of Calgary student, Jordan Stosky, who successfully matched to the University of Calgary Radiation Oncology Resident Training Program to start in July 2014. A goal is to substantially increase medical student clinical rotations in the next two years.

GRADUATE

Nine faculty members supported 13 MSc or PhD candidates as a member of their thesis committee or as supervisor of projects.

POSTGRADUATE

The division supported ten residents working through a five-year, fully-accredited, Royal College of Physicians and Surgeons training program in Radiation Oncology. The Program Director is Dr. Michael Sia. University of Calgary candidates presenting to their final examinations have had a 100% pass rate since the training program’s inception in 2001. Divisional members are pleased to welcome Drs. Ravinder Clayton and Clement Ho as professional peers following their success at the June 2014 examinations. A goal for 2014-2015 is to have residents rotating to Lethbridge and Red Deer to expand the residents’ clinical experience and in particular, illustrate the benefits and differences of practicing in a smaller cancer centre as compared to their training centre in Calgary.

EDUCATION PROGRAMS

In addition, division members provided training in the division of Radiation Oncology for 14 learners undertaking palliative medicine, medical oncology, gynecologic oncology and surgical oncology resident or fellow training through the University of Calgary.

The division has also supported an active Clinical Research Fellowship program since 2007. The two most recent graduates of the fellowship program, Dr. Hongwei Liu and Dr. Boris Valev, secured permanent faculty positions in 2013-2014, at the Central Alberta Cancer Centre (Red Deer) and the BC Cancer Agency, Centre for the North (Prince George), respectively.

SURGICAL ONCOLOGY

TRAINING PROGRAM

GRADUATE

Dr. Lloyd Mack continues as Program Director for the Section of General Surgery.

POSTGRADUATE

Dr. Temple assumed the role of Program Director for the Section of Surgical Oncology. The Surgical Oncology program is certified by both the Society of Surgical Oncology as well as the Royal College. One Fellow graduated in 2014 and has taken a position at the University of Manitoba. The program remains in the international match for approved programs and continues to receive large numbers of Canadian and international applicants.

Dr. Temple-Oberle initiated a fellowship in oncologic reconstruction and successfully graduated Dr. A. Grant in June 2014. This will be an ongoing training program expanded to one year.

Dr. Arlette continues the Mohs surgery program and had a successful graduate in 2014.

TRANSLATIONAL RESEARCH & LABORATORIES

TRAINING PROGRAMS

UNDERGRADUATE

Dr. Don Morris

2013-2014

Sean Choi, Medical Student

2013

Peter Liu, Summer Student

Dr. Gwyn Bebb

2014/08 - 2014/10

Nick Bosma, Med440

2013/09 - 2014/04

Rachel Yee, CMMB 528 - Independent Studies in Cellular, Molecular and Microbial Biology: ATM Status in Lung Cancer

EDUCATION PROGRAMS

2013/06 - 2013/09	Rachel Yee, Summer Student. Research project: Chemo-sensitivity of ATM deficient non-small cell lung cancer cell lines in vitro
GRADUATE	
Dr. Don Morris	
2014 - Present	Ahmed Mostafa, Postdoctoral Fellow
2013 - 2014	Chandini Thirukkumaran, Research Associate Professor
Dr. Gwyn Bebb	
2014/01 - Present	Supervisory Committee, Shahil Amin, MSc
POSTGRADUATE	
Dr. Don Morris	
1997 - 2014	Oncology Core Curriculum, Lectures (N=44 lectures; 1997-present), University of Calgary, Calgary, Alberta
2014/07	Mandip Puri, MSc student, Cancer Biology, University of Calgary.
2014/05 - Present	Winston Yuen, BHSc honors student, Translational Laboratories, University of Calgary
2014/04 - Present	Rosy Dabas, PhD Student, MSc in Cancer Biology, University of Calgary
2014/03 - Present	Erin Degelman, BHSc Student, University of Calgary.
2014/03 - Present	Kenneth Fuh, PhD Student, Biomedical Engineering Graduate Program, University of Calgary
2014/02 - 2014/04	Andrew Andrawes, International Medical Graduate (ASCAP)
2014/01 - Present	Gina Marie Crovetto, MSc in Cancer Biology, University of Calgary
2014/01 - Present	Darren Brenner, AIHS Postdoctoral Fellow, University of Calgary
2013/12 - Present	Ahmed Mostafa, Postdoctoral Fellow, Translational Laboratories, University of Calgary
2013/10 - Present	Liane Babes, PhD Student, University of Calgary
2013/07 - Present	Sean Choi, MSc Student, University of Calgary
2013/07 - Present	Hamika Dastidar, MSc Student, Signaling Models, University of Calgary
Dr. Gwyn Bebb	
2014/03 - Present	Rene Razzak, PhD, Experimental Surgery, Doctoral Oral Exam
2014/01 - Present	Jenny Ko, Medical Oncology Fellow, Lung Cancer Research Project, Mentoring

EDUCATION PROGRAMS

CONTINUING PROFESSIONAL DEVELOPMENT

Dr. Don Morris	
2014/04/29	“Novel Cancer Therapeutics for the Treatment of Cancer”, University of Calgary Leaders in Medicine Joint Journal Club and Speaker Series, Health Sciences Centre, Calgary, Alberta.
2014	Member, Calgary Cancer Project AHS Clinical Advisory Group
2014	Member, Department of Oncology Palliative Medicine Search and Selection Committee
2013 - Present	Member, Zone Clinical Department of Oncology Divisions Head Executive Committee, Tom Baker Cancer Centre
2013 - Present	Member, Zone Clinical Department of Oncology Executive Committee, Tom Baker Cancer Centre
2013 - Present	Chair, Search and Selection Committee – Medical Oncology - Tom Baker Cancer Centre
2013 - Present	Member, Provincial Systemic Services Council, Alberta Health Services CancerControl
2013 - Present	Chair, Systemic Treatment Program Committee, Tom Baker Cancer Centre
2013 - Present	Section Chief, Section of Medical Oncology, Clinical Department of Oncology, Calgary Zone, CancerControl Alberta, Alberta Health Services.
2014	CIHR Collaborative Health Research Projects – NSERC Partnered Committee
Dr. Gwyn Bebb	
2014/02/26	“Oncology of a never-smoked lung cancer patient”, Workshops / Seminars, Radon Webinar with the Alberta Lung Association, Calgary, AB
2014/06/23	“Late and Long-terms Effects of Cancer Treatments and What to do About Them” Living Your Best Life - With Cancer and Beyond. Patient Education Session, Patient Education Seminar, Department of Oncology, Tom Baker Cancer Centre, Calgary, AB

TRANSLATIONAL RESEARCH & LABORATORY

TRAINING PROGRAM

UNDERGRADUATE

Dr. Don Morris	
2013 - 2014	Sean Choi, Medical Student
2013	Peter Liu, Summer Student

EDUCATION PROGRAMS

Dr. Gwyn Bebb	
2014/08 - 2014/10	Nick Bosma, Med440
2013/09 - 2014/04	Rachel Yee, CMMB 528 - Independent Studies in Cellular, Molecular and Microbial Biology: ATM Status in Lung Cancer
2013/06 - 2013/09	Rachel Yee, Summer Student. Research project: Chemo-sensitivity of ATM deficient non-small cell lung cancer cell lines in vitro

GRADUATE

Dr. Don Morris	
2014 - Present	Ahmed Mostafa, Postdoctoral Fellow
2013 - 2014	Chandini Thirukkumaran, Research Associate Professor

Dr. Gwyn Bebb	
2014/01 - Present	Supervisory Committee, Shahil Amin, MSc

POSTGRADUATE

Dr. Don Morris	
1997 – 2014	Oncology Core Curriculum, Lectures (N=44 lectures; 1997-present), University of Calgary, Calgary, Alberta
2014/07	Mandip Puri, MSc student, Cancer Biology, University of Calgary.
2014/05 - Present	Winston Yuen, BHSc honors student, Translational Laboratories, University of Calgary
2014/04 - Present	Rosy Dabas, PhD Student, MSc in Cancer Biology, University of Calgary
2014/03 - Present	Erin Degelman, BHSc Student, University of Calgary.
2014/03 - Present	Kenneth Fuh, PhD Student, Biomedical Engineering Graduate Program, University of Calgary
2014/02 - 2014/04	Andrew Andrawes, International Medical Graduate (ASCAP)
2014/01 - Present	Gina Marie Crovetto, MSc in Cancer Biology, University of Calgary
2014/01 - Present	Darren Brenner, AIHS Postdoctoral Fellow, University of Calgary
2013/12 - Present	Ahmed Mostafa, Postdoctoral Fellow, Translational Laboratories, University of Calgary
2013/10 - Present	Liane Babes, PhD Student, University of Calgary
2013/07 - Present	Sean Choi, MSc Student, University of Calgary
2013/07 - Present	Hamika Dastidar, MSc Student, Signaling Models, University of Calgary

EDUCATION PROGRAMS

Dr. Gwyn Bebb

2014/03 - Present

Rene Razzak, PhD, Experimental Surgery, Doctoral Oral Exam

2014/01 - Present

Jenny Ko, Medical Oncology Fellow, Lung Cancer Research Project, Mentoring

CONTINUING PROFESSIONAL DEVELOPMENT

Dr. Don Morris

2014/04/29

“Novel Cancer Therapeutics for the Treatment of Cancer”, University of Calgary Leaders in Medicine Joint Journal Club and Speaker Series, Health Sciences Centre, Calgary, Alberta.

2014

Member, Calgary Cancer Project AHS Clinical Advisory Group

2014

Member, Department of Oncology Palliative Medicine Search and Selection Committee

2013 - Present

Member, Zone Clinical Department of Oncology Divisions Head Executive Committee, Tom Baker Cancer Centre

2013 - Present

Member, Zone Clinical Department of Oncology Executive Committee, Tom Baker Cancer Centre

2013 - Present

Chair, Search and Selection Committee – Medical Oncology - Tom Baker Cancer Centre

2013 - Present

Member, Provincial Systemic Services Council, Alberta Health Services CancerControl

2013 - Present

Chair, Systemic Treatment Program Committee, Tom Baker Cancer Centre

2013 - Present

Section Chief, Section of Medical Oncology, Clinical Department of Oncology, Calgary Zone, CancerControl Alberta,, Alberta Health Services

2014

CIHR Collaborative Health Research Projects – NSERC Partnered Committee

Dr. Gwyn Bebb

2014/02/26

“Oncology of a never-smoked lung cancer patient”, Workshops / Seminars, Radon Webinar with the Alberta Lung Association, Calgary, AB

2014/06/23

“Late and Long-terms Effects of Cancer Treatments and What to do About Them” Living Your Best Life - With Cancer and Beyond. Patient Education Session, Patient Education Seminar, Department of Oncology, Tom Baker Cancer Centre, Calgary, AB

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
FUNDAMENTAL RESEARCH						
No report was submitted for the 2013-2014 academic year						
GYNECOLOGIC ONCOLOGY						
1	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson G.	2012-2014	AMGEN	AMG 386 (1129): A phase 3, randomized, double-blind trial of weekly paclitaxel plus AMG 386 or placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers.	\$4,200
2	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2013-2014	NCIC	IND 206: A phase II study of sunitinib or temsirolimus in patients with advanced rare tumours.	\$15,500
3	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2012-2013	Morphotek	MORab 003: A randomized, double-blind placebo controlled study of the efficacy and safety of MORab-003: (Farletuzumab) in combination with paclitaxel therapy in subjects with platinum resistant or refractory relapsed ovarian cancer MORab-004: Randomized double-blind placebo controlled phase 3 study to assess the efficacy and safety of weekly farletuzumab (MORab-003) in combination with carboplatin and taxane in subjects with platinum sensitive ovarian cancer in first relapse.	\$45,760
4	Ghatage, P.	Chu, P. Craighead, P. Doll, C. Glaze, S. Nation, J. Nelson, G. Phan, T.	2011-2014	NCIC	NCIC CTG EN.7/PORTEC-3: Randomized phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma.	-
5	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2012-2014	Roche	Rosia – MO22923: A phase 3 open-label trial of the addition of bevacizumab to carboplatin and paclitaxel therapy in patients with ovarian cancer.	-
6	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2013	Pfizer	Pfizer – B1271004: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of DMUC5754A and DNIB0600A administered intravenously to patients with platinum-resistant ovarian cancer.	-

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
7	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2013-2014	Endocyte	Protocol EC-FV-06: A randomized double-blind phase 3 trial comparing EC145 and pegylated liposomal doxorubicin (PLD/DOXIL/CAELYX) in combination versus pld in participants with platinum-resistant ovarian cancer.	\$192,673
8	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2014	Astex	Astex SGI-110-02: A randomized, controlled, open-label, phase 2 trial of SGI-110 and carboplatin in subjects with platinum-resistant recurrent ovarian cancer.	\$10,408
9	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2013-2014	Incyte	Incyte – INCB 24360-210: A randomized, open-label, phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical – recurrent – only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer following complete remission with first-line chemotherapy.	\$6,148
10	Ghatage, P.	Doll, C. Koebel, M. Lees-Miller, S.	2013-2016	HIS-CRIO	PIK3CA: Mutation and associated pathway activation status and survival in patients with cervical cancer: Quantifying the risk and testing the solution.	\$250,000
11	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2012-2013	Amgen	AMGEN 508: A phase 3, randomized, double-blind trial of weekly paclitaxel plus AMF 386 or placebo in women with recurrent partially. Platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers.	\$79,686
12	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2012-2014	Amgen	Amgen 20060342: Phase 3 AMG 386 in combination with paclitaxel for subjects with advanced recurrent epithelial ovarian or primary peritoneal cancer.	\$76,703
13	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2014	Tesaro	Tesaro: A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum sensitive ovarian cancer.	-
14	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2014	Clovis	Clovis Ariel 2 CO-338-017: A phase 2, open-label study of rucaparib in patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.	-

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
15	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2014	Clovis	Clovis Ariel 3 CO-338-014: A multicentre, randomized, double-blind, placebo-controlled phase 3 study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer.	-
16	Ghatage, P.	Chu, P. Glaze, S. Nation, J. Nelson, G.	2013-2014	Arrau	Arrau 162-311: (MEK inhibitor in low-grade serous ovarian cancer) a multinational, randomized, open-label phase 3 study of MEK162 vs physician's choice of chemotherapy in patients with recurrent or persistent low-grade serious carcinomas of the ovary, fallopian tube or primary peritoneum.	-
17	Nelson, G.	Duggan, M. Nation, J.	2012-2014	Gyne Onc Division / Dept of Pathology	Post colposcopy management of ASCUS and LSIL pap tests (PALS) randomized controlled trail: A pilot study of 100 women.	\$5,000
18	Nelson, G.	Gramlich, L.	2014-Present	AIHS-PRIHS	Enhancing patients' recovery after surgery (ERAS): Strategy to transform care and maximize the expected value.	\$250,000
HEMATOLOGIC MALIGNANCIES & BMT (AHS Proposed)						
1	Bahlis, N. J.	Neri, P.	2013-2017	CIHR	Bortezomib mediated BRCAness in Myeloma cells: Novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors.	\$144,000
2	Bahlis, N. J.		2012-2013	CIHR/ACF	Bortezomib mediated BRCAness in Myeloma cells: Novel therapeutic approach combining PARP1-2 and 26S Proteasome Inhibitors.	\$100,000
3	Bahlis, N. J.	Neri, P.	2011-2013	Multiple Myeloma Research Foundation	Combination of PARP and Proteasome inhibitors in multiple myeloma.	\$100,000
4	Daly, A.		2014	Calgary Health Trust/ Division of Hematology	Influence of fludarabine pharmacokinetics on outcome of stem cell transplant with fludarabine-busulfan-tbi conditioning.	\$10,000
5	Geddes, M.		2012-2014	Celgene Canada	Myelodysplastic Syndromes (MDS) in Canada: A national prospective study of the epidemiology, quality of life and impact of co-morbidity on disease outcome.	\$20,300

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
6	Geddes, M.	Savoie, L.	2013	Novartis	Banking for Myelodysplastic Syndromes and Acute Myeloid Leukemia.	\$21,000
7	Owen, C.		2012-2014	Calgary Health Trust/ Division of Hematology	Molecular basis of familial hematological malignancies.	\$4,400
8	Stewart, D.		2014	Calgary Health Trust/ Division of Hematology	Follicular lymphoma: Identifying a “Proliferative Molecular Signature” as a predictor of aggressive clinical disease and its validation through routine Immunohistochemistry techniques.	\$15,000
9	Stewart, D.		2014	Calgary Health Trust/ Division of Hematology	Metabolomic profiling of follicular lymphoma.	\$15,000
10	Storek, J.		2014-2017	Alberta Cancer Foundation/AHS- Cancer Care Investigator-Initiated Trial Award	Preemptive Therapy of GVHD.	\$2,130
11	Storek, J.		2014-2017	Calgary Health Trust/ Division of Hematology	Identification of patients at high risk of developing PTLD and leukemia relapse using EBV specific T-cells and NK-cells.	\$11,000
12	Storek, J.		2013-2015	CLS	IL-10 gene profile of allogeneic HCT donors as a biomarker of GVHD.	\$2,500
13	Storek, J.		2013-2015	CIHR	Toward improved outcomes of ATG-conditioned (Albertan) hematopoietic cell transplantation.	\$250,000
14	Storek, J.		2012-2015	CIHR	Biomarkers of Chronic Graft-vs-Host Disease.	\$16,667
15	Storek, J.		2008-2017	NIH	COT (Scleroderma-Cyclophosphamide or Transplantation?) trial.	\$18,000
16	Street, L.		2012-2014	Department of Medicine	ISACAN/Confocal Endomicroscopy as Novel Endoscopic Technique for Evaluating Gastric and Intestinal Lymphoma.	\$5,000
MEDICAL ONCOLOGY						
1	Bebb, G.	Tang, P.	2011–Present	Breast Cancer Foundation	Identifying ATM deficient breast cancer by quantitative immunohistochemistry.	\$9,599
2	Bebb, G.		2010–2014	Private Donations	Creation and expansion of the Glans-Look lung cancer database: Generation of a retrospective and prospective lung cancer clinical pathological data base.	\$275,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
3	Bonni, S.	Morris, D.	2014–2015	Breast Cancer Society of Canada	Characterizing the expression and subcellular localization of the SUMO E3 ligase PIAS1 in a Calgary breast cancer cohort: PIAS1 as a potential novel predictive and prognostic biomarker in breast cancer.	\$15,000
4	Brockton, N	Magliocco, T. Friedenreich, C. Paterson, A.	2007–Present		Breast to bone project.	\$150,000
5	Cheng, T.		2012–Present	Alberta Cancer Foundation	An Alberta-wide database and registry of patients diagnosed with melanoma in Alberta.	\$32,800
6	Cheng, T.		2007–Present	Pfizer Pharmaceutical	Multicentre Canadian clinical study: An open label, phase II study of anti-CTLA4 (CP-675,206) in patients with advanced or metastatic uveal melanoma.	\$60,195
7	Cheng, T.		2006–Present	Canadian Urological Oncology Cooperative Group (COUG)/ National Cancer Institute of Canada (NCIC)	Multicentre randomized placebo-controlled phase II study to compare the efficacy and safety of SU011248 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced urothelial transitional cell carcinoma who have failed or are intolerant to cisplatin-based chemotherapy.	\$51,254
8	Friedenreich, C.	Morris, D.	2013–2016	Canadian Institutes of Health Research (CIHR)	Alberta physical activity and breast cancer prevention trial: Ancillary study examining the effect of exercise on oxidative stress, telomere length and DNA methylation.	\$50,708
9	Friedenreich, C.	Morris, D.	2012–2015	Canadian Breast Cancer Foundation (CBCF)	Impact of salicylate co-administration on chemotherapeutic efficacy in breast cancer.	\$82,574
10	Goodarzi, A.	Morris, D.	2013–2014	Cancer Research Society	Radon gas exposure and development of lung cancer in never smokers.	\$58,878
11	Hack, T.	Ruether, D.	2013–2016	Canadian Institutes of Health Research	Impact of treatment consultation recordings on new cancer patient outcomes: A prospective, parallel, randomized controlled trial.	\$14,883
12	Hao, D.	Shack, L. Dort, J. Doll, C. Lau, H.	2012–2014	Alberta Health Services – Alberta Cancer Research Institute	Risk factors and epidemiology of HPV associated cancers in Alberta.	\$4,000
13	Heng, D.		2012-2015	Canadian Institute of Health Research (CIHR)	Personalized medicine lead, Kidney Cancer Research Network of Canada.	\$150,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
14	Heng, D.		2012–Present	Calgary Lab Services, Alberta Health Services	Comparison of the 21 gene recurrence score with immunohistochemical assessment of estrogen receptor, progesterone receptor, HER2-neu, and ki67 in patients with estrogen receptor positive, node negative breast cancer.	\$11,666
15	Heng, D.		2011–Present	Breast Cancer Society of Canada	Circulating tumor cell expression of RANK in metastatic breast cancer.	\$12,500
16	Heng, D.		2010–Present	Pfizer Oncology Research	Metastatic renal cell carcinoma: Outcomes of targeted therapy by ethnicity.	\$8,000
17	Heng, D.		2012–2013	Alberta Cancer Foundation	OZM-042: A phase II multi-centre, study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.	\$5,000
18	Henning, J. W.		2013–Present	Breast Cancer Society of Canada	Tamoxifen and hormonal levels in premenopausal women with early breast cancer. Phase I.	\$1,250
19	Henning, J. W.		2013–Present	Breast Cancer Society of Alberta	Tamoxifen and hormonal levels in premenopausal women with early breast cancer. Phase II.	\$7,500
20	Hyndman, M.	Morris, D.	2014–2016	Alberta Innovates Health Solutions (AIHS)	Innovative diagnostics to improve the management of urothelial carcinoma.	\$250,000
21	Kurz, E.	Morris, D.	2013–2015	Canadian Cancer Society (CCS)	Alberta physical activity (ALPHA) and breast cancer prevention trial: An ancillary study examining anti-inflammatory markers and oxidative stress.	\$55,450
22	Mansoor, A.	Stewart, D.	2012–2014	Alberta Cancer Foundation	Creation of a lymphoma tissue bank through establishing a cancer research fellowship.	\$83,333
23	Morris, D.		2013–2014	Cancer Research Society	Radon gas exposure and development of lung cancer in never smokers.	\$50,878
24	Morris, D.		2013–2015	Cancer Research Society Operating Grant	Reovirus as a viable therapeutic option to target therapy resistance of multiple myeloma.	\$40,000
25	Morris, D.		2013–2016	Alberta Innovates Health Solutions CRIO Grant	Immunotherapy for cancer – repurposing targeted therapies with oncolytic viruses.	\$250,000
26	Morris, D.		2013–2014	Alberta Cancer Foundation Transition Funding Opportunity	Biomarker discovery and implementations unit.	\$127,750

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
27	Morris, D.		2012–2015	Private Donor Dollars, University of Calgary	Strategic initiative for the treatment of lung cancer in Alberta.	\$300,000
28	Morris, D.		2011–2013	Breast Cancer Society of Canada (BCSC)	Determination of the role of CXCL12/CXCR4 axis in breast cancer metastasis in bone.	\$16,000
29	Morris, D.		2011–2014	Canadian Breast Cancer Foundation (CBCF)	Oncolytic viral immunotherapy for breast cancer.	\$93,750
30	Morris, D.		2010–2014	Breast Cancer Society of Canada (BCSC)	A proposal to develop a molecular classification algorithm for Calgary breast cancer patients.	\$9,470
31	Morris, D.		2009–2013	Alberta Cancer Research Institute (ACRI)	A strategic initiative for the treatment of lung cancer in Alberta.	\$81,400
32	Morris, D.		2008–2013	Alberta Cancer Research Institute (ACRI)	A proteomic approach for functional stratification of early breast cancer to optimize treatment selection using routine archival formalin-fixed clinical specimens.	\$50,000
33	Morris, D.		2014–2015	Breast Cancer Society of Canada	Oncolytic viral therapy augmented by immune check point inhibition as a novel treatment strategy for breast cancer.	\$20,000
34	Morris, D.	Stewart, D.	2013–2015	Cancer Research Society	Reovirus as a viable therapeutic option to target resistance of multiple myeloma.	\$40,000
35	Riabowol, K.	Morris, D.	2014–2016	Alberta Innovates Health Solutions (AIHS)	Developing and testing a new treatment for oral squamous cell carcinoma.	\$250,000
36	Robbins, S.	Morris, D.	2013–2014	Alberta Cancer Foundation Transition Funding Opportunity	Applied precision cancer medicine.	\$97,750
37	Storek, J.	Morris, D.	2013–2015	Alberta Innovates Health Solutions (AIHS)	Toward improved outcomes of ATG-conditioned (Albertan) hematopoietic cell transplantation.	\$663,333
38	Stewart, D.		2007–2014	Hoffman La Roche	FDG-PET-Stratified R-DICEP and R-BEAM/ASCT for diffuse large B-cell lymphoma.	\$81,519
39	Stewart, D.		2009–2013	Terry Fox Research Initiative Grant	Predicting benefit and improving outcomes of high dose therapy (HDT) and autologous stem cell transplantation (SCT) for lymphoma (NHL) and myeloma (MM) patients through tissue arrays based classifications, sensitive detection of minimal residue disease (MRD) and reovirus purging.	\$263,021

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
40	Stewart, D.		2009–2014	Hoffman La Roche, Canada	Alberta lymphoma/myeloma clinical database project.	\$52,500
41	Stewart, D.		2011–2014	Alberta Cancer Foundation	Predicting benefit of salvage and high dose chemotherapy with autologous stem cell transplantation for relapsed and diffuse large B-cell lymphoma patients through tissue array based biomarker classifications.	\$10,326
42	Stewart, D.		2012–2014	Division of Hematology and Hematologic Malignancies – Calgary Health Trust	Predicting benefit of salvage and high dose chemotherapy with autologous stem cell transplantation for relapsed and diffuse large B-cell lymphoma patients through tissue array based biomarker classifications.	\$5,333
43	Stewart, D.		2012–2015	Alberta Cancer Foundation	Establishment of a lymphoma clinical outcomes unit.	\$75,000
44	Stewart, D.		2012–2014	Alberta Cancer Foundation	Prediction of benefit of rituximab resistance in B-cell lymphoma/-150 freezer.	\$16,763
45	Stewart, D.		2014–2015	Division of Hematology and Hematologic Malignancies – Calgary Health Trust	Metabolomic profiling of follicular lymphoma.	\$7,500
46	Stewart, D.		2014–2015	Division of Hematology and Hematologic Malignancies – Calgary Health Trust	Follicular lymphoma: Identifying a “Proliferative Molecular Signature” as a predictor of aggressive clinical disease and its validation through routine immune – histochemistry techniques.	\$7,500
47	Tam, V.		2012-2014	University of Calgary Starter Grant	Development of Canadian core competencies in oncology for undergraduate and post graduate medical education: A survey of existing oncology curricula used by Canadian medical schools and residency programs.	\$1,667
48	Tam, V.		2012-2013	National Cancer Institute of Canada (NCIC)	NCIC HEC.1(CALGB 80802): Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).	\$2,000
49	Tang, P.	Ezeife, D.	2013-2015	Alberta Cancer Foundation	Assessment of clinical trial endpoints in Cancer Patients.	\$1,750
50	Tang, P.		2012–2013	Calgary Medical Oncology Research Grant	Assessment of burnout in Canadian oncologists.	\$5,000
51	Tang, P.	Heng, D.	2009–Present	CLS Health Services Research	The role of PTCH1 and GLI1 in breast cancer.	\$5,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
52	Tang, P.		2012–2013	Calgary Lab Services	The role of ATM in patients with locally advanced rectal cancer.	\$17,500
53	Tang, P.		2012–2013	Calgary Lab Services	Comparison of the 21 gene recurrence score with immunohistochemical assessment of estrogen receptor, progesterone receptor, HER2-neu, and Ki67 in patients with estrogen receptor positive, node negative breast cancer.	\$17,500
54	Vickers, M.		2012–2015	Calgary Laboratory Services Medical Operations	Influence of ATM expression on outcome in patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.	\$8,733
55	Vickers, M.		2013–Present	Clinical Research Unit, Alberta Cancer Foundation	Phase II trial of rosuratatin combined with standard chemoradiation in the treatment of high-risk advanced rectal cancer.	\$75,000
PALLIATIVE MEDICINE						
1	Bremault-Phillips, S.	Borneman, T. Brett-Maclean, P. Ferrell, B. Magnus, R. Olson, J. Oneschuk, D. Puchalski, C. M. Sinclair, S.	2014–2015	Covenant Health, Faith, Spirituality and Health Research Grant	Use of the FICA tool: Integrating spirituality as a key component of care by inter-professional palliative and geriatric hospital based teams.	\$25,000
2	Carlson, L.	Specia, M. Collie, K. Sinclair, S.	2012-2014	Wings of Hope	Healing through the creative arts: Arts based workshops for breast cancer survivors.	\$24,780
3	Cory, S.	Horst, G. Sinclair, S.	2014-2017	Canadian Partnership against Cancer	CPAC cultural tools project with the Canadian Virtual Hospice (CVH).	\$60,000
4	Hagen, N.	Simon, J. Fasbender, K.	2013-2018	AIHS	Advance care planning and goals of care Alberta: A population based knowledge translation intervention study.	\$500,000
5	Selman, L.	Allsop, A. Egan, R. Grant, L. Karvinen, I. Kumar, S. Leget, C. Mosoiu, D. Powell, T. Vermandere, M. Young, J.	2013-2014	The Sir Halley Stewart Trust Fund	Spiritual care in palliative care: An international qualitative study service of users' experiences, needs, and preferences (InSpirit).	£13,440
6	Simon, J. E.	Sargious, P.	2011–2014	AIHS (& CIHR with Heyland, D. as PI)	ACCEPT: Advance care planning in elderly patients.	\$45,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
7	Simon, J. E.		2014-2015	Alberta Cancer Foundation	Division of palliative medicine research assistant support funding.	\$47,000
8	Sinclair, S.		2012-2014	Alberta Cancer Foundation, Innovation Projects	Identifying the optimal psycho/social/spiritual care delivery model within the TBCC BMT Clinic.	\$27,643
9	Sinclair, S.	Chochinoc, H. M. Hack, T. Hagen, N. McClement, S. Raffin Bouchal, S.	2013-2014	CIHR	Understanding compassion: An empirical approach to cancer patients perspectives and experiences of compassion at the end of life.	\$88,410
10	Sinclair, S.	Civitella, M. Hall, O. Butler, M.	2013-2015	Alberta Cancer Foundation	Provincial cancer care healing arts program.	\$540,000
11	You, J.	Simon, J.	2014–2017	Technology Evaluation in the Elderly Network (TVN)	Improving DECISION-making about goals of care for hospitalized, elderly patients: A “multi-incubator unit” study (iDECIDE).	\$23, 660
PEDIATRIC ONCOLOGY						
1	Bobilev, D.	Truong, T.	2012-Ongoing	Sanofi Inc and Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC)	A phase 1-2 dose finding, safety and efficacy study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.	\$8,037
2	Lafay-Cousin, L.	Strother, D.	2011-Ongoing	F. Hoffman Laroche Ltd.	A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in pediatric patients with newly diagnosed supratentorial high-grade glioma.	\$7,909
3	Lafay-Cousin, L.		2012-2017	Children’s Oncology Group	Study chair: NIH COG chair grant (UA10CA098543) for study ACNS 1221.	\$8,295
4	Lafay-Cousin, L.		2012-2015	C17 Oncology Network	Identification childhood ATRT.	\$98,829
5	Lewis, V.		2013-2014	NCIC Clinical Trials Group (NCIC CTG)	A pilot study of Imetelstat given intravenously on day 1 and 8 of a 21 day schedule alone and with standard 13-cis-retinoic acid in children with recurrent and/or refractory neuroblastoma.	\$9,000
6	Narendran, A.		2013-2015	The Morgan Adams Foundation	New therapies for relapsed pediatric leukemia.	\$20,000
7	Narendran, A.		2013-2014	Stem Cell Network	Identification of inhibitors to cyclin-dependent kinase inhibitors (CDKis) for use in regenerative medicine strategies.	\$75,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
8	Narendran, A.		2011-2014	EISAI Inc. Sponsor	NCIC CTG protocol number: IND.212.	\$12,320
9	Narendran, A.		2011-Ongoing	Bristol-Myers Pharmaceuticals	A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia or with ph+ leukemias resistant or intolerant to Imatinib (protocol # CA180226).	\$1,235
10	Rizzo, J. D.	Lewis, V. (ACH)	Ongoing	Center for International Blood and Marrow Transplant Centre	Protocol for a research database for hematopoietic stem cell transplantation and marrow toxic injuries.	\$8,037
11	Schatzl, H. M.		2013-2016	Alberta Innovates Bio Solutions	A new anti-prion strategy: modulation of prnp transcriptional activity.	\$372,000
12	Strother, D.		Ongoing	Children's Oncology Group	Community clinical oncology (CCOP) no. U10CA095861:CFDA #93.395.	\$13,889
13	Strother, D.		Ongoing	Children's Oncology Group	St. Baldricks MA-I FP12931_SUB29_01 St. Baldrick's Foundation supplemental funding.	\$23,900
14	Strother, D.		Ongoing	Children's Oncology Group	Per case reimbursement MA -1 FP12931_SUB29_01.	\$60,040
15	Strother, D.		Ongoing	Children's Oncology Group	NIH COG chair grant (U10CA098543).	\$11,433
16	Strother, D.	Anderson, R. Truong, T. Lafay-Cousin, L. Guilcher, G. Narendran, A. Lewis, V.	Ongoing	Children's Oncology Group	ANHL 1131 - F.Hoffman LaRoche, LTD. B025380 intergroup trial for children or adolescents with B-Cell NHL or B-AL: Evaluation of rituximab efficacy and safety in high risk patients.	\$3,745
17	Strother, D.	Anderson, R. Truong, T. Lafay-Cousin, L. Guilcher, G. Narendran, A. Lewis, V.	Ongoing	Children's Oncology Group	Study: CA180-372: PH11 pediatric – ph+all (AALL 1122).	\$4,658
18	Strother, D.	Anderson, R., Truong, T., Lafay-Cousin, L., Guilcher, G., Narendran, A., Lewis, V.	Ongoing	Children's Oncology Group	COG AAML 1031 - A phase III randomized trial for patients with de novo AML using Bortezomid (NSC# 681239) and Sorafenib (BAY 43-9006, NSC#724772) for patients with high allelic ratio FLT2/ITD.	\$3,105
19	Zelcer, S.	Strother, D.	Ongoing	C17 Oncology Network	Development of the P-SCS: The pediatric supportive care scale.	\$2,575

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
PREVENTIVE ONCOLOGY						
1	Ashbury, F.		2013-2014	Canada Health Infoway	Evaluation of the implementation of an oncology information system in four ambulatory cancer care practice settings.	\$250,000
2	Ashbury, F.	Jenkins, D.	2013-2017	Canadian Institutes of Health Research	Canada-wide human nutrition trialists' network.	\$414,558
3	Briollais, L.	Choi, Y. H. Kopciuk, K.	2013-2016	Canadian Institute of Health Research	Development, application and evaluation of multistate models for risk estimation and screening interventions in Lynch syndrome families and familial colorectal cancer type X families.	\$91,111
6	Brockton, N. T.		2010-2013	Alberta Cancer Research Institute	The role of vitamin D and inflammation in colorectal cancer metastases (CR2L).	\$181,082
7	Brockton, N. T.	Friedenreich, C. M.	2008-2019	Alberta Cancer Research Institute	Breast cancer to bone metastases (B2B) research program: A multidisciplinary approach to the investigation of bone metastasis of breast cancer.	\$278,178
8	Courneya, K. S.	Friedenreich, C. M.	2011-2016	Canadian Institutes of Health Research	CIHR team in physical activity: Alberta moving beyond breast cancer study (AMBER).	\$504,647
9	Friedenreich, C. M.	McGregor, S. E.	2009-2014	Alberta Cancer Research Institute	PHRU priority funding request 2009-2012-priority #1 - population health research unit.	\$281,076
10	Friedenreich, C. M.	Kopciuk, K.	2009-2014	Alberta Cancer Research Institute	PHRU priority funding request 2009-2012-priority #2 - data support unit infrastructure and equipment.	\$262,263
11	Friedenreich, C. M.		2008-2015	AHFMR -Senior Health Science Scholar	Health senior scholar - physical activity in cancer control: From observational to intervention research.	\$162,143
12	Friedenreich, C. M.	Courneya, K. S.	2011-2013	Canadian Cancer Society Research Institute	Breast cancer and exercise trial in Alberta ancillary study: Long-term effects of a year-long exercise program in postmenopausal women.	\$197,947
13	Friedenreich, C. M.		2010-2013	Alberta Cancer Research Institute	Breast cancer and exercise trial in Alberta: The BETA trial.	\$539,394
14	Friedenreich, C. M.		2013-2016	Canadian Institutes of Health Research	ALPHA trial ancillary study: Effect of exercise on oxidative stress, telomere length and DNA methylation.	\$165,208

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
15	Friedenreich, C. M.		2014-2016	Alberta Cancer Foundation	Enhancing capacity for lifestyle and cancer epidemiology in Alberta. Alberta Cancer Foundation Foundational Infrastructure 2013.	\$150,721
16	Friedenreich, C. M.		2013-2015	Canadian Cancer Society Research Institute	Alberta physical activity (ALPHA) and breast cancer prevention trial: An ancillary study examining anti-inflammatory markers and oxidative stress.	\$83,176
17	Kelemen, L. E.		2008-2014	Canadian Institutes of Health Research	Genetic variation in the one carbon transfer pathway and ovarian cancer risk: A replication-association study.	\$161,319
18	Kelemen, L. E.	Brockton, N. T.	2008-2013	Alberta Cancer Research Institute	Division of population health and information; priority funding II request 2007-DNA extraction and plating.	\$139,445
19	Kelemen L. E.	Friedenreich, C. M. Brockton, N. T.	2009-2014	Alberta Cancer Research Institute	PHRU priority funding request #4 - research biospecimen processing core facility and equipment.	\$256,854
20	Kopciuk, K.	Friedenreich, C. M.	2008-2014	Alberta Cancer Research Institute	Division of population health and information; priority funding I request 2007 - capacity building for high throughput data analysis.	\$57,389
21	McGregor, S. E.		2011-2014	Alberta's Health Research Innovation Strategy Emerging Team Grant Program; University of Calgary and AHS	Optimizing population-based colorectal cancer screening team.	\$100,000
22	McGregor, S. E.	Hilsden, R.	2009-2013	Alberta Cancer Research Institute	PHRU priority funding request 2009-2012- priority #3 - CCSC biorepository and equipment.	\$157,246
23	McGregor, S. E.		2007-2013	Alberta Cancer Board	Engaging family physicians and patients in an intervention to increase uptake of colorectal cancer screening.	\$114,077
24	Vallance, J.		2013-2014	Athabasca University	Objectively assessed physical activity and sedentary time among adults living in Southeastern Alberta: Examining the rural and urban divide.	\$6,000
25	Vallance, J.		2013-2014	Canadian Institute of Health Research	Canadian Institutes for Health Research Cafe Scientifique Program. Cancer: What's physical activity got to do with it?	\$2,800
26	Vallance, J.		2013-2014	Cancer Foundation for Innovation	Examining distance-based health promotion in the chronic disease context.	\$13,854

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
PSYCHOSOCIAL ONCOLOGY						
1	Alibhai, S. M. H.	Culos-Reed, S. N. Krahn, M. Matthew, A. Ritvo, P. Santa Mina, D. Segal, R. Tomlinson, G. Warde, P. Lukka, H.	2013	Prostate Cancer Canada	A pilot RCT and economic analysis of three exercise delivery methods in men with prostate cancer on ADT.	\$199,265
2	Bultz, B. D.		2013-2018	USA: National Institute of Health (NIH)	Building, Implementing and Evaluating Supportive Care Programs Workshop Grant.	\$160,049
3	Campbell, T.		2010-2014	Canadian Institutes of Health Research (CIHR)	Fetal Programming of Infant Stress Reactivity.	\$124,830
4	Campbell, T. S.	Carlson, L. E. Simpson, J. S. Ancoli-Israel, S. Savard, J.	2012-2014	Canadian Cancer Society Research Institute Innovation Grant	A randomized controlled trial of light therapy on biomarkers, sleep/wake activity and quality of life in individuals with post-treatment cancer-related fatigue.	\$100,000
5	Campbell, T. S.		2014-2019	Canadian Institutes of Health Research	A motivational intervention to improve adherence to dyslipidemia medication	\$145,668
6	Carlson, L. E.		2008-2016.	Alberta Heritage Foundation	Medical Research Health Scholar Award. Salary support and research allowance.	\$109,375
7	Carlson, L. E.	Zernicke, K.	2011-2013	Francisco J. Varela Research Grant, Mind and Life Institute	The eCALM Study: Online Mindfulness-based stress reduction program for underserved cancer patients in Alberta: A randomized wait-list controlled trial.	\$7,500
8	Carlson, L. E.		2012-2017	Enbridge Inc., Canadian Cancer Society (Alberta, NWT Division) and Alberta Cancer Foundation	Enbridge Research Chair in Psychosocial Oncology.	\$150,000
9	Carlson, L. E.	Speca, M. Sinclair, S. Collie, K.	2012-2013	Wings of Hope. Funded	Healing through creative arts.	\$48,104
10	Carlson, L. E.	Beattie, T. Giese-Davis, J. Tamagawa, R. Fick, L.	2012-2014	Alberta Cancer Foundation	Bridge Grant-Effects of mindfulness-based stress reduction (MBSR) and Supportive Expressive Therapy (SET) on biomarkers of cell aging, Immune function and stress in breast cancer survivors.	\$25,000
11	Carlson, L. E.	Giese-Davis, J.	2012-2014	Alberta Cancer Foundation	Enbridge Research Chair Psychosocial Oncology Survivorship Grant. Private Donors	\$50,400

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
12	Chandramohan, K.	Thomas, B. C. Sebastian, P.	2011-2014	State Committee on Science Technology and Environment Scientific Research Fund, Kerala, India	Development of new quality of life questionnaire for colorectal cancer patients with special relevance to Indian subcontinent.	\$8,333
13	Classen, C.	Robinson, J. Brotto, L. A. Barbera, L. Chivers, M. Ferguson, S. Urowitz, S. Carter, J. Koval, J. Wiljer, D.	2012-2014	Canadian Institutes of Health Research Operating Grant and Ovarian Cancer Canada	A randomized controlled trial of an online support group for sexual distress due to gynecologic cancer.	\$50,000
14	Classen, C.	Barbera, L. Chivers, M. Robinson, J.	2012-2016	Canadian Cancer Society Research Institute Operating Grant	A randomized controlled trial of an online support group for sexual distress due to gynecologic cancer.	\$181,965
15	Cory, S.	Horst, G. Sinclair, S. Thomas, B. C. Canadian Virtual Hospice	2013-2017	Canadian Partnership Against Cancer – Palliative and End-of-Life Care Initiative	Knowledge Tools to Address National Gaps: Cultural and Religious Perspectives Tool.	\$81,250
16	Couper, J.	Pollard, A. Castle, P. Carlson, L.	2011-2013	The beyond blue Victorian Centre of Excellence (bbVCoE) Research Grant	Pilot project: Mindfulness-Based Stress Reduction with Head and Neck Cancer patients receiving treatment of curative intent.	\$75,000
17	Culos-Reed, S. N.	Zahavich, A.	2014-2017	Prostate Cancer Canada	Lifestyle Management Wellness Initiatives.	\$387,667
18	Culos-Reed, S. N.		2013-2014	Wings of Hope Network	Exercise and wellness program for women living with breast cancer.	\$50,000
19	Culos-Reed, S. N.		2013-2015	Canadian Breast Cancer Foundation	Salary Assistance.	\$72,500
20	Giese-Davis, J.		2012-2013	Alberta Cancer Foundation	Grant for Alberta CancerBridges Provincial Survivorship Program.	\$50,000
21	Giese-Davis, J.		2012-2013	Canadian Cancer Society Alberta	Rural Peer Partners Program,	\$10,000
22	Giese-Davis, J.		2013-2014	Canadian Cancer Society Alberta	CancerBridges.	\$10,000
23	Giese-Davis, J.	Watson, L. McDougall, L. Bryant-Lukosius, D.	2013-2016	Alberta Cancer Prevention Legacy Fund	Building CAPACITIES: Cancer Prevention And Collaborative Initiatives To Empower Survivors.	\$314,935
24	Lavoie, K.	Campbell, T. S.	2011-2015	Canadian Institutes of Health Research (CIHR)	The impact of a brief motivational intervention on adherence behavior in asthmatics: A randomized controlled trial.	\$112,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
25	Loiselle, C. G.	Bultz, B. D. Bottorff, J. L. Hack, T. F. Carlson, L. E. Maunsell, E. Howell, D. Olfiffe, J. Grunfeld, E.	2009–2015	(STIHR) CIHR/ICR	Psychosocial Oncology Research Training (PORT): A renewal application. Strategic Training Initiative in Health Research.	\$325,000
26	Matthew, A.	Robinson, J.	2014-2017	Movember and Prostate Cancer Canada	Sexual Health Solution, A Survivorship Action Plan.	\$196,000
27	Reynolds, K. Spavor, M.	Giese-Davis, J. Carlson, L. E. Schulte, F. Anderson, R. Grundy, P.	2012-2014	Kids Cancer Care Foundation of Alberta Chair in Pediatric Oncology	A Comparison of Two Models of Follow-up Care for Adult Survivors of Childhood Cancer.	\$12,500
28	Robinson, J.	Giese-Davis, J. Wallace, K. Ruether, D. North, S. Watson, L. Walker, L. Culos-Reed, N. Dunlop, B. Watson, L. North, S. Wallace, K. Donnelly, B. Thompson, L.	2014-2017	ASAP initiative	(ASAP Network Alberta Team in collaboration with other national network members) A Survivorship Action Partnership (ASAP). The androgen deprivation educational program: ASAP initiative.	\$225,870
29	Speckens, A.	van der Lee, M. Pet, A. Aukema, E. Bronner, M. Remie, M. Witvoet, G. Ottevanger, N. Donders, R. Adang, E. Carlson, L. (Consultant)	2013-2017	Stitching Pink Ribbon	(Cost) effectiveness of Mindfulness Based Cognitive Therapy (MBCT) in breast cancer patients: a superiority trial of online and face-to-face treatment versus treatment as usual (TAU).	€10,000
30	Stephen, J. E.	Giese-Davis, J. Linden, W. Chia, S. Specia, M. Taylor-Brown, J. Fergus, K. Keller-Olaman, S. Fillion, L.	2009-2014	Canadian Breast Cancer Research Alliance, Psychosocial Aspects of Breast Cancer	An RCT Testing Efficacy of Professionally and Peer-led Online Support Groups for Young Canadian Breast Cancer Survivors.	\$116,599
31	Thomas, B. C.	Specia, M.	2013-2015	Alberta Network of Immigrant Women (Community Partner), Cancer Screening Program (Area Specialist). Canadian Breast Cancer Foundation (CBCF) Community	Investigating Health Literacy of South Asian Women in Calgary and Piloting a Community Resource to Increase Breast Cancer Awareness and Improve Health Care Access/Utilization.	\$72,278
32	Wassersug, W.	Robinson, J.	2014-2017	funded by Movember and Prostate Cancer Canada	The Androgen Deprivation Therapy Education Program. A Survivorship Action Plan.	\$135,522

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
RADIATION ONCOLOGY						
1	Doll, C.	Lees-Miller, S.	2013-2016	AIHS CRIO Cancer Care Grant	PIK3CA mutational status and pathway activation in patients with cervical cancer.	\$250,000
2	Doll, C.		2012-2014	Alberta Cancer Foundation	Identification of predictive factors of response to chemoradiation therapy in patients with carcinoma of the cervix.	\$11,050
3	Doll, C.		2012-2015	Alberta Cancer Foundation	Identification of predictive factors of response to chemoradiation therapy in patients with carcinoma of the cervix.	\$2,000
4	Doll, C.		2011-2013	Canadian Association of Radiation Oncology – RAZCER award	Expression of non-homologous end-joining pathway markers in cervical cancer and stromal tissues: Implications for chemoradiation response and targeted therapy.	\$11,350
5	Husain, S.		2010-2015	Alberta Cancer Foundation	Prostate brachytherapy outcomes analysis.	\$70,000
6	Husain, S.		2011-2016	Alberta Cancer Foundation	Initiation and evaluation of Permanent Breast Seed Implants in for accelerated partial breast RT following breast conserving surgery.	\$50,000
7	Husain, S.		2010-2015	Alberta Cancer Foundation	Prostate brachytherapy database.	\$10,000
8	Kerba, M.		2013-2015	Alberta Cancer Foundation Investigator Initiated Trial Grant	Phase II study of chemo-radiation with carboplatin in non-curative treatment of cancer of the esophagus.	\$70,500
9	Culos-Reed, N.	Lau, H.	2012-2013	Alberta Cancer Foundation	Physical activity and nutrition in Head and Neck Oncology – building a clinic-supported program.	\$24,978
10	Olivotto, I. A.	French, J. Olson, R. Stephen, J. Beckham, W.	2012-2014	Centre of Excellence for Applied Research in Cancer Control	Assessing utility and motivating practice change in palliative radiation therapy.	\$45,377
11	Olivotto, I. A.	Beckham, W.	2013-2016	Varian Medical Systems-BCCA Research Agreement	Prospective Outcomes and Support Initiative.	\$358,000
12	Sinha, R.		2013	Sanofi-Aventis	For development of a website and portal for patients with colorectal cancer.	\$10,000
SURGICAL ONCOLOGY						
1		Bathe, O.	2010–2013	Alberta Cancer Research Institute	The role of vitamin D and inflammation in colorectal cancer metastases.	\$181,082

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
2		Bathe, O.	2011–2014	National Cancer Institute of Canada (NCIC)	Vascular heterogeneity in colorectal cancer: Regulation of VEGFR2 by TGF-beta.	\$139,282
3		Bathe, O.	2011–2016	Canadian Institutes of Health Research	Genetic and molecular basis of sever muscle wasting (sarcopenia).	\$21,000
4		Dixon, E.	2001–Present	MSI Foundation	Improving safety in the operating room: Evaluating implementation of the Safe Surgery Checklist.	\$24,500
5		Dixon, E.	2008–Present	Canadian Institutes of Health Research	Effect of physician alternative payment plans on the completeness and validity of administrative data.	\$38,415
6		Dixon, E.	2010–Present	Calgary Surgical Research Development Fund	Laparoscopic cholecystectomy for acute calculous cholecystitis: How urgent is 'urgent'?	\$2,300
7		Dixon, E.	2012–Present	University of Calgary Department of Medicine and Department of Surgery Research Development Fund Award	Predictors of acute kidney injury after major surgical procedures.	\$6,250
8		Dort, J. C.	2010–Present	Alberta Ingenuity Centre for Machine Learning	Machine learning and MR texture analysis to assess human papilloma virus (HPV) status in head and neck tumors.	-
9		Dort, J. C.	2011–Present	Calgary Surgical Research Development Fund	Post-operative pulmonary complications in patients undergoing head and neck reconstructive surgery at FMC.	-
10		Matthews, T. W.	2011–2014	Non-funded research	Head and neck cancer dysphagia outcomes.	-
11		Matthews, T. W.	2011–2016	Terry Fox Research Institute	Pan Canadian optically guided approach for oral lesions surgical trial.	\$157,800
12	Arlette, J. P.	Guillemaud, J. P.	2013–2014	College of Physicians and Surgeons of Alberta	Upstaging of melanoma at the time of Mohs surgery.	\$2,960
13	Ball, C.	Dixon, E.	2013-2015	Calgary Surgical Research Development Fund	The use of wound protectors to prevent surgical site infection in patients undergoing pancreatoduodenectomy with intrabiliary stents a randomize controlled trial.	\$1,930
14	Ball, C. G.	Sutherland, F. R.	2013–2015	Non-funded research	Preoperative steroid utilization in liver resections: A randomized clinical trial.	-

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
15	Baracos, V.	Bathe, O.	2011–2014	Canadian Institutes of Health Research	Canadian-international network for the advancement of the treatment of cancer-associated cachexia.	\$127,000
16	Bathe, O.		1992–2020	Novartis Nutrition Corporation	Randomized controlled trial of early enteral feeding via a new gastrojejunostomy tube in patients undergoing laparotomy for periampullary and pancreatic neoplasms.	-
17	Bathe, O.		1999–Present	Novartis	Prospective, randomized controlled trial of early enteral feeding via a new gastrojejunostomy tube in patients undergoing laparotomy for periampullary and pancreatic neoplasms.	-
18	Bathe, O.		2011–Present	Breast Cancer Society of Canada	The biological role of TEM8 in human breast cancer.	-
19	Bathe, O.		2012–Present	NSERC	Metabolomic biomarker development for metastatic colorectal cancer.	-
20	Bathe, O.		2013–2013	National Cancer Institute	Tissue procurement for The Cancer Genome Atlas Project.	-
21	Bathe, O.		2013–2014	Breast Cancer Society of Canada	Development of a metabolomic response biomarker.	\$6,055
22	Chandarana, S.	Matthews, T. W.	2011–Present	University of Calgary Office of Surgical Research – Research Prize	The impact of CAIX in cervical node metastases in oral cavity squamous cell carcinoma.	-
23	Coomber, B.	Bathe, O.	2012–2014	Canadian Cancer Research Society	Predicting and improving responses of colorectal cancer patients to anti-VEGF therapy.	\$49,874
24	Damaraju, S.	Bathe, O.	2013–2018	Canadian Institutes of Health Research	Cancer cachexia: Phenotype definition, markers for genetic predisposition and prognosis.	\$94,073
25	Dixon, E.		2008–2014	Canadian Institutes of Health Research	Rate and waits for cancer surgery in Canada: Mixed method assessment.	\$53,750
26	Dixon, E.		2008–Present	MSI Foundation	Postoperative outcomes following colectomy in elderly ulcerative colitis patients.	\$7,930
27	Dixon, E.		2010–Present	Calgary Surgical Research Development Fund	The effects of call and call scheduling on general surgeons' and general surgery resident's perceived quality of life.	\$1,230
28	Dixon, E.		2013–2015	Memorial Sloan-Kettering Cancer Center, New York (lead center)	Resectable colonic hepatic metastases: Type of initial referral, time to surgical intervention and disease free survival.	-

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
29	Dort, J. C. (local)		2011–2015	Terry Fox Research Institute	Efficacy of optically-guided surgery in the management of early-stage oral cancer.	\$22,500
30	Dort, J. C. Chandarana, S. P. Bose, P. Brockton, N.	Matthews, T. W.	2011–2014	Non-funded research	Head and neck oncology outcomes.	-
31	Dort, J. C. Chandarana, S. P. Fritz, D.	Matthews, T. W.	2012–2014	Ohlson Research Initiative	Does the harmonic scalpel reduce operating time and blood loss in patients undergoing major surgery for oral cavity squamous cell carcinoma?: A prospective randomized trial.	\$5,000
32	Fear, E.	Mew, D.	2011–2013	Alberta Cancer Foundation High Risk for High Return Program	Clinical evaluation of a new approach to breast imaging with microwaves.	\$18,000
33	Karanicolas, P. Guyatt, G.	Dixon, E.	2013-2014	Canadian Institutes of Health Research	Establishment of the hepatopancreaticobiliary community of surgical oncologists: Clinical, evaluative and prospective.	\$24,900
34	Karanicolas, P. Guyatt, G.	Dixon, E.	2014–2016	Canadian Institutes of Health Research	Tranexamic acid versus placebo to reduce perioperative blood transfusion in patients undergoing major liver resection: A pilot randomized controlled trial.	\$10,000
35	Mack, L. A.		2005–Present	Non-funded research	Feasibility and outcomes with cytoreduction surgery and hyperthermic intraperitoneal chemotherapy.	-
36	Mack, L. A.		2007–Present	Non-funded research	Perioperative outcomes in patients with extremity soft tissue sarcomas treated with preoperative chemoradiation and limb salvage surgery.	-
37	Mack, L. A.		2010–Present	Non-funded research	Population-based retrospective analysis of outcomes in patients with superficial soft tissue sarcoma treated by surgical management alone.	-
38	McKinnon, J. G. (local)		2005–2015	John Wayne Cancer Center and NCI	Multicenter selective lymphadenectomy trial II.	-
39	Quan, M. L.		2014-2019	CBCF/CIHR	Towards better outcomes for young women with breast cancer: A Pan-Canadian collaborative.	\$1,139,061
40	Schachar, N.		2008–2015	Private Donor – Biological Solutions for Traumatic and Degenerative Joint Disease	Primary lead in research development.	\$250,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
41	Schachar, N.		2014–2016	University of Calgary – Orthopaedic Research	Establishing a culture of mindful practice in surgery at a new orthopaedic centre.	\$4,486
42	Schachar, N. (local)		2011–Present	Continuing Medical Education	How to design a research study.	\$2,011
43	Temple, W. J.		2012–2014	Canadian Partnership Against Cancer	Synoptic reporting tool project.	\$287,233
44	Temple, W. J.		2012–2014	Canada Health Infoway	Interactive patient portal project.	\$1,250,000
45	Temple, W. J.		2012–2014	AHS PMO	WebSMR migration to Synoptec.	\$490,000
46	Temple-Oberle, C. F.		2011–2014	Canadian Society of Plastic Surgeons	Patient satisfaction following breast reconstruction.	\$2,000
47	Temple-Oberle, C. F.		2013–2014	Non-funded research	Improving quality of recovery: A same day discharge pathway for women undergoing lumpectomy, mastectomy and mastectomy with implant reconstruction.	-
48	Temple-Oberle, C. F.		2013–2015	University of Calgary Department of Surgery Education Grant	Leadership skills to enhance personal effectiveness as an educator.	\$5,500
49	Temple-Oberle, C. F.		2014–2015	Allergan	ABRA investigates breast reconstruction programs in Western Canada: A step toward Alberta's breast reconstruction program.	\$10,000
50	Temple-Oberle, C. F.		2012–2014	Canadian Breast Cancer Foundation – Ontario Chapter	The use of human acellular dermal matrix in one-stage implant breast reconstruction: A multicenter, randomized, controlled trial.	\$20,000
TRANSLATIONAL RESEARCH & LABORATORIES						
1	Bebb, G.		2011–2014	Alberta Innovates Health Solutions (AIHS)	PARP-1 inhibition in ATM deficient gastric and lung cancer.	\$150,000 (Yr 2)
2	Bebb, G.		2011–2014	Breast Cancer Society of Canada (BCSC)	Identifying ATM deficient breast cancer by immunohistochemistry.	\$38,396
3	Bebb, G.		2010–2015	Multiple Sources	Lung cancer research.	-
4	Bebb, G.		2010–2014	Private Donations	Creation and expansion of the Glans-Look lung cancer database: Generation of a retrospective and prospective lung cancer clinical pathological data base.	\$275,000

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
5	Daly, A.	Kangaroo, S. B.	2012-2013	Division of Hematology Research Fund	Influence of fludarabine pharmacokinetics on outcome of allogeneic stem cell transplantation with fludarabine-busulfan conditioning.	-
6	Lewis, V.	Kangaroo, S. B.	2011-2014	Alberta Children's Hospital Foundation	Childhood cancer collaborative funding – BMT growth – pharmacokinetic clinical research.	\$320,000
7	Morris, D.		2011-2013	Breast Cancer Society of Canada (BCSC)	Determination of the role of CXCL12/CXCR4 axis in breast cancer metastasis in bone.	\$49,208
8	Morris, D.		2011-2014	Canadian Breast Cancer Foundation (CBCF)	Oncolytic viral immunotherapy for breast cancer.	\$125,000 (Yr 3)
9	Morris, D.		2009-2013	Alberta Cancer Research Institute (ACRI)	A strategic initiative for the treatment of lung cancer in Alberta.	\$147,100
10	Morris, D.	Magliocco, T.	2010-2013	Alberta Cancer Foundation (ACF)	Evaluation of circulating tumor cells (CTCs) the veridex cell search system.	\$194,000
11	Morris, D.	Magliocco, T.	2010-2014	Breast Cancer Society of Canada (BCSC)	A proposal to develop a molecular classification algorithm for Calgary breast cancer patients.	\$47,350
12	Morris, D.	Magliocco, T.	2009-2015	Canadian Institutes of Health Research (CIHR) and Terry Fox Research Institute (TFRI)	The Terry Fox foundation strategic health research training program in molecular pathology of cancer.	\$35,000 (Yr 3)
13	Morris, D.	Magliocco, T.	2009-2015	Alberta Cancer Foundation (ACF) and Terry Fox Research Institute (TFRI)	ACRI co-funding for Alberta trainees of the Terry Fox foundation strategic health research training program in cancer research.	\$35,000 (Yr 3)
14	Morris, D.	Magliocco, T.	2008-2013	Alberta Cancer Research Institute (ACRI)	A proteomic approach for functional stratification of early breast cancer to optimize treatment selection using routine archival formalin-fixed clinical specimens.	\$147,150 (Yr 2)
15	Morris, D.		2012-2013	University of Calgary (UofC)	Flow cytometer, PGM sequencer and bioanalyzer.	\$223,857
16	Morris, D.		2011-2013	Alberta Cancer Foundation (ACF)	Oncolytic reovirus therapy for renal cell carcinoma Keith Lawson fellowship.	\$40,000
17	Morris, D.		2012-2014	UofC Donor Designated	Salary for project manager - lung cancer initiative.	\$83,300 (Yr 2)
18	Morris, D.		2013-2014	Alberta Cancer Foundation (ACF)	Biomarker discovery and implementation unit.	\$255,600

GRANTS

	PI	Co-PI	Year(s)	Granting Agency	Title	Award
19	Morris, D.		2013-2016	Alberta Innovates Health Solutions (AIHS)	Immunotherapy for cancer - repurposing targeted therapeutics with oncolytic viruses.	\$250,000 (Yr 1)
20	Morris, D.		2012-2100	Multiple Sources	Paul Clark lung cancer fellowship.	\$100,420
21	Morris, D.		2012-2100	Multiple Sources	Lung cancer research initiative.	\$300,000
22	Morris, D.		2013-2015	Cancer Research Society Operating Grant	Reovirus as a viable therapeutic option to target therapy resistance of multiple myeloma.	\$40,000
23	Morris, D.		2014-2015	Breast Cancer Society of Canada	Oncolytic viral therapy augmented by immune check point inhibition as a novel treatment strategy for breast cancer.	\$20,000
24	Morris, D.	Stewart, D.	2013-2015	Cancer Research Society	Reovirus as a viable therapeutic option to target resistance of multiple myeloma.	\$40,000
25	Russell, J. A.	Kangarloo, S. B.	2008- Ongoing	PDL Pharma Inc. / Otsuka	IV busulfan – validation of fixed-infusion rate test dose protocol and pharmacokinetics of once daily i.v. busulfan.	\$250,000
26	Tang, P.	Kangarloo, S. B. Magliocco, A. M.	2011-2014	Breast Cancer Society of Canada	Phenotype screening of CYP2D6 activity in tamoxifen patients based on metabolic ratio of tamoxifen – tamoxifen metabolites.	\$70,000
27	Webster, M.	Kangarloo, S. B. Magliocco, A. M. Walley, B.	2010-2014	Alberta Cancer Research Institute	Inter-patient variability in pharmacokinetics of herceptin in relation to circulating serum HER-2 levels.	\$138,044 (Yr 3)
28	Webster, M.	Magliocco, A. M.	2011-2013	Breast Cancer Society of Canada (BCSC)	Identification of the optimal clinical assay for the determination of endocrine treatment response in breast cancer patients in Calgary.	\$20,750

FUNDAMENTAL RESEARCH

NO REPORT WAS SUBMITTED FOR THE 2013-2014 ACADEMIC YEAR.

GYNECOLOGIC ONCOLOGY**PEER REVIEWED**

1. Altman, A. D., Liu, X. Q., **Nelson, G., Chu, P., Nation, J. G., & Ghatage, P.** (2013). The effects of anemia and blood transfusion on patients with stage III-IV ovarian cancer. *International Journal of Gynecologic Cancer*, 23(9), 1569-76.
2. Altman, A. D., **Nelson, G. S., Ghatage, P.**, McIntyre, J. B., Capper, D., **Chu, P., Nation, J. G.**, Karnezis, A. N., Han, G., Kalloger, S. E., & Koebel, M. (2013). The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumours. *Mod Pathol*, 26(9), 1255-63.
3. Bures, N., **Nelson, G.**, Demetrick, D., Duan, Q., & Duggan, M. A. (2013). Primary squamous cell carcinoma of the endometrium: Clinico-pathological and molecular characteristics. *International Journal of Gynecologic Pathology*, 32(6), 566-75.
4. Despierre, E., Yesilyurt, B. T., Lambrechts, S., John, N., Verheijen, R., van der Burg, M., . . . EORTC GCG and EORTC GCG Translational Research Group (**Ghatage, P.**). (2014). Epithelial ovarian cancer: Rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. *Int J. Gynecol Cancer*, 24(3), 468-77.
5. Escobar, J., Klimowicz, A. C., Dean, M., **Chu, P., Nation, J. G., Nelson, G. S., Ghatage, P.**, Kalloger, S. E., & Koebel, M. (2013). Quantification of ER/PR expression in ovarian low-grade serous carcinoma. *Gynecol Oncol*, 128(2), 371-6.
6. Gage, J. C., Duggan, M. A., **Nation, J. G.**, Gao, S., & Castle, P. E. (2013). Comparative risk of high-grade histopathology diagnosis after a CIN 1 finding in endocervical curettage versus cervical biopsy. *J Low Genit Tract Dis*, 18(2), 137-41.
7. Greimel, E., Kristensen, G. B., van der Burg, M., Coronado, P., Rustin, G., del Rio, A. S., . . . European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group (**Ghatage, P.**). (2013). Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. *Gynecologic Oncology*, 131(2), 437-444.
8. Lee, S., **Nelson, G.**, Duan, Q., Magliocco, A., & Duggan, M. A. (2013). Precursor lesions and prognostic factors in primary peritoneal serous carcinoma. *International Journal of Gynecological Pathology*, 32(6), 547-55.
9. McIntyre, J. B., **Nelson, G. S., Ghatage, P.**, Morris, D., Duggan, M. A., Lee, C. H., Doll, C. M., & Koebel, M. (2014). PIK3CA missense mutation is associated with unfavourable outcome in grade 3 endometrial carcinoma but not in serous endometrial carcinoma. *Gynecologic Oncology*, 132(1), 188-93.
10. **Nelson, G.**, Pink, A., Lee, S., Duggan, M. A., Han, G., Limowicz, A. P., Ogilvie, T., & Koebel, M. (2014). MMR deficiency is common in high grade endometrial carcinomas and is associated with an unfavourable outcome. *Gynecologic Oncology*, 131(2), 309-14.

HEMATOLOGIC MALIGNANCIES & BMT (AHS Proposed)**PEER REVIEWED**

1. Anderson, K. R., Chambers, C. R., Lam, N., Yau, P. S., Cusano, F., **Savoie, M. L.** & Sheikh, N. (2014). Medication adherence among adults prescribed imatinib, dasatinib or nilotinib for the treatment of chronic myeloid leukemia. *Journal of Oncology Pharmacy Practice* [Epub ahead of print].
2. Churpek, J. E., Lorenz, R., Nedumgottil, S., Onel, K., Olopade, O., Sorrell, A., **Owen, C. J.**, Bertuch, A. A., & Godley, L. A. (2013). A proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. *Leuk Lymphoma*, 54(1), 28-35.
3. Couban, S., **Savoie, L.**, Mourad, Y. A., Leber, B., Minden, M., Turner, R., Palada, V., Shehata, N., Christofides, A., & Lachance, S. (2014). Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: A Canadian consensus. *Current Oncology*, 21(2), 265-309.
4. DeAngelo, D. J., Stevenson, K. E., Dahlberg, S. E., Silverman, L. B., Couban, C., Suplo, J. G., . . . Sallan, S. E. (2014). Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults ages 18 to 50 with newly diagnosed acute lymphoblastic leukemia. *Leukemia* [Epub ahead of print].
5. Foran, J. M., Pavletic, S. Z., Logan, B. R., Agov-Johnson, M. A., Perez, W. S., **Savoie, M. L.**, . . . Weisdorf, D. J. (2013). Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myeloid leukemia: A study from the CIBMTR. *Biology of Blood and Marrow Transplantation*, 19(7), 1102-8.
6. Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., **Owen, C. J.**, . . . Hallek, M. N. (2014). Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *New Engl J Med*, 370(12), 1101-10.
7. **Griffiths, C. D.**, Ng, E. S., Kangaroo, S. B., Williamson, T. S., Chaudhry, M. A., Booker, R., **Duggan, P.**, Yue, P., **Savoie, L.**, **Brown, C.**, Cox-Kennett, N., **Russell, J. A.**, **Daly, A.**, & **Storek, J.** (2014). Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function. *Bone Marrow Transplant*, 49(4), 589-91.
8. Hoegh-Petersen, M., Amin, M. A., Liu, Y., Ugarte-Torres, A., Williamson, T. S., Podgorny, P. J., **Russell, J. A.**, Grigg, A., Ritchie, D., & **Storek, J.** (2013). Antithymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse. *Bone Marrow Transplant*, 48, 105-114.
9. Iacucci, M., **Daly, A.**, **Chaudhry, A.**, **Duggan, P.**, Gui, X., Love, J., & Ghosh, S. (2013). Assessment of the early regenerative therapeutic response in graft versus host disease using high definition technology with virtual i-Scan chromoendoscopy. *Endoscopy*, 45(Suppl 2), e389-90.
10. Jakubowiak, A. J., Siegel, D. S., Martin, T., Wang, M., Vij, R., **Bahlis, N.**, . . . Jagannath, S. (2013). Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. *Leukemia*, 27(12), 2351-6.

11. **Jamani, K., Russell, J. A., Daly, A., Stewart, D., Savoie, L., Duggan, P., & Storek, J.** (2013). Prognosis of grade 3-4 acute GVHD continues to be dismal. *Bone Marrow Transplant*, 48(10), 1359-61.
12. Kornblit, B., Maloney, D. G., Storb, R., **Storek, J.**, Hari, P., Vucinic, V., . . . Sandmaier, B. M. (2013). Fludarabine/2 Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related HCT: A phase III randomized trial. *Biol Blood Marrow Transplant*, 19, 1340-1347.
13. **Neri, P., & Bahlis, N. J.** (2013). Pinning down myeloma with Pim2 inhibitors! *Blood*, 122(9), 1534-6.
14. Podgorny, P. J., Liu, Y., Dharmani-Khan, P., Pratt, L. M., **Jamani, K.**, Luider, J., Auer-Grzesiak, I., Mansoor, A., Williamson, T. S., Ugarte-Torres, A., Hoegh-Petersen, M., **Stewart, D. A., Daly, A., Khan, F. M., Russell, J. A., & Storek, J.** (2014). Immune cell subset counts associated with graft-versus-host disease. *Biol Blood Marrow Transplant*, 20(4), 450-62.
15. Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., **Bahlis, N.**, . . . Anderson, K. C. (2014). Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study. *Blood*, 123(12), 1826-32.
16. **Russell, J. A.**, Kangarloo, S. B., Williamson, T., **Chaudhry, M. A., Savoie, M. L.**, Turner, A. R., Larratt, L., **Storek, J., Bahlis, N. J., Shafey, M., Brown, C. B., Yang, M., Geddes, M., Zacarias, N., Yue, P., Duggan, P., Stewart, D. A., & Daly, A.** (2013). Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. *Biol Blood Marrow Transplant*, 19(9), 1381-6.
17. **Stewart, D. A.,** Kloiber, R., **Owen, C., Bahlis, N. J., Duggan, P.,** Mansoor, A., & Bence-Bruckler, I. (2014). Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. *Leuk Lymphoma*, 55(9), 2064-70.
18. **Storek, J.,** LeClercq, S. A., & Aaron, S. L. (2013). Lack of sustained response of advanced dermatomyositis to autologous hematopoietic cell transplantation (letter). *Scand J Rheumatol*, 42, 421-422.
19. Thirukkumaran, C. M., Shi, Z. Q., Luider, J., Kopciuk, K., **Bahlis, N., Neri, P., Pho, M., Stewart, D.,** Mansoor, A., & Morris, D. G. (2014). Reovirus as a successful ex vivo purging modality for multiple myeloma. *Bone Marrow Transplant*, 49(1), 80-6.
20. Vijay, A., Duan, Q., Henning, J. W., **Duggan, P., Daly, A., Shafey, M., Bahlis, N. J., & Stewart, D. A.** (2013). High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*, 54(12), 2620-6.
21. Zuccolo, J., Deng, L., Unruh, T. L., Sanyal, R., Bau, J. A., **Storek, J.,** Demetrick, D. J., Luider, J. M., Auer-Grzesiak, I. A., Mansoor, A., & Deans, J. P. (2013). Expression of MS4A and TMEM176 genes in human B lymphocytes. *Frontiers in Immunol*, 4, 195.

ABSTRACTS

1. Burton, J. M., **Storek, J., Duggan, P.,** Costello, P., Genest, D., Bell, R., & Metz, L. (2013). Autologous haematopoietic stem cell transplant in patients with neuromyelitis optica [Abstract]. *International Journal of MS Care*, 15(3), 13.

2. Dimopoulos, M. A., Weisel, K., Song, K. W., Delforge, M., Karlin, L., **Bahlis, N. J.**, . . . San Miguel, J. F. (2013). Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) [Abstract]. *Blood*, *122*, 408.
3. Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A. R., **Bahlis, N. J.**, . . . Benboubker, L. (2013). Initial phase 3 results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT) [Abstract]. *Blood*, *122*, 2.
4. **Griffiths, C. D.**, Ng, E. S., Kangarloo, B., Williamson, T. S., Booker, R., Yue, P., **Duggan, P.**, **Savoie, M. L.**, **Brown, C.**, **Daly, A.**, **Russell, J. A.**, & **Storek, J.** (2013). Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function [Abstract]. *Bone Marrow Transplantation*, *49*, 589-591.
5. Mahe, E., Le, A., **Street, L.**, Akhtar, A., Pournaziri, P., Kosari, F., Shabani-Rad, M., **Stewart, D.**, & Mansoor, A. (2013). DNA damage repair protein (PARP1, ATM & p53) expression and its association with proliferation index (Ki67) and overall survival in mantle cell lymphoma [Abstract]. *Blood*.
6. Mahe, E., Le, A., **Street, L.**, Akhtar, A., Pournaziri, P., Kosari, F., Shabani-Rad, M., **Stewart, D.**, & Mansoor, A. (2014). DNA damage repair protein (PARP1, ATM & p53) expression and its association with proliferation index (Ki67) and overall survival in mantle cell lymphoma [Abstract]. *Modern Pathology*, *27*(2), 360A.
7. Shah, M. Y., Martinez, E., Popovic, R., Ezponda, T., Small, E. C., Will, C., **Neri, P.**, **Bahlis, N. J.**, & Licht, J. (2013). MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents [Abstract]. *Blood*, *122*, 808.
8. **Neri, P.**, Gratton, K., Ren, L., **Slaby, J.**, Tagoug, I., & **Bahlis, N. J.** (2013). RNA-sequencing of paired pre-treatment and relapse samples reveals differentially expressed genes associated with lenalidomide resistance in multiple myeloma [Abstract]. *Blood*, *122*, 530.
9. **Neri, P.**, **Duggan, P.**, Gratton, K., Ren, L., **Stewart, D. A.**, Keats, J., & **Bahlis, N. J.** (2013). Outcomes and correlative studies of a phase I trial with the oral PARP1-2 inhibitor veliparib in combination with bortezomib in patients with relapsed or refractory multiple myeloma [Abstract]. *Blood*, *22*(21).
10. Rossi, M. R., Newman, S., Nooka, A., Kaufman, J., **Bahlis, N. J.**, **Neri, P.**, . . . & Lonial, S. (2013). Using RNA-Seq, SNP-CN and targeted deep sequencing to Improve the diagnostic paradigm In multiple myeloma [Abstract]. *Blood*, *122*, 1856.
11. San Miguel, J. F., Weisel, K., Song, K. W., Delforge, M., Karlin, L., **Bahlis, N. J.**, . . . Dimopoulos, M. A. (2013). Patient outcomes by prior therapies and depth of response: Analysis of MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) [Abstract]. *Blood*, *122*, 686.
12. Siegel, D. S., Richardson, P. G., Dimopoulos, M. A., Chen, C., Song, K., Vij, R., **Bahlis, N. J.**, . . . Anderson, K. (2013). Efficacy and safety of pomalidomide plus low-dose dexamethasone in advanced multiple myeloma: Results of randomized phase 2 and 3 trials (MM-002/MM-003) [Abstract]. *Blood*, *122*, 3185.

13. **Slaby, S.**, Tagoug, I., **Neri, P.**, Simms, J., Babich, J., Gratton, K., Ren, L., & **Bahlis, N. J.** (2013). Lenalidomide induces a ribosomal stress response in multiple myeloma (MM) cells [Abstract]. *Blood*, *122*, 3161.
14. Song, K. W., Dimopoulos, M. A., Weisel, K., Delforge, M., Karlin, L., **Bahlis, N. J.**, ... San Miguel, J. F. (2013). Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) improves health-related quality of life (HRQoL) vs high-dose dexamethasone (HiDEX) in relapsed refractory multiple myeloma (RRMM) patients enrolled in MM-003 phase 3 randomized trial [Abstract]. *Blood*, *122*, 2939.
15. Tagoug, I., **Neri, P.**, **Slaby, J.**, Babich, J., Simms, J., Gratton, K., Ren, L., & **Bahlis, N. J.** (2013). XPO1 inhibition disrupts ribosomal subunits assembly and induces multiple myeloma (MM) cell death [Abstract]. *Blood*, *122*, 3165.

BOOK CHAPTERS

1. **Duggan, P. R.** (2013). Polycythemia vera. In *Conn's Current Therapy* (pp. 848-854). Philadelphia, PA: Elsevier.

MEDICAL ONCOLOGY

PEER REVIEWED

1. Aebi, S., Gelber, S., Anderson, S. J., Lang, I., Robidoux, A., Martin, M., **Paterson, A. H. G.**, ... Wapnir, I. L. (2014). Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomized trial. *Lancet Oncol*, *15*(2), 156-63.
2. Alimohamed, N., Lee, J. L., Srinivas, S., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., ... **Heng, D. Y.** (2013). A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. *Clin Genitourin Cancer*, *12*(4), e127-131.
3. Azad, A. A., Eigl, B. J., Leibowitz-Amit, R., Lester, R., Kollmannsberger, C., Murray, N., Clayton R, **Heng D. Y.**, Joshua A. M., & Chi K. N. (2014). Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. *Eur Urol*. doi:10.1016/j.euro.2014.10.030
4. Beck, J. T., Hortobagyi, G. N., Campone, M., Lebrun, F., Deleu, I., **Heng, D. Y.**, ... Piccart, M. (2014). Everolimus plus exemestane as a first-line therapy in HR+, HER2 – advanced breast cancer in BOLERO-2. *Breast Cancer Res Treat*, *143*(3), 459-467.
5. Campone, M., Beck, J. T., Gnant, M., Neven, P., Pritchard, K. I., **Heng, D. Y.**, ... Burris, H. A. 3rd. (2013). Health-related quality of life and disease symptoms in post menopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. *Curr Med Res Opin*, *29*(11), 1463-1473.
6. Chawla, S., Dharmani, P., Liu, Y., Prokopishyn, N., Munir, M. A., Griffiths, C., Khan, F. M., **Stewart, D. A.**, Russell, J. A., Daly, A., & Storek, J. (2014). High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic but not acute graft-vs-host disease. *Biol Blood and Marrow Transplantation*, *20*(8), 1156-162.

7. Choueiri, T. K., Je, Y., Sonpavde, G., Kaymakcalan, M., Galsky, M. D., Nguyen, P. L., Schutz, F. A. B., **Heng, D. Y.**, & Richards, C. J. (2013). Incidence and risk of treatment related mortality in cancer patients treated with mammalian target of rapamycin inhibitors. *Ann Oncol*, 24(8), 2092-2097.
8. Escudier, B., **Heng, D. Y.**, Smyth-Medina, A., & Porta, C. (2014). Considerations for the design of future clinical trials in metastatic renal cell carcinoma. *Clin Genitourin Cancer*, 12(1), 1-12.
9. Freeman, G. A., Kimmelman, J., Dancey, J., & **Monzon, J.** (2013). Reporting of pharmacodynamic studies involving invasive research procedures in cancer trials. *British Journal of Cancer*, 109(4), 897-908.
10. Guilcher, G., & **Stewart, D.** (2014). Relapsed Hodgkin lymphoma in adolescents – focus on current high-dose chemotherapy and autologous stem cell transplant. *Clinical Oncology in Adolescents and Young Adults*, 4, 1-14.
11. **Heng, D. Y.**, Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., ... Wood, L. A. (2014). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. *Ann Oncol*, 25(1), 149-154.
12. Imbulgoda, A., **Heng, D. Y.**, & Kollmannsberger, C. (2014). Sunitinib in the treatment of advanced solid tumors. *Recent Results Cancer Res*, 201, 165-84.
13. Jamani, K., Russell, J. A., Daly, A., **Stewart, D.**, Savoie, L., Duggan, P., & Storek, J. (2013). Prognosis of grade 3-4 acute graft-versus-host disease continues to be dismal. *Bone Marrow Transplantation*, 48(10), 1359-1361.
14. Karanicolos, P. J., Metrakos, P., Chan, K., Asmis, T., Chen, E., **Dowden, S.**, ... Ko, Y. J. (2014). Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. *Curr Oncol*, 21(1), e129-136.
15. Ko, Y. J., Choueiri, T. K., Rini, B. I., Lee, J. L., Kroeger, N., Srinivas, S., ... **Heng, D. Y.** (2014). First-, second-, third-line therapy for mRCC: Benchmarks for trial design from the IMDC. *Br J Cancer*, 110(8), 1917-1922.
16. Kokolo, M. B., Fergusson, D., O'Neil, J., Tay, J., Tinmouth, A. T., **Stewart, D.**, & Bredeson, C. (2014). Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. *Leuk Lymphoma*. doi:10.3109/10428194.2014.889825
17. Kroeger, N., Xie, W., Lee, J. L., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., ... **Heng, D. Y.** (2013). Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. *Cancer*, 119(16), 2999-3006.
18. Kroeger, N., Choueiri, T. K., Lee, J. L., Bjarnason, G. A., Knox, J. J., ... **Heng, D. Y.** (2013). Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. *Eur Urol*, 65(6), 1086-1092.
19. McKay, R. R., Kroeger, N., Xie, W., Lee, J. L., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., Rha, S. Y., Pal, S. K., Donskov, F., Tantravahi, S. K., Rini, B. I., **Heng, D. Y.**, & Choueiri, T. K. (2014). Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. *Eur Urol*, 65(3), 577-584.
20. McKay R. R., Lin, X., Perkins, J. J., **Heng, D. Y.**, Simantov, R., & Choueiri, T. K. (2014). Prognostic significance of bone metastases and biophosphonate therapy in patients with renal cell carcinoma. *Eur Urol*. doi:10.1016/j.eururo.2014.02.040

21. McKay, R. R., Kroeger, N., Xie, W., Lee, J. L., Knox, J. J., Bjarnason, G. A., Mackenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., Rha, S. Y., Pal, S. K., Donskov, F., Tantravahi, S. K., Rini, B. I., **Heng, D. Y.**, & Choueiri, T. K. (2013). Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. *Eur Urol*, 65(3), 577-584.
22. Molina, A., Motzer, R. J., & **Heng, D. Y.** (2014). Systemic treatment options for untreated patients with metastatic clear cell renal cancer. *Semin Oncol*, 40(4), 436-443.
23. **Monzon, J. G.**, & **Heng, D. Y.** (2014). Management of metastatic kidney cancer in the era of personalized medicine. *Crit Rev Clin Lab Sci*, 51(2), 85-97.
24. North, S., Basappa, N., Bjarnason, G., Blais, N., Canil, C., **Heng, D.**, ... Wood, L. (2013). Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. *Can Urol Assoc J*, 7(7-8), 238-243.
25. Olney, H., Freeman, M., **Stewart, D.**, Mangel, J. E., White, D. J., Gaudet, G., & Elia-Pacitti, J. (2014). Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine – tositumomab for relapsed/refractory, rituximab-exposed, indolent non-Hodgkin lymphoma. *Leukemia and Lymphoma*. doi:10.3109/10428194.2014.894190 [Epub ahead of print].
26. **Paterson, A. H. G.**, & Shea-Budgell, M. A. (2013). Bone health in patients with breast cancer: Recommendations from an evidence-based Canadian guideline. *Journal of Clinical Medicine*, 2, 283-301.
27. Podgorny, P., Liu, Y., Dharmani-Khan, P., Pratt, L. M., Luidar, J., **Stewart, D. A.**, ... Storek, J. (2014). Immune cell subset counts associated with graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, 20(4), 450-462.
28. Pritchard, K. I., Burris, H. A. 3rd, Ito, Y., Rugo, H. S., Dakhil, S., **Heng, D. Y.**, ... Gnant, M. (2013). Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. *Clin Breast Cancer*, 13(6), 421-432.
29. Reaume, M. N., Graham, G. E., Tomiak, E., Kamel-Reid, S., **Heng, D. Y.**, **Ruether, D.**, ... Pautler, S. E. (2013). Kidney Cancer Research Network of Canada. Canadian guideline on genetic screening for hereditary renal cell cancers. *Can Urol Assoc J*, 7(9-10), 319-323.
30. Russell, J. A., Kangarloo, S. B., Williamson, T., Chaudhry, M. A., Savoie, M. L., Turner, A. R., Larratt, L., Storek, J., Bahlis, N., Brown, C., Yang, M., Geddes, M., Zacarias, N., Yue, P., Duggan, P., **Stewart, D.**, & Daly, A. (2013). Establishing a target exposure for once daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. *Biol Blood Marrow Transplant*, 19(9), 1381-1386.
31. Sapkota, Y., Mackey, J., Lai, R., Franco-Villalobos, C., Bryant, H., **Lupichuk, S.**, Robson, P., Kopciuk, K., Cass, C., Yasui, Y., & Damaraju, S. (2013). Assessing SNP-SNP interactions among select DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility. *PLoS ONE*, 8(6), e64896.
32. Schutz, F. A., Xie, W., Donskov, F., Sircar, M., McDermott, D. F., **Heng, D. Y.**, ... Choueiri, T. K. (2014). The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. *Eur Urol*, 65(4), 723-730.

-
33. **Stewart, D. A.**, Kloiber, R., Owen, C., Bahlis, N. J., Duggan, P., Mansoor, A., & Bence-Bruckler, I. (2013). Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. *Leukemia and Lymphoma* [Epub ahead of print].
 34. Owen, C. J., & **Stewart, D. A.** (2014). Obinutuzumab for B-cell malignancies. *Expert Opin Biol Ther*, *14*(8), 1197-1205.
 35. Stiff, P. J., Unger, J. M., Cook, J. R., Constine, L. S., Couban, S., **Stewart, D. A.**, ... Fisher, R. I. (2013). Autologous transplantation as consolidation for aggressive Non-Hodgkin's lymphoma. *New England Journal of Medicine*, *369*(18), 1681-1690.
 36. **Tam, V. C.**, Berry, S., Hsu, R., North, S., Neville, A., Chan, K., & Verma, S. (2014). Oncology education in Canadian undergraduate and postgraduate medical programs: A survey of educators and learners. *Current Oncology*, *21*(1), e75-88.
 37. **Tam, V C.**, Ko, Y. J., Mittmann, N., Cheung, M. C., Kumar, K., Hassan, S., & Chan, K. K. (2013). Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. *Current Oncology*, *20*(2), e90-e106.
 38. Thirukkumaran, C., Zhong, Q., Luidier, J., Kopcuik, K., Bahlis, N., Neri, E. P., Pho, M., **Stewart, D.**, Mansoor, A., & **Morris, D.** (2014). Reovirus as a successful ext vivo purging modality for multiple myeloma. *Bone Marrow Transplantation*, *49*(1), 80-86.
 39. **Vickers, M. M.**, Al-Harbi, H., Choueiri, T. K., Kollmannsberger, C., North, S., Mackenzie, M., Knox, J. J., Rini, B. I., & **Heng, D. Y.** (2013). Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: Results from the international metastatic renal cell carcinoma database consortium. *Clin Genitourin Cancer*, *11*(3), 311-315.
 40. **Vickers, M. M.**, Al-Harbi, H., Choueiri, T. K., Kollmannsberger, C., North, S., MacKenzie, M., Knox, J. J., Rini, B. I., & **Heng, D. Y.** (2013). Prognostic factors of survival for metastatic renal cell carcinoma (mRCC) patients with brain metastases treated with targeted therapy: results from the International mRCC Database Consortium. *Clin Genitourin Cancer*, *11*(3), 311-315.
 41. Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., **Dowden, S.**, ... Renschler, M. F. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med*, *369*(18), 1691-1703.
 42. Wang, Y., Chouerir, T. K., Lee, J. L., Tan, M. H., Rha, S. Y., North, S. A., Kollmannsberger, C. K., McDerott, D. F., & **Heng, D. Y.** (2014). Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients. *Br J Cancer*, *110*(6), 1433-1437.
 43. Wood, L., Bjarnason, G. A., Black, P. C., Cagiannos, I., **Heng, D. Y.**, Kapoor, A., ... Finelli, A. (2013). Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. *J Oncol Pract*, *9*(5), e262-267.
 44. Yilmaz, A., **Cheng, T.**, Zhang, J., & Trpkov, K. (2013). Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors. *Mod Pathol*, *26*(4), 579-586.

ABSTRACTS

1. Andrew, P., **Vickers, M.**, O'Connor, S., & **Tang, P. A.** (2014). Media reporting of practice-changing clinical trials in oncology – a North American perspective [Abstract]. American Society of Clinical Oncology, Annual Meeting. *J Clin Oncol*, *32*(5).

2. Armstrong, D. E., Raissouni, S., Price-Hiller, J. A., Mercer, J., Powell, E. D., MacLean, A., Jiang, M., Doll, C. M., Goodwin, R. A., Batuyong, E., Zhou, K., **Monzon, J. G., Tang, P., Heng, D. Y.,** Cheung, W. Y., & **Vickers, M. M.** (2014). Predictors of pathological complete response after neoadjuvant treatment for rectal cancer: A multicenter study [Abstract]. American Society of Clinical Oncology, GI Symposium. *J Clin Oncol*, 32.
3. **Bebb G.** (2013). ATM deficiency increases radiation sensitivity in NSCLC cell lines in vitro and confers a poor outcome in early resected NSCLC [Abstract]. *Journal of Thoracic Oncology*, 8(2), s441.
4. Elegbede, A., **Bebb, G.,** Petersen, L., Kubota, E., & Lees-Miller, S. (2013). Role of ATM in response of NSCLC cell lines to therapeutic agents [Abstract]. *Journal of Thoracic Oncology*, 8(2), s1061.
5. Feng, X., Smylie, M., **Cheng, T., Monzon, J.,** & Lee-Ying, R. (2014). The Impact of Clinical Response to Anti-CTLA4 Treatment on Overall Survival (OS) in Metastatic Melanoma (MM) [Abstract]. Canadian Association of Medical Oncologists Meeting. Chicago, Illinois. *J Clin Oncol*, 32(5).
6. **Hao, D.,** Lau, H. Y., Huang, L. L., Doll, C., Dort, J., & Shack, L. (2013). An analysis of the temporal, age and gender trends in human papillomavirus (HPV)-related versus non-HPV related head and neck cancers (HNC) in Alberta, Canada [Abstract]. *J Clin Oncol*, 31, e12505.
7. Jiang, M., Raissouni, S., Mercer, J., Kumar, A., Goodwin, R. A., **Heng, D. Y., Tang, P. A.,** Doll, C. M., MacLean, A., Powell, E. D., Price-Hiller, J. A., **Monzon, J. G., Vickers, M. M.,** & Cheung, W. Y. (2014). Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer [Abstract]. American Society of Clinical Oncology, Gastrointestinal Cancers Symposium. *J Clin Oncol*, 32(5).
8. Kangarloo, S. B., Ng, E. S. M., **Bramwell, V. H. C., Pritchard, K. I., Shepherd, L. E., Tu, D., Magliocco, A. M., & Tang, P. A.** (2014). Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial [Abstract]. American Society of Clinical Oncology meeting. *J Clin Oncol*, 32(5).
9. Khanna, S. K., Boyko, M., **Heng, D., Vickers, M., & Tam, V. C.** (2013). Concordance between abstracts, virtual meeting (VM) presentations, and final publication of phase III clinical trials [Abstract]. American Society of Clinical Oncology, Annual Meeting. *J Clin Oncol*, 31.
10. Ko, Y. J., **Tam, V. C.,** Mittmann, N., Pasteka, M., & Chan, K. K. (2013). A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer [Abstract] Presented at the 2013 American Society of Clinical Oncology, Annual Meeting. *J Clin Oncol*, 31, e17569.
11. **Lupichuk, S., Railton, C.,** Ko, J., McCormick, J., Zhong, L., Joy, A., **Walley, B.,** & Giese-Davis, J. (2013). Assessing the need for a nurse-led breast cancer telephone follow-up clinic in Alberta Canada [Abstract]. *J Clin Oncol*, 31(26).
12. Mahe, E., Le, A., Street, L., Akhtar, A., Pournaziri, P., Kosar, F., Shabani-Rad, M. T., **Stewart, D.,** & Mansoor, A. (2014). DNA damage repair protein (PARP1, ATM&p53) expression and its association with proliferation index (Ki67) and overall survival in mantle cell lymphoma [Abstract]. *Modern Pathology*, 27(2), 360A.

13. Otsuka, S., Boland, W., **Hao, D., Morris, D., & Bebb, G.** (2013). Metastatic NSCLC outcomes at a single Canadian institution over a decade [Abstract]. *Journal of Thoracic Oncology*, 8(2), s1182.
14. Petersen, L., McIntyre, J., Elegbede, A., Lees-Miller, S., & **Bebb, G.** (2013). Deep-sequencing mutational analysis of ATM in NSCLC cell lines [Abstract]. *Journal of Thoracic Oncology*, 8(2), s1055.
15. Raissouni, S., Armstrong, D. E., Price-Hiller, J. A., Mercer, J. M., Powell, E. D., MacLean, A., Jiang, M., Doll, C. M., Goodwin, R. A., Batuyong, E., Zhou, K., **Monzon, J. G., Tang, P., Heng, D. Y.,** Cheung, W. Y., & **Vickers, M. M.** (2014). Predictors of treatment interruption/dose reduction of neoadjuvant chemotherapy for rectal cancer: A multicenter study [Abstract]. American Society of Clinical Oncology, GI Symposium. *J Clin Oncol*, 32.
16. Raissouni, S., Mercer, J., Gresham, G., Kumar, A., Goodwin, R. A., Jiang, M., Leung, A., **Heng, D. Y., Tang, P.,** Doll, C., MacLean, A., Powell, E. D., Price-Hiller, J. A., **Monzon, J. G.,** Cheung, W. Y., & **Vickers, M. M.** (2014). External validation of the neoadjuvant rectal (NAR) score and Valentini prediction nomogram (VPN): A multicenter study [Abstract]. American Society of Clinical Oncology, Annual Meeting. *J Clin Oncol*, 32(5).
17. Renouf, D., **Tang, P. A.,** Hedley, D., Chen, E., Kamel-Reid, S., Tsao, M. S., Tran-Thanh, D., Gill, S., Dhani, N., Au, H. J., Wang, L., & Moore, M. (2014). A phase II Study of erlotinib in gemcitabine refractory advanced pancreatic cancer [Abstract]. *Eur J Cancer*, 50 (11),1909-15.
18. Thirukkumaran, C., & **Morris, D.** (2014) Reovirus synergy with proteasome inhibitor carfilzomib and Akt inhibitor perifosone overcomes therapy resistance of multiple myeloma: Promising preclinical activity [Abstract]. American Association of Cancer Research, Annual Meeting. *J Clin Oncol*, 32(5).
19. Withecomb, S., Otsuka, S., Klimowicz, A., Pohorelic, B., Kopciuk, K., Zhang, Y., Petersen, L., Konno, M., **Morris, D., & Bebb, G.** (2013). Implications of CXCR4 and estrogen/progesterone receptor (ER/PR) pathway activity in NSCLC [Abstract]. *Journal of Thoracic Oncology*, 8(2), s760.

BOOK CHAPTERS

1. **Vickers, M. M., & Heng, D.** (2013). Prognostic factors in metastatic renal cell carcinoma. In S. C. Campbell, & B. Rini (Eds.) *Renal Cell Carcinoma Clinical Management* (pp. 249-256) Cleveland, Ohio: Humana Press.

MEDICAL PHYSICS

PEER REVIEWED

1. Balderson, M., & **Kirkby, C.** (2014). Potential implications on TCP for external beam prostate cancer treatment when considering the bystander effect in partial exposure scenarios. *Int. J. Radiat. Biol*, 90(2) 133-141.
2. Becker, N., **Quirk, S.,** Kay, I., Braverman, & **Smith, W. L.** (2013). A comparison of phase, amplitude, and velocity binning for cone-beam computed tomographic projection-based motion reconstruction. *Prac Rad Oncol*, 3(4), e209-e217.

3. Clark, B. G., Brown, R. J., Ploquin, J., & **Duncombe, P. B.** (2013). Patient safety improvements in radiation treatment through 5 years of incident learning. *Practical Radiation Oncology*, *3*, 157-163.
4. Donaldson, K. H., Cao, J., French, J., Gillan, C., Milosevic, M., Lam, C., & **Duncombe, P. B.** (2013). Quality standards in radiation medicine. *Practical Radiation Oncology*, *4*(4), 208–214. doi:10.1016/j.prro.2013.11.07
5. Einck, J., **Hudson, A.**, Yashar, C., Dieng, M., Gaye, M., Diagne, M., . . . Shulman, A. (2013). Implementation of a novel high-dose-rate brachytherapy program for the treatment of carcinoma of the cervix in Sénégal: A model for the developing world. *Int Journal of Rad Onc, Biol, Phys*, *89*(3), 462-7. doi: 10.1016/j.ijrobp.2013.12.008
6. Flück, D., Beaudin, A. E., Steinback, C. D., Kumarpillai, G., Shobha, M., McCreary, C. R., . . . **Peca, S.** (2014). Effects of aging on the association between cerebrovascular responses to visual stimulation, hypercapnia and arterial stiffness. *Frontiers in Physiology*, *5*, 49. doi:10.3389/fphys.00049.2014.02.19
7. **Gräfe, J. J.**, **Poirier, Y.**, **Jacso, F.**, **Khan, R.**, Liu, H. W., & **Villarreal-Barajas, J. E.** (2014). Assessing the deviation from the inverse square law for orthovoltage beams with closed-ended applicators. *J Appl Clin Med Phys*, *15*(4), 356-366.
8. **Kirkby, C.**, **Ghasroddashti, E.**, Kovalchuk, A., Kolb, B., & Kovalchuk, O. (2013). Monte Carlo-based dose reconstruction in a rat model for scattered ionizing radiation investigations. *Int. J. Radiat. Biol*, *89*(9), 741-749.
9. **Kirkby, C.**, **Ghasroddashti, E.**, **Poirier, Y.**, Tambasco, M., & Stewart, R. D. (2013). RBE of kV CBCT radiation determined by Monte Carlo DNA damage simulations. *Phys Med Biol*, *58*(16) 5693-5704.
10. **Khan, R.**, **Villarreal-Barajas, J. E.**, Lau, H., & Wei-Liu, H. (2014). Effect of acuros XB algorithm on monitor units for stereotactic body radiotherapy planning of lung cancer, *Medical Dosimetry*, *39*(1), 83-87.
11. **Khan, Y.**, **Villarreal-Barajas, J. E.**, Udowicz, M., Sinha, R., Muhammad, W. Abbasi, A. N., & Hussain, A. (2013). Clinical and dosimetric implications of air gaps between bolus and skin surface during radiation therapy. *J Cancer Therapy*, *4*, 1251-1255.
12. Liu, H. W., Nugent, Z., Clayton, R., **Duncombe, P.**, Lau, H., & **Khan, R.** (2014). Clinical impact of using the deterministic patient dose calculation algorithm Acuros XB for lung stereotactic body radiation therapy. *Acta Oncol*, *53*(3), 324-9.
13. Liu, H., **Khan, R.**, Krobutschek, K., Nugent, Z., & Lau, H. (2013). Factors influencing intra-fractional target shifts in lung stereotactic body radiotherapy. *Practical Radiation Oncology*, *4*(1), 312-316.
14. Liu, H. W., Nugent, Z., Krobutschek, K., **Duncombe, P.**, & Lau, H. (2014). Factors influencing intrafractional target shifts in lung stereotactic body radiotherapy. *Practical Radiation Oncology*, *4*, e45-51.
15. **Peca, S.**, McCreary, C. R., Donaldson, E., Kumarpillai, G., Shobha, N., Sanchez, K., . . . Charlton, A. (2013). Neurovascular decoupling is associated with cerebral amyloid angiopathy severity. *Neurology*, *81*, 1659-1665.
16. **Poirier, Y.**, Kouznetsov, A., **Koger, B.**, & Tambasco, M. (2014). Experimental validation of a kilovoltage x-ray source model for computing imaging dose. *Med. Phys*, *41*(4), 041915.
17. **Quirk, S.**, Becker, N., & **Smith, W.** (2013). External respiratory motion analysis and statistics for patients and volunteers. *J Appl Clin Med Phys*, *14*(2), 90-101.

18. Stanley, J., **Duncombe, P.**, Lau, H., Burns, P., Lim, G., Liu, H. W., . . . Nordal, R. (2013). The effect of contouring variability on dosimetric parameters for brain metastases treated with stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys*, 87(5), 924-31.
19. Tambasco, M., Nygren, I., Yorke-Slader, E., & **Villarreal-Barajas, J. E.** (2013). FracMod: A computational tool for assessing IMRT field modulation. *Phys Med*, 29(5), 537-544.
20. **Villarreal-Barajas, J. E.**, & **Khan, R.** (2013). Energy response of EBT3 radiochromic film - implications for dosimetry in kilo voltage range. *J Appl Clin Med Phys*, 15(1), 4439.

ABSTRACTS

1. **Balderson, M. J.**, **Brown, D. W.**, & **Kirkby, C.** (2013). Model the effects of dose heterogeneity on mean TCP of an intermediate risk prostate population [Abstract]. *Radiother Oncol*, 108, s107-108.
2. Chugh, B., & **Smith, W. L.** (2013). Measurement of time delays in gated radiotherapy for realistic breath motions [Abstract]. *Med Phys*, 40, 231.
3. **Conroy, L.**, **Quirk, S.**, & **Smith, W. L.** (2013). Population-based dosimetric margins for respiratory motion and setup errors in partial breast irradiation [Abstract]. *Radiother Oncol*, 108, s107.
4. **Gräfe, J. L.**, **Poirier, Y.**, **Jacso, F.**, **Khan, R.**, Liu, H. W., & **Villarreal-Barajas, J. E.** (2014). Assessing the divergence from the inverse square law for orthovoltage beams with closed-ended applicators [Abstract]. *J Appl Clin Med Phys*, 15(4).
5. **Kirkby, C.**, **Ghasroddashti, E.**, **Poirier, Y.**, Tambasco, M., & Stewart, R. D. (2013). Monte Carlo simulation of relative DNA damage from KC CBCT radiation [Abstract]. *Med Phys*, 40(6), 319.
6. Liu, D., **Meyer, T.**, Usmani, N., Kay, I., Husain, S., Angyalfi, S., & Sloboda, R. (2013). Transrectal ultrasound probe-related seed movement in prostate brachytherapy [Abstract]. *Radiotherapy & Oncology*, 108, s100.
7. **McGeachy, P.**, & **Khan, R.** (2013). Developing photon beamlet energy optimization criteria for modulated photon radiotherapy (XMRT) [Abstract]. *Radiotherapy and Oncology*, 108, s269.
8. **McGeachy, P.**, & **Khan, R.** (2013). Incorporating photon beamlet energy in optimization of intensity modulated beams [Abstract]. *Medical Physics*, 40, 291.
9. **McGeachy, P.**, & **Khan, R.** (2013). Comparison of an open source genetic algorithm to the commercially used ISA for generation of seed distributions in LDR prostate brachytherapy [Abstract]. *Medical Physics*, 39, 4625.
10. Nygren, I., **Meyer, T.**, **Smith, W.**, & **Spencer, D. P.** (2013). Detection and correction of MLC bank non-parallelism using 1D and 2D dosimetric leaf gap measurement. [Abstract]. *Radiotherapy & Oncology*, 108, s98.
11. **Peca, S.**, **Quirk, S.**, Granville, D., & **Brown, D.** (2013). A simple 2D in-vivo dosimetry using the EPID during treatment [Abstract]. *Radiotherapy and Oncology*, 108 (1), s126.
12. **Quirk, S.**, Becker, N., & **Smith, W. L.** (2013). External respiratory motion analysis and statistics for patients and volunteer [Abstract]. *J Appl Clin Med Phys*, 14 (2), 4051.
13. **Quirk, S.**, **Conroy, L.**, & **Smith, W. L.** (2013). Deliverability of partial breast IMRT with escalating respiratory motion [Abstract]. *Radiother Oncol*, 108, s112.
14. **Quirk, S.**, **Conroy, L.**, & **Smith, W. L.** (2013). Population based respiratory analysis of partial breast IMRT and impact of breast shape and size [Abstract]. *Med Phys*, 40, 349.

-
15. Starkschall, G., & **Smith, W. L.** (2013). AAPM medical physics student meeting: Pathways to a career in medical physics [Abstract]. *Med Phys*, 40, 82.

PALLIATIVE MEDICINE

PEER REVIEWED

1. Chochinov, H. M., McClement, S. E., Hack, T., **Sinclair, S.**, Taylor-Brown, J., & Rach, A. (2013). Healthcare provider communication: An empirical model of therapeutic effectiveness. *Cancer*, 119(9), 1706-1713.
2. Dyason, C., **Simon, J.**, & Wityk Martin, T. L. (2013). Advance care planning discussions among residents of long term care planning – A qualitative descriptive study of the perspectives of seriously ill, older patients and their families. *BMJ Supportive and Palliative Care*, 0, 1-6 [Epub ahead of print].
3. Handzo, G. F., Cobb, M., Holmes, C., Kelly, E., & **Sinclair, S.** (2014). Outcomes for professional health care chaplaincy: An international call to action. *Journal of Health Care Chaplaincy*, 20(2), 43-53.
4. Hill, M. D., Chen, S., & **Simon, J.** (2014). There is always something we can do – palliative and end-of-life care in stroke. *Stroke*, 45, 1887-1916 [Epub ahead of print].
5. Green, T., Gandhi, S., Kleissen, T., **Simon, J.**, Raffin-Bouchal, S., & Rykborst, K. (2014). Advance care planning in stroke: Influence of time on engagement in the process. *Patient Preference and Adherence*, 8, 119-126.
6. Jung, H., **Sinnarajah, A.**, Enns, B., Voroney, J. P., Murray, A., Pelletier, G., & Wu, J. (2013). Managing brain metastases patients with and without radiotherapy: Initial lessons from a team-based consult service through a multidisciplinary integrated palliative oncology clinic. *Support Care Cancer*, 21(12), 3379-3386.
7. **Simon, J.**, Porterfield, P., Raffin, R., & Heyland, D. (2013). “Not Yet” and “Just Ask”: Barriers and facilitators to advance care planning – A qualitative descriptive study of the perspectives of seriously ill, older patients and their families. *BMJ Supportive and Palliative Care*, 0, 1-9 [Epub ahead of print].
8. **Wasylenko, E.** (2013). Jugglers, tightrope walkers, and ringmasters: Priority setting, allocation, and reducing moral burden. *Healthcare Management Forum*. 26, 77-81.

PEDIATRIC ONCOLOGY

PEER REVIEWED

1. Bachanova, V., Marks, D. I., Zhang, M. J., Wang, H., de Lima, M., **Lewis, V. A.**, ... Weisdorf, D. J. (2014). Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease. *Leukemia*, 28(3), 658-65.
2. Bartels, U., Wolff, J., Gore, L., Dunkel, I., Gilheeny, S., **Strother, D.**, ... Bouffet, E. (2014). Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. *Neuro Oncol* [Epub ahead of print].

3. Buczkowicz, P., Hoeman, C., Rakopoulos, P., Pajovic, S., Letourneau, L., **Lafay-Cousin, L.**, ... Hawkins, C. (2014). Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations, *Nat Genet*, *46*, 451-456.
4. Effinger, K. E., Migliorati, C. A., Hudson, M. M., McMullen, K. P., Kaste, S. C., Ruble, K., **Guilcher, G. M. T.**, Shah, A. J., & Castellino, S. M. (2014). Oral and dental late effects in survivors of childhood cancer: A children's oncology group report. *Support Care Cancer*, *22*(7), 2009-19.
5. Gore, L., Trippett, T. M., Katzenstein, H. M., Boklan, J., **Narendran, A.**, Smith, A., ... Nieder, M. (2013). A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. *Clin Cancer Res*, *19*(13), 3649-58.
6. **Guilcher, G. M.**, Fernandez, C. V., & Joffee, S. (2014). Are hybrid umbilical cord blood banks really the best of both worlds? *J Med Ethics*. doi: 10.1136/101673 [Epub ahead of print].
7. **Guilcher, G. M. T.**, & Stewart, D. A. (2014). Relapsed Hodgkin lymphoma in adolescents: Focus on current high-dose chemotherapy and autologous stem cell transplant. *Clinical Oncology in Adolescents and Young Adults*, *4*, 1-12.
8. Hale, G. A., Arora, M., Ahn, K. W., He, W., Camitta, B., **Lewis, V. A.**, ... Grupp, S. A. (2013). Allogeneic hematopoietic cell transplantation for neuroblastoma: The CIBMTR experience. *Bone Marrow Transplant*, *48*(8), 1056-64.
9. Hoag, J., Kupst, M. J., Briere, M. E., Mabbott, D., Elkin, T. D., Trask, C. L., Isenberg, J., Holm, S., Ambler, C., & **Strother, D. R.** (2014). Feasibility of conducting long-term follow-up of children and infants treated for CNS tumors on the same cooperative group clinical trial protocol. *J Clin Psychol Med Settings*, *21*(2), 136-43.
10. Jayanthan, A., Cooper, T. M., Hoeksema, K. A., Lotfi, S., Woldum, E., **Lewis, V. A.**, & **Narendran, A.** (2013). Occurrence and modulation of therapeutic targets of aurora kinase inhibition in pediatric acute leukemia cells. *Leuk Lymphoma*, *54*(7), 1505-16.
11. Johnston, D. L., **Lewis, V.**, Yanofsky, R., Gillmeister, B., Ethier, M. C., Mitchell, D., ... Sung, L. (2013). Invasive fungal infections in paediatric acute myeloid leukaemia. *Mycoses*, *56*(4), 82-7.
12. Kurtzberg, J., Prockop, S., Teira, P., Bittencourt, H., **Lewis, V.**, Chan, K. W., Horn, B., Yu, L., Talano, J. A., Nemecek, E., Mills, C. R., & Chaudhury, S. (2014). Allogeneic human mesenchymal stem cell therapy (Remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. *Biol Blood Marrow Transplant*, *20*(2), 229-35.
13. **Lafay-Cousin, L.**, Hader, W., Wei, X. C., Nordal, R., **Strother, D.**, Hawkins, C., & Chan, J. A. (2013). Post-chemotherapy maturation in supratentorial primitive neuroectodermal tumors. *Brain Pathol*, *24*(2), 166-72.
14. Lui, J., **Narendran, A.**, & Cawthorpe, D. (2014). What can population-based physician billing data tell us about the prevalence, costs and disorders associated with different types of cancers based on the 16 years prevalence of cancer diagnosis? *Journal of Hospital Administration*, *3*(4), 9-19.
15. Lun, X., Ruan, Y., Jayanthan, A., Liu, D. J., Singh, A., Trippett, T., Bell, J., Forsyth, P., Johnston, R. N., & **Narendran, A.** (2013). Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors, *Mol Oncol*, *7*(5), 944-54.

16. Maziarz, R. T., Wang, Z., Zhang, M. J., Bolwell, B. J., Chen, A. I., **Lewis, V. A.**, . . . Hari, P. N. (2013). Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *Br J Haematol*, *162*(5), 648-56.
17. Mobahat, M., **Narendran, A.**, & Riabowol, K. (2014). Survivin as a preferential target for cancer therapy. *Int J Mol Sci*, *15*(2), 2494-516.

ABSTRACTS

1. Cooper, T., Baker, S., Drenzo, J., Trippett, T., Gore, L., **Narendran, A.**, August, K., Absalon, M., Boklan, J., Pollard, J., Magoon, D., Sison, E., & Brown, P. (2013). Chemosensitization and mobilization Of AML/ALL/MDS with plerixafor (AMD 3100), a CXCR4 antagonist: A phase I study of plerixafor + cytarabine and etoposide in pediatric patients with acute leukemia and MDS [Abstract]. *Blood*, *122*, 2680.
2. Jayanthan, A., Ruan, Y., Hagerty, M., Shah, R., **Truong, T.**, **Lewis, V.**, Boklan, J., Trippett, T., Gore, L. & **Narendran, A.** (2013). In vitro growth inhibition, target modulation and drug synergy in pediatric leukemia by the novel proteasome inhibitor carfilzomib [Abstract]. *Blood*, *122*, 2673.

PREVENTIVE ONCOLOGY

PEER REVIEWED

1. Amankwah, E. K., **Friedenreich, C. M.**, Magliocco, A. M., Brant, R., Speidel, T., Rahman, W., & Cook, L. S. (2013). Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors. *Cancer Epidemiol Biomarkers Prev*, *22*(7), 1325-1331. doi: 10.1158/1055-9965.EPI-13-0105
2. **Ashbury, F. D.**, Little, J., Ioannidis, J. P., Kreiger, N., Palmer, L. J., Relton, C., & Taylor, P. (2014). A vision for chronic disease prevention intervention research: Report from a workshop. *Can J Public Health*, *105*(2), e150-153
3. Bose, P., **Brockton, N. T.**, & Dort, J. C. (2013). Head and neck cancer: From anatomy to biology. *Int J Cancer*, *133*(9), 2013-2023. doi: 10.1002/ijc.28112
4. Bose, P., Dort, J. C., & **Brockton, N. T.** (2013). Identifying the stromal cell type that contributes to tumor aggressiveness associated with carbonic anhydrase IX. *Cell Cycle*, *12* (16), 2535-2536.
5. Butts, C., Kamel-Reid, S., Batist, G., Chia, S., Blanke, C., Moore, M., . . . **Ashbury, F. D.** (2013). Benefits, issues, and recommendations for personalized medicine in oncology in Canada. *Curr Oncol*, *20*(5), e475-483. doi: 10.3747/co.20.1253
6. Charbonneau, B., Block, M. S., Bamlet, W. R., Vierkant, R. A., Kalli, K. R., Fogarty, Z., **Kelemen, L.E.**, (one of co-authors). . . Goode, E. L. (2014). Risk of ovarian cancer and the NF-kappaB pathway: Genetic association with IL1A and TNFSF10. *Cancer Res*, *74*(3), 852-861. doi: 10.1158/0008-5472.CAN-13-1051
7. Chen, M. M., Crous-Bou, M., Setiawan, V. W., Prescott, J., Olson, S. H., **Friedenreich, C. M.**, . . . De Vivo, I. (2014). Exome-wide association study of endometrial cancer in a multiethnic population. *PLoS One*, *9*(5), e97045. doi: 10.1371/journal.pone.0097045
8. Choi, Y. H., Briollais, L., Green, J., Parfrey, P., & **Kopciuk, K.** (2014). Estimating successive cancer risks in Lynch syndrome families using a progressive three-state model. *Stat Med*, *33*(4), 618-638. doi: 10.1002/sim.5938

9. Cook, L. S., Dong, Y., Round, P., Huang, X., Magliocco, A. M., & **Friedenreich, C. M.** (2014). Hormone contraception before the first birth and endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev*, *23*(2), 356-361. doi: 10.1158/1055-9965.EPI-13-0943
10. Cook, L. S., Nelson, H. E., Stidley, C. A., Dong, Y., Round, P. J., Amankwah, E. K., . . . **Friedenreich, C. M.** (2013). Endometrial cancer and a family history of cancer. *Gynecol Oncol*, *130*(2), 334-339. doi: 10.1016/j.ygyno.2013.04.053
11. Courneya, K. S., Forbes, C. C., Trinh, L., Sellar, C. M., **Friedenreich, C. M.**, & Reiman, T. (2013). Patient satisfaction with participation in a randomized exercise trial: Effects of randomization and a usual care posttrial exercise program. *Clin Trials*, *10*(6), 959-966. doi: 10.1177/1740774513495985
12. Courneya, K. S., McKenzie, D., Gelmon, K. A., Mackey, J., Reid, R. D., Yasui, Y., **Friedenreich, C. M.**, . . . Segal, R. J. (2014). A multicenter randomized trial of the effects of exercise dose and type on psychosocial distress in breast cancer patients undergoing chemotherapy. *Cancer Epidemiol Biomarkers Prev*, *23*(5), 857-864. doi: 10.1158/1055-9965.EPI-13-1163
13. Courneya, K. S., McKenzie, D. C., Mackey, J. R., Gelmon, K., **Friedenreich, C. M.**, Yasui, Y., . . . Segal, R. J. (2013). Effects of exercise dose and type during breast cancer chemotherapy: Multicenter randomized trial. *J Natl Cancer Inst*, *105*(23), 1821-1832. doi: 10.1093/jnci/djt297
14. Courneya, K. S., Segal, R. J., Mackey, J. R., Gelmon, K., **Friedenreich, C. M.**, Yasui, Y., . . . McKenzie, D. C. (2014). Effects of exercise dose and type on sleep quality in breast cancer patients receiving chemotherapy: A multicenter randomized trial. *Breast Cancer Res Treat*, *144*(2), 361-369. doi: 10.1007/s10549-014-2883-0
15. Courneya, K. S., Segal, R. J., McKenzie, D. C., Dong, H., Gelmon, K., **Friedenreich, C. M.**, . . . Mackey, J. R. (2014). Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. *Med Sci Sports Exerc*, *46*(9), 1744-51. doi: 10.1249/MSS.0000000000000297
16. **Csizmadi, I., Kelemen, L. E.**, Speidel, T., Yuan, Y., **Friedenreich, C. M.**, Dale, L., & Robson, P. J. (2014). Are physical activity levels linked to nutrient adequacy? Implications for cancer risk. *Nutr Cancer*, *66*(2), 214-224.
17. De Vivo, I., Prescott, J., Setiawan, V. W., Olson, S. H., Wentzensen, N., Australian National Endometrial Cancer Study., . . . Kraft, P. (2014). Genome-wide association study of endometrial cancer in E2C2. *Hum Genet*, *133*(2), 211-224. doi: 10.1007/s00439-013-1369-1
18. Dinu, I., Wang, X., **Kelemen, L. E.**, Vatanpour, S., & Pyne, S. (2013). Linear combination test for gene set analysis of a continuous phenotype. *BMC Bioinformatics*, *14*, 212. doi: 10.1186/1471-2105-14-212
19. Earp, M. A., **Kelemen, L. E.**, Magliocco, A. M., Swenerton, K. D., Chenevix-Trench, G., Australian Cancer, . . . Ovarian Cancer Association. (2013). Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Hum Genet*. doi: 10.1007/s00439-013-1383-3
20. **Friedenreich, C. M.**, Langley, A. R., Speidel, T. P., Lau, D. C., Courneya, K. S., **Csizmadi, I.**, . . . Cook, L. S. (2013). Case-control study of inflammatory markers and the risk of endometrial cancer. *Eur J Cancer Prev*, *22*(4), 374-379. doi: 10.1097/CEJ.0b013e32835b3813

21. **Friedenreich, C. M.**, Speidel, T. P., Neilson, H. K., Langley, A. R., Courneya, K. S., Magliocco, A. M., & Cook, L. S. (2013). Case-control study of lifetime alcohol consumption and endometrial cancer risk. *Cancer Causes Control*, 24(11), 1995-2003. doi: 10.1007/s10552-013-0275-0
22. Johnson, S. T., Eurich, D. T., & **Vallance, J. K.** (2014). Physical activity information sources and achieving public health guidelines among older adult males. *Public Health*, 128(1), 110-113. doi: 10.1016/j.puhe.2013.10.002
23. **Kelemen, L. E.**, Brenton, J. D., Parkinson, C., Whitaker, H., Piskorz, A. M., **Csizmadi, I.**, & Robson, P. J. (2014). Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women. *PLoS One*, 9(5), e96542. doi: 10.1371/journal.pone.0096542
24. **Kelemen, L. E.**, Kobel, M., Chan, A., Taghaddos, S., & Dinu, I. (2013). Differentially methylated loci distinguish ovarian carcinoma histological types: Evaluation of a DNA methylation assay in FFPE tissue. *Biomed Res Int*, 2013, 815894. doi: 10.1155/2013/815894
25. Klimowicz, A. C., Bose, P., Petrillo, S. K., Magliocco, A. M., Dort, J. C., & **Brockton, N. T.** (2013). The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. *British Journal of Cancer*, 109(7), 1859-1866.
26. Kobel, M., Kalloger, S. E., Lee, S., Duggan, M. A., **Kelemen, L. E.**, Prentice, L., . . . Ovarian Tumor Tissue Analysis Consortium. (2013). Biomarker-based ovarian carcinoma typing: A histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiol Biomarkers Prev*, 22(10), 1677-1686. doi: 10.1158/1055-9965.EPI-13-0391
27. Lalla, R. V., & **Ashbury, F. D.** (2013). The mascc/isoo mucositis guidelines: Dissemination and clinical impact. *Support Care Cancer*, 21(11), 3161-3163. doi: 10.1007/s00520-013-1924-2
28. Lamarche, K., & **Vallance, J.** (2013). Prescription for physical activity a survey of Canadian nurse practitioners. *Can Nurse*, 109(8), 22-26.
29. Latner, J. D., Mond, J. M., **Vallance, J. K.**, Gleaves, D. H., & Buckett, G. (2013). Quality of life impairment and the attitudinal and behavioral features of eating disorders. *J Nerv Ment Dis*, 201(7), 592-597. doi: 10.1097/NMD.0b013e3182982bbe
30. Lynch, B. M., **Friedenreich, C. M.**, **Kopciuk, K. A.**, Hollenbeck, A. R., Moore, S. C., & Matthews, C. E. (2014). Sedentary behavior and prostate cancer risk in the NIH-AARP Diet and Health Study. *Cancer Epidemiol Biomarkers Prev*. doi: 10.1158/1055-9965.EPI-13-0808
31. McCormack, G. R., **Friedenreich, C. M.**, Giles-Corti, B., Doyle-Baker, P. K., & Shiell, A. (2013). Do motivation-related cognitions explain the relationship between perceptions of urban form and neighborhood walking? *J Phys Act Health*, 10(7), 961-973.
32. McCormack, G. R., Shiell, A., Doyle-Baker, P. K., **Friedenreich, C. M.**, & Sandalack, B. A. (2014). Subpopulation differences in the association between neighborhood urban form and neighborhood-based physical activity. *Health Place*, 28, 109-115. doi: 10.1016/j.healthplace.2014.04.001
33. Neilson, H. K., Conroy, S. M., & **Friedenreich, C. M.** (2014). The influence of energetic factors on biomarkers of postmenopausal breast cancer risk. *Curr Nutr Rep*, 3, 22-34. doi: 10.1007/s13668-013-0069-8
34. Rabeneck, L., Paszat, L. F., Hilsden, R. J., **McGregor, S. E.**, Hsieh, E., Tinmouth J., . . . Stock, D. (2014). Advanced proximal neoplasia of the colon in average-risk adults. *Gastrointest Endosc*. doi: 10.1016/j.gie.2014.02.001

35. Rinaldi, S., Kaaks, R., **Friedenreich, C. M.**, Key, T. J., Travis, R., Biessy, C., . . . Romieu, I. (2014). Physical activity, sex steroid, and growth factor concentrations in pre- and postmenopausal women: A cross-sectional study within the EPIC cohort. *Cancer Causes Control, 25*(1), 111-124. doi: 10.1007/s10552-013-0314-x
36. Sabiston, C. M., Brunet, J., **Vallance, J. K.**, & Meterissian, S. (2014). Prospective examination of objectively assessed physical activity and sedentary time after breast cancer treatment: Sitting on the crest of the teachable moment. *Cancer Epidemiol Biomarkers Prev, 23*(7), 1324-1330. doi: 10.1158/1055-9965.EPI-13-1179
37. Setiawan, V. W., Yang, H. P., Pike, M. C., McCann, S. E., Yu, H., **Friedenreich, C. M.**, . . . Horn-Ross, P. L. (2013). Type I and II endometrial cancers: Have they different risk factors? *J Clin Oncol, 31*(20), 2607-2618. doi: 10.1200/JCO.2012.48.2596
38. **Shack, L.**, Bryant, H., Lockwood, G., & Ellison, L. F. (2013). Conditional relative survival: A different perspective to measuring cancer outcomes. *Cancer Epidemiol, 37*(4), 446-448. doi: 10.1016/j.canep.2013.03.019
39. Speed-Andrews, A. E., McGowan, E. L., Rhodes, R. E., Blanchard, C. M., Culos-Reed, S. N., **Friedenreich, C. M.**, & Courneya, K. S. (2014). Identification and evaluation of the salient physical activity beliefs of colorectal cancer survivors. *Cancer Nurs, 37*(1), 14-22. doi: 10.1097/NCC.0b013e3182813972
40. Tam, C., Li, Q., **Friedenreich, C. M.**, Martin, L. J., Hislop, G., Hanley, A. J., . . . Boyd, N. F. (2013). Lifetime physical activity in postmenopausal Caucasian and Chinese-Canadian women. *Eur J Cancer Prev, 23*(2), 90-95.
41. Taylor, L. M., Johnson, S. T., **Vallance, J. K.**, Stadnyk, J., & Basualdo-Hammond, C. (2014). Food and physical activity behaviours of adults attending a prediabetes education class. *Can J Diabetes*. doi: 10.1016/j.jcjd.2014.01.010
42. Thirukkumaran, C. M., Shi, Z. Q., Luider, J., **Kopciuk, K.**, Bahlis, N., Neri, P., . . . Morris, D. G. (2014). Reovirus as a successful ex vivo purging modality for multiple myeloma. *Bone Marrow Transplant, 49*(1), 80-86. doi: 10.1038/bmt.2013.130
43. Tinmouth, J., Ritvo, P., **McGregor, S. E.**, Patel, J., Guglietti, C., Levitt, C. A., . . . Rabeneck, L. (2013). Coloncancercheck primary care invitation pilot project: Patient perceptions. *Can Fam Physician, 59*(12), e541-549.
44. **Vallance, J. K.**, Lavalley, C., Culos-Reed, N., & Trudeau, M. (2013). Rural and small town breast cancer survivors' preferences for physical activity. *Int J Behav Med, 20*(4), 522-528. doi: 10.1007/s12529-012-9264-z
45. **Vallance, J. K.**, Boyle, T., Courneya, K. S., & Lynch, B. M. (2014). Associations of objectively assessed physical activity and sedentary time with health-related quality of life among colon cancer survivors. *Cancer, 120*(18), 2919-26. doi: 10.1002/cncr.28779
46. **Vallance, J. K.**, Eurich, D. T., Gardiner, P. A., Taylor, L. M., Stevens, G., & Johnson, S. T. (2014). Utility of telephone survey methods in population-based health studies of older adults: An example from the Alberta older adult health behavior (ALERT) study. *BMC Public Health, 14*, 486. doi: 10.1186/1471-2458-14-486
47. Woolcott, C. G., Courneya, K. S., Boyd, N. F., Yaffe, M. J., McTiernan, A., Brant, R., . . . **Friedenreich, C. M.** (2013). Longitudinal changes in IGF-I and IGFBP-3, and mammographic density among postmenopausal women. *Cancer Epidemiol Biomarkers Prev, 22*(11), 2116-2120. doi: 10.1158/1055-9965.EPI-13-0401

ABSTRACTS

1. Hao, D., Lau, H. Y., Huang, L., Doll, C. M., Dort, J. C., & **Shack, L. G.** (2013). ASCO an analysis of the temporal, age, and gender trends in human papillomavirus (HPV)-related versus non-HPV-related head and neck cancers (HNC) in Alberta, Canada [Abstract]. *J Clin Oncol*, *31*(suppl).
2. Karvinen, K. H., Balneaves, L., Perry, B., Courneya, K. S., Truant, T., & **Vallance, J. K.** (2014). Bridging the gap from physical activity and cancer research to practice: A knowledge translation strategy for oncology nurses [Abstract]. *Annals of Behavioral Medicine*, *47*(Suppl), C-023, s189.
3. Karvinen, K. H., & **Vallance, J. K.** (2013). Outcome expectations and physical activity levels of breast and colorectal cancer survivors [Abstract]. *Annals of Behavioral Medicine*, *45*(Suppl), C-020, s196.
4. Sabiston, C., & **Vallance, J. K.** (2013). Prospective assessment of accelerometer-determined physical activity and sedentary time among breast cancer survivors following systemic treatment [Abstract]. *Annals of Behavioral Medicine*, *45*(Suppl), B-034, p. s105.
5. **Shack, L. G.**, Lu, S., Weeks, L. A., Craighead, P. S., & Kerba, M. (2013). Determining the need and utilization of radiotherapy in cancers of the breast, cervix, lung, prostate and rectum in Alberta, Canada [Abstract]. *J Clin Oncol*, *31*(suppl 31).
6. **Vallance, J. K.**, Culos-Reed, S. N., Lavalley, C., & Trudeau, M. G. (2013). Rural and small town breast cancer survivors' programming and counseling preferences for physical activity [Abstract]. *Annals of Behavioral Medicine*, *45*(Suppl), A-029, s10.

PSYCHOSOCIAL ONCOLOGY**PEER REVIEWED**

1. Alibhai, S. M. H., O'Neill, S., Fisher-Schlombs, K., Breunis, H., Timilshina, N., Brandwein, J. M., ... **Culos-Reed, S. N.** (2014). A pilot phase II RCT of a home-based exercise intervention for survivors of AML. *Supportive Care in Cancer*, *22*(4), 881-9.
2. Bacon, S., **Campbell, T.**, Arsenaault, A., & Lavoie, K. (2014). The impact of mood and anxiety disorders on incident hypertension at one year. *International Journal of Hypertension*, *2014* (2014). doi: 10.1155/2014/953094.
3. Beck, A. M., **Robinson, J. W.**, **Carlson, L. E.** (2013). Sexual values as the key to maintaining satisfying sex after prostate cancer treatment: The physical pleasure-relational intimacy model of sexual motivation. *Archives of Sexual Behavior*, *42*(8), 1637-47.
4. Breitbart, W., **Bultz, B. D.**, Dunn, L., Grassi, L., & Watson, M. (2013). Editorial: 2012 president's plenary International Psycho-Oncology Society: Future directions in psycho-oncology. *Psycho-Oncology: Oncology Exchange*, *2013*(22), 1439-43.
5. Broderick, J. M., Guinan, E., Kennedy, M. J., Hollywood, D., Courneya, K. S., **Culos-Reed, S. N.**, ... Hussey, J. (2013). Feasibility and efficacy of a supervised exercise intervention in de-conditioned cancer survivors during the early survivorship phase: The PEACH trial. *Journal of Cancer Survivorship*, *7*(4), 551-62.
6. **Bultz, B. D.**, Waller, A., Cullum, J., Jones, P., Halland, J., Groff, S.L., ... **Carlson, L. E.** (2013). Implementing routine screening for distress, the sixth vital sign, for patients with head and neck and neurologic cancers. *Journal Natl Compr Canc Netw*, *2013*(11), 1249-1261.

7. **Bultz, B. & Carlson, L. E.** (2014). Editorial: Effects of screening for psychological distress on patient outcomes in cancer: A systematic review. *Journal of Psychosomatic Research*, 21(2), e330–e333.
8. Camacho, A. A., Garland, S. N., Martopullo, C., & Pelletier, G. (2013). Positive and negative meanings are simultaneously ascribed to colorectal cancer: Relationship to quality of life and psychosocial adjustment. *Palliative and Supportive Care*, 12(4), 277-86.
9. Campbell, D. J. T., Ronksley, P. E., Manns, B. J., Tonelli, M., Sanmartin, Campbell, T., ... Hemmelgarn, B. R. (2014). The association of income with health behavior change and disease monitoring among patients with chronic disease. *PloS one*, 9(4), e94007.
10. **Campbell, T. S., Séguin, J. R., Vitaro, F., Tremblay, R. E., & Ditto, B.** (2013). Childhood socioeconomic position and blood pressure dipping in early adulthood: A longitudinal study. *Annals of Behavioral Medicine*. 46(2), 227-31.
11. Capozzi, L. C., Nishimura, K. C., Lau, H., McNeely, M. L., & **Culos-Reed, S. N.** (2014). Physical activity to improve health related fitness and quality of life for head and neck cancer patients: A systematic review. *International Journal of Physical Medicine and Rehabilitation*, 41(1), 32–47.
12. **Carlson, L. E.** (2013). Screening alone is not enough: The importance of appropriate triage, referral, and evidence-based treatment of distress and common problems. *Journal of Clinical Oncology*, 31(29), 3616-7.
13. **Carlson, L. E.** (2013). Mindfulness-based cancer recovery, the development of an evidence-based psychosocial oncology intervention. *Oncology Exchange*, 12(2).
14. **Carlson, L. E.,** Doll, R., Stephen, J., Faris, P., Tamagawa, R., Drysdale, R., & **Specia, M.** (2013). Randomized controlled trial of mindfulness-based cancer recovery versus supportive expressive group therapy for distressed survivors of breast cancer. *Journal of Clinical Oncology*, 31(25), 3119-26.
15. **Carlson, L. E.,** Waller, A., Groff, S. L., & **Bultz, B.** (2013). Reply to Dekker et al: Comment on ‘online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: Randomised controlled trial of computerised vs. personalised triage’ – Psychological distress in patients with cancer: Is screening the effective solution? *British Journal of Cancer*, 108, 2631–2632.
16. **Carlson, L. E,** Waller, A., Groff, S. L., Zhong, L., & **Bultz, B. D.** (2013). Reply: Benefits of screening cancer patients for distress still not demonstrated. *Br J Cancer*, 108(3), 738-9.
17. **Carlson, L. E.** (2014). Reply to W Hollingworth, et al. *Journal of Clinical Oncology*, 36(9), 970-971.
18. **Carlson, L. E.** (2013). Mind-body therapies for cancer patients: Overview and focus on mindfulness based cancer recovery. *Italian Psychoneuroendocrinological Society Journal*, 6(2), 33-42.
19. **Carlson, L. E.,** Waller, A., **Groff, S., Giese-Davis, J., & Bultz, B.** (2013). What goes up doesn't always come down: Patterns of distress, physical and psychosocial morbidity in people with cancer over a one year period. *Psycho-oncology*, 22(1), 168-176. doi: 10.1002/pon.2068
20. Chamorro-Vina, C., Wurz, A. J., & **Culos-Reed, S. N.** (2013). Promoting physical activity in pediatric oncology. Where do we go from here? *Frontiers in Oncology*, 3(173), 1-4.
21. Collie, K., McCormick, J., Waller, A., Railton, C., Shirt, L., **Carlson, L. E., . . . Giese-Davis, J.** (2014). Care plans for breast and head and neck cancer survivors in Canada: A qualitative analysis. *Current Oncology*, 21(1), e18-28.

-
22. **Culos-Reed, S. N.**, & Capozzi, L.C. (2013). Physical activity and patient reported outcomes: Enhancing impact. *European Review of Ageing and Physical Activity, Special Issue, 10*, 37-40.
 23. Dasgupta, K., Quinn, R. R., **Campbell, T. S.**, Padwal, R. S., . . . Poirier, L. (2014). The 2014 Canadian hypertension education program (CHEP) recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. *Canadian Journal of Cardiology, 30* (5), 485-501.
 24. Ellington, L., Reblin, M., Berry, P., **Giese-Davis, J.**, & Clayton, M. F. (2013). Reflective research: Supporting researchers engaged in analyzing end-of-life communication. *Patient Education and Counseling, 91*(1), 126-8.
 25. Enns, A., Waller, A., Groff, S. L., **Bultz, B.**, Fung, T., & **Carlson, L. E.** (2013). Risk factors for continuous distress over a 12-month period in newly diagnosed cancer outpatients. *Journal of Psychosocial Oncology, 2013*(31), 489–506.
 26. Garland, S. N., **Campbell, T.**, Samuels, C., & **Carlson, L. E.** (2013). Dispositional mindfulness, insomnia, sleep quality and dysfunctional sleep beliefs in post-treatment cancer patients. *Personality and Individual Difference, 55*(3), 306-311.
 27. Garland, S. N., **Carlson, L. E.**, Antle, M., Stephens, A. J., Samuels, C., & **Campbell, T.** (2014). Mindfulness-based stress reduction compared to cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: A randomized, partially blinded, non inferiority trial. *Journal of Clinical Oncology, 32*(5), 449-57.
 28. Giesbrecht, G. F., Poole, J. C., Letourneau, N., **Campbell, T.**, Kaplan, B. J., & APrON Study Team. (2013). The buffering effect of social support on hypothalamic-pituitary-adrenal axis function during pregnancy. *Psychosomatic Medicine, 75*(9), 856.
 29. Giesbrecht, G. F., **Campbell, T.**, Letourneau, N., & Kaplan, B. J. (2013). Advancing gestation does not attenuate biobehavioural coherence between psychological distress and cortisol. *Biological Psychology, 93*, 45-51.
 30. Giesbrecht, G. F., Granger, D. A., **Campbell, T.**, Kaplan, B., & APrON Study Team. (2013). Salivary alpha-amylase during pregnancy: Diurnal course and associations with obstetric history, maternal demographics, and mood. *Developmental Psychobiology, 55*(2), 156-167.
 31. **Giese-Davis, J.**, Tamagawa, R., Yutsis, M., Twirbutt, S., Piemme, K., Neri, E., . . . Spiegel, D. (2014). Which symptoms matter? Self-report and observer discrepancies in repressors and high-anxious women with metastatic breast cancer. *Journal of Behavioral Medicine, 37*, 22–36.
 32. Hack, T., Cummings, G., Green, E., **Bultz, B.**, Fitzgerald, B., McLeod, D., & Bottorff, J. (2013). Organizations collaborate to speed implementation on a global scale. Psychosocial care in Oncology. *Oncology Exchange, 3*(12), 10-12.
 33. Hackam, D. G., Quinn, R. R., Ravani, P., Rabi, D. M., Dasgupta, K., Daskalopoulou, S.S., . . . **Campbell, T. S.** (2013). The 2013 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Canadian Journal of Cardiology, 29*(5), 528-542.
 34. Hampton, A. J., **Walker, L. M.**, Beck, A. M., & **Robinson, J. W.** (2013). A brief couples' workshop for improving sexual experiences after prostate cancer treatment: A feasibility study. *Journal of Supportive Cancer Care, 21*(12), 3043-3409.
-

-
35. Hughes, J. W., Fresco, D. M., Myerscough, R., Van Dulmen, M., **Carlson, L. E.**, & Josephson, R. (2013). Randomized controlled trial of mindfulness-based stress reduction for prehypertension. *Psychosomatic Medicine*, 75(8), 721-728.
 36. Johnson, J. A., Key, B. L., Routledge, F. S., Gerin, W., & **Campbell, T. S.** (2014). High trait rumination is associated with blunted nighttime diastolic blood pressure dipping. *Annals of Behavioural Medicine*. doi: 10.1007/s12160-014-9617-8 [Epub ahead of print].
 37. Jones, P., Blunda, M., Biegel, G., **Carlson, L. E.**, Biel, M., & Wiener, L. (2013). Can mindfulness based interventions help adolescents with cancer? *Psycho-Oncology*, 22(9), 2148-51.
 38. Mackenzie, M. J., **Carlson, L. E.**, Ekkekakis, P., Paskevich, D. M., & **Culos-Reed, S. N.** (2013). Affect and mindfulness as moderators of change in mood disturbance, stress symptoms and quality of life in a community-based yoga program for cancer survivors. *Evidence-Based Complementary and Alternative Medicine*, 2013, 419496.
 39. Mackenzie, M. J., Ekkekakis, P., **Carlson, L. E.**, Paskevich, D. M., Wurz, A., Wytsma, K., Krenz, K. A., & **Culos-Reed, S. N.** (2014). Associations between affect, attention and heart rate variability in a single yoga session for cancer survivors: A neurophenomenological approach. *Consciousness & Cognition*, 27, 129-46.
 40. McGowan, E., Speed-Andrews, A. E., Rhodes, R., Blanchard, C., **Culos-Reed, S. N.**, Friedenreich, C. M., & Courneya, K. S. (2013). Sport participation in colorectal cancer survivors: An unexplored approach to promoting physical activity. *Supportive Care in Cancer*, 21, 139-147.
 41. McGowan, E. L., Speed-Andrews, A. E., Blanchard, C. M., Rhodes, R. E., Friedenreich, C. M., **Culos-Reed, S. N.**, & Courneya, K. S. (2013). Physical activity preferences among a population-based sample of colorectal cancer survivors. *Oncology Nursing Forum*, 40(1), 44-52.
 42. Palesh, O., Aldridge-Gerry, A., Zeitzer, J. M., Koopman, C., Neri, E., **Giese-Davis, J.**, Jo, B., . . . Spiegel, D. (2014). Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. *Sleep*, 37(5), 837-842.
 43. Rash, J. A., Aguirre-Camacho, A., & **Campbell, T. S.** (2013). Oxytocin and pain: A review and synthesis of the literature. *The Clinical Journal of Pain*, 30(5), 453-62.
 44. Sauder, K. A., Skulas-Ray, A. C., **Campbell, T. S.**, Johnson, J. A., Kris-Etherton, P. M., & West, S. G. (2013). Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia. *Psychosomatic Medicine*, 75(4), 382-389.
 45. Speed-Andrews, A. E., Rhodes, R. E., Blanchard, C. M., **Culos-Reed, S. N.**, Friedenreich, C. M., Belanger, L. J., & Courneya, K. S. (2013). Correlates of strength exercise in colorectal cancer survivors. *American Journal of Health Behavior*, 37(2), 162-170.
 46. Tamagawa, R., **Specia, M.**, **Giese-Davis, J.**, Doll, R., Stephen, J., & **Carlson, L. E.** (2013). Trait mindfulness, dispositional emotion regulation, and self-reported mood and symptoms of stress among breast cancer patients. *Journal of Clinical Psychology*, 69, 264-277.
 47. Thomas, B., Waller, A., Malhi, R., Fung, T., **Carlson, L. E.**, Groff, S. L., & **Bultz, B. D.** (2014). A longitudinal analysis of symptom clusters in cancer patients and their sociodemographic predictors. *J Pain Symptom Manage*, 47(3), 566-78.
 48. Tran, S., **Walker, L. M.**, Wassersug, R. W., Matthew, A. G., McLeod, D. L., & **Robinson, J. W.** (2014). What do Canadian uro-oncologists believe patients should know about androgen deprivation therapy? *Journal of Oncology Pharmacy Practice*, 20, 199-209.
-

49. Walker, L. M., Hampton, A. J., Wassersug, R. J., **Thomas, B. C.**, & **Robinson, J. W.** (2013). Beyond the abstract: Androgen deprivation therapy and intimacy: A pilot educational intervention to help prostate cancer patients and their partners maintain intimacy in the face of ADT. *Beyond the Abstract – Uro Today*, Available at <http://www.urotoday.com/UroToday/Prostate-Cancer/the-influence-of-distress-on-knowledge-transfer-for-men-newly-diagnosed-with-prostate-cancer-abstract.html>.
50. **Walker, L. M.**, Hampton, A. J., & **Robinson, J. W.** (2013). Assessment of relational intimacy: Factor analysis of the personal assessment of intimacy in relationships questionnaire. *PsychoOncology*, 23(3), 346-9.
51. **Walker, L. M.**, Tran, S., & **Robinson, J. W.** (2013). Luteinizing hormone--releasing hormone agonists: A quick reference for prevalence rates of potential adverse effects. *Clinical Genitourinary Cancer*, 11(4), 375-384.
52. Waller, A., Williams, A. D., Groff, S. L., **Carlson, L. E.**, & **Bultz, B.** (2013). Screening for distress, the 6th vital sign: Examining self-referral in people with cancer over a one year period. *Psycho-oncology*, 22(2), 388-95.
53. Wurz, A., Chamorro-Vina, C., Guilcher, G., Schulte, F., & **Culos-Reed, S. N.** (2014). The feasibility and benefits of a 12-week yoga intervention for pediatric cancer outpatients. *Pediatric Blood Cancer*, 61(10), 1828-34.
54. Wurz, A. J., Capozzi, L. C., Mackenzie, M. J., Danhauer, S. C., & **Culos-Reed, S. N.** (2013). Translating knowledge: A framework for evidence-informed yoga programs in oncology. *International Journal of Yoga Therapy*, 23(2), 85-90.
55. Zernicke, K. A., **Campbell, T. S.**, **Specia, M.**, McCabe-Ruff, K., Flowers, S., & **Carlson, L. E.** (2014). A randomized wait-list controlled trial of feasibility and efficacy of an online mindfulness-based cancer recovery program for underserved distressed cancer survivors: The eCALM trial. *Psychosomatic Medicine*, 76(4), 257-67.
56. Zernicke, K. A., **Campbell, T. S.**, **Specia, M.**, McCabe-Ruff, K., Flowers, S., Dirkse, D. A., & **Carlson, L. E.** (2013). Online mindfulness-based cancer recovery program for underserved individuals living with cancer in Alberta: Protocol development for a randomized wait-list controlled clinical trial. *BMC Complementary and Alternative Medicine*, 2013(13), 34.

ABSTRACTS

1. **Carlson, L. E.**, Beattie, T., **Giese-Davis, J.**, Faris, P., Tamagawa, R., Fick, L., Stebner, E., & **Specia, M.** (2014). Mindfulness-based cancer recovery (MBCR) and supportive expressive therapy (SET) maintain telomere length (TL) and cortisol slopes relative to control in distressed breast cancer survivors [Abstract]. *The Journal of Alternative and Complementary Medicine*, 20(6), a24-5.
2. **Carlson, L. E.**, Beattie, T., **Giese-Davis, J.**, Faris, P., Tamagawa, R., Fick, L., Stebner, E., & **Specia, M.** (2013). Mindfulness-based cancer recovery (MBCR) and supportive expressive therapy (SET) maintain telomere length (TL) and cortisol slopes relative to control in distressed breast cancer survivors [Abstract]. *Annals of Behavioral Medicine*, 45, s177.

3. **Carlson, L. E.**, Tamagawa, R., Stephen, J., Doll, R., & **Specia, M.** (2013). Randomized-controlled multi-site trial of mindfulness-based cancer recovery (MBCR) versus supportive expressive group therapy (SET) among breast cancer survivors (MINDSET): Long-term follow-up results [Abstract]. *Psycho-Oncology: IPOS 15th World Congress of Psycho-Oncology: Rotterdam, Netherlands*, 22(suppl. 3), 103-104.
4. **Carlson, L. E.**, Doll, R., Stephen, J., Tamagawa, R., Faris, P., & **Specia, M.** (2013). Mindfulness based cancer recovery (MBCR) vs. supportive expressive therapy (SET) in breast cancer survivors (The MINDSET Trial): Impact of patient preferences and personality on outcomes [Abstract]. *Annals of Behavioral Medicine*, 45, s177.
5. Couper, J., Pollard, A., Castle, D., Neilson, K., Burchell, J., ... Ftanou, M. (2013). Phase I pilot of a mindfulness-based stress reduction intervention for head and neck cancer patients receiving radiotherapy of curative intent [Abstract]. *Psycho-Oncology: IPOS 15th World Congress of Psycho-Oncology, Rotterdam, the Netherlands*, 22(suppl. 3), 247-248.
6. Chamorro-Vina, C., Wurz, A., Keats, M., & **Culos-Reed, S. N.** (2014). POEM (pediatric oncology exercise manual): A knowledge synthesis to improve awareness about physical activity benefits during and after childhood cancer [Abstract]. *46 Congress of International Society of Pediatric Oncology: Toronto, Canada, 2013(3)*, 173.
7. Fitch, M., Bradley, H., Eaton, G., **Giese-Davis, J.**, Sisler, J., & Taylor-Brown, J. (2014). Implementing survivorship care plans in the Canadian cancer setting [Abstract]. *Psycho-Oncology*, 23, 123-124.
8. Garland, S., **Carlson, L.E.**, & **Campbell, T.** (2014). A comparison of mindfulness-based stress reduction and cognitive behavioral therapy for improving sleep and mood outcomes in cancer patients with insomnia [Abstract]. *The Journal of Alternative and Complementary Medicine*, 20(6), a56-7.
9. Garland, S. N., **Campbell, T. S.**, & **Carlson, L. E.** (2013). Associations between dispositional mindfulness, insomnia, sleep quality and dysfunctional sleep beliefs in post-treatment cancer patients [Abstract]. *Annals of Behavioral Medicine*, 42(Suppl. 2), s6.
10. Giesbrecht, G. F., **Campbell, T. S.**, Letourneau, N., & Kaplan, B. (2013). Biobehavioural coherence between psychological distress and cortisol over the course of pregnancy: Implications for fetal programming by maternal stress [Abstract]. *Psychosomatic Medicine*, 75(3).
11. Groff, S., Holroyd-Leduc, J., White, D., & **Bultz, B.** (2013). Examining the sustainability of screening for distress, the 6th vital sign, in 2 outpatient oncology clinics [Abstract]. *Psycho-Oncology*, 22(Suppl. 3), 299-300.
12. Haig, T., Giesbrecht, G., **Campbell, T. S.**, & Letourneau, N. (2013). Sleep duration but not sleep disruption is associated with diurnal cortisol in pregnant women [Abstract]. *Psychosomatic Medicine*, 75(3).
13. King, N., Balneaves, L., Card, C., Nation, J., Nguyen, T., & **Carlson, L. E.** (2014). Surveys of cancer patients and cancer care providers regarding complementary therapy use, communication and information needs [Abstract]. *The Journal of Alternative and Complementary Medicine*, 20(6), a98-a99.
14. Lang, M., **Campbell, D.**, & **Giese-Davis, J.** (2013). Using a publicly funded population level survey to explore psychosocial outcomes in cancer survivors [Abstract]. *Psycho Oncol*, 22, 40-41.

15. O'Brien, M., Li, L. Y., O'Brien, T., & **Giese-Davis, J.** (2013). The relationship between emotional expression and resilience in a long-term telephone group for women with secondary breast cancer [Abstract]. *Psycho Oncol*, 22, 266-266.
16. Poole, J., Giesbrecht, G., **Campbell, T. S.**, & Letourneau, N. (2013). Social support alters biobehavioural coherence between affect and cortisol during pregnancy [Abstract]. *Psychosomatic Medicine*, 75(3).
17. Rash, J. A., Prkachin, K. M., & **Campbell, T. S.** (2013). When you are anxious, pain is taken more seriously [Abstract]. *American Psychosomatic Society Meeting Abstracts*, 75(3), A-132.
18. Rouleau, C. R., Giesbrecht, G. F., **Campbell, T. S.**, & Letourneau, N. (2013). Bio-behavioural coherence between mood and heart rate variability during pregnancy [Abstract]. *Psychosomatic Medicine*, 75(3), 843.
19. Tamagawa, R., **Specia, M.**, Doll, R., Stephen, J., & **Carlson, L. E.** (2013). Home practice of yoga and meditation among breast cancer patients in a mindfulness-based stress reduction program: Baseline characteristics and post-intervention effects. Annual Meeting and Scientific Sessions, Rapid Communications [Abstract]. *Annals of Behavioral Medicine*, 45, 64.
20. Zernicke, K., **Campbell, T.**, **Specia, M.**, McCabe, K., Flowers, S., & **Carlson, L. E.** (2013). The e-CALM study: E-therapy for cancer applying mindfulness. Online mindfulness-based cancer recovery (MBCR) for undeserved cancer patients in Alberta: Feasibility data [Abstract]. *Annals of Behavioral Medicine*, 45(Abstract Supplement), 4.

BOOKS

1. **Culos-Reed, S. N.**, Daroux-Cole, L. M., & Capozzi, L. C. (2013). *Cancer and exercise: Training manual for fitness professionals*. Calgary, Alberta: University of Calgary.

BOOK CHAPTERS

1. **Bultz, B. D.**, & Mitchell, A. (2014). Psychological assessment in psychopharmacology. In L. Grassi, M. Riba (Eds.), *Psychopharmacology in oncology and palliative care-A practical manual* (pp. 49-67). New York, New York: Springer.
2. Capozzi, L., & **Culos-Reed, S. N.** (2014). Population considerations for promoting PA behavior change. In Nigg (Ed.), *ACSM's behavioral aspects of exercise*. Philadelphia, United States: Wolters Kluwer/Lippincott Williams & Wilkins Health.
3. **Culos-Reed, S. N.** (2013). Quality of life in special populations. In Ekkekakis (Ed.), *Handbook of physical activity and mental health* (pp. 491-555). London: Routledge Press.
4. Sametband, I., Wilson, T., & **Tsai, C. P.** (2014). Sensing, understanding, moving beyond intercultural pathologizing interpersonal patterns. In K. Tomm, S. St. George, D. Wulff, & T. Strong (Eds.), *Inviting relational understanding for therapeutic change* (pp. 168-186). New York: Routledge.
5. Vallance, J. K., **Culos-Reed, S. N.**, Mackenzie, M. J., & Courneya, K. S. (2013). Physical activity and quality of life in cancer survivors. In P. Ekkekakis (Ed.), *Handbook of physical activity and mental health* (pp. 518-529). London: Routledge Press.

RADIATION ONCOLOGY**PEER REVIEWED**

1. **Banerjee, R.**, Chakraborty, S., Nygren, I., & **Sinha, R.** (2013). Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: An independent validation study comparing peritoneal space versus small bowel loop contouring techniques. *International Journal of Radiation Oncology, Biology, Physics*, 85(5), 1225-31.
2. **Banerjee, R.**, Roxin, G., Eliasziw, M., Joseph, K., MacLean, A., Buie, D., & **Doll, C.** (2013). The prognostic significance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy. *Diseases of the Colon & Rectum*, 56, 1036-1042.
3. **Banerjee, R.**, Dundas, G., & **Doll, C.** (2013). Positron emission tomography for locally advanced cervical cancer: A survey assessing Canadian practice patterns and access. *Current Oncology*, 20(6), 333–337.
4. Bultz, B. D., Waller, A., Cullum, J., Jones, P., Halland, J., Groff, S. L., Leckie, C., Shirt, L., Blanchard, S., **Lau, H.**, Easaw, J., Fassbender, K., & Carlson, L. E. (2013). Implementing routine screening for distress, the sixth vital sign, for patients with head and neck and neurologic cancers. *Journal of the National Comprehensive Cancer Network*, 11(10), 1249-1261.
5. Clayton, R., **Liu, H.**, Khan, R., Udowicz, M., Bayliss, Y., Krobutschek, K., Herring, C., & **Lau, H.** (2013). Implementation of lung stereotactic ablative radiotherapy at a regional cancer centre. *Journal of Medical Imaging and Radiation Sciences*, 43(4), 245-252.
6. **Doll, C.**, Winter, K., Gaffney, D., Rhu, J., Jhilgran, A., Dicker, A. P., Weidhaas, J., Miller, B. E., & Magliocco, A. M. (2013). COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: A quantitative immunohistochemical analysis of RTOG C0128. *International Journal of Gynecological Cancer*, 23(1), 176-83.
7. **Doll, C.**, Aquino-Parson, C., Pintilie, M., Klimowicz, A., Petrillo, S. K., Milosovic, M., **Craighead, P. S.**, Clarke, B., Lees-Miller, S. P., Fyles, A., & Magliocco, A. M. (2013). The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiotherapy: A multicenter clinicopathologic analysis. *International Journal of Radiation Oncology, Biology, Physics*, 85(3), 721-727.
8. Grender, J., Grendarova, P., **Sinha, R.**, & Dixon, E. (2013). Neoadjuvant therapy for down staging of locally advanced hilar cholangiocarcinoma: A systematic review. *Hepato-Pancreato-Biliary Journal (HPB)*, 16(4), 297–303.
9. Jagdis, A., **Phan, T.**, Klimowicz, A. C., Laskin, J. J., **Lau, H.**, Petrillo, S., Siever, T., Thomson, T., Magliocco, A., & Hao, D. (2013). Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment. *International Journal of Radiation Oncology, Biology, Physics*, 85, 1340-1345.
10. Jung, H., Sinnarajah, A., Enns, B., **Voroney, J-P.**, Murray, A., Pelletier, G., & **Wu, J.** (2013). Managing brain metastases patients with and without radiotherapy: Initial lessons from a team-based consult service through a multidisciplinary integrated palliative oncology clinic. *Supportive Care in Cancer*, 21(12), 3379-86.

11. Kamrava, M., Rwigema, J. C., Chung, M., **Banerjee, R.**, Wang, J., Steinberg, M., & Demanes, D. J. (2013). Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for prostate cancer. *Journal of Contemporary Brachytherapy*, 5 (3), 127-133.
12. Kennecke, H. F., Speers, C. H., Ennis, C. A., Gelmon, K., **Olivotto, I.**, & Hayes, M. (2013). Impact of routine pathology review on treatment for node-negative breast cancer. *Journal of Clinical Oncology*, 30, 2227-31.
13. Lefresne, S., **Olivotto, I. A.**, Joe, H., Blood, P. A., & Olson, R. A. (2013). Impact of quality assurance rounds in a Canadian radiation therapy department. *International Journal of Radiation Oncology Biology, Physics*, 85, e117-21.
14. Li, Y., Bai, S., Carroll, W., Dayan, D., Dort, J., **Lau, H.**, ... Brandwein-Gensler, M. (2013). Validation of the risk model: High-risk classification and tumor pattern of invasion predict outcome for patients with low-stage oral cavity squamous cell carcinoma. *Head Neck Pathology*, 7(3), 211-23.
15. **Liu, H. W.**, Khan, R., D'Ambrosi, R., Krobutschek, K., Nugent, Z., & **Lau, H.** (2013). The influence of target and patient characteristics on the volume obtained from cone beam CT in lung stereotactic body radiation therapy. *Radiotherapy and Oncology*, 106(3), 312-316.
16. McIntyre, J. B., **Wu, J.**, **Phan, T.**, **Craighead, P. S.**, Lees-Miller, S., Kobel, M., Ghatage, P., Magliocco, A. M., & **Doll, C.** (2013). PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. *Gynecological Oncology*, 128(3), 409-14.
17. Moretto, P., Wood, L., Urban, E., Blais, N., Mukherjee, S. D., **Balogh, A.**, ... Canil, C. M. (2013). Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). *Canadian Urological Association Journal*, 7(1-2), e44-56.
18. **Olivotto, I. A.**, Whelan, T. J., Parpia, S., Kim, D. H., Berrang, T., **Trotter, T.**, ... Julian, J. A., on behalf of the RAPID trial investigators. (2013). Interim cosmetic and toxicity results from RAPID: A randomized clinical trial of accelerated partial breast irradiation (APBI) using 3-dimensional, conformal radiation therapy. *Journal of Clinical Oncology*, 31, 4038-45.
19. Olson, R. A., Nichol, A., Caron, N. R., **Olivotto, I. A.**, Speers, C., Chia, S., Davidson, A., Coldman, A., Bajdik, C., & Tyldesley, S. (2013). Effect of community population size on breast cancer screening, stage distribution, treatment use and outcomes. *Canadian Journal of Public Health*, 103, 46-52.
20. Park, S. J., Chung, M., Demanes, D. J., **Banerjee, R.**, Steinberg, M., & Kamrava, M. (2013). Dosimetric comparison of 3D planning techniques using an intra-vaginal multichannel balloon applicator for high dose rate gynecologic brachytherapy. *International Journal of Radiation Oncology, Biology, Physics*, 87(4), 840-6.
21. Popescu, C. C., Beckham, W. A., Patenaude, V. V., **Olivotto, I. A.**, & Vlachaki, M. T. (2013). Simultaneous couch and gantry dynamic arc rotation (CG-Darc) in the treatment of breast cancer with accelerated partial breast irradiation (APBI): A feasibility study. *Journal of Applied Clinical Medical Physics*, 14, 4035.
22. Stanley, J., Dunscombe, P., **Lau, H.**, Burns, P., **Lim, G.**, **Liu, H-W.**, **Nordal, R.**, Starreveld, Y., **Valev, B.**, **Voroney, J-P.**, & Spencer, D. P. (2013). The effect of contouring variability on dosimetric parameters for brain metastases treated with stereotactic radiosurgery. *International Journal of Radiation Oncology, Biology, Physics*, 87(5), 924-931.

ABSTRACTS

1. Balogh, R., Nichols, A., George, K. L., Zeitzer, L., Souhami, M. H., Leibenhaut, M., Rotman, E. M., & **Balogh, A.** (2013). Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on RTOG 9408 [Abstract]. Presented at ASTRO Meeting. *International Journal of Radiation Oncology Biology Physics*, 87(2), s125.
2. **Banerjee, R.**, Demanes, J., Wang, J., & Kamrava, M. (2013). High dose rate brachytherapy combined with external beam radiotherapy for prostate cancer: Long term biochemical progression free survival results in a cohort of 858 patients [Abstract]. Oral presentation at the American Brachytherapy Society, New Orleans, LA. *Brachytherapy*, 12(1), s14-15.
3. Chow, E., Van Der Linden, Y., Roos, D., Hartsell, W., Hoskin, P., **Wu, J. S.**, . . . Wong, R. (2013). A randomized trial of single versus multiple fractions for re-irradiation of painful bone metastases: NCIC CTG SC 20 [Abstract]. Presented at ASCO Annual Meeting, Chicago, IL. *Journal of Clinical Oncology*, 31, 2013.
4. Gaudet, M., **Olivotto, I.**, Santibanez, P., & Tyldesley, S. (2013). Radiation oncologist treatment workload volume by tumor group in one Canadian province [Abstract]. Presented at CARO, Montreal, Quebec. *Radiotherapy and Oncology*, 108(1), s94.
5. Grendarova, G., Sinnarajah, A., **Trotter, T.**, Card, C., Hagen, N., & **Wu, J. S.** (2013). Intensity of radiotherapy and chemotherapy in the final month of life [Abstract]. Resident presentation at CARO Annual Scientific Meeting, Montreal. *Radiotherapy Oncology*, 108 (1).
6. Hao, D., **Lau, H. Y.**, Huang, L., **Doll, C.**, Dort, J., & Shack, L. (2013). An analysis of the temporal, age, and gender trends in human papillomavirus virus (HPV)-related versus non-HPV-related head and neck cancers (HNC) in Alberta, Canada [Abstract]. Presented at the ASCO Meeting. *Journal Clinical Oncology*, 31.
7. Ho, C., Ruether, D., Donnely, B., & **Kerba, M.** (2013). A population based study examining the impact of a multidisciplinary rapid access clinic on utilization of initial treatment options for patients with localized prostate cancer [Abstract]. *Journal of Clinical Oncology*, 31(31).
8. Kamrava, M., Mesko, S., **Banerjee, R.**, Ramen, S., Marks, L., Demanes, J., & Margolis, D. (2013). Evaluating the utility of a multi-parametric MRI based cancer suspicion score in defining brachytherapy focal therapy targets for prostate cancer [Abstract]. Presented at the American Brachytherapy Society Meeting. *Brachytherapy*, 12(1), s33.
9. Kamrava, M., Loh, C., **Banerjee, R.**, Colturatto, R., Lee, P., Sheng, K., Demanes, J., & Park, S-J. (2013). Dosimetric comparison of image guided interstitial liver brachytherapy vs. stereotactic body radiation therapy [Abstract]. Presented at the American Brachytherapy Society Meeting. *Brachytherapy*, 12(1), s18.
10. Lafay-Cousin, L., Lindzon, G., Bouffet, E., Taylor, M., Hader, W., **Nordal, R.**, Hawkins, C., Laperriere, N., & Laughlin, S. (2014). Successful treatment of primary intracranial sarcoma with ice chemotherapy and focal radiation in children [Abstract]. Presented at the Society of Paediatric Neuro-Oncology, Singapore. *Neuro-Oncology Journal*, 16, i127–136.
11. Park, S-J., Kamrava, M., **Banerjee, R.**, & Demanes, J. (2013). Effects of source step size on dose distribution in high-dose-rate brachytherapy for esophageal cancer [Abstract]. Presented at the American Brachytherapy Society Meeting. *Brachytherapy*, 12(1), s60.

12. Peterson, D., **Olivotto, I.**, Whelan, T., Truong, P., Parpia, S., **Trotter, T.**, ... Leong, C. (2013). Predictors of cosmetic outcome from RAPID [Abstract]. Presented at CARO, Montreal, Quebec. *Radiotherapy and Oncology*, 108(1), s19.
13. Pisansky, T. M., Hunt, D., Gomella, L. G., Amin, M. G., **Balogh, A. G.**, Chinn, D. M., Seider, M., Duclos, M., & Rosenthal, S. A. (2013). Radiation therapy oncology group 9910: Phase 3 trial to evaluate the duration of neoadjuvant (NEO) total androgen suppression (TAS) and radiation therapy (RT) in intermediate-risk prostate cancer (PCa) [Abstract]. Presented at ASTRO Meeting, Atlanta, GA. *International Journal of Radiation Oncology Biology Physics*, 87(2), s1.
14. **Phan, T.**, Mula-Hussain, L., Pavamani, S., Pearce, A., D'Souza, D., Patil, N., Traptow, L., **Craighead, P.**, & **Doll, C.** (2013). The changing landscape of brachytherapy for cervical cancer: A Canadian pattern of practice survey update, 2009-2012 [Abstract]. Presented at the CARO-COMP Joint Scientific Meeting, Montreal QC. *Radiotherapy and Oncology*. 108 (1), s33.
15. Shack, L., Lu, S. Weeks, L. A., Craighead, P., & **Kerba, M.** (2013). Determining the need and utilization of radiotherapy in cancers of the breast, cervix, lung, prostate and rectum in Alberta, Canada [Abstract]. *Journal of Clinical Oncology*, 31, s31.

SURGICAL ONCOLOGY

PEER REVIEWED

1. Badenduck, L. A., **Matthews, T. W.**, McDonough, A., **Dort, J. C.**, Wiens, K., Kettner, R., Crawford, S., & Kaplan, B. J. (2014). Fiber-optic endoscopic evaluation of swallowing to assess swallowing outcomes as a function of head position in a normal population. *J Otolaryngol Head Neck Surg*, 43, 9.
2. **Ball, C. G.** (2014). Current management of penetrating torso trauma: Nontherapeutic is not good enough anymore. *Can J Surg*, 57(2), e36-43.
3. **Ball, C. G.** (2014). Damage control resuscitation: History, theory and technique. *Can J Surg*, 57(1), 55-60.
4. **Ball, C. G.**, **Dixon, E.**, MacLean, A. R., Kaplan, G. G., Nicholson, L., & **Sutherland, F. R.** (2014). The impact of an acute care surgery clinical care pathway for suspected appendicitis on the use of CT in the emergency department. *Can J Surg*, 57(3), 194-8.
5. **Ball, C. G.**, **Dixon, E.**, Parry, N., Salim, A., Pasley, J., Inaba, K., & Kirkpatrick, A. W. (2013). Celebrity traumatic deaths: Are gangster rappers really "gangsta"? *Can J Surg*, 56 (4), e59-62.
6. Baxter, N. N., Bleier, J. I., Champagne, B. J., Moloo, H., **Dixon, E.**, & Members of the Evidence-Based Reviews in Surgery Group. (2014). Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons and the American Society of Colorectal Surgeons evidence-based reviews in surgery—colorectal surgery. *Dis Colon Rectum*, 57(4), 553-5.
7. Blackmore, C., Ouellet, J. F., Niven, D., Kirkpatrick, A. W., & **Ball, C. G.** (2014). Prevention of delirium in trauma patients: Are we giving thiamine prophylaxis a fair chance? *Can J Surg*, 57(2), 78-81.
8. Bose, P., Brockton, N. T., & **Dort, J. C.** (2013). Head and neck cancer: From anatomy to biology. *Int J Cancer*, 133(9), 2013-23.

9. Bose, P., **Dort, J. C.**, & Brockton, N. T. (2013). Identifying the stromal cell type that contributes to tumor aggressiveness associated with carbonic anhydrase IX. *Cell Cycle*, 12(16), 2535-6.
10. Bose, P., Thakur, S. S., Brockton, N. T., Klimowicz, A. C., Kornaga, E., Nakoneshny, S. C., Riabowol, K. T., & **Dort, J. C.** (2014). Tumor cell apoptosis mediated by cytoplasmic ING1 is associated with improved survival in oral squamous cell carcinoma patients. *Oncotarget*, 5(10), 3210-9.
11. Brar, M. S., Roxin, G., Yaffe, P. B., Stanger, J., MacLean, A. R., & **Buie, W. D.** (2013). Colonoscopy following nonoperative management of uncomplicated diverticulitis may not be warranted. *Dis Colon Rectum*, 56(11), 1259-64.
12. Brown, C. J., Achkar, J. P., Bressler, B. L., Maclean, A. R., Remzi, F. H., **Dixon, E.**, & Evidence Based Reviews in Surgery Group. (2014). Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons and the American Society of Colorectal Surgeons Evidence Based Reviews in Surgery - colorectal surgery. *Dis Colon Rectum*, 57(2), 278-81.
13. Butte, J. M., **Ball, C. G.**, & **Dixon, E.** (2014). Treatment of unresectable liver-only disease: Systematic therapy versus locoregional therapy. *Curr Surg Rep*, 2(4), 50.
14. **Chandarana, S. P.**, Lee, J. S., Chanowski, E. J., Sacco, A. G., Bradford, C. R., Wolf, G. T., . . . Chepeha, D. B. (2013). Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. *Head Neck*, 35(8), 1083-90.
15. Chin-Lenn, L., Craighead, P., Bryant, H. E., **Mack, L.**, **Temple, W.**, Ghali, W., & **Quan, M. L.** (2013). Quality indicators for ductal carcinoma in situ (DCIS) of the breast: Development using a multidisciplinary delphi process and its use in monitoring population-based treatment. *J Surg Oncol*, 108(6), 348-51.
16. Chin-Lenn, L., **Mack, L. A.**, **Temple, W.**, Cherniak, W., Quinn, R. R., Ravani, P., Lewin, A. M., & **Quan, M. L.** (2014). Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. *Ann Surg Oncol*, 21(1), 66-73.
17. Chin-Lenn, L., Murynka, T., **McKinnon, J. G.**, & **Arlette, J. P.** (2013). Comparison of outcomes for malignant melanoma of the face treated using Mohs micrographic surgery and wide local excision. *Dermatol Surg*, 39(11), 1637-45.
18. Cho, J. J., Taylor, R. C., Deutschmann, M. W., **Chandarana, S. P.**, & Marck, P. A. (2013). Polyethylene implants in nasal septal restoration. *JAMA Facial Plast Surg*, 15(4), 275-9.
19. Cirocco, W. C., Steele, S. R., & **Buie, W. D.** (2014). Advancing standards of rectal cancer care: Lessons from Europe adapted to the vast expanse of North America. *Dis Colon Rectum*, 57(2), 260-6.
20. D'Amours, S. K., Rastogi, P., & **Ball, C. G.** (2013). Utility of simultaneous interventional radiology and operative surgery in a dedicated suite for seriously injured patients. *Curr Opin Crit Care*, 19(6), 587-93.
21. Dautremont, J. F., Rudmik, L. R., Yeung, J., Asante, T., Nakoneshny, S. C., Hoy, M., Lui, A., **Chandarana, S. P.**, **Matthews, T. W.**, Schrag, C., & **Dort, J. C.** (2013). Cost-effectiveness analysis of a postoperative clinical care pathway in head and neck surgery with microvascular reconstruction. *J Otolaryngol Head Neck Surg*, 42, 59.

22. Deutschmann, M. W., McDonough, A., **Dort, J. C.**, Dort, E., Nakoneshny, S., & **Matthews, T. W.** (2013). Fiber-optic endoscopic evaluation of swallowing (FEES): Predictor of swallowing-related complications in the head and neck cancer population. *Head Neck*, 35(7), 974-9.
23. **Dixon, E., Buie, W. D.**, Heise, C. P., & Members of the Evidence-Based Reviews in Surgery Group. (2013). What is the preferred surgery for perforated left-sided diverticulitis? *J Am Coll Surg*, 218(3), 495-7.
24. **Dixon, E.**, Raval, M. J., Salit, I. E., Welton, M. L., & Members of the Evidence Based Reviews in Surgery Group. (2013). Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons and the American Society of Colorectal Surgeons evidence based reviews in surgery - colorectal surgery. *Dis Colon Rectum*, 56(9), 1105-7.
25. Dumestre, D., Yeung, J. K., & **Temple-Oberle, C.** (2014). Evidence-based microsurgical skill-acquisition series part 1: Validated microsurgical models--A systematic review. *J Surg Educ*, 71(3), 329-38.
26. Edwards, J. P., Stuart, H. C., Urbanski, S. J., & **Pasiaka, J. L.** (2014). A rare cavernous hemangioma of the adrenal gland. *Int J Surg Case Rep*, 5(2), 52-5.
27. Grendar, J., Grendarova, P., Sinha, R., & **Dixon, E.** (2014). Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: A systematic review. *HPB (Oxford)*, 16(4), 297-303.
28. **Harvey, A.** (2014). Hyperaldosteronism: Diagnosis, lateralization and treatment. *Surgical Clinics of North America*, 94(3), 643-56.
29. **Harvey, A.**, Vickers, J. N., Snelgrove, R., Scott, M. F., & Morrison, S. (2014). Expert surgeon's quiet eye and slowing down: Expertise differences in performance and quiet eye duration during identification and dissection of the recurrent laryngeal nerve. *American Journal of Surgery*, 207(2), 187-93.
30. Hurdle, V., Ouellet, J. F., **Dixon, E.**, Howard, T. J., Lillemoe, K. D., Vollmer, C. M., **Sutherland, F. R.**, & **Ball, C. G.** (2014). Does regional variation impact decision-making in the management and palliation of pancreatic head adenocarcinoma? Results from an international survey. *Can J Surg*, 57(3), e69-74.
31. Kaplan, G. G., Tanyingoh, D., **Dixon, E.**, Johnson, M., Wheeler, A. J., Myers, R. P., . . . Villeneuve, P. J. (2013). Ambient ozone concentrations and the risk of perforated and nonperforated appendicitis: A multicity case-crossover study. *Environ Health Perspect*, 121(8), 939-43.
32. Karanicolas, P. J., Metrakos, P., Chan, K., Asmis, T., Chen, E., Kingham, T. P., Kemeny, N., Porter, G., Fields, R. C., Pingpank, J., **Dixon, E.**, Wei, A., Cleary, S., Zogopoulos, G., Dey, C., D'Angelica, M., Fong, Y., Dowden, S., & Ko, Y. J. (2014). Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: Expert consensus statement. *Curr Oncol*, 21(1), e129-36.
33. Klimowicz, A. C., Bose, P., Petrillo, S. K., Magliocco, A. M., **Dort, J. C.**, & Brockton, N. T. (2013). The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. *Br J Cancer*, 109(7), 1859-66.
34. Kline, G. A., **Pasiaka, J. L.**, **Harvey, A.**, So, B., & Dias, V. C. (2013). Medical or surgical therapy for primary aldosteronism: Post-treatment follow-up as a surrogate measure of comparative outcomes. *Annals of Surgical Oncology*, 20(7), 2274-8.

35. Kline, G. A., **Pasieka, J. L., Harvey, A.**, So, B., & Dias, V. C. (2014). High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false-positive diagnoses. *J Clin Hypertens (Greenwich)*, *16*(7), 488-96.
36. Kline, G. A., So, B., Dias, V. C., **Harvey, A., & Pasieka, J. L.** (2013). Catheterization during adrenal vein sampling for primary aldosteronism: Failure to use (1-24) ACTH may increase apparent failure rate. *J Clin Hypertens (Greenwich)*, *15*(7), 480-4.
37. Li, Y., Bai, S., Carroll, W., Dayan, D., **Dort, J. C.**, Heller, K., . . . Brandwein-Gensler, M. (2013). Validation of the risk model: High-risk classification and tumor pattern of invasion predict outcome for patients with low-stage oral cavity squamous cell carcinoma. *Head Neck Pathol*, *7*(3), 211-23.
38. Lui, J. T., Khalil, M. N., & **Chandarana, S. P.** (2014). Primary squamous cell of the thyroid – An abbreviated clinical presentation. *J Otolaryngol Head Neck Surg*, *43*(1), 17.
39. MacLean, A. R., **Dixon, E., & Ball, C. G.** (2013). Effect of noise on auditory processing in the operating room. *J Am Coll Surg*, *217*(6), 1154.
40. Mastracci, T. M., Greenberg, C. C., Kortbeek, J. B., **Dixon, E.**, & Members of the Evidence-Based Reviews in Surgery Group. (2013). What are the effects of introducing the WHO "surgical safety checklist" on in-hospital mortality? *J Am Coll Surg*, *217*(6), 1151-3.
41. McColl, R. J., Shaheen, A. A., Brar, B., Kaplan, G., Myers, R., **Sutherland, F., & Dixon, E.** (2013). Survival after hepatic resection: Impact of surgeon training on long-term outcome. *Can J Surg*, *56*(4), 256-62.
42. McConnell, Y. J., **Mack, L. A.**, Gui, X., Carr, N. J., Sideris, L., **Temple, W. J.**, Dubé, P., Chandrakumaran, K., Moran, B. J., & Cecil, T. D. (2014). Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: An emerging treatment option for advanced goblet cell tumors of the appendix. *Ann Surg Oncol*, *21*(6), 1975-82.
43. Metcalfe, K. A., **Quan, M. L.**, Eisen, A., Cil, T., Sun, P., & Narod, S. A. (2013). The impact of having a sister diagnosed with breast cancer on cancer-related distress and breast cancer risk perception. *Cancer*, *119*, 1722-1728.
44. Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., **McKinnon, J. G.**, . . . MSLT Group. (2014). Final trial report of sentinel-node biopsy versus nodal observation in melanoma. *N Engl J Med*, *370*(7), 599-609.
45. Munene, G., Parker, R., Larrigan, J., Wong, J., **Sutherland, F., & Dixon, E.** (2013). Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases. *World Journal of Surgical Oncology*, *11*, 134.
46. Munene, G., Parker, R. D., Shaheen, A. A., Myers, R. P., **Quan, M. L., Ball, C. G., & Dixon, E.** (2013). Disparities in the surgical treatment of colorectal liver metastases. *J Natl Med Assoc*, *105*(2), 128-37.
47. Ng, D., Falck, V., McConnell, Y. J., **Mack, L. A., Temple, W. J., & Gui, X.** (2014). Appendiceal goblet cell carcinoid and mucinous neoplasms are closely associated tumors: Lessons from their coexistence in primary tumors and concurrence in peritoneal dissemination. *J Surg Oncol*, *109*(6), 548-55.
48. Parvez, E., Hodgson, N., Cornacchi, S. D., Ramsaroop, A., Gordon, M., Farrokhyar, F., Porter, G., **Quan, M. L.**, Wright, F., & Lovrics, P. J. (2014). Survey of American and Canadian general surgeons' perceptions of margin status and practice patterns for breast conserving surgery. *Breast J*. doi: 10.1111/tbj.12299 [Epub ahead of print].

-
49. **Pasieka, J. L.**, Longman, R. S., Chambers, A. J., Rorstad, O., Rach-Longman, K., & **Dixon, E.** (2014). Cognitive impairment associated with carcinoid syndrome. *Ann Surg*, 259(2), 355-9.
 50. Poulin, P., Austen, L., Scott, C. M., Poulin, M., Gall, N., Seidel, J., & **Lafrenière, R.** (2013). Introduction of new technologies and decision making processes: A framework to adapt a Local Health Technology Decision Support Program for other local settings. *Med Devices (Auckl)*, 6, 185-93.
 51. Poulin, P., Austen, L., Scott, C. M., Waddell, C. D., **Dixon, E.**, Poulin, M., & **Lafrenière R.** (2013). Multi-criteria development and incorporation into decision tools for health technology adoption. *J Health Organ Manag*, 27(2), 246-65.
 52. **Quan, M. L.**, Osman, F., McCready, D., Fernandes, K., Sutradhar, R., & Paszat, L. (2014). Postmastectomy radiation and recurrence patterns in breast cancer patients younger than age 35 years: A population-based cohort. *Ann Surg Oncol*, 21(2), 395-400.
 53. Randall, D. R., Lysack, J. T., Hudon, M. E., Guggisberg, K., Nakoneshny, S. C., **Matthews, T. W.**, **Dort, J. C.**, & **Chandarana, S. P.** (2013). Diagnostic utility of central node necrosis in predicting extracapsular spread among oral cavity squamous cell carcinoma. *Head Neck*, doi: 10.1002/hed.23562 [Epub ahead of print].
 54. Rivard, J. D., McConnell, Y. J., **Temple, W. J.**, & **Mack, L. A.** (2014). Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: Are we excluding patients who may benefit? *J Surg Oncol*, 109(2), 104-9.
 55. Rivard, J. D., **Temple, W. J.**, McConnell, Y. J., Sultan, H., & **Mack, L. A.** (2014). Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. *Am J Surg*, 207(5), 760-4.
 56. Roberts, D. J., Das, D., Mercado, M., Vis, C., Kortbeek, J. B., Kirkpatrick, A. W., & **Ball, C. G.** (2014). A booming economy means a bursting trauma system: Association between hospital admission for major injury and indicators of economic activity in a large Canadian health region. *Am J Surg*, 207(5), 653-7.
 57. Roberts, D. J., Leigh-Smith, S., Faris, P. D., **Ball, C. G.**, Robertson, H. L., Blackmore, C., **Dixon, E.**, Kirkpatrick, A. W., Kortbeek, J. B., & Stelfox, H. T. (2014). Clinical manifestations of tension pneumothorax: Protocol for a systematic review and meta-analysis. *Syst Rev*, 3, 3.
 58. Roberts, D. J., Ouellet, J. F., McBeth, P. B., Kirkpatrick, A. W., **Dixon, E.**, & **Ball, C. G.** (2014). The "weekend warrior": Fact or fiction for major trauma? *Can J Surg*, 57(3), e62-8.
 59. Shea-Budgell, M., **Quan, M. L.**, Mehling, B., **Temple-Oberle, C. F.**, & Members of the Alberta Breast Reconstruction Working Group. (2014). Breast reconstruction following prophylactic or therapeutic mastectomy for breast cancer: Recommendations from an evidence-based provincial guideline. *Past Surg*, 22(2), 103-111.
 60. Smith, A., Ouellet, J. F., Niven, D., Kirkpatrick, A. W., **Dixon, E.**, D'Amours, S., & **Ball, C. G.** (2013). Timeliness in obtaining emergent percutaneous procedures in severely injured patients: How long is too long and should we create quality assurance guidelines? *Can J Surg*, 56(6), e154-7.
 61. Smith, K. A., **Matthews, T. W.**, Dubé, M., Spence, G., & **Dort, J. C.** (2014). Changing practice and improving care using a low-risk tracheotomy clinical pathway. *JAMA Otolaryngol Head Neck Surg*, 140(7), 630-4.
-

62. Steele, S. R., Perry, W. B., Mills, S., **Buie, W. D.**, & Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. (2013). Practice parameters for the management of pilonidal disease. *Dis Colon Rectum*, 56(9), 1021-7.
63. Stuart, H. C., **Harvey, A.**, & **Pasieka, J. L.** (2014). Normocalcemic hyperparathyroidism: Preoperatively a disease, postoperatively cured? *Am J Surg*, 207(5), 673-80.
64. **Temple, W. J.**, Chin-Lenn, L., **Mack, L. A.**, & Cancer Surgery Alberta. (2014). Evaluating population-based breast cancer surgical practice in real time with a web-based synoptic operative reporting system. *Am J Surg*, 207(5), 693-6.
65. **Temple-Oberle, C. F.**, Byers, B. A., Hurdle, V., Fyfe, A., & **McKinnon, J. G.** (2014). Intra-lesional interleukin-2 therapy for in transit melanoma. *J Surg Oncol*, 109(4), 327-31.
66. Walker, R. L., Chen, G., McAlister, F. A., Campbell, N. R., Hemmelgarn, B. R., **Dixon, E.**, . . . Hypertension Outcome and Surveillance Team. (2013). Hospitalization for uncomplicated hypertension: An ambulatory care sensitive condition. *Can J Cardiol*, 29(11), 1462-9.
67. Wang, T. S., **Pasieka, J. L.**, & Carty, S. E. (2014). Techniques of parathyroid exploration at North American endocrine surgery fellowship programs: What the next generation is being taught. *Am J Surg*, 207(4), 527-32.
68. Wei, A. C., Devitt, K. S., Wiebe, M., **Bathe, O. F.**, McLeod, R. S., & Urbach, D. R. (2014). Surgical process improvement tools: Defining quality gaps and priority areas in gastrointestinal cancer surgery. *Curr Oncol*, 21(2), e195-202.
69. Wells, B. J., **Quan, M. L.**, & Coyte, P. C. (2013). The ever-diminishing role of axillary lymph node dissection in breast cancer. *Breast J*, 19(6), 691-2.
70. Wells, B., Saskin, R., Wright, F., McCreedy, D., & **Quan, M. L.** (2013). Measuring the quality of sentinel lymph node biopsy (SLNB) for breast cancer: A population-based evaluation. *Annals of Surgical Oncology*, 20, 615-619.
71. Yeung, J. K., Dautremont, J. F., Harrop, A. R., Asante, T., Hirani, N., Nakoneshny, S. C., de Haas, V., McKenzie, D., **Matthews, T. W.**, **Chandarana, S. P.**, Schrag, C., & **Dort, J. C.** (2014). Reduction of pulmonary complications and hospital length of stay with a clinical care pathway after head and neck reconstruction. *Plast Reconstr Surg*, 133(6), 1477-84.
72. Yeung, J. K., Harrop, R., McCreary, O., Leung, L. T., Hirani, N., McKenzie, D., de Haas, V., **Matthews, T. W.**, Nakoneshny, S., **Dort, J. C.**, & Schrag, C. (2013). Delayed mobilization after microsurgical reconstruction: An independent risk factor for pneumonia. *Laryngoscope*, 123(12), 2996-3000.
73. Zhong, T., **Temple-Oberle, C.**, Hofer, S., Beber, B., Semple, J., Brown, M., Macadam, S., Lennox, P., Panzarella, T., McCarthy, C., Baxter, N., & MCCAT Study Group. (2013). The Multi Centre Canadian Acellular Dermal Matrix Trial (MCCAT): Study protocol for a randomized controlled trial in implant-based breast reconstruction. *Trials*, 14, 356.

ABSTRACTS

1. Ayeni, O., **Temple-Oberle, C.**, Ayeni, B., Bettger-Hahn, M., & Mychailysyn, N. (2013). Customizing the reconstruction plan to achieve good satisfaction in women undergoing various forms of breast reconstruction [Abstract]. *Can J Plast Surg*, 21(2), 140.
2. Byers, B., **Temple-Oberle, C.**, **McKinnon, J. G.**, & Hurdle, V. (2013). Treatment of in transit melanoma with intra-lesional Interleukin-2: A systematic review [Abstract]. *Can J Plast Surg*, 21(2), 142.

3. Grendar, J., Ouellet, J. F., **Sutherland, F. R., Bathe, O. F., Ball, C. G., & Dixon, E.** (2014). In search of the best reconstructive technique in the Whipple operation – Pancreaticojejunostomy versus pancreaticogastrostomy: A randomized clinical trial [Abstract]. *HPB*, 16(Suppl. 1), 1.
4. Lutz, K., Hayward, V., Joseph, M., Wong, E., & **Temple-Oberle, C.** (2013). Current biopsy practices for suspected melanoma: A survey of Southwestern Ontario family physicians [Abstract]. *Can J Plast Surg*, 21(2), 118.
5. **Temple-Oberle, C.**, Shea-Budgell, M., **Quan, M.**, Mehling, B., & **Lindsay, R.** (2013). Provincial evidence-based guidelines for breast reconstruction [Abstract]. *Can J Plast Surg*, 21(2), 134.
6. **Temple-Oberle, C.**, Webb, C., & Stone, J. (2013). Direct to implant with “Autoderm”: Achieving breast reconstruction satisfaction in the setting of elevated BMI and significant ptosis [Abstract]. *Can J Plast Surg*, 21(2), 115.

BOOK CHAPTERS

1. **Bathe, O. F.** (2014). Characterizing the metabolomic effects of pancreatic cancer. In A. S. Azmi (Ed.), *Molecular Diagnostics and Treatment of Pancreatic Cancer: Systems and Network Biology Approaches* (pp. 323-343). USA: Academic Press.
2. **Bathe, O. F.**, & Burak, K. W. (2013). Liver and biliary tract carcinoma surveillance counterpoint: Canada. In D. Y. Johnson, C. C. Earle, & K. S. Virgo (Eds.), *Patient Surveillance after Cancer Treatment* (pp. 169-178). New York, USA: Springer Science & Business Media.
3. **Harvey, A. M.**, & **Pasieka, J. L.** (2014). Conventional parathyroid surgery: Bilateral exploration. In D. Terris, W. Duke, & **J. L. Pasieka** (Eds.), *Parathyroid Surgery: Fundamental and Advanced Concepts*. San Diego, USA: Plural Publishing Inc.
4. **Pasieka, J. L.**, & van Heerden, J. V. (2014). History of parathyroid surgery. In D. Terris, W. Duke, & **J. L. Pasieka** (Eds.), *Parathyroid Surgery: Fundamental and Advanced Concepts*. San Diego, USA: Plural Publishing Inc.

TRANSLATIONAL RESEARCH & LABORATORIES

PEER REVIEWED

1. Altman, A. D., Nelson, G. S., Ghatage, P., **McIntyre, J. B.**, Capper, D., Chu, P., Nation, J. G., Karnezis, A. N., Han, G., Kalloger, S. E., & Köbel, M. (2013). The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. *Mod Pathol*, 26(9), 1255-63. doi: 10.1038/modpathol.2013.55
2. Diestelhorst, C., Boos, J., McCune, J. S., Russell, J., **Kangarloo, S. B.**, & Hempel, G. (2013). Physiologically based pharmacokinetic modeling of busulfan: A new approach to describe and predict the pharmacokinetics in adults. *Cancer Chemother Pharmacol*, 72(5), 991-1000.
3. Diestelhorst, C., Boos, J., McCune, J. S., Russell, J., **Kangarloo, S. B.**, & Hempel, G. (2013). Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. *Pediatr Hematol Oncol* [Epub ahead of print].

4. Doll, C. M., Aquino-Parsons, C., Pintilie, M., **Klimowicz, A. C.**, Petrillo, S. K., Milosevic, M., Craighead, P. S., Clarke, B., Lees-Miller, S. P., Fyles, A. W., & Magliocco, A. M. (2013). The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: A multicenter clinicopathologic analysis. *Int J Radiat Oncol Biol Phys*, 85(3), 721-7.
5. Escobar, J., **Klimowicz, A. C.**, **Dean, M.**, Chu, P., Nation, J. G., Nelson, G. S., Ghatage, P., Kalloger, S. E., & Koebel, M. (2013). Quantification of ER/PR expression in ovarian low-grade serous carcinoma. *Gynecologic Oncology*, 128(2), 371-376.
6. Griffiths, C. D., **Ng, E. S.**, **Kangarloo, S. B.**, Williamson, T. S., Chaudhry, M. A., Booker, R., Duggan, P., Yue, P., Savoie, L., Brown, C., Cox-Kennett, N., Russell, J. A., Daly, A., & Storek, J. (2014). Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function. *Bone Marrow Transplant*, 49(4), 589-91.
7. Kelemen, L., Köbel, M., **Chan, A.**, Taghaddos, S., & Dinu, I. (2013). Differentially methylated loci distinguish ovarian carcinoma histological types: Evaluation of a DNA methylation assay in FFPE tissue. *BioMed Research International* [Epub].
8. **Klimowicz, A. C.**, Bose, P., Petrillo, S. K., Magliocco, A. M., Dort, J. C., Brockton, N. T. (2013). The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. *Br J Cancer*, 109(7), 1859-66.
9. **Ng, E. S.**, **Kangarloo, S. B.**, & Daly, A. (2013). Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*, 15(931), 103-10.
10. **Ng, E. S.**, **Kangarloo, S. B.**, **Konno, M.**, Paterson, A., & Magliocco, A. M. (2014). Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: An innovative quantitation method using liquid chromatography and tandem mass spectrometry. *Cancer Chemother Pharmacol*; 73(3):475-84.
11. Russell, J. A., **Kangarloo, S. B.**, Williamson, T., Chaudhry, M. A., Savoie, M. L., Turner, A. R., Larratt, L., Storek, J., Bahlis, N., Brown, C., Yang, M., Geddes, M., Zacarias, N., Yue, P., Duggan, P., Stewart, D., & Daly, A. (2013). Establishing a target exposure for once daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. *Biol Blood Marrow Transplant*, 19(9), 1381-1386.
12. **Thirukkumaran, C.**, Zhong, Q., Luidier, J., Kopcuik, K., Bahlis, N., Neri, E. P., Pho, M., **Stewart, D.**, Mansoor, A., & **Morris, D.** (2014). Reovirus as a successful ext vivo purging modality for multiple myeloma. *Bone Marrow Transplantation*, 49(1), 80-86.

ABSTRACTS

1. Elegbede, A., **Bebb, G.**, **Petersen, L.**, Kubota, E., & Lees-Miller, S. (2013). Role of ATM in response of NSCLC cell lines to therapeutic agents [Abstract]. *Journal of Thoracic Oncology*. 8(2), s1061.
2. **Otsuka, S.**, Boland, W., Hao, D., **Morris, D.**, & **Bebb, G.** (2013). Metastatic NSCLC outcomes at a single Canadian institution over a decade [Abstract]. *Journal of Thoracic Oncology*, 8(2), s1182.
3. **Petersen, L.**, **McIntyre, J.**, Elegbede, A., Lees-Miller, S., & **Bebb, G.** (2013). Deep-sequencing mutational analysis of ATM in NSCLC cell lines [Abstract]. *Journal of Thoracic Oncology*, 8(2), s1055.

PUBLICATIONS

4. **Thirukkumaran, C., & Morris, D.** (2014) Reovirus synergy with proteasome inhibitor carfilzomib and akt inhibitor perifosone overcomes therapy resistance of multiple myeloma: promising preclinical activity [Abstract]. Presented at the American Association of Cancer Research, Annual Meeting. *J Clin Oncol*, 32, s5.
5. Withecomb, S., **Otsuka, S., Klimowicz, A., Pohorelic, B.**, Kopciuk, K., Zhang, Y., **Petersen, L., Konno, M., Morris, D., & Bebb, G.** (2013). Implications of CXCR4 and estrogen/progesterone receptor (ER/PR) pathway activity in NSCLC [Abstract]. *Journal of Thoracic Oncology*, 8(2), s760.

2013

September 1

Research: Should It Be Woven Into the Fabric of Patient Care

Don Morris, MD, PhD, FRCPC

Section Chief and Division Head, Medical Oncology / Associate Professor, Faculty of Medicine, University of Calgary

September 18

The War on Cancer: An Examination of Society's Language and its Impact in Patient Care

Heather Shantz, MN, RN, CHPCN(C)

Clinical Nurse Specialist, Palliative Care Consult Services / Clinical Associate, Faculty of Nursing, University of Calgary

September 25

Collateral Damage: The Untold Story of Cancer Supporters

Michael Lang, MSc Student

CancerBridges Program Coordinator

October 2

Intensity of End-of-Life Cancer Therapies at TBCC: Variations by Tumor Groups from 2003 to 2010

Jackson Wu, MD, MSc (c. epi.), FRCPC

Clinical Associate, Faculty of Medicine, University of Calgary

October 9

Integrating Palliative Care in Outpatient Oncology: Lessons from TBCC Multidisciplinary Brain Metastases Clinic

Jackson Wu, MD, MSc (c. epi.), FRCPC

Clinical Associate, Faculty of Medicine, University of Calgary

October 16

What Differences Should Palliative Care Make?

David C. Currow, BMed, MPH, FRACP, FChPM

Professor, Discipline of Palliative and Supportive Services, Flinders University, Adelaide, Australia

October 23

Dying in Canada: A Quality Finish?

Daren Heyland, MD, MSc, FRCPC

Professor Medicine, Department of Medicine, Queen's University

October 30

Germ Cell Tumors of the Mediastinum

Kenneth A. Kesler, MD

Professor of Surgery, Thoracic Division, Cardiothoracic Surgery

November 6

What is it with the REB?!

Glenys Godlovitch, BA, LLB, PhD

Chair, ACREC

November 20

State of the Art Management of Breast Cancer

Edith A. Perez, MD

Director of Breast Cancer Translational Genomic Program & the Breast Program-Mayo Clinic Florida

November 22

The Care Trajectory of a Patient with Early Breast Cancer: Key Aspects and Interesting Asides from the Perspective of the Breast Tumour Group

Sasha Lupichuk, MD, FRCPC, MSc

Medical Oncologist & Chair, Southern Alberta Breast Tumour Group

and

Members of the Southern Alberta Breast Tumour Group

November 27

The Multidisciplinary Management of Advanced GIST

Danielle Bischof, MD, FRCSC

Surgical Oncology Fellow, Johns Hopkins Hospital

December 4

A Clinically Feasible Source Model for Calculating Patient Imaging Dose from Kilovoltage CBCT Imaging

Yannick Poirier, PhD

Medical Physics Resident, Department of Oncology

and

Which PBI IMRT Patients Need Respiratory Management: A Study of the Impact of Respiratory Motion on Plan Quality

Sarah Quirk, PhD

Medical Physics Resident, Department of Oncology

December 5

Health Economics in Radiation Oncology, ESTRO H.E.R.O. Project: A European Perspective

Cai Grau, MD, DMSc

Professor, Department of Oncology, Aarhus University Hospital, Denmark

December 6

Protons: What is the Clinical Evidence that Population Based Proton Therapy Should Exist

Cai Grau, MD, DMSc

Professor, Department of Oncology, Aarhus University Hospital, Denmark

2014

January 22

The Sweet Side of Cancer

Ravi Ramjeesingh, MD, PhD, FRCPC

Translational Research Fellow, Department of Medical Oncology, Queen's University

January 24

Genomics Guided Therapy for Multiple Myeloma: Are We There Yet?

Nizar Bahlis

Associate Professor, Faculty of Medicine, University of Calgary / Hematology Tumour Group

January 29

Population Health Outcomes: A Valuable Source of Information

Aalok Kumar, B.Esc, MD, FRCPC

Fellow, Gastro-Intestinal and Gynecologic Oncology, Department of Medical Oncology, University of British Columbia

February 5

Cancer Associated Thrombosis: How Can We Do Better?

Susan R. Kahn, MD, MSc, FRCPC

Professor of Medicine, McGill University, Director, McGill Thrombosis Fellowship, Director, JGH Centre of Excellence in Thrombosis & Anticoagulation Care, Division of Internal Medicine & Center for Clinical Epidemiology, Jewish General Hospital

February 12

The Prince and the Pauper: Advances in Prostate Cancer and Challenges in Bladder Cancer

Nimira Alimohamed, MD, FRCPC

Fellow, Medical Oncology, Princess Margaret Cancer Centre

February 28

Introduction to Pathways in the Lung Tumour Group

Diagnosis: AB Thoracic Oncology Program

Surgery Update

Fast Track Clinic

Advances in Lung RT

Challenges in Personalized Systemic Therapy for Lung Cancer

Hellen Jung, RN, MSN CON(C), BScN

Laura Hampton, RN, MN, NP
David Skarsgard, MD, FRCPC
Elizabeth Kurien, MD, CM
Desiree Hao, MD
Anna Sienko, MD
Members of the Lung Tumour Group

March 5

Dr. Diversity

Helgi Eyford, PhD
Former Diversity Educator with Alberta Health Services / Team Lead, Leadership Development with Savanna Energy

March 19

Waiting to Exhale: Respiratory Motion in Radiotherapy

Wendy Smith, PhD, FCCPM
Medical Physicist, Division of Medical Physics, Department of Oncology, Faculty of Medicine, University of Calgary

March 28

**Meeting the Nutritional Needs of Esophageal Cancer Patients, Can we do Better?
Liver Radiation Treatment Program Overview**

Update on GI Clinical Trials

Bottoms Up Campaign

Colleen Cuthbert, MN, RN, NP (adult)
Richie Sinha, MD, FRCPC
Jose Monzon, PhD, MD, FRCPC
Marc Kerba, MD, FRCPC

April 2

**Think Outside the Box and Open Up New Horizons to Better Cancer Care Today
& Tomorrow**

Sha Xiao Chang, PhD
Associate Professor, Departments of Radiation Oncology, Physics & Astronomy & Biomedical Engineering, Lineberger Comprehensive Clinical Cancer Center, University of North Carolina

April 9

Dropping the Ball in Healthcare – Mapping the Patient Care Journey to Life-Saving Therapy

W. Ward Flemons, MD, FRCPC
Professor, Department of Medicine, Faculty of Medicine, University of Calgary / Staff Physician, Respiratory Medicine, Foothills Medical Centre / Medical Advisor, Health Quality Council of Alberta

April 25

Advanced Epithelial Ovarian Cancer; Diagnostic Challenges and Treatment Dilemmas

Robyn Comeau, MD, FRCSC

Gynecologic Oncology Fellow, Gynecologic Tumour Group, Department of Oncology

April 30

Proton Therapy Physics: Past, Present and Predictions

Dennis Mah, PhD

Director, Medical Physics and Dosimetry, ProCure Proton Therapy Center

May 21

Cardio-Oncology Getting to the Heart of the Matter

James McMeekin, MD, FRCPC

Department of Cardiac Sciences, University of Calgary

and

James White, MD, FRCPC

Department of Cardiac Sciences, University of Calgary

and

Neil Filipchuk, MD, FRCPC

Department of Cardiac Sciences, University of Calgary

May 23

Treatment, Research and Patient Perspectives from the Head & Neck Tumour Group

Joseph C. Dort, MD, MSc, BSc, FRCSC, FACS

Ohlson Professor of Head & Neck Surgery

and

Lauren Capozzi, MD/PhD Candidate

Exercise Physiologist, Faculty of Kinesiology, University of Calgary

and

Tom Ambrose

and

Glenn Gould

and

Cary Ross

June 4

Pharmacists with Additional Prescribing Authority: Implications for CancerControl Alberta

Melanie Danilak, BSc Pharm, ACPR

Pharmacy Educator, Cross Cancer Institute

and

Frances Cusano, BSc Pharm, ACPR

Pharmacy Clinical Practice Leader for Adult Cancer, Tom Baker Cancer Centre

June 18

Management of Retroperitoneal Sarcoma – Where Are We Now?

Trevor Hamilton, MD, FRCSC

Surgical Oncology Fellow, University of Toronto

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

ALIMOHAMED, NIMIRA
Medical Oncology
P: 403.521.3093
F: 403.283.1651
Nimira.Alimohamed@albertahealthservices.ca

ANDERSON, RONALD A.
Pediatric Oncology
P: 403.955.7203
F: 403.955.2645
Ronald.Anderson@albertahealthservices.ca

ANGYALFI, STEVE J.
Radiation Oncology
P: 403.521.3095
F: 403.283.1651
Steve.Angyalfi@albertahealthservices.ca

ARLETTE, JOHN P.
Surgical Oncology
P: 403.216.4685
F: 403.216.4689
dra@johnarlette.com

ASHBURY, FRED
Preventive Oncology
P: 416.915.3780 ext 2031
F: 416.915.3910
fashbury@picepsconsultants.com

BAHLIS, NIZAR J.
Hematologic Malignancies & BMT
P: 403.944.1880
F: 403.944.2102
nbahlis@ucalgary.ca

BALL, CHAD
Surgical Oncology
P: 403.944.3417
F: 403.944.8799
Chad.Ball@albertahealthservices.ca

BALOGH, ALEXANDER G.
Radiation Oncology
P: 403.521.3095
F: 403.283.1651
Alex.Balogh@albertahealthservices.ca

BANERJEE, ROBYN
Radiation Oncology
P: 403.521.3077
F: 403.283.1651
Robyn.banerjee@albertahealthservices.ca

BATHE, OLIVER F.
Surgical Oncology
P: 403.521.3275
F: 403.944.3926
Oliver.Bathe@albertahealthservices.ca

BEATTIE, TARA L.
Biochemistry & Molecular Biology
P: 403.220.8328
tbeattie@ucalgary.ca

BEBB, D. GWYN
Medical Oncology
P: 403.521.3166
F: 403.283.1651
Gwyn.Bebb@albertahealthservices.ca

BISMAR, TAREK
Pathology & Laboratory Medicine
P: 403.943.8430
tarek.bismar@cls.ab.ca

BLAHEY, WALTER B.
Hematologic Malignancies & BMT
P: 403.266.1246
F: 403.233.9278
wbblahey@telus.net

BOYAR, M. AVIS
Palliative Oncology
P: 403.943.3223
F: 403.943.1632
Avis.Boyar@albertahealthservices.ca

BRAMWELL-WESLEY, VIVIAN H. C.
Medical Oncology
P: 403.521.3707
F: 403.283.1651
Vivien.Bramwell@albertahealthservices.ca

BRAUN, TED C.
Family Medicine/ Palliative Oncology
P: 403.943.1170
Ted.Braun@albertahealthservices.ca

BREITMAN, KAREN E.
Medical Physics
P: 403.521.3790
F: 403.283.1651
Karen.Breitman@albertahealthservices.ca

BRENNER, DARREN
Preventive Oncology
Darren.Brenner@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

BRIGDEN, MALCOLM
Medical Oncology
P: 403.388.6869
Malcolm.Brigden@albertahealthservices.ca

BROCKTON, NIGEL
Preventive Oncology
P: 403.521.3924
F: 403.270.8003
Nigel.Brockton@albertahealthservices.ca

BROWN, CHRISTOPHER B.
Hematologic Malignancies & BMT
P: 403.944.5246
F: 403.944.1647
cbrown@ucalgary.ca

BUIE, W. DONALD
Surgical Oncology
P: 403.944.2020
F: 403.270.8004
Donald.Buie@albertahealthservices.ca

BULTZ, BARRY D.
Psychosocial Oncology
P: 403.355.3205
F: 403.355.3206
Barry.Bultz@albertahealthservices.ca

BURAK, KELLY
Medical Oncology
P: 403.592.5037
F: 403.592.5090
kwburak@ucalgary.ca

CAIRNCROSS, J GREGORY
Medical Oncology
P: 403.944.1260
F: 403.270.7878
jgcairn@ucalgary.ca

CAMPBELL, TAVIS
Psychosocial Oncology
P: 403.220.7490 / 403.998.0706
F: 403.282.8249
t.s.campbell@ucalgary.ca

CARD, CYNTHIA M.
Medical Oncology
P: 403.521.3688
F: 403.283.1651
Cynthia.Card@albertahealthservices.ca

CARLSON, LINDA E.
Psychosocial Oncology
P: 403.355.3209
F: 403.355.3206
lcarlso@ucalgary.ca

CHAMBERS, CAROLE R.
Oncology
P: 403.521.3045
F: 403.521.3326
Carole.Chambers@albertahealthservices.ca

CHAN, JENNIFER
Pathology & Laboratory Medicine
P: 403.944.4755
jennifer.chan@cls.ab.ca

CHANDARANA, SHAMIR
Surgical Oncology
P: 403.944.3954
F: 403.944.3926
Shamir.Chandarana@albertahealthservices.ca

CHARY, SRINIVASA (SRINI)
Palliative Oncology
P: 403.944.2304
F: 403.270.9652
Srini.Chary@albertahealthservices.ca

CHAUDHRY, M. AHSAN R.
Hematologic Malignancies & BMT
P: 403.944.1157
F: 403.944.2714
Ahsan.Chaudhry@albertahealthservices.ca

CHENG, TINA
Medical Oncology
P: 403.521.3706
F: 403.283.1651
Tina.Cheng@albertahealthservices.ca

CHU, PAMELA
Gynecologic Oncology
P: 403.521.3721
F: 403.521.3573
Pamela.Chu@albertahealthservices.ca

COBB, JENNIFER A.
Biochemistry & Molecular Biology
P: 403.220.8580
jcobb@ucalgary.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

CRAIGHEAD, PETER S.
Division Head / Radiation Oncology
P: 403.521.3701
F: 403.944.2331
Peter.Craighead@albertahealthservices.ca

CSIZMADI, ILONA
Preventive Oncology
P: 403.955.4704
F: 403.270.8003
Ilona.Csizmadi@albertahealthservices.ca

CULOS-REED, S. NICOLE
Psychosocial Oncology
P: 403.220.7540
Lab: 403.210.8482
F: 403.284.3553
nculosre@ucalgary.ca

DALY, ANDREW S.
Hematologic Malignancies & BMT
P: 403.943.2501
F: 403.943.4017
Andrew.Daly@albertahealthservices.ca

DAWES, JEFFRY
Surgical Oncology
P: 403.944.8022
F: 403.944.3926
Jeff.Dawes@albertahealthservices.ca

de GROOT, JANET M.
Psychosocial Oncology
P: 403.698.8185
F: 403.355.3206
Janet.deGroot@albertahealthservices.ca

de HAAS, WILLIAM G.
Surgical Oncology
P: 403.571.3150
F: 403.571.3133
William.DeHaas@albertahealthservices.ca

de ROBLES, PAULA
Medical Oncology
P: 403.944.3544
F: 403.944.3519
Paula.DeRobles@albertahealthservices.ca

DEMETRICK, DOUGLAS J.
Pathology & Laboratory Medicine / Biochemistry &
Molecular Biology
P: 403.220.2890
demetric@ucalgary.ca

DHARMAWARDENE, MARISA
Palliative Oncology
P: 403.944.8903
Marisa.Dharmawardene@albertahealthservices.ca

DiFRANCESCO, LISA M.
Pathology & Laboratory Medicine
P: 403.944.4756
F: 403.944.4748
difrance@ucalgary.ca

DIXON, ELIJAH
Surgical Oncology
P: 403.944.3045
F: 403.944.1277
Elijah.Dixon@albertahealthservices.ca

DOLL, CORINNE M.
Radiation Oncology
P: 403.521.3708
F: 403.283.1651
Corinne.Doll@albertahealthservices.ca

DONNELLY, BRYAN J.
Surgical Oncology
P: 403.259.2676
F: 403.640.9199
donnelly@ucalgary.ca

DORT, JOSEPH C.
Surgical Oncology
P: 403.220.4307
F: 403.270.3145
jdort@ucalgary.ca

DOWDEN, SCOT D.
Medical Oncology
P: 403.521.3166
F: 403.283.1651
Scot.Dowden@albertahealthservices.ca

DUGGAN, PETER R.
Hematologic Malignancies & BMT
P: 403.944.5246
F: 403.944.1647
Peter.Duggan@albertahealthservices.ca

EASAW, JACOB C.
Medical Oncology
P: 403.521.3446
F: 403.283.1651
Jay.Easaw@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

ESMAIL, ROSMIN
Palliative Oncology
P: 403.944.3123
F: 403.944.1740
Rosmin.Esmail@albertahealthservices.ca

FALK, DAVID W.
Palliative Oncology
P: 403.251.5727
F: 403.521.1916
David.Falk@albertahealthservices.ca

FORESTELL, CLAIR F.
Medical Oncology
P: 403.328.8101 / 403.327.5977
F: 403.328.8150
forecf@uleth.ca

FRIEDENREICH, CHRISTINE
Preventive Oncology
P: 403.955.4701
F: 403.270.8003
Christine.Friedenreich@albertahealthservices.ca

GALLOWAY, LYLE
Palliative Oncology
P: 403.944.1147
F: 403.270.4349
Lyle.Galloway@albertahealthservices.ca

GEDDES, MICHELLE
Hematologic Malignancies & BMT
P: 403.944.8047
Michelle.Geddes@albertahealthservices.ca

GELFAND, GARY A. J.
Surgical Oncology
P: 403.944.4268
F: 403.270.8431
gelfand@ucalgary.ca

GHASRODDA, ESMAEEL
Medical Physics
Esmael.Ghasrodda@albertahealthservices.ca

GHATAGE, PRAFULL
Gynecologic Oncology
P: 403.521.3721
F: 403.521.3573
Prfull.Ghatage@albertahealthservices.ca

GHOSE, ABHIJIT
Radiation Oncology
P: 403.388.6860
F: 403.283.1651
Ghose.Abhijit@albertahealthservices.ca

GIESE-DAVIS, JANINE
Psychosocial Oncology
P: 403.698.8139
F: 403.355.3206
Janine.Giese-Davis@albertahealthservices.ca

GLAZE, SARAH
Gynecologic Oncology
P: 403.521.3721
F: 403.521.3573
Sarah.Glaze@albertahealthservices.ca

GOODARZI, AARON
Biochemistry & Molecular Biology
P: 403.220.4896
A.goodarzi@ucalgary.ca

GOODYEAR, DAWN
Hematologic Malignancies & BMT
P: 403.944.3265
F: 403.944.8352
mdawn.goodyear@albertahealthservices.ca

GRAHAM, ANDREW J.
Surgical Oncology
P: 403.944.8258
F: 403.270.8431
Andrew.Graham@albertahealthservices.ca

GREWAL, SAVRAJ S.
Biochemistry & Molecular Biology
P: 403.210.6535
grewalss@ucalgary.ca

GROSSMAN, JENNIFER
Hematologic Malignancies & BMT
P: 403.944.1880
F: 403.94.2102
jkgrossman2@gmail.com

GUILCHER, GREGORY M. T.
Pediatric Oncology
P: 403.955.7272
F: 403.955.2645
Greg.Guilcher@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

HANLEY, DAVID A.
Medical Oncology
P: 403.220.3037
F: 403.270.0979
dahanley@ucalgary.ca

HAO, DESIRÉE
Medical Oncology
P: 403.521.3706
F: 403.283.1651
Desiree.Hao@albertahealthservices.ca

HARVEY, ADRIAN
Surgical Oncology
P: 403.944.0966
Adrian.Harvey@albertahealthservices.ca

HENG, DANIEL Y. C.
Medical Oncology
P: 403.521.3166
F: 403.283.1651
Daniel.Heng@albertahealthservices.ca

HENNING, JAN-WILLEM
Medical Oncology
P: 403.521.3196
F: 403.283-1651
Jan-Willem.Henning@albertahealthservices.ca

HERX, LEONIE
Palliative Oncology
P: 403.944.8903
F: 403.270.9652
Leonie.Herx@albertahealthservices.ca

HUDSON, ALANA
Medical Physics
P: 403-521-3996
F: 403.521.3327
Alana.Hudson@albertahealthservices.ca

HUNTER, J. BRAD
Palliative Oncology
P: 403.944.2304
Brad.Hunter@albertahealthservices.ca

HUSAIN, SIRAJ
Radiation Oncology
P: 403.521.3164
F: 403.283.1651
Siraj.Husain@albertahealthservices.ca

HUSSAIN, SEEMA
Psychosocial Oncology
P: 403.944.3369
F: 403.944.8340
Seema.Hussain@albertahealthservices.ca

JENKINS, DEIRDRE A.
Medical Oncology
P: 403.944.4451
F: 403.944.1647
Deirdre.Jenkins@albertahealthservices.ca

JERRY, L. MARTIN
Medical Oncology
P: 403.678.2082
F: 403.678.9750
mjerry@cb.monarch.net

JIMENEZ-ZEPEDA, VICTOR
Hematologic Malignancies & BMT
P: 403.944.5246
F: 403.944.1647
Victor.Zepeda@albertahealthservices.ca

JOHNSTON, RANDAL N.
Biochemistry & Molecular Biology
P: 403.220.8692
F: 403.270.0834
rjohnst@ucalgary.ca

KELLY, JOHN
Clinical Neurosciences
P: 403.944.3239
John.Kelly@albertahealthservices.ca

KERBA, MARC
Radiation Oncology
P: 403.521.3164
F: 403.283.1651
Marc.Kerba@albertahealthservices.ca

KHAN, RAO F.H.
Medical Physics
P: 403.521.3088
F: 403.521.3327
Rao.Khan@albertahealthservices.ca

KIRKBY, CHARLES
Medical Physics
P: 403.388.6872
Charles.Kirkby@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

KLIMOWICZ, ALEXANDER
Pathology & Laboratory Medicine
P: 403.521.3313
F: 403.270.8243
Alexander.Klimowicz

KOPCIUK, KAREN A.
Preventive Oncology
P: 403.955.4699
F: 403.270.8003
Karen.Kopciuk@albertahealthservices.ca

KRAUSE, VANESSA S.
Medical Oncology
P: 403.521.3093
F: 403.283.1651
Vanessa.Krause@albertahealthservices.ca

KUMAR, AALOK
Medical Oncology
P: 403.521.3196
F: 403.283.1651
Aalok.Kumar@albertahealthservices.ca

KURIEN, ELIZABETH C.
Radiation Oncology
P: 403.521.3095
F: 403.283.1651
Elizabeth.Kurien@albertahealthservices.ca

KURWA, HABIB
Medical Oncology
P: 403.944.8068
Habib.Kurwa@albertahealthservices.ca

LABRIE, MARTIN J.
Palliative Oncology
P: 403.944.2304
F: 403.270.9652
Martin.Labrie@albertahealthservices.ca

LAFAY-COUSIN, LUCIE
Pediatric Oncology
P: 403.955.7203 / 403.955.2554
F: 403.955.2645
Lucie.Lafay-Cousin@albertahealthservices.ca

LAFRENIÈRE, RENÉ
Surgical Oncology
P: 403.944.2835
F: 403.270.0671
rlafreni@ucalgary.ca

LATEGAN, JOHANNES C.
Hematologic Malignancies & BMT
P: 403.943.5423
F: 403.943.5520
Johan.Lategan@albertahealthservices.ca

LAU, HAROLD Y.
Radiation Oncology
P: 403.521.3077
F: 403.283.1651
Harold.Lau@albertahealthservices.ca

LE, DOAN T.
Pediatric Oncology
P: 403.955.7770
F: 403.955.3055
Doan.Le@albertahealthservices.ca

LEE, ADRIENNE
Hematologic Malignancies & BMT
P: 403.944.1564
F: 403.944.2102
adrlee@ucalgary.ca

LEES-MILLER, SUSAN P.
Biochemistry & Molecular Biology
P: 403.220.7628
F: 403.210.3899
leesmill@ucalgary.ca

LEMIEUX, LAURIE
Palliative Oncology
P: 403.943.1800
F: 403.943.1632
Laurie.Lemieux@hospicecalgary.com

LEWIS, VICTOR A.
Pediatric Oncology
P: 403.955.7272
F: 403.955.2645
Victor.Lewis@albertahealthservices.ca

LI, HAOCHENG
Oncology
Haocheng.Li@ucalgary.ca

LIM, GERALD
Radiation Oncology
P: 403.521.3095
F: 403.283.1651
Gerald.Lim@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

LINDSAY, ROBERT L.
Surgical Oncology
P: 403.571.3155
F: 403.571.3138
rllinsa@ucalgary.ca

LIU, HONG W.
Oncology
P: 403-521-3997
Hongwei.Liu@albertahealthservices.ca

LUPICHUK, SASHA M.
Medical Oncology
P: 403.521.3093
F: 403.283.1651
Sasha.Lupichuk@albertahealthservices.ca

MacEACHERN, PAUL
Medical Oncology
P: 403.220.6882
F: 403.283.1651
Prmaceac@uclagary.ca

MACK, LLOYD
Surgical Oncology
P: 403.521.3169 / 403.521.3104
F: 403.521.3744
Lloyd.Mack@albertahealthservices.ca

MacKINNON, JOHN (JACK) A.
Radiation Oncology
P: 403.521.3164 / 403.863.7512
F: 403.283.1651
Jack.Mackinnon@albertahealthservices.ca

MAGI, ENZIO
Surgical Oncology
P: 403.571.3130
F: 403.571.3133

MAGLIOCCO, ANTHONY
Pathology and Laboratory Medicine
P: 403.521.3165
magilocc@ucalgary.ca

MARR, HUBERT K-M.
Palliative Oncology
P: 403.943.4950 / 403.943.5547
F: 403.943.4141
Hubert.Marr@albertahealthservices.ca

MATTHEWS, T. WAYNE
Surgical Oncology
P: 403.944.4501
F: 403.944.1277
Wayne.Matthews@albertahealthservices.ca

McFADDEN, SEAN
Surgical Oncology
P: 403.944.4279
F: 403.270.8431
Sean.Mcfadden@albertahealthservices.ca

McGREGOR, ELIZABETH
Preventive Oncology
P: 403.521.3754
F: 403.270.8003
Elizabeth.McGregor@albertahealthservices.ca

McKINNON, J. GREGORY
Surgical Oncology
P: 403.521.3179
F: 403.944.3926
mckinnon@ucalgary.ca

McWHAE, JOHN A.
Surgical Oncology
P: 403.640.1900
F: 403.640.4858
John.McWhae@albertahealthservices.ca

MEW, DAPHNE J. Y.
Surgical Oncology
P: 403.220.8598
F: 403.944.4352
dmew@ucalgary.ca

MEYER, TYLER
Medical Physics
P: 403.521.3839
F: 403.521.3327
Tsmeyer@ucalgary.ca

MONZON, JOSE
Medical Oncology
P: 403.521.3196
F: 403.283.1651
Jose.Monzon@albertahealthservices.ca

MORRIS, DONALD G.
Medical Oncology
P: 403.521.3347
F: 403.283.1651
Don.Morris@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

MURPHY, LINDY
Palliative Oncology
P: 403.944.2304
F: 403.270.9652
Lindy.Murphy@albertahealthservices.ca

NARENDRAN, ARU
Pediatric Oncology
P: 403.955.7203
Lab: 403.210.6418
F: 403.955.2645
anarendr@ucalgary.ca

NATION, JILL G.
Gynecologic Oncology
P: 403.521.3721
F: 403.521.3573
Jill.Nation@albertahealthservices.ca

NELSON, GREGORY
Gynecologic Oncology
P: 403.521.3721
F: 403.521.3573
Gregg.Nelson@albertahealthservices.ca

NERI, E. PAOLA
Hematologic Malignancies & BMT
P: 403.220.3668
F: 403.944.2102
Ernesta.Neri@albertahealthservices.ca

NORDAL, ROBERT
Radiation Oncology
P: 403.521.3708
F: 403.283.1651
Robert.Nordal@albertahealthservices.ca

OLIVOTTO, IVO
Radiation Oncology
P: 403.521.3105
F: 403.283.1651
Ivo.Olivotto@albertahealthservices.ca

OWEN, CAROLYN
Hematologic Malignancies & BMT
P: 403.944.3265
F: 403.944.8352
Carolyn.Owen@albertahealthservices.ca

PASIEKA, JANICE L.
Surgical Oncology
P: 403.944.2491
F: 403.283.4130
Janice.Pasieka@albertahealthservices.ca

PATERSON, A. (SANDY) H. G.
Medical Oncology
P: 403.521.3688
F: 403.283.1651
Alexander.Paterson@albertahealthservices.ca

PAWLIK, SARA
Palliative Oncology
P: 403.944.2304
F: 403.270.9652
Sara.pawlik@albertahealthservices.ca

PELLETIER, GUY
Psychosocial Oncology
P: 403.355.3212
F: 403.355.3206
Guy.Pelletier@albertahealthservices.ca

PHAN, TIEN
Radiation Oncology
P: 403.944.1775
F: 403.283.1651
Tien.Phan@albertahealthservices.ca

PICKERING, TARA L.
Medical Oncology
P: 403.521.3093 / 403.944.1707
F: 403.283.1651
Tara.Pickering@albertahealthservices.ca

PIERCE, GREG
Medical Physics
P: 403.521.3259
Greg.Pierce@albertahealthservices.ca

PLOQUIN, NICOLAS
Medical Physics
P: 403.521.3749
Nicolas.Ploquin@albertahealthservices.ca

POON, MAN-CHIU
Medical Oncology
P: 403.944.1564
F: 403.944.2102
mcpoon@ucalgary.ca

QUAN, MAY LYNN
Surgical Oncology
P: 403.944.0966
MayLynn.Quan@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

RANCOURT, DERRICK E.
Biochemistry & Molecular Biology
P: 403.220.2888
F: 403.283.8727
rancourt@ucalgary.ca

RATTNER, JEROME B.
Biochemistry & Molecular Biology
P: 403.220.4478
F: 403.283.8731
rattner@ucalgary.ca

RIABOWOL, KARL T.
Biochemistry & Molecular Biology
P: 403.220.8695
F: 403.270.0834
karl@ucalgary.ca

ROBBINS, STEPHEN M.
Biochemistry & Molecular Biology
P: 403.210.4304
F: 403.283.8727
srobbins@ucalgary.ca

ROBINSON, JOHN W.
Psychosocial Oncology
P: 403.355.3211
F: 403.355.3206
John.Robinson@albertahealthservices.ca

ROLDAN URGOITI, GLORIA
Medical Oncology
P: 403.521.3810
F: 403.283.1651
Gloria.RoldanUrgoiti@albertahealthservices.ca

RUETHER, J. DEAN
Medical Oncology
P: 403.521.3093
F: 403.283.1651
Dean.Ruether@albertahealthservices.ca

RYDZ, NATALIA
Hematologic Malignancies & BMT
P: 403.944.1993
F: 403.270.7891
natalia.rydz@albertahealthservices.ca

SAVOIE, M. LYNN
Hematologic Malignancies & BMT
P: 403.944.1564
F: 403.944.2102
Lynn.Savoie@albertahealthservices.ca

SCHRIEMER, DAVID C.
Biochemistry & Molecular Biology
P: 403.220.3811
F: 403.270.0834
dschriem@ucalgary.ca

SCHULTE, FIONA
Biochemistry & Molecular Biology
P: 403.955.2879
F: 403.955.2645
Fiona.Schulte@albertahealthservices.ca

SENGER, DONNA L.
Fundamental Research
P: 403.220.5042
F: 403.270.0834
senger@ucalgary.ca

SHACK, LORRAINE
Preventive Oncology
P: 403.476.0320
F: 403.355.3292
Lorraine.Shack@albertahealthservices.ca

SHAFEY, MONA
Hematologic Malignancies & BMT
P: 403.944.8047
F: 403.270.7891
Mona.Shafey@albertahealthservices.ca

SIA, MICHAEL A.
Radiation Oncology
P: 403.521.3095
F: 403.283.1651
Michael.Sia@albertahealthservices.ca

SIMON, JESSICA E.
Palliative Oncology
P: 403.944.2304
F: 403.270.9652
Jessica.Simon@albertahealthservices.ca

SIMPSON, J. STEVEN A.
Psychosocial Oncology
P: 403.698.8028
F: 403.355.3206
Steve.Simpson@calgaryhealthregion.ca

SINCLAIR, SHANE
Palliative Oncology
P: 403.220.2925
sinclair@ucalgary.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

SINHA, RICHIE
Radiation Oncology
P: 403.521.3708
F: 403.283.1651
Richie.Sinha@albertahealthservices.ca

SINNARAJAH, AYNHARAN
Palliative Oncology
P: 403.944.1147
F: 403.250.3102
Ayn.Sinnarajah@albertahealthservices.ca

SKARSGARD, DAVID P.
Radiation Oncology
P: 403.521.3708
F: 403.283.1651
David.Skarsgard@albertahealthservices.ca

SLABY, JIRI
Hematologic Malignancies & BMT
P: 403.943.2502
F: 403.943.4017
Jirr.Slaby@albertahealthservices.ca

SLAWNYCH, MICHAEL
Palliative Oncology
Michael.slawnych@albertahealthservices.ca

SMITH, WENDY L.
Medical Physics
P: 403.521.3422
F: 403.521.3327
Wendy.Smith@albertahealthservices.ca

SPECA, MICHAEL
Psychosocial Oncology
P: 403.355.3216
F: 403.355.3206
Michael.Speca@albertahealthservices.ca

SPENCER, DAVID P.
Medical Physics
P: 403.521.3064
F: 403.521.3327
David.Spencer@albertahealthservices.ca

SPICE, RONALD N.
Palliative Oncology
P: 403.995.2714
F: 403.995.2619
Ron.Spice@albertahealthservices.ca

STEELE, J. MACGREGOR
Pediatric Oncology
P: 403.955.3035
MacGregor.Steele@albertahealthservices.ca

STEWART, DOUGLAS A.
Medical Oncology
P: 403.521.3347
F: 403.283.1651
Douglas.Stewart@albertahealthservices.ca

STOREK, JAN
Hematologic Malignancies & BMT
P: 403.210.8630
F: 403.283.1267
jstorek@ucalgary.ca

STREET, LESLEY
Hematologic Malignancies & BMT
P: 403.956.24.68
F: 403.956.2991
lestreet@ucalgary.ca

STROTHER, DOUGLAS
Pediatric Oncology
P: 403.955.7203
F: 403.955.2645
Doug.Strother@albertahealthservices.ca

SUTHERLAND, FRANCIS
Surgical Oncology
P: 403.944.1253
F: 403.944.1277
Francis.Sutherland@albertahealthservices.ca

SYME, RACHEL
Palliative Oncology
P: 403.521.3388
F: 403.283.1158
Rachel.Syme@albertahealthservices.ca

TAENZER, PAUL A.
Medical Oncology
P: 403.943.9902 / 403.943.9900
F: 403.209.2955
Paul.Taenzer@albertahealthservices.ca

TAM, VINCENT
Medical Oncology
P: 403.521.3706
F: 403.283.1651
Vincent.Tam@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

TANG, PATRICIA
Medical Oncology
P: 403.521.3093
F: 403.283.1651
Patricia.Tang@albertahealthservices.ca

TEMPLE, WALLEY J.
Surgical Oncology
P: 403.521.3914
F: 403.944.3926
Walley.Temple@albertahealthservices.ca

TEMPLE-OBERLE, CLAIRE
Surgical Oncology
P: 403.521.3012
F: 403.944.3926
Claire.Temple-Oberle@albertahealthservices.ca

THAELL, J. F. (TED)
Hematologic Malignancies & BMT
P: 403.956.2468
F: 403.956.2991
jthaell@ucalgary.ca

THIRUKKUMARAN, CHANDINI M.
Fundamental Research
P: 403.521.3060 / 403.521.3844
F: 403.270.8243
cmthiruk@ucalgary.ca

THOMAS, BEJOY
Psychosocial Oncology
P: 403.355.3213
F: 403.355.3206
Bejoy.Thomas@albertahealthservices.ca

TREMBLAY, ALAIN
Medical Oncology
P: 403.210.3866
F: 403.283.6151
alain.tremblay@ucalgary.ca

TROTTER, MARTIN J.
Pathology & Laboratory Medicine
P: 403.770.3202
F: 403.770.3741
martin.trotter@cls.ab.ca

TROTTER, THERESA
Radiation Oncology
P: 403.521.3708
F: 403.283.1651
Theresa.Trotter@albertahealthservices.ca

TRUONG, ANTHONY
Pediatric Oncology
P: 403.955.2946
F: 403.955.2645
Tony.Truong@albertahealthservices.ca

TSANG, ROGER
Medical Oncology
P: 403.521.3688
F: 403.283.1651
Roger.Tsang@albertahealthservices.ca

VALENTINE, KAREN
Hematologic Malignancies & BMT
P: 403.944.4451
F: 403.944.1647
karen.valentine@albertahealthservices.ca

VALLANCE, JEFFREY
Preventive Oncology
P: 866.441.4651
F: 866.492.7183
jeffy@athabascau.ca

van der HOORN, FRANCISCUS A.
Biochemistry & Molecular Biology
P: 403.220.3323
F: 403.283.8727
fvdhoorn@ucalgary.ca

VILLARREAL-BARAJAS, JOSE E.
Medical Physics
P: 403.521.3598
F: 403.521.3327
Eduardo.VillarrealBarajas@albertahealthservices.ca

VORONEY, JON-PAUL
Radiation Oncology
P: 403.521.3164
F: 403.283.1651
Jon-Paul.Voroney@albertahealthservices.ca

WALLEY, BARBARA A.
Medical Oncology
P: 403.521.3688
F: 403.283.1651
Barbara.Walley@albertahealthservices.ca

WASYLENKO, ERIC
Palliative Oncology
P: 403.943.1267
F: 403.943.1294
Eric.Wasylenko@albertahealthservices.ca

2015 DIRECTORY
AREA CODE 403 UNLESS OTHERWISE NOTED

WEBSTER, MARC A.
Medical Oncology
P: 403.521.3093
F: 403.283.1651
Marc.Webster@albertahealthservices.ca

WILSON, JANE
Radiation Oncology
P: 403.388.6860
Jane.Wilson@albertahealthservices.ca

WONG, MICHAEL
Hematologic Malignancies & BMT
P: 403.943.5425
F: 403.943.4017
Michael.Wong2@albertahealthservices.ca

WRIGHT, NICOLA A.M.
Pediatric Oncology
P: 403.955.3035
F: 403.955.3055
Nicola.Wright@albertahealthservices.ca

WU, JACKSON S.Y.
Radiation Oncology
P: 403.521.3708
F: 403.283.1651
Jackson.Wu@albertahealthservices.ca

YAU, ANNIE (CLAUDE)
Clinical Neurosciences
P: 403.212.8223 #04471
F: 403.283.1651
annie.yau@ucalgary.ca

YONG, V. WEE
Clinical Neurosciences
P: 403.220.3544 / 403.220.8965
F: 403.283.8731
vyong@ucalgary.ca

YOUNG, DALLAN B.
Biochemistry & Molecular Biology
P: 403.220.3030
F: 403.283.8727
young@ucalgary.ca



**UNIVERSITY OF
CALGARY**

Department of **Oncology**

Tom Baker Cancer Centre
Department of Oncology
1331-29 Street NW
Calgary, Alberta
T2N 4N2

Phone: 403-521-3408
Fax: 403-944-2331

<http://www.departmentofoncology.com/>